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Chapter 1 Introduction  
 
BACKGROUND 
Current trends of urbanization have had several benefits. These have contributed to adapt the 
environment where the human society thrives and to reduce the burden of multiple diseases with 
high and acute mortality, thus contributing largely to the extension of human life expectancy.1 
Nevertheless, urbanization has also increased the exposure to several risks that menace both the 
environment and global health,1,2 such as the man-made acceleration of climate change and the 
widespread of antibiotic resistance due to misuse of antibiotics. This burden is projected to 
increase progressively, as with the extension of life expectancy and average age, so does the pool of 
population with a high susceptibility to environmental challenges and chronic diseases. 
Specifically in the elderly, the higher susceptibility occurs, among others, due to the age-related 
decline of physiological reserve capacity, the deterioration in the responding immune system, and 
reductions in cognitive capacity. 
In spite there is consensus that the ongoing trend of climate change is mostly caused by 
man-made actions,3 the current course of action seems unable to stop, let alone reverse, its 
progression. Therefore, it is necessary to anticipate the challenges of environmental deterioration 
and climate change, in order to enhance the adaptive capacity of the society, understood as the 
reduction of disease, mortality and poor quality of life.4 A first step implies understanding the 
health burden that is attributable to environmental factors. For example, whereas the seasonality 
of the cardiovascular risk is a well described phenomenon,5,6 it remains unclear the contribution 
of meteorological factors7-15 and the seasonality of lifestyle factors, such as physical activity 16,17 
and diet.18-21 Additionally, it is necessary to understand the susceptibility of population 
subgroups, such as the elderly. For example, elderly populations are more susceptible to 
meteorological challenges given the age-related impairment of thermoregulation and the 
occurrence of comorbidities. The coping capabilities are further impaired by a higher 
vulnerability, given the frequently observed isolation, disability, and poverty of this subgroup.22 
During the scientific work presented in this thesis, susceptibility is understood as the biological 
responses to environmental stressors, such as the age-related impairment of thermoregulation 
mechanisms and comorbidities. Vulnerability is understood as the capacity to cope with 
environmental stressors.22  This vulnerability contributes to reduce the adaptive capacity of the 
population. 
In this thesis, I examined some of the most urgent health issues that potentially will 
affect the susceptibility of elderly population under the upcoming challenges of climate change, 
including the seasonal variation of lifestyle factors, cardiovascular risk factors, cognition, and 
antibiotic resistance; and exposure to air pollution. 
 
OUTLINE OF THE THESIS 
This thesis is composed of two parts. In part 1 I examined the seasonal variation and the 
influence of meteorological factors in the seasonal variation of lifestyle factors, cardiovascular risk 
factors, and cognition in the Rotterdam Study; furthermore, I evaluated the seasonality of 
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antibiotic resistance using a systematic review of the literature. In part 2, I examined the exposure 
to air pollution according to mode of transport in two systematic reviews and describe the 
exposure to air pollution in the population of the Rotterdam Study. 
All but the systematic reviews studies were based in the Rotterdam Study, a prospective 
Dutch cohort comprised in 1987 with middle-aged and elderly population living in the district of 
Ommoord, in Rotterdam.23 The cohort is comprised by three cohorts, the first one which started 
in 1987, the second one in 1996 and the third one in 2006. The age for inclusion in the cohort 
has moved across the cohorts, with participants being recruited at age of 55 in the first cohort 
and currently, being recruited at age of 45.  
The relevant visits varied across the studies included in this thesis, depending on the aim 
of the specific study. In the  
Figure 1 (page 8) we show the overview of the cohorts as well as the relevant visits for 
each study that composes the chapters regarding seasonal variation and health effects of air 
pollution. 
 
Figure 1. Overview of the Rotterdam Study 
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Seasonal variation of lifestyle factors in aging population 
Previous studies have examined the seasonality of lifestyle factors, namely physical activity and 
diet, in several populations. First, in winter months, physical activity levels are usually lower,16,17 
while sedentary behavior increases.24,25 However, it has not been examined if nighttime sleep 
duration is also related to this variation. Additionally, both age and meteorological factors have 
been suggested to be important determinants of the seasonality of activity levels,26,27 but an age-
specific assessment of the impact of meteorological factors in the seasonal variation of activity 
levels has not been performed. Therefore, in chapter 2.1.1 I examined the seasonality of the 
complete 24-hour spectrum, including physical activity, sedentary behavior, and sleep, measured 
objectively with accelerometers, according to an age-specific approach, while accounting for the 
influence of meteorological factors in the seasonal variation.  Additionally, although several 
studies showed a seasonal variation of food groups and nutrients intake,18-21 these do not take 
into account the high inter-correlation of food groups and nutrients within the diet. Such inter-
correlation could also lead to a seasonality of the overall diet quality, hence potentially explaining 
the seasonality of morbidity and mortality of diet-related health outcomes, such as cardiovascular. 
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Yet, the seasonality of overall diet quality has not been examined. Therefore, in chapter 2.1.2 I 
examined the seasonality of diet quality among the participants of the Rotterdam Study. 
 
Seasonal variation of morbidity in aging population 
Although the seasonality of cardiovascular risk has been widely described,5,28-33 the mechanisms 
underlying this phenomenon are not well understood. It is suggested that the variation can be 
attributed to the seasonality of lifestyle markers,17,34 such as body mass index or physical activity, 
but meteorological factors may also contribute.7-15 However, the influence of both lifestyle 
markers and meteorological factors on the seasonality of cardiovascular risk factors have not been 
investigated. Moreover, it was unclear if such influence differs according to age. Understanding 
the mechanisms underlying the seasonality of cardiovascular risk is relevant to identify 
interventions that are more likely to mitigate the potential influence of this phenomenon on the 
well-described seasonality of cardiovascular risk and the upcoming challenges of climate change. 
Therefore, in chapter 2.2.2 I examined the role of lifestyle markers and meteorological factors on 
the seasonality of seven hemodynamic, metabolic, and anthropometric risk factors, stratified by 
age (middle-aged (<65 years) vs elderly (≥65 years)).  
The aging trend of the population has also increased the burden of cognitive decline, 
thus the need to understand its causes and determinants. Previous studies have shown that 
besides individual factors, such as educational attainment, vascular and lifestyle factors, cognitive 
decline can also relate with environmental factors,35 some of which could have a seasonal 
influence. Nevertheless, few studies have addressed the seasonal variation of cognitive function in 
the general population 36,37 and the findings are contradictory. We examine in chapter 2.2.3 the 
seasonality of cognitive functioning among community-dwelling individuals. 
The potential burden of infectious diseases within the current trends of climate change 
cannot be overstated, given the expected increase of environmental conditions that will favor the 
widespread of infections.4 Elderly populations are among the most threatened population, as they 
are more sensitive to become infected and experience complications due to reduced 
responsiveness of immune system and presence of comorbidities; and are extra vulnerable, due to 
isolation and economic insecurity.22 In this scenario, the widespread of antibiotic resistance may 
worsen the consequences of climatic change, by reducing the therapeutic alternatives to treat 
infections and by increasing the fatal outcomes of previous underlying health conditions. 
Especially, given the rapid worldwide increase of the intake of last-resort antibiotics.38 Much of 
these infections, such as respiratory infections, have a well described seasonal variation that may 
lead to a seasonal variation of antibiotic resistance as well,39-45 either because the circulating 
resistant strains increase, or induced by the increase of antibiotic use, or most likely a 
combination of both. Nevertheless, since these conditions underlying the development of 
antibiotic resistance change across settings, there is great heterogeneity in the evidence regarding 
the seasonality of antibiotic resistance. Therefore, in chapter 2.2.4 I systematically review the 
evidence about the seasonal variation of antibiotic resistance in bacteria that pose a serious threat 
to public health and examine the sources of heterogeneity of such variation. 
 
Air pollution exposure and health effects in aging population 
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Air pollution is one of the other great threats of climate change. Air pollution is composed, 
among others, by heat-trapping gases, which are an important cause of climate change, and under 
and scenario of global warming, air pollution levels will worsen due to temperature inversion. 
Traffic emissions are an important source of air pollution,46 and air pollution exposure while 
commuting often reaches levels above air quality standards.47 Active commuters are usually 
considered as less exposed to air pollutants compared to motorized commuters.48,49 However, 
active commuters are more likely to inhale more air pollutants due to larger trip times and 
breathing parameters. Although active and public transport are encouraged as environmentally-
friendly and healthier (e.g. increased physical activity), it is necessary to better understand what 
determines the exposure to air pollution while commuting and the health effects of exposure to 
air pollution. I undertook a systematic review of available studies that compared the exposure to 
five air pollutants (CO, BC, NOx, fine particles (particulate matter ≤ 2.5µm) and coarse particles 
(PM<10µm)) in chapter 3.1 and ultrafine particles in chapter 3.2 between active and motorized 
commuters. Previous systematic reviews have addressed the comparison of air pollution exposure 
between modes of transport,48-50 but do not address the positive effect of physical activity and the 
difference of inhaled pollutants dose, taking into account length of the trip and increased 
breathing parameters. 
By 2012, outdoor air pollution exposure caused about 3 million deaths worldwide, about 
94% occurring in adults and up to 72% due to stroke, and ischemic heart disease, followed by 
chronic obstructive pulmonary disease and lung cancer.51 Although traffic is the major source of 
pollutants in urban areas, it is less clear which are the components of traffic explaining its health 
effects. Indeed, in spite air pollution exposure is a strong candidate, traffic also increases the 
exposure to other risk factors, such as noise,52 less green space, and heat islands, which are 
strongly spatially correlated, what makes difficult to disentangle their individual effects. Few 
previous studies have approached the environmental risk factors affecting elderly populations, air 
pollution exposure among the most important. Addressing the health effects of traffic related air 
pollution exposure in the population of the Rotterdam Study, which comes from the relatively 
small geographic area (about 4.5km2), has the value of contributing to control for traffic-related 
covariates that may confound such associations, for example those related to the urban built 
environment. Moreover, the detailed longitudinal nature of the Rotterdam Study data permits a 
better characterization of the health outcomes related to air pollution exposure. In this context, 
we estimated the exposure to traffic-related air pollutants (NO2, NOx, PM10, PM2.5, and PM2.5 
absorbance) using a model previously validated for the Netherlands, which allow to estimate 
geographical gradients of air pollution in this small area. In chapter 3.3, I describe the methods 
for the estimation of pollutants in one specific visit of the cohort, where the exposure was 
calculated up to the writing of this thesis. Additionally, I describe the distribution of the 
pollutants according to selected characteristics of the participants at the visit date. 
 
Discussion 
In the last section, we discuss the methodological implications of our findings and discuss the 
major findings of our study in relation with the seasonality of mortality and morbidity, climate 
change, and air pollution exposure among elderly population.
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Chapter 2 Seasonality and meteorological factors 
2.1 Seasonality of lifestyle factors 
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2.1.1 Seasonality of physical activity, sedentary behavior, and sleep in a middle-aged and elderly 
population: the Rotterdam Study  
 
Magda Cepeda*, Chantal M. Koolhaas*, Frank J.A. van Rooij, Henning Tiemeier, Mònica 
Guxens, Oscar H. Franco†, Josje D. Schoufour† 
*These authors have contributed equally to this paper. †These authors share last authorship 
 
Adapted from Maturitas 2018; 110:41-50. 
 
ABSTRACT 
Introduction: Physical activity (PA) and sedentary behavior (SB) have seasonal patterns. It 
remains unclear how these patterns are associated with sleep, meteorological factors, and health. 
 
Methods: Activity levels were continuously measured with an accelerometer for seven days 
between July- 2011 and May- 2016, among middle-aged (50-64 years), young-elderly (65-74 years) 
and old-elderly (≥75 years) participants of a population-based Dutch cohort study (n=1,116). 
Meteorological factors (ambient temperature, wind speed, sunlight hours, precipitation, and 
minimum visibility) were locally recorded. We first examined the seasonality of PA, SB, and 
nighttime sleep, stratified by age group. Second, we examined the influence of meteorological 
factors. Third, we modeled the potential seasonality of the all-cause mortality risk due to the 
seasonality of PA and SB, by using previously published relative risks. 
 
Results: Levels of light and moderate-to-vigorous PA were higher in summer than in winter 
among middle-aged (seasonal variation=18.1 and 14.8 minutes/day) and young-elderly adults 
(12.8 and 8.6 minutes/day). The pattern was explained by ambient temperature and sunlight 
hours. Nighttime sleep was 31.8 minutes/day longer in winter among middle-aged adults. SB did 
not show a seasonal pattern. No seasonality in activity levels was observed among old-elderly 
adults. The all-cause mortality risk may be higher in winter than in summer due to the 
accumulation of low levels of moderate to vigorous PA and high levels of SB.  
 
Conclusion: PA has a larger degree of seasonality than SB and nighttime sleep among middle-
aged and young-elderly adults. SB appears strongly ingrained in daily routine. Recommending the 
interruption of SB with light PA might be a good starting point for public health institutions. 
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INTRODUCTION 
Population ageing, urbanization, and automatization of daily activities have contributed to a 
predominantly sedentary lifestyle, with low levels of physical activity (PA) and high levels of 
sedentary behavior (SB), but also to suboptimal nighttime sleep duration (i.e. not sleeping 7-8 
hours).53,54 However, although low levels of PA cluster with high SB and suboptimal nighttime 
sleep duration 53,55, these are partly independent phenomena. Moreover, the proportions of the 
various types of daily (in) activity (i.e. PA, SB, sleep) may influence cardio-metabolic health 
beyond their independent effects. 56-58 Therefore, there is increasing interest in the factors 
determining the composition of daily activity levels. 
Objective measurements with accelerometers have demonstrated that levels of PA and 
SB are not constant throughout the year. Studies performed in young and middle-aged 
population report that time spent in PA decreases in winter,16,17 whereas sedentary time 
increases.24,25 However, it is unclear whether sleep duration is related to this variation because 
previous studies have used sleep diaries 25 rather than objective measures or because sleep was 
omitted within daily routine.24 
Several factors determine the seasonality of activity levels. For example, with increasing 
age, time spent in PA and nighttime sleep tends to decrease, while sedentary behavior 
increases.59,60 Retirement may also explain this pattern, as leisure PA is more sensitive to seasonal 
changes than occupational PA.17 Additionally, age interacts with meteorological factors to 
influence PA levels 26,27 and PA seasonality is more marked in geographical regions with more 
climatic variation.61,62 However, an age-specific assessment of the impact of meteorological factors 
on the seasonality of activity levels has not been performed. 
The seasonality of activity levels is of relevance to public health, as PA is often prescribed 
as a first means to improve health, e.g. to reduce dyslipidemia and high blood pressure. 63 Indeed, 
it is hypothesized that the seasonal pattern of cardio-metabolic risk and mortality can be partly 
explained by the seasonality of PA.16,32 Nevertheless, it is not clear whether this seasonality is large 
enough to influence all-cause mortality on a seasonal basis.  
We therefore examined the seasonality of objectively measured daily levels of PA, SB, 
and nighttime sleep duration according to age, using around-the-clock measurements. 
Furthermore, we examined to what extent meteorological factors explained the seasonality of 
activity levels. Finally, we modeled the seasonality of the all-cause mortality risk produced by the 
seasonal variation in levels of moderate to vigorous PA and SB. 
 
METHODS 
Study design 
We performed a cross-sectional study to analyze the annual seasonal variation in PA, SB and 
nighttime sleep duration. This study was embedded in The Rotterdam Study (RS), a prospective 
population-based cohort established in 1989, which has invited the participation of all middle-
aged and elderly people living in the Ommoord district of Rotterdam, the Netherlands. Baseline 
invitations were sent to all the home addresses within the district, including senior housing 
facilities, retirement homes and assisted living facilities. The aim of the Rotterdam Study was to 
examine the incidence of risk factors for neurological, cardiovascular, psychiatric, and other 
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chronic diseases.23 The study is composed by three cohorts (RS-I, RS-II and RS-III) and follow-up 
visits are performed every five years.23 The Rotterdam Study has been approved by the Medical 
Ethics Committee of the Erasmus MC (MEC 02.1015) and by the Ministry of Health, Welfare 
and Sport of the Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population 
Studies Act: Rotterdam Study). All participants provided written informed consent to their 
involvement in the study and to obtain information from their treating physicians. 
Between June-2011 and June-2014 (wave 1) and between July-2014 and May-2016 (wave 
2), 3,507 participants were invited to wear an accelerometer for seven days, to measure their 
activity levels. 482 participants were invited in both waves. Along with wearing the accelerometer, 
participants reported overnight sleep periods in a sleep diary. For the current study, we selected 
1,166 sets of observations (48 from participants who participated in both wave 1 and wave 2) 
obtained from non-disabled participants. Disability was defined as having a disability index > 
0.5.64 The participation flowchart is provided in Appendix 1 (page 29).  
 
Physical activity, sedentary behavior and nighttime sleep duration 
To measure activity, we used a GENEActiv device (GENEActiv; Activinsights Ltd, Kimbolton, 
Cambridgeshire, UK, http://www.GENEActiv.org/), a tri-axial accelerometer that can be worn 
like a watch. Participants were instructed to wear the accelerometer on the non-dominant wrist 
for 7 consecutive days and nights. Accelerometer data were extracted and used to designate SB, as 
well as light, moderate, or vigorous PA. Detailed information on the assessment of accelerometer-
derived PA can be found in the Appendix 2 (page 30) and has been described in detail 
elsewhere.65 Nighttime sleep duration was detected using a validated algorithm,66 which combines 
the accelerometer data and the time when participants reported they went to bed and the 
reported time of waking from the sleep diary. Time-in-bed was also extracted from sleep diaries. 
Sleep efficiency was calculated as (nighttime sleep duration/time in bed)*100. 
 
Meteorological factors 
Daily information on meteorological factors in Rotterdam was obtained from the Koninklijk 
Nederlands Meteorologisch Instituut (KNMI).67 The monitor is located approximately 8km from 
the Ommoord district (coordinates: 51° 58' N 04° 27' E). The daily meteorological data were 
linked to the dates on which the accelerometer was worn. In the current study, we included daily 
average temperature (˚C), average relative humidity (percentage), total number of sunlight hours, 
accumulated precipitation (mm), average wind speed (m/s), and minimum visibility (km), 
classified as <1.8 km, 1.8-3.9 km, 3.9-7 km, 7-12 km and ≥12 km.  
 
Covariates 
Data on covariates were collected through home interviews or measured at the Rotterdam Study 
research center by trained research assistants,68 and included sex, age (years), body mass index 
(BMI) (kg/m2), history of comorbidities (cardiovascular disease, diabetes, cancer or chronic 
obstructive pulmonary disease), smoking behavior, housing status, disability score, occupation, 
and alcohol intake. Data collection procedures are described in detail in Appendix 2 (page 30).  
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Statistical methods 
All analyses were stratified by age group: 50-64 years (middle-aged), 65-74 years (young-elderly) 
and aged 75 years or older (old-elderly). General characteristics of the population are presented as 
absolute frequencies and percentage for categorical variables and as median and interquartile 
range (25th and 75th percentile) for continuous variables. Differences in distributions between the 
age- groups were evaluated using the Kruskal-Wallis test for continuous variables and the χ2 test 
for categorical variables. 
In our analysis, we first examined the seasonality of light and moderate-to-vigorous PA, 
SB, and nighttime sleep duration (in minutes/day) using a linear mixed effects model to account 
for the correlation within days contributed per participant. We used the participant id as 
clustering variable. Because 48 participants wore the accelerometer in both waves, we accounted 
for the correlation between these repeated measurements by adding a second random intercept, 
using the wave as clustering variable. The seasonality was evaluated using a cosinor model 
assuming a sinusoidal pattern with a period of one year,17 by adding sine and cosine terms of the 
accelerometer wear-date in the fixed part of the model.69 All models were adjusted for the 
covariates listed above, plus the day of the week (weekday or weekend day).  
The seasonality is reported as the seasonal variation, corresponding to the peak-to-nadir 
difference in activity levels throughout the year. Procedures to estimate the seasonal variation are 
provided elsewhere.69 A subgroup analysis stratified by sex was performed, including the seasonal 
variation in time in bed (minutes/day) and sleep efficiency (%). 
Second, to examine to what extent the meteorological factors explained the seasonality of 
activity levels, we included one meteorological factor at a time in the fully adjusted model. Then, 
we calculated the difference of the seasonal variation before and after the inclusion of the 
meteorological factor. The influence of a meteorological factor on the seasonality of activity levels 
was considered significant if the seasonal variation became non-significant or was reduced by 
more than 5%. Average temperature was categorized in quintiles to account for the non-linear 
association. Wind speed, sunlight hours, precipitation, and humidity were converted to z-scores 
and added as continuous variables.  
Finally, we examined the potential seasonality of the all-cause mortality risk as a function 
of moderate to vigorous PA and SB, as described in detail in Appendix 3 (page 31). Briefly, we 
first multiplied the time/day spent in moderate-to-vigorous PA and in SB with the log 
transformed relative risk (RR) for the association of moderate to vigorous PA (RR=0.72) and SB 
(RR=1.24) with all-cause mortality, as obtained from published meta-analyses.70,71 The sum of 
these products was considered the hypothetical all-cause mortality risk due to moderate to 
vigorous PA and SB combined. Next, we modeled the seasonality of this hypothetical all-cause 
mortality risk using cosinor analysis, adjusted for the covariates listed above, and stratified by age-
group. Using the seasonal variation obtained in the previous step, we calculated the hypothetical 
all-cause mortality risk at the peak and the nadir of the seasonal variation and, using standard life 
tables, we calculated the corresponding life expectancy at each extreme. The difference between 
the life expectancy at the peak and at the nadir is expressed in months. The analyses were 
repeated for PA and SB separately and using the lower and upper boundaries of the 95% 
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confidence interval of the RRs. All analyses were performed in Stata version 14.1 SE (StataCorp 
LP, College Station, Texas).72 
 
RESULTS 
General characteristics 
A total of 1,166 sets of measurements were included, 34% (n=394) among middle-aged adults, 
39% among young-elderly (n=449), and 28% among old-elderly participants (n=323). Old-elderly 
adults more often participated in the study during winter than during summer (43.6% vs. 6.2% 
of the days contributed). The other age-groups did not show this difference in participation across 
the seasons. Additionally, old-elderly adults were more often living in assisted living facilities and 
were less often in paid employment than middle-aged and young-elderly adults (Table 1, page 21).  
 
Seasonal variation in activity levels 
Among middle-aged participants, levels of light PA were highest in early August (seasonal 
variation=18.1 minutes/day (standard error (SE)=4.0)), and levels of moderate-to-vigorous PA 
were highest in late-July (seasonal variation=14.8 minutes/day (SE=3.8)), whereas nighttime sleep 
duration was highest mid-January (seasonal variation=31.8 minutes/day (SE=6.6)). No significant 
seasonal variation in SB was observed (Figure 2, page 21). Among young-elderly adults, levels of 
light PA and moderate-to-vigorous PA were highest in late-July (seasonal variation=12.8 
minutes/day (SE=3.9) and 9.9 minutes/day (SE=3.3), respectively), but no significant seasonal 
variation was observed for nighttime sleep duration. Among old-elderly participants, no 
significant seasonal variation was observed for any activity level. No large sex differences in the 
seasonality of activity levels were observed (Appendix 4, page 33). 
 
Impact of meteorological factors on seasonality of activity levels 
Among middle-aged adults, the seasonality of levels of light PA was explained by ambient 
temperature (seasonal variation change=-16.3%) and sunlight hours (-16.0%). The seasonality of 
levels of moderate-to-vigorous PA was explained by sunlight hours (-21.5%) and the seasonality of 
nighttime sleep duration was explained by ambient temperature (-49.4%). Among young-elderly 
participants, the seasonality of levels of light PA was explained by ambient temperature (-46.7%) 
and relative humidity (-17.7%), and the seasonality of levels of moderate to vigorous PA was 
explained by ambient temperature (-14.0%), minimum visibility (-12.7%), and relative humidity (-
11.0%). The meteorological factors had a large significant association with PA levels among the 
old-elderly, but none explained the seasonality (Table 2 and Table 3, pages 23 and 25). 
 
Seasonal variation in all-cause mortality risk and life expectancy as a function of the seasonality of activity 
levels  
If the all-cause mortality risk depended entirely on the levels of moderate to vigorous PA 
and SB, it would increase by 1.09 (95%CI 0.99, 1.21) times in winter compared with summer 
among middle-aged participants, 1.11 (95%CI 1.01, 1.21) times in winter compared with summer 
among young-elderly participants, and 1.04 (95%CI 0.95, 1.15) times in autumn compared with 
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spring among old-elderly participants (Table 4, page 26). The estimates were similar when using 
the 95% CI of the RR (Appendix 5, page 34). 
 
DISCUSSION 
In this population-based cohort, middle-aged and young-elderly participants spent more time in 
light and moderate to vigorous PA in summer than in winter, but no seasonality of PA was 
observed among old-elderly adults. Also, no seasonality was observed for SB in any age group. 
Nighttime sleep duration was higher in winter than in summer among middle-aged participants. 
The seasonality of PA and nighttime sleep duration was mostly explained by ambient temperature 
and sunlight hours. The modeled all-cause mortality risk might increase in winter because of the 
accumulation of low levels of moderate to vigorous PA and high levels of SB. 
The heterogeneous seasonal patterns according to activity levels and age group can be 
explained by several factors. First, the magnitude of the seasonal variation in PA decreased with 
age, which can be explained by the age-specific domain composition of PA (i.e. occupational, 
transportation, leisure, and household). Indeed, while up to 30% of daily PA among middle-aged 
adults corresponds to occupational PA,59 this domain nearly disappears after retirement, around 
age 65 (i.e. the young-elderly).59 Therefore, the summer increase in PA among middle-aged 
participants, and to a lesser extent among young-elderly participants, likely reflects an increase in 
leisure, household, and transportation PA, while levels of occupational PA remain constant. In 
contrast, because old-elderly adults have less structured daily PA (due to absence of occupational 
PA), they are less sensitive to the variation led by holidays and vacations. Second, the summer 
reduction in nighttime sleep duration among middle-aged adults suggests its seasonality is led by 
PA, which appears to replace sleep time in summer. Third, a small and non-statistically significant 
seasonality of SB was observed in our population (about 10 minutes/day), which is in contrast 
with O’Connell et al, who reported a winter increment of SB of about 30 minutes/day.25 This 
difference could be explained by the large proportion of the waking time our population spent in 
SB (around 77%), and because we classified the non-sleep time in bed as SB time. Taken 
together, our findings suggest that middle-aged and young-elderly participants replaced their 
nighttime sleep with more light and moderate to vigorous PA, and that SB is much more 
ingrained in the daily routine of the population. 
We found a discrete influence of meteorological factors on the seasonality of activity 
levels. Klenk et al 73 similarly found a strong association of objectively measured daily walking 
time with several meteorological factors, but not with season, among elderly German participants. 
The domain composition of activity levels could contribute to this finding. For example, while 
active transportation might be sensitive to meteorological factors, it represents a small proportion 
of the daily PA. In contrast, indoors occupational PA would be less sensitive to meteorological 
factors, but corresponds to a larger proportion of daily PA. Leisure PA could also be sensitive to 
meteorological conditions, 62 but people will remain sedentary if it is ingrained in their daily 
occupational routine,74,75 irrespective of favorable weather. Therefore, although meteorological 
factors have a strong influence on daily activity levels, they may be less relevant than the domain 
composition of PA and SB to explain the seasonality in activity levels. 
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Previous evidence suggested that the seasonality of PA plays a role in the well-described 
seasonality of cardiovascular disease and mortality.5,16,32 Our results suggest that the all-cause 
mortality risk will increase in winter among middle-aged and young-elderly adults due the 
accumulation of low levels of moderate to vigorous PA and high levels of SB. Our results need to 
be interpreted cautiously, because this approach does not take into account physical fitness, as a 
measure of functional reserve.76 Also, we assumed a linear association of PA with all-cause 
mortality risk, although it is suggested that the association is steeper at lower than at higher PA 
levels.71 Nevertheless, this analysis illustrates the potential seasonality of all-cause mortality risk as 
a function of the seasonal variation in activity levels. Consequently, these findings suggest that 
season and age should be taken into consideration when interventions are designed to improve 
activity levels both in clinical practice and in public health. For example, interventions can be 
designed to avoid people replacing active time with SB. Strategies may include promoting active 
transportation, by offering facilities to change wet clothes, fans and showers, encouraging people 
to wear lighter clothes during warm and humid days, and ensuring safe transportation during 
adverse climate conditions (e.g. snow and high wind speed). People can also be encouraged to 
exercise (e.g. yoga and strength training) and to undertake regular activities of daily living of light 
and moderate intensity, such as housework. These interventions could also contribute to 
interrupting long bouts of SB, since SB is also associated with several adverse health outcomes.56-
58,77 
There is an ongoing discussion regarding the potential of accelerometers and other 
wearable devices that measure activity levels within interventions aimed to promote PA and 
reduce SB. Based on our findings, wearable devices could provide feedback regarding the 
declining levels of PA in winter and could prompt people to interrupt long SB periods, even in 
real time. The high compliance with accelerometer use in our study showed the relative ease of 
evaluating activity in a middle-aged and elderly population, using a device with a minimal burden 
for the participant, as it is worn as a watch and participants did not have to remove it during the 
measurement week. This improves the precision of the measurements 78 and avoids the need for 
assumptions to be made about activity levels when the device is not being worn.78,79 Nevertheless, 
there is controversy regarding the effectiveness of interventions based on wearable devices to 
change behavior,80,81 partly because these changes appear not to be sustained in the longer term.82 
Additionally, it is yet to be examined whether there are differences in the effectiveness of 
interventions using standard feedback based on average individual data 80 and that of 
personalized feedback and targets. These issues are sensitive to an elderly population, for whom 
standard targets for moderate to high intensity PA may be less feasible than improving light PA 81 
and reducing long SB periods; but also because barriers, either individual (e.g. lack of self-efficacy, 
frailty, or fear of falling) or environmental (e.g. meteorological conditions and built 
environment),83 may hamper the effectiveness of such interventions. Therefore, improving PA 
and reducing SB through the use of wearable devices may be a promising strategy in clinical 
practice. Nevertheless, long-term clinical trials are required of interventions with user-friendly, 
precise, and low-cost devices,80 with relevant, age-appropriate targets for PA and SB. 
 
Strengths and limitations 
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The main strength of our study is the objective round-the-clock measurement of activity levels in 
middle-aged and elderly adults, allowing us to evaluate the seasonality of 24-hour age-specific 
activity levels. Moreover, we improved the accuracy of SB and nighttime sleep measurements, 
because our participants were instructed not to remove the accelerometer during the 
measurement week and because we calculated non-sleep time in bed, which seemed to contribute 
to overall sedentary time. Second, to our knowledge, we are the first to examine the seasonality of 
the all-cause mortality risk and life expectancy, under the assumption that it will depend solely on 
levels of moderate-to-vigorous PA and SB. In these analyses, we used RR estimates obtained from 
comprehensive systematic reviews with meta-analysis,70,71 thereby enhancing the 
representativeness of our modeling. Third, all our participants were resident in a single area, the 
Ommoord district, which reduces the variation in activity levels that can be attributed to other 
determinants, such as the built environment.  
Nevertheless, we acknowledge several limitations. First, we could not test which domains 
of PA and SB might explain seasonality. Furthermore, we had repeated sets of measurements of 
activity for only 48 participants and each participant contributed only one week of data in each 
wave. Given their uneven participation throughout the year, this might lead to under- or over-
representation of certain traits at specific periods of the year. Therefore, some seasonal variation 
could be explained by residual confounding or selection bias. The lack of detailed information on 
the type of jobs participants engaged in and the lack of information on community-based seasonal 
activities (e.g. walking or cycling events) might also have contributed to residual confounding. 
Second, our all-cause mortality risk estimations are based on a modeled distribution of the all-
cause mortality risk and were assumed to be determined only by the seasonality of activity levels. 
Moreover, although we adjusted all our estimates by several covariates, the generalizability of our 
findings is limited to middle-aged and elderly adults with rather high BMIs and a high prevalence 
of comorbidities. Third, we used the same cut-offs to define activity intensity in middle-aged, 
young-elderly and old-elderly adults, whereas it might be argued that a particular activity would be 
experienced as vigorous by old-elderly adults but as moderate activity by middle-aged adults. 
Consequently, we might have some misclassification of activity. Finally, not all physical activities 
are captured by the device, as it depends on acceleration of the wrist to detect movement. 
Therefore, we may have not captured activities performed mostly by the legs, such as cycling, 
which is a common mode of transport in the Netherlands. 
In conclusion, middle-aged and young-elderly adults spent more time in light and 
moderate to vigorous PA in the summer than in the winter. In the summer, PA appears to 
replace nighttime sleep, especially among middle-aged adults. The small seasonal variation 
observed in SB may be explained by the large proportion of the day dedicated to SB, as this is a 
behavior strongly ingrained in the daily routine. Meteorological factors had a discrete impact on 
the seasonality of activity levels. However, on a daily basis, the meteorological factors had a strong 
association with PA and SB, especially among old-elderly individuals. The all-cause mortality risk 
would increase in winter due to the accumulation of low levels of PA and high levels of SB.  
The use of wearable devices may contribute to the design of interventions to improve PA 
and reduce SB, which are relevant targets within clinical practice to improve health. These 
interventions should be designed to attend to specific needs according to season and age. Since 
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we observed the largest seasonality in levels of light PA, recommending the interruption of SB 
with light PA might be a good starting point for public health interventions. 
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Table 4. Variation of Life Expectancy Along With Seasonal Variation of Moderate-to-Vigorous 
PA and SB, The Rotterdam Study, the Netherlands, 2011-2016 
Age group a,b 
Peak-to-nadir all-cause  
mortality risk ratio c 
Peak 
Life expectancy at 
the peak of the 
variation (years) 
Life expectancy at 
the nadir of the 
variation (years) 
Peak-to-nadir 
difference of life 
expectancy d 
(months) 
Seasonal 
variation 
95% CI 
 
(a) Variation due to both moderate-to-vigorous PA and sedentary behavior combined 
Middle-aged 1.09 0.99, 1.21 23-Feb 16.6 17.2 -8.2 
Young-elderly 1.11 1.01, 1.21 4-Feb 8.1 8.5 -4.5 
Old-elderly 1.04 0.95, 1.15 13-Sep 2.6 2.7 -1.4 
 
(b) Variation due to moderate-to-vigorous PA alone 
Middle-aged 1.08 1.04, 1.13 25-Jan 27.5 28.0 -6.3 
Young-elderly 1.06 1.02, 1.09 27-Jan 16.1 16.4 -3.7 
Old-elderly 1.02 0.99, 1.06 18-Sep 9.1 9.3 -2.4 
 
(c) Variation due to sedentary behavior alone 
Middle-aged 1.04 0.97, 1.12 27-Apr 19.2 20.0 -9.0 
Young-elderly 1.05 0.98, 1.12 13-Feb 18.7 19.3 -7.8 
Old-elderly 1.02 0.95, 1.10 8-Sep 18.6 19.0 -5.3 
CI: Confidence interval. PA: Physical activity. Bold estimates are statistically significant at 95% confidence level. a Age 
groups are: middle-aged (40-64 years), young-elderly (65-75 years) and old-elderly (≥76 years). b For middle-aged and young-
elderly, estimates are calculated at the middle of the range: 57 years and 69.5 years, respectively. For old-elderly, estimates 
are obtained at 79 years for analysis with moderate-to-vigorous PA component, and at 80 years for analysis with light-to-
moderate PA component. c Represents the risk ratio of all-cause mortality at the peak of the seasonal variation, compared 
with its nadir. d Life expectancy for Dutch population at each age categories was 24.4, 13.8 and 7.1 years, respectively, 
using mortality rates from .84 
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Figure 2. Seasonal pattern of activity levels according to age group 
 
Monthly averages of A) light physical activity; B) moderate-to-vigorous physical activity; C) Sedentary behavior; D) 
Nighttime sleep behavior. PA: Physical activity. All estimates are adjusted for cosinor terms, sex, age, body mass index, 
prevalent comorbidities (cancer, cardiovascular disease, diabetes, and chronic obstructive pulmonary disease), smoking 
behavior, housing status, occupation, alcohol intake, disability index and day of the week. Middle-aged participants 
included those aged 50-64 years, young-elderly participants included those aged 65-74 years and old-elderly included adults 
aged ≥75 years. 
 
29 | Chapter 2.1 
 
SUPPLEMENTARY MATERIAL 
 
Appendix 1. Flow chart of participant inclusion for the Rotterdam Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† The ActiWatch could not be used to measure physical activity. *The 1,166 observations included 48 participants with 
two sets of observations. ‡In wave 1, participants from the fifth follow-up visit of RS-I (RS-I-5), the third visit of RS-II (RS-
II-3), and the second visit of RS-III (RS-III-2) were invited. In wave 2, participants from the sixth follow-up visit of RS-I 
(RS-I-6) and the fourth visit of RS-II (RS-II-4) were invited.   
833 observations excluded from participants 
who did not want to participate 
306 participants declined in wave 1 
485 participants declined in wave 2 
21 participants declined in both waves 
729 observations excluded that were obtained 
with the ActiWatch†  
 
55 participants excluded due to 
malfunctioning device 
29 observations lost due to processing error 
3,156 observations 
2,427 observations 
 
2,372 observations 
2,113 observations with valid data 
230 participants without valid data:   
30 participants did not complete one week of 
wearing the device 
154 participants with invalid data i.e. not 
having 4 days with >1200 min/day 
8 participants lost their device 
38 participants for whom it is unclear why no 
valid data 
2,142 observations 
1,166 observations included in the analysis* 
947 observations excluded from participants 
considered disabled (disability index >0.5) 
3,989 observations 
 
3,507 participants invited to wear an 
accelerometer between June 2011 and June 2014 
(wave 1) and between July 2014 and May 2016 
(wave 2) ‡, of whom 482 participants were invited 
in both waves 
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Appendix 2. Covariates data collection and analysis procedures 
 
Physical activity, sedentary behavior and nighttime sleep duration calculation based on GENEActiv devices 
The GENEActiv was sampled at 50 Hz and acceleration was expressed relative to gravity (g units; 1 g =9.81 m/s2).85-87 To 
quantify acceleration related to the movement registered, we computed the high-pass filtered vector magnitude (HPFVM). 
Accelerometer data were processed in Python (2.6.6) using the open access PAMPRO software.88 Data were extracted from 
the first wearing day up to seven days later. Participants were included in the analysis if they wore the watch for >1,200 
min/day, for at least 4 days.   Activity was categorized into sedentary (<48 mg), light (48 < 154 mg), moderate (154 <389 
mg) and vigorous activity (>389 mg), based on a recent validation study.89 
 
Covariates 
Data on covariates were collected through home interviews or measured in the Rotterdam Study research center by 
trained research assistants.68 Height and weight were measured and were used to calculate body mass index (BMI; 
calculated as weight divided by height squared). History of cardiovascular disease, diabetes mellitus, chronic obstructive 
pulmonary disease (COPD) and cancer at the visit date was obtained from medical records. Smoking behavior was 
categorized as never, current or former and requested via questionnaires. Housing condition was classified as living 
independent vs. living in assisted living facilities (i.e., service flat, nursing home).  A disability index was calculated using 
the Stanford Health Assessment Questionnaire.64 Depression was screened during the home interview using the Center 
for Epidemiology Studies Depression Scale (CES-D Scale).90 Alcohol intake was obtained using the AUDIT tool.91 
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Appendix 3. Procedures for the modeling of the all-cause mortality risk and LE as function of moderate to vigorous PA 
and SB 
 
To examine the potential health impact of the seasonality of moderate to vigorous PA and SB, we modeled the all-cause 
mortality risk using risk ratios (RR) and the estimates for the 95% confidence interval (95%CI) obtained from literature. 
For moderate to vigorous PA, we extracted the RR (95%CI) of 0.72 (0.65, 0.80) from a recently published systematic 
review with meta-analysis.71 The RR expresses the all-cause mortality risk of those achieving an equivalent of 150 minutes 
of moderate-to-vigorous PA per week, compared to those not achieving this equivalent. We assumed the RR was 
equivalent to achieving 30 minute/day of moderate-to-vigorous PA,92 to be able to use our daily data.  
For SB, we used the RR (95%CI) of 1.24 (1.09, 1.41) reported in a recent review and meta-analysis.70 It 
expresses the all-cause mortality risk of people with high SB levels compared to those with low SB. Because no specific cut-
off was provided to define high SB, we used the median of the cut-offs indicated in the primary studies included in the 
review to define high versus low SB (8 hours/day). 
 
Hypothetical all-cause mortality risk due to moderate-to-vigorous PA 
For each participant, we modeled the all-cause mortality risk due to moderate-to-vigorous PA. To do so, we multiplied the 
time/day spent in moderate to vigorous PA with the natural log transformed risk ratio of the association of moderate-to-
vigorous PA with all-cause mortality, estimated by Hupin et al 71 (RR=0.72; log transformed = -0.33). Because the RR 
represents the association between accumulating 150 minutes/week of moderate-to-vigorous PA vs. less than 150 
minutes/week, we did two assumptions: 1) that the RR would be equivalent if the person accumulated 30minutes/day of 
moderate to vigorous PA, 2) that the association is linear, and the RR represents the reduction of the risk when 
accumulating 150 minutes per day, and could increase or reduce linearly and proportionally to the levels of moderate-to-
vigorous PA of the participants. To fulfill these assumptions, we first centered the moderate-to-vigorous variable at 30 
minutes/day, by subtracting 30 and then, dividing the difference by 60, to express the difference in hours. To model the 
lower and upper boundary of the 95% confidence interval (95%CI), we used the lower and upper boundary of the 95%CI 
of the risk ratio (0.65 and 0.80) 
 
Hypothetical all-cause mortality risk due to SB 
For each participant, we modeled the all-cause mortality risk due to SB. To do so, we repeated the previous process but 
using the SB variable and the natural log transformed risk ratio of the association between SB and all-cause mortality, as 
estimated by Biswas et al70 (RR=1.24; log transformed = 0.22). We modeled the 95%CI by using the lower and upper 
boundary of the 95%CI of the risk obtained risk ratio (1.09 and 1.41). The RR calculated by Biswas et al represents the 
increment of the all-cause mortality risk at high levels of SB, compared to low. They meta-analyzed the RR at the levels of 
high SB as defined by every paper included in the meta-analysis, so the definition of high SB corresponds to a range of 
categories between ≥4hours/day to ≥11 hours/day. We defined high SB at the median of the cut-offs of the studies 
included in the meta-analysis, at 8 hours/day. Therefore, for the calculation of the daily individual mortality risk due to 
SB, the time was centered at 8 hours/day. 
 
Hypothetical all-cause mortality risk due to PA and SB 
The newly generated variables of the modeled all-cause mortality risk per participant and day recorded are summed up 
between them.  
 
Example: The average middle-aged participant of the study had 99minutes/day of moderate-to-vigorous PA and 
805minutes/day of SB. The centered time of moderate-to-vigorous PA would be calculated as (99-30)/60=1.15, and for SB 
would be (805-480)/60=5.4. Therefore, the all-cause mortality risk due to moderate-to-vigorous PA would be 
ln(0.72)*1.15=-0.38, and for SB would be ln(1.24)*5.4=1.16. Therefore, the overall all-cause mortality risk would be (-
0.38)+1.16=0.78. This procedure was performed for each participant for each day contributed per participant. Also, the 
procedure was calculated using the lower and upper boundaries of the 95% confidence intervals of the RR for both 
moderate-to-vigorous PA and SB, for sensitivity analyses. 
 
Seasonality of the hypothetical all-cause mortality risk 
The seasonality of the modeled overall (PA and SB) all-cause mortality risk was calculated using the standard cosinor 
analysis. The seasonal variation (peak-to-nadir difference of the risk) was estimated in this analysis. The difference between 
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the modeled risk at the peak and at the nadir represents the seasonal variation of the modeled all-cause mortality risk. 
Because the difference is expressed in log units, the exponential of this difference represents the quotient between the risk 
at the peak and at the nadir of the variation, it means, the risk ratio for the modeled mortality risk. Therefore, a RR 
higher than one can be interpreted as the number of times the modeled all-cause mortality risk ratio increases at the peak 
compared to the nadir of the variation. Because the PA seasonal patterns were different for each age group, the seasonality 
of the modeled all-cause mortality risk was calculated stratified according to age group, the same way the seasonality of the 
activity levels was calculated. 
 
Seasonality of the life expectancy as a consequence of the hypothetical all-cause mortality risk 
To calculate how the variation of the modeled all-cause mortality risk would impact the life expectancy (LE), we created a 
hypothetical baseline scenario, using the age-specific mortality rates in the Dutch population in 2015, obtained from the 
Global Burden of Disease (GBD) data. Using these mortality rates, a standard life table was constructed.  
Then, to calculate how would be the LE at the peak of the seasonality of the hypothetical mortality risk, we 
multiplied the mortality rate of each group by the exponential of the sum of the predicted all-cause mortality risk of each 
age group plus the amplitude of the seasonal variation [mortality rate (expressed in deaths/100,000) * exp(average adjusted 
all-cause mortality risk+amplitude of the seasonality of all-cause mortality risk)]. The average adjusted all-cause mortality 
risk was obtained with the Stata postestimation command margins after fitting the cosinor model of the all-cause mortality 
risk. The amplitude corresponds to the seasonal variation divided by two. The updated mortality rates at the peak of the 
seasonality of the all-cause mortality risk provided the LE at the peak of the seasonal pattern.  
To calculate how would be the LE at the nadir of the seasonality of the hypothetical mortality risk, we 
multiplied the mortality rate of each group by the exponential of the difference between the predicted all-cause mortality 
risk of each age group (same as defined above) and the amplitude of the seasonal variation (same as defined above) 
[mortality rate (expressed in deaths/100,000)*exp(average adjusted all-cause mortality risk - amplitude of the seasonality of 
all-cause mortality risk)]. The updated mortality rates were used to calculate the LE at the nadir of the seasonal pattern. 
Finally, the difference in months of the LE was calculated as the difference between the peak and the nadir of 
the seasonal variation of the all-cause mortality risk. 
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Appendix 5. Potential seasonality of all-cause mortality risk as a function of moderate-to-vigorous PA and SB, sensitivity 
analyses 
Age group1,2 
Peak-to-nadir all-cause 
mortality risk ratio3 
Peak 
LE at the  
peak of the 
variation (years) 
LE at the  
nadir of the 
variation 
(years) 
Peak-to-nadir 
difference of 
LE4 
(months) 
Seasonal variation 95% CI 
Sensitivity analysis 1: Lower 95%CI boundary of all-cause mortality risk estimates  
(a) Variation due to both moderate-to-vigorous PA and sedentary behavior combined   
Middle-aged 1.11 1.03 1.20 4-Feb 23.3 24.1 -8.6 
Young-elderly 1.09 1.03 1.17 31-Jan 12.6 13.0 -4.9 
Old-elderly 1.04 0.97 1.11 15-Sep 6.0 6.2 -2.6 
        
(b) Variation due to moderate-to-vigorous PA alone     
Middle-aged 1.11 1.05 1.18 25-Jan 28.5 29.2 -8.2 
Young-elderly 1.07 1.02 1.12 27-Jan 16.9 17.3 -5.0 
Old-elderly 1.03 0.98 1.08 18-Sep 9.8 10.1 -3.4 
        
(c) Variation due to sedentary behavior alone     
Middle-aged 1.02 0.99 1.05 27-Apr 39.6 40.2 -6.4 
Young-elderly 1.02 0.99 1.05 13-Feb 39.4 39.8 -5.6 
Old-elderly 1.01 0.98 1.04 8-Sep 39.3 39.7 -4.4 
Sensitivity analysis 2: Upper 95%CI boundary of all-cause mortality risk estimates  
(a) Variation due to both moderate-to-vigorous PA and sedentary behavior combined   
Middle-aged 1.09 0.96 1.24 18-Mar 10.6 11.2 -7.3 
Young-elderly 1.12 1.00 1.26 8-Feb 5.1 5.5 -4.3 
Old-elderly 1.05 0.92 1.20 11-Sep 1.1 1.2 -0.7 
        
(b) Variation due to moderate-to-vigorous PA alone     
Middle-aged 1.06 1.03 1.09 25-Jan 26.5 26.8 -4.3 
Young-elderly 1.04 1.01 1.06 27-Jan 15.3 15.5 -2.4 
Old-elderly 1.01 0.99 1.04 18-Sep 8.4 8.5 -1.5 
        
(c) Variation due to sedentary behavior alone     
Middle-aged 1.07 0.96 1.19 27-Apr 9.6 10.2 -7.8 
Young-elderly 1.08 0.98 1.20 13-Feb 8.9 9.5 -7.3 
Old-elderly 1.04 0.92 1.17 8-Sep 8.8 9.1 -4.0 
Bold estimates are statistically significant. 1 Age groups are: middle-aged (40-64 years), young-elderly (65-75 years) and old-
elderly (>=76 years). 2For middle-aged and young-elderly, estimates are calculated at the middle of the range: 57 years and 
69.5 years, respectively. For old-elderly, estimates are obtained at 79 years for analysis with moderate-to-vigorous PA 
component, and at 80 years for analysis with light-to-moderate PA component. 3 Represents the risk ratio of all-cause 
mortality at the peak of the seasonal variation, compared with its nadir. 4 Life expectancy for Dutch population at each age 
categories was 24.4, 13.8 and 7.1 years, respectively, using mortality rates from. 84 CI: Confidence interval. LE: Life 
expectancy. 
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based cohort 
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ABSTRACT 
Introduction: Several studies have reported seasonal variation in intake of food groups and 
certain nutrients. However, whether this could lead to a seasonal pattern of diet quality has not 
been addressed. We aimed to describe the seasonality of diet quality, and to examine the 
contribution of the food groups included in the dietary guidelines to this seasonality. 
 
Methods: Among 9,701 middle aged and elderly participants of the Rotterdam Study, a 
prospective population-based cohort, diet was assessed using food-frequency questionnaires 
(FFQ). Diet quality was measured as adherence to the Dutch dietary guidelines and expressed in a 
diet quality score ranging from 0-14 points. The seasonality of diet quality and of the food group 
intake was examined using cosinor linear mixed models. Models were adjusted for sex, age, 
cohort, energy intake, physical activity, body mass index, comorbidities, and education.  
 
Results: Diet quality had a seasonal pattern with a winter-peak (seasonal variation=0.10 points, 
December-peak) especially among participants who were men, obese and of high socio-economic 
level. This pattern was mostly explained by the seasonal variation in the intake of legumes 
(seasonal variation=3.52 grams/day, December-peak), nuts (seasonal variation=0.78 grams/day, 
January-peak), sugar-containing beverages (seasonal variation=12.96 milliliters/day, June-peak), 
and dairy (seasonal variation=17.52 grams/day, June-peak). 
 
Conclusion: Diet quality varies seasonally with a heterogeneous seasonality of food groups 
counteractively contributing to the seasonal pattern in diet quality. This seasonality should be 
considered in future research on dietary behavior. Also, season specific recommendations and 
policies are required to improve diet quality throughout the year.  
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INTRODUCTION 
There are several approaches to study diet behavior, including the ‘nutrient approach’, ‘foods or 
food group approach’ and ‘dietary pattern approach’.93,94 The food group and nutrient 
approaches have contributed to identify specific diet components and nutrients that are relevant 
for health.95,96 However, these approaches often do not account for the high correlation between 
nutrients and food groups.94 Therefore, there is increasing interest in dietary pattern approaches 
to study dietary behavior,93,94,97 for example, using diet quality scores. 
Several factors determine the diet quality of individuals. Diet quality varies across age 
groups, sex, ethnicity,98 and socio-economic status (SES).99,100 Emerging evidence shows that diet 
is not constant throughout the year, as nutrient and food groups intake follow a seasonal 
pattern.18-21 Nevertheless, less is known about how diet quality varies throughout the year and 
how food groups interact to convey such variation. 
Understanding the seasonality of diet quality can contribute to unveil determinants 
underlying the variation between seasons of diet behavior as a lifestyle factor and the seasonality 
of diet-related morbidity and mortality 6,101. It also contributes to the ongoing debate regarding 
the factors that could be efficiently targeted to improve diet quality and to identify the role of 
specific food groups on diet quality. Therefore, we aimed to describe the seasonality of diet 
quality defined as adherence to dietary guidelines, and to examine which food groups included in 
these guidelines explain the seasonal pattern of diet quality in the population of the Rotterdam 
Study. 
 
METHODS 
Study design and participants 
This is a cross-sectional analysis based on the Rotterdam Study, a large prospective population-
based cohort initiated in 1989 including adults living in the Ommoord district in Rotterdam, the 
Netherlands. The Rotterdam Study was initially designed to examine risk factors of 
cardiovascular, neurological, respiratory, psychiatric, locomotor, ophthalmological, endocrine, 
and dermatological diseases.23 The study is composed by three sub-cohorts (RS-I: 7,893 
participants aged 55 years or above; RS-II: 3,011 participants aged over 55 years of age or who 
moved into the district; and RS-III: 3,932 participants aged 45 years and over). Study visits are 
scheduled throughout the year at participant convenience. Follow-up visits are performed every 
four to five years.23  
We selected cohort visits with available data of dietary intake using a semi-quantitative 
food frequency questionnaire (FFQ), i.e. first and fifth visits of first cohort (RS-I-1, RS-I-5), first 
and third visits of the second cohort (RS-II-1, RS-II-3), and first visit of the third cohort (RS-III-1). 
Each participant contributed with up to two visits (observations). Out of 13,008 observations 
with diet data available, we excluded those that reported unreliable data or reported daily energy 
intakes <500 kcal or ≥5,000 kcal (n=419). Consequently, our sample was 12,589 observations 
obtained from 9,701 participants (full flowchart provided in Appendix 6, page 49). 
 
Diet quality assessment 
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For visits RS-I-1 and RS-II-1, a self-administrated FFQ with 170 food items was used; a trained 
dietician identified the amounts of food intake over the past year and estimated the daily average 
intakes. This FFQ was previously validated against four 24h urinary excretion samples and fifteen 
24h dietary records, which showed adequate ability to rank participants’ food group and nutrient 
intake.102 For visits RS-I-5, RS-II-3 and RS-III-1, an extended self-administrated FFQ based on 389 
food items about the frequency and amount of consumed food items in days, weeks, and months 
according to the previous month, and was filled out at home. This FFQ was previously validated 
against a 9-day dietary record and a 4-week dietary history among two Dutch populations.103,104 To 
estimate portion sizes in grams, standardized household measures were applied.105 For calculation 
of the nutritional data, the Dutch Food Composition Table (NEVO) was used.106  
Based on the FFQ, adherence to the Dutch dietary guidelines was calculated and 
expressed in a score.107,108 This a priori dietary index is based on the Dutch dietary guidelines 
2015 for an optimal healthy diet,108,109 consisting of fifteen components: vegetables and fruit, 
whole grain products, legumes, nuts, dairy, fish, tea, coffee, unsaturated fats and oils ratio, whole 
grain ratio, red and processed meat, sugar-containing beverages, alcohol, salt, and supplement 
use.109 For the purpose of this study, we omitted coffee and supplements because no complete 
information was available.108 Adherence for each food group was predefined at specific cut-off 
values (Table 5, page 34); adherence per food group was scored as 1 and non-adherence as 0. 
Thus, total diet quality ranged from zero to fourteen points, with a higher score representing a 
higher adherence, i.e. a better diet quality.  
 
Covariates assessment 
Data collection included a standardized home interview and two visits to the research center for 
clinical examination and blood sampling. Energy intake was estimated from FFQ responses. 
Weight and height were measured with participants standing straight without wearing shoes or 
heavy clothes. Weight was measured in kilograms using an electronic floor scale and height was 
measured in centimeters with a wall-mounted stadiometer. BMI was calculated dividing weight by 
height squared (kg/m2), and was stratified into normal weight (18.5 – 25 kg/m2) and 
overweight/obesity (>25 kg/m2). Participants’ level of education, monthly household income, 
living status and smoking behavior was obtained by trained interviewers. Level of education was 
expressed in primary (primary education), low-intermediate (lower/intermediate general 
education or lower vocational education), intermediate-high (intermediate vocational education 
or higher general education) or high (higher vocational education or university). Monthly 
household income was classified as <€1,500 or ≥ €1,500. Education and income information 
were used to calculate SES; low SES was defined as low primary/low education level or income 
below <€1500, high SES was defined as intermediate/high education and income 
≥€1,500100,110,111 Living status was expressed as ‘living alone’ or ‘living with partner, relatives, or 
others’. Smoking status was expressed as ‘never smoked’, ‘ever smoked’, or ‘current smoker’. 
Prevalent comorbidities was determined by a combination of blood examinations, continuous 
digital linkage of medical records and by information of medical specialists,112-114 it was 
operationalized as “yes” if at least one of the following was present: myocardial infarction (MI), 
stroke, type 2 diabetes mellitus (T2DM), and cancer, and “no” otherwise. Physical activity at RS-I-
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3 (as a proxy for RS-I-1) and RS-II-1 was assessed using a validated version of the Zutphen Physical 
Activity Questionnaire,115 and was expressed in MET-hours/week.116 At RS-I-5 and RS-II-3, 
physical activity was assessed using the LASA Physical Activity Questionnaire (LAPAQ) and 
expressed in MET-hours/week.117 We accounted for heterogeneity between the questionnaires by 
estimating a cohort and follow-up visit specific z-score of the MET-hours/week. 
 
Statistical analyses 
Characteristics of the participants at study visit are described per season using descriptive 
statistics. Absolute values and percentages were used for categorical variables and medians and 
interquartile ranges (IQRs) for continuous variables; differences per season were tested with Chi-
Square test and Kruskal-Wallis Test, respectively. Seasons were defined according to the light 
season definition, centered at the equinoxes (winter: November 6 to February 4; spring: February 
5 to May 6; summer: May 7 to August 5; and fall: August 6 to November 5).32 
To account for potential bias associated with missing data, we imputed missing values of 
covariates using multiple imputation (n=5 imputations) by chained equations.118 Further details 
of imputation procedures are provided in Appendix 6 (page 49). 
We examined the seasonality of diet quality and daily intake (grams, milliliters or ratio 
per day) of each food group using cosinor linear mixed models.18 Date of study visit was included 
in the model transformed into its cosinor terms (i.e. sine and cosine) 101,119 with an assumed 
annual seasonality.19 The model was further adjusted for age, sex, cohort, and kilocalories/day 
(Model 1). The coefficients of the cosinor terms were used to calculate the amplitude, seasonal 
variation, and the date with highest (peak) or lowest (nadir) diet quality score.119 The amplitude is 
the distance from the annual average of diet quality to the peak or the nadir. The seasonality was 
presented as the seasonal variation, which is the maximal difference between the peak and nadir, 
i.e. 2*amplitude. Detailed descriptions to estimate the amplitude, seasonal variation, peak, and 
nadir are provided elsewhere.101,119 The variance of the seasonal variation was estimated using the 
delta method.120 
Model 2 was fitted to examine the seasonality of the diet quality after taking into account 
the non-random attendance of the participants to the study center throughout the year. The 
potential covariates were selected on the basis of literature,99,121-123 of the differences of the 
population at specific periods of the year, and the percentage of change in the amplitude. The 
final set of covariates included physical activity, BMI, smoking, prevalent comorbidities, living 
status, income and education (Model 2). 
Subsequently, we examined the seasonality of each food group included in the Dutch 
dietary guidelines. Model 1 and Model 2 were fitted for each of the fourteen food groups, using 
as outcome the continuous daily intake of each food group. The seasonality of total energy intake 
was also examined. To provide consistency and comparability, Models 1 and 2 included the same 
covariates as for the diet quality score. To examine what food groups contributed the most to the 
seasonality of diet quality, we re-calculated the seasonal variation of the diet quality score after 
excluding one food group at a time from the total score. 
Finally, we performed several subgroup analyses to test effect modification. We 
performed stratified analyses for age,124,125 sex,126 BMI,127 SES,100,110 and living status.128,129 As two 
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different types of FFQs were used to measure dietary intake, we also performed a stratified 
analysis to assess differences in seasonality of diet quality according to FFQ. Finally, to better 
characterize the population according to diet quality score, we compared participants with low 
diet quality (below one standard deviation of adjusted average diet quality score), high diet quality 
(above one standard deviation), and intermediate diet quality (in between low and high diet 
quality). For all analysis, we used Stata version 14.1 SE (StataCorp LP, College Station, Texas).72 
 
RESULTS 
Characteristics of the study population 
Overall, the study population comprised more women than men (58% vs 42%) and the median 
age was approximately 66 years (IQR: 59 – 74), most of the participants had a lower/intermediate 
education (68.9%) and median BMI was 26.5 kg/m2 (IQR: 24.3 – 29.1). Participants attending in 
autumn were about three years older than those who attended in summer, and a larger 
consumption of energy intake was observed in autumn than in summer. Participants with 
comorbidities were more likely to attend in winter than in summer (Table 6, page 44). 
 
Seasonality of diet quality and daily intake of food groups 
Diet quality had a significant seasonality with peak in December (seasonal variation=0.10, 95%-
CI: 0.01 to 0.18), indicating a higher adherence to guidelines in winter than in summer. Seasonal 
variation was observed for intake of legumes, nuts, tea, red and processed meat, salt and 
kilocalories, with a winter peak; and for sugar-containing beverages, dairy, and fish intake, with a 
summer peak (Figure 3, page 47). The largest seasonal variation was observed for legumes, with an 
intake of up to 3.5 grams/day higher in winter than in summer, which represented 39% relative 
to the average legumes intake (9.1 grams/day) (Table 7, page 45). No large seasonality was 
observed for intake of vegetables, fruits, whole grain products, whole grains ratio, unsaturated fats 
and oils ratio, or alcohol. Results were similar when using the non-imputed dataset (Appendix 7, 
page 50). 
Diet quality seasonality was reduced by 80% after excluding legumes from score, by 40% 
after excluding fruit, and by 30% after excluding nuts. In contrast, diet quality seasonality 
increased by 30% and 20% after excluding dairy and vegetables from the score, respectively 
(Table 8, page 46). 
 
Subgroup analyses 
Diet quality and more food groups had a larger seasonal variation among men, participants with 
BMI >25 kg/m2, those living with relatives/others, and participants with high SES, than among 
their respective counterparts. No large differences in seasonal pattern were observed according to 
age group or FFQ used (Appendix 8 to Appendix 13, pages 51 to 56). 
Participants with a lower overall diet quality were more likely to be men, lower educated, 
current or ever smokers, were more often having comorbidities, and living with relatives. In 
addition, participants with a lower diet quality had a lower energy intake (Appendix 14, page 57). 
 
DISCUSSION 
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In this Dutch population, diet quality had a seasonal pattern with a peak, i.e. better diet quality, 
in winter. This pattern was mostly explained by the seasonality of legumes, nuts, sugar-containing 
beverages, dairy, fruits, and vegetables intake. A larger seasonality in more food groups and a 
lower diet quality was observed among men, subjects with a higher BMI, higher SES, and those 
living with a partner or relatives, than among their respective counterparts. 
Diet quality increased in winter, mostly due to the winter peak of legumes and nuts 
intake and to the summer peak (and winter nadir) of dairy and sugar-containing beverages intake. 
The winter peak of legumes intake has been previously reported,20,130 and is likely explained by 
the preference among Dutch population to consume legume-based dishes during the winter, such 
as lentil- and split pea soup. We are not aware of comparable studies addressing the seasonality of 
nuts intake, although people could prefer them in colder months for its fat content. The summer 
peak of sugar-containing beverages intake has also been reported before 131,132, and is attributed to 
the preference for sweet refreshing beverages in summer. Probably, these are replaced in winter by 
warmer beverages, such as tea and coffee, as we and others 132 found. Finally, the summer peak of 
dairy intake is consistent with one study performed among Spanish men, but not among Finnish 
women.20,132 In our population, the pattern could be attributed to the increment of ice creams 
intake in summer. 
Interestingly, the seasonal pattern was also modified by vegetables and fruits intake, 
which did not show a significant seasonality. We hypothesize that the exclusion of vegetables 
from the score reveals the pattern of a lower diet quality, which is less stable throughout the year. 
Indeed, diet quality and vegetables intake among people who regularly eat vegetables may be less 
influenced by season because of diet consciousness. As for fruits intake, we hypothesize that those 
who do not eat fruits regularly are more likely to eat it along with other food groups with a strong 
seasonal pattern, e.g. legumes and nuts. The stable intake of vegetables and fruits throughout the 
year in our study opposes the seasonality observed in previous studies,19,20,130,131 and could be 
attributed to the constant availability of affordable vegetables and fruits in the Netherlands.133 
However, because only 50% of our population met the guidelines for vegetables and fruits 
intake,108 aiming to increase the intake of vegetables and fruits may contribute to enhance overall 
diet quality. 
Overall, a larger seasonality was observed in those food groups for which less people 
followed the intake guideline recommendations (i.e. fish, tea, nuts and legumes). For these food 
groups, intake was below the recommendations in more than 60% of the participants.108 This 
suggests that addressing the mechanisms underlying the large seasonal variation of these food 
groups could contribute to improve the adherence to guideline recommendations. 
Seasonality of alcohol intake appears also influenced by age. In contrast with previous 
studies showing a summer peak of alcohol intake among younger population,20 we did not find 
such variation in our study. Arguably, our middle-aged and elderly population would be less 
inclined to increase their alcohol intake during summer activities. 
A larger seasonality in diet quality and in more food groups was observed among men 
and among participants with high BMI than in their counterparts. The sex-differences in the 
seasonality of food groups are in agreement with previous studies18,20,131 and can be explained by a 
better diet consciousness among women.108,134 A better diet consciousness could also explain the 
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more stable diet quality of participants with lower BMI. Interestingly, participants with higher 
SES and subjects living with a partner or relatives exhibited a larger seasonality of food groups’ 
intake than their corresponding counterparts. However, this pattern appears to reflect that of 
men, as the proportion of men was higher among participants with higher SES and those living 
with a partner or relatives. The larger seasonality of food groups’ consumption among 
participants with high SES also contradicted our working hypothesis about the role of the price of 
food products on the seasonality of diet,135 which would lead to a larger seasonality in the lower 
SES-group. However, it is possible that those in the lower-SES group replace food items with 
other less expensive within the same food group, or that they purchase food items without prices 
varying seasonally. These hypotheses need to be tested in other populations with different 
distribution of SES. 
Taken together, our findings suggest that policies aimed to improve diet quality need to 
address the seasonal factors leading to a lower intake of legumes, nuts, and tea in summer and of 
fish in winter. Because the seasonality of the food groups appears to have cultural and behavioral 
mechanisms underlying, stakeholders can collaborate with markets and food producers to make 
certain food groups more attractive when the intake is anticipated to decline. For example, 
legumes intake could be promoted during summer with legume-based salads or other palatable 
recipes containing legumes. Also, fish intake could be promoted to replace red and processed 
meat, which appeared strongly ingrained in our population diet. Indeed, less than 20% of the 
participants reported an intake of red and processed meat below 300g/w, and the intake had a 
small seasonality. In contrast, fish intake had a summer-peak that coincided with the period of 
lowest intake of red and processed meat, but also with the traditionally Dutch herring season. 
Therefore, the factors underlying the summer preference for fish could be accounted for to 
increase the intake in other seasons. Finally, the summer-peak of sugar-containing beverages 
intake can be reduced by aiming to replace it by other non-sugar-containing beverages during 
summer activities. 
Several strengths of this study are worth mentioning. To our knowledge, we are the first 
to address the seasonality of diet quality and to examine the food groups that influence this 
pattern. In addition, we used validated FFQs to determine dietary intake 102,103. Furthermore, our 
study uses data from a large population-based study and is representative for the general adult and 
elderly population; and we accounted for the non-randomness of the participation over the 
season by adjusting for several covariates. However, some limitations need to be acknowledged. 
First, we used two different FFQs to assess diet quality; one asks about dietary intake in the past 
year and the other requests for the intake of the last month. However, this had a small impact in 
our findings, as these remained similar in the stratified analysis according to FFQ. Nevertheless, 
the fact that the seasonality estimates remained similar in the stratified analysis suggests that 
people are more likely to report their current diet behavior than the actual average during the last 
year.136 Therefore, researchers addressing the long-term diet behavior need to account for this 
limitation, especially in geographic areas with seasonal variation. Second, the use of the FFQ to 
measure dietary intake, instead of 24h dietary recalls or dietary records to avoid recalling bias 
could have led to an underestimation of the actual seasonality. Third, we were able to include up 
to two repeated measurements per participant, what reduced the within-subject variation of our 
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seasonality estimates. It would be valuable to conduct a similar study using dietary record 
methods with more measurements per person during different seasons to improve the 
understanding of the seasonal patterns. 
In conclusion, diet quality has a significant seasonality, with specific food groups 
counteractively contributing to this pattern. The pattern was mostly explained by the seasonality 
in intake of legumes, sugar-containing beverages, tea, dairy and nuts. Men and those with highest 
BMI had the largest seasonality of diet quality and food groups’ intake throughout the year. 
Season should be accounted for when measuring diet quality. Reducing the seasonality in the 
intake of the food groups with largest seasonality could contribute to improve the adherence to 
intake guidelines recommendations, and arguably, to improve the overall diet quality.  
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Table 5. Components of the Dutch dietary guidelines 2015 and corresponding cut-off scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Total fats: margarine, oils and butter. Healthy fats: soft margarine, oils 
 
  
Ítem Food groups Guideline 
1 Vegetables ≥200 g/d 
2 Fruit ≥200 g/d 
3 Whole grain products ≥90 g/d 
4 Legumes ≥135 g/wk 
5 Nuts ≥15 g/d 
6 Dairy ≥350 g/d 
7 Fish ≥100 g/wk 
8 Tea ≥450 ml/d 
9 Unsaturated fats and oils ratio Replace fats ≥50% of  total fats as 
healthy fats1 
10 Whole grains ratio Replace refined grains  
≥50% of total grains as whole grains 
11 Red and processed meat <300 g/wk 
12 Sugar-containing beverages <150 ml/d 
13 Alcohol ≤10 g/d 
14 Salt ≤6 g/d 
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Table 7. Seasonality of the diet quality score and of each contributing food group 
Outcome Model 
Seasonal 
variation 
** 
95%-confidence 
interval 
Mean daily 
score/ 
intake 
Seasonal 
variation in 
percentages1 
Peak Nadir 
Diet quality score (0-14) 
 
Model 1 0.12 0.03 - 0.21*     
Model 2 0.10 0.01 - 0.18* 6.72 1.49 19-Dec 19-Jun 
Kilocalories/day 
 
Model 1 45.93 17.92 - 73.95*     
Model 2 46.03 18.27 - 73.80* 2067.43 2.23 29-Nov 30-May 
Food groups        
Vegetables (g/d) 
 
Model 1 4.67 -2.19 - 11.54     
Model 2 4.81 -1.96 - 11.58 210.09 2.29 1-Sep 2-Mar 
Fruits (g/d) 
 
Model 1 6.57 -5.360 - 18.50     
Model 2 3.18 -8.63 - 14.99 284.84 1.12 3-Dec 4-Jun 
Wholegrain (g/d) 
 
Model 1 2.95 -0.37 - 6.27     
Model 2 2.95 -0.37 - 6.27 125.36 2.35 12-Feb 12-Aug 
Legumes (g/d) 
 
Model 1 3.52 2.62 - 4.42*     
Model 2 3.51 2.61 - 4.41* 9.09 38.61 30-Dec 30-Jun 
Nuts (g/d) 
 
Model 1 0.82 0.20 - 1.45*     
Model 2 0.78 0.16 - 1.41* 8.25 9.45 25-Jan 26-Jul 
Dairy (g/d) 
 
Model 1 16.95 5.03 - 28.87*     
Model 2 17.52 5.60 - 29.44* 365.65 4.79 17-Jun 16-Dec 
Fish (g/d) 
 
Model 1 1.45 0.57 - 2.33*     
Model 2 1.52 0.64 - 2.40* 14.82 10.26 1-Jun 30-Nov 
Tea (mL/d) 
 
Model 1 21.48 9.21 - 33.76*     
Model 2 19.82 7.65 - 32.00* 288.42 6.87 9-Feb 9-Aug 
Whole grains ratio 
 
Model 1 0.59 -0.66 - 1.83     
Model 2 0.50 -0.75 - 1.75 68.54 0.73 10-Oct 10-Apr 
Unsaturated fats and oils ratio 
 
Model 1 0.45 -1.00 - 1.91     
Model 2 0.32 -1.16 - 1.79 52.41 0.61 19-Feb 19-Aug 
Red and processed meat (g/d) 
 
Model 1 2.11 -0.26 - 4.47     
Model 2 2.43 0.11 - 4.75* 89.70 2.71 4-Nov 6-May 
Sugar-containing beverages 
(mL/d) 
 
Model 1 13.01 7.22 - 18.80*     
Model 2 12.96 7.16 - 18.77* 75.52 17.16 1-Jun 1-Dec 
Alcohol (g/d) 
 
Model 1 0.41 -0.25 - 1.07     
Model 2 0.34 -0.31 - 0.99 11.47 2.96 16-Jun 16-Dec 
Salt (mg/d) 
 
Model 1 84.87 18.37 - 151.38*     
Model 2 80.70 14.50 - 146.90* 5658.87 1.43 5-Feb 5-Aug 
Model1 includes cosinor terms, sex, age, cohort and energy intake 
Model 2 additionally adjusted for physical activity, smoking behaviour, body mass index, prevalent diseases (stroke, 
myocardial infarction, diabetes mellitus type 2, and cancer), and education. ** Seasonal variation = maximum difference 
between the highest annual average (peak) and lowest annual average (nadir). * Statistically significant 1 Seasonal variation 
in percentages (seasonal variation/mean daily score or intake*100%) 
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Table 8. Seasonal variation of diet quality score excluding one food group at a time 
Outcome 
Seasonal variation 
** 
95%-confidence 
interval 
%1 
Diet quality score 0.10 0.01 - 0.18*  
Diet quality score excluding    
 vegetables 0.12 0.04 – 0.20* +20 
 fruit 0.06 -0.02 – 0.13 -40 
 wholegrain products 0.10 0.02 – 0.18* 0 
 legumes 0.02 -0.06 – 0.10 -80 
 nuts 0.07 -0.01 – 0.16 -30 
 dairy 0.13 0.05 – 0.21* +30 
 fish 0.11 0.03 – 0.19* +10 
 tea 0.08 -0.00 – 0.17 -20 
 wholegrains ratio 0.09 0.01 – 0.17* -10 
 unsaturated fats and oils ratio 0.10 0.02 – 0.18* 0 
 red and processed meat 0.11 0.03 – 0.20* +10 
 sugar-containing beverages 0.07 -0.01 – 0.15 -30 
 alcohol 0.09 0.01 – 0.17* -10 
 salt 0.11 0.03 – 1.19* +10 
Estimates are adjusted for cosinor terms, sex, age, cohort, energy intake, physical activity, smoking behaviour, body mass 
index, prevalent diseases (stroke, myocardial infarction, diabetes mellitus type 2, and cancer), and education. ** Seasonal 
variation = maximum difference between the highest annual average (peak) and lowest annual average (nadir)  
* Statistically significant. 1 Percentage reduction or increment of the seasonal variation by excluding food groups, 
compared to the total diet score (SV - 0.10/(0.10*100%)). 
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Figure 3 (a – p). Seasonal variation of diet quality and food groups  
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Graphical representation of the seasonal variation of the diet quality score and food groups intake. The gray area 
represents the 95% confidence interval around the pattern. Estimates are adjusted for cosinor terms, age, sex, cohort, 
(kilocalories), physical activity, smoking behavior, BMI, diseases and education. 
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SUPPLEMENTARY MATERIAL 
Appendix 6. Flowchart of sample size selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imputation procedures: Sequential multiple imputation using chained equations was performed to impute missing values 
only of covariates. The predictors used to impute the covariates were age, sex, cohort, standardized MET hours/week, 
smoking behavior, BMI, education, diet quality score. We performed the imputation stratified per number of visits, in 
order to use the data from other visits for those participants with more than one visit. For ordered categorical variables 
(education) we used an ordered logit function. For categorical non-ordered variables (smoking behavior) we used 
multinomial logit function. For BMI and physical activity, we used linear functions. To ensure reproducibility, we used a 
random seed (2005). We created five imputed datasets. Covariates with missing values were: education: 111missing, 
smoking behavior: 53missing, BMI: 192missing, physical activity: 2177missing. Imputations were performed using the mi 
impute command of Stata software. 
 
  
18,966 observations 
15,226 observations 
13,008 observations 
12,589 observations 
Participant did not attend the study center; n=3,740 
observations 
Pilot phase of the RS; n= 271,  
suspected of suffering dementia; n = 122,  
logistic reasons; n = 481, 
the participant did not return the questionnaire; n 
= 1,344  
Unreliable data or reported daily energy intakes 
<500 kcal or ≥5000 kcal; n = 419 observations 
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Appendix 7. Seasonal variation of diet quality score and of contributing food group, based on non-imputed dataset. 
Outcome Model 
Seasonal 
variation 
** 
95%-confidence 
interval 
Peak Nadir Observations 
Diet quality score (0-14) 
 
Model 1 0.12 0.03 – 0.21* 14-Dec 14-Jun 12,589 
Model 2 0.15 0.06 – 0.25* 14-Dec 14-Jun 10,173 
Kilocalories/day 
 
Model 1 45.93 17.92 – 73.95* 20-Nov 22-May 12,589 
Model 2 43.58 13.08 – 74.07* 12-Dec 12-Jun 10,173 
Food groups       
Vegetables (g/d) 
 
Model 1 4.67 -2.19 – 11.54 13-Sep 14-Mar 12,589 
Model 2 6.46 -1.23 – 14.15 30-Sep 31-Mar 10,173 
Fruits (g/d) 
 
Model 1 6.57 -5.36 – 18.50 2-Dec 3-Jun 12,589 
Model 2 1.54 -12.08 – 15.16 27-Nov 28-May 10,173 
Wholegrain (g/d) 
 
Model 1 2.95 -0.37 – 6.27 7-Feb 8-Aug 12,589 
Model 2 3.51 -0.17 – 7.19 2-Mar 31-Aug 10,173 
Legumes (g/d) 
 
Model 1 3.52 2.62 – 4.42* 29-Dec 29-Jun 12,589 
Model 2 4.01 2.95 – 5.07* 26-Dec 26-Jun 10,173 
Nuts (g/d) 
 
Model 1 0.82 0.20 – 1.45* 25-Jan 25-Jul 12,589 
Model 2 1.11 0.40 – 1.81* 11-Jan 12-Jul 10,173 
Dairy (g/d) 
 
Model 1 16.95 5.03 – 28.87* 15-Jun 15-Dec 12,589 
Model 2 16.67 3.58 – 29.75* 12-Jun 11-Dec 10,173 
Fish (g/d) 
 
Model 1 1.45 0.57 – 2.33* 2-Jun 2-Dec 12,589 
Model 2 1.23 0.25 – 2.22* 10-Jun 9-Dec 10,173 
Tea (mL/d) 
 
Model 1 21.48 9.21 – 33.76* 6-Feb 6-Aug 12,589 
Model 2 19.65 6.05 – 33.25* 7-Feb 7-Aug 10,173 
Whole grains ratio 
 
Model 1 0.59 -0.66 – 1.83 13-Oct 13-Apr 12,589 
Model 2 0.40 -0.90 – 1.69 25-Jan 25-Jul 10,173 
Unsaturated fats and oils ratio 
 
Model 1 0.45 -1.00 – 1.91 19-Jan 20-Jul 12,589 
Model 2 0.81 -0.82 – 2.45 28-Nov 29-May 10,173 
Red and processed meat (g/d) 
 
Model 1 2.11 -0.26 – 4.47 31-Oct 1-May 12,589 
Model 2 1.93 -0.65 – 4.50 28-Oct 29-Apr 10,173 
Sugar-containing beverages (mL/d) 
 
Model 1 13.01 7.22 – 18.80 2-Jun 2-Dec 12,589 
Model 2 12.14 5.56 – 18.73 1-Jun 1-Dec 10,173 
Alcohol (g/d) 
 
Model 1 0.41 -0.25 – 1.07 4-Jun 4-Dec 12,589 
Model 2 0.71 -0.02 – 1.44 1-Jun 1-Dec 10,173 
Salt (mg/d) 
 
Model 1 84.87 18.37 – 151.28* 4-Feb 5-Aug 12,589 
Model 2 93.17 19.20 – 167.15* 15-Jan 15-Jul 10,173 
Model1 includes cosinor terms, sex, age, cohort and energy intake 
Model 2 additionally adjusted for physical activity, smoking behaviour, body mass index, prevalent diseases (stroke, 
myocardial infarction, diabetes mellitus type 2, and cancer), and education.  ** Seasonal variation = maximum difference 
between the highest annual average (peak) and lowest annual average (nadir). * Statistically significant  
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Appendix 13. Stratified analyses: Seasonal variation of diet quality according to FFQ 
Outcome 
Seasonal 
variation* 
95%-confidence interval Peak Nadir 
FFQ 170 items, n= 8,572.observations 
Diet quality score  (0-14) 0.10 -0.01 - 0.20 2-Jan 3-Jul 
FFQ 389 items, n= 4,017 observations 
Diet quality score (0-14) 0.13 -0.02 - 0.29 17-Dec 18-Jun 
 
FFQ = Food Frequency Questionnaire. * Seasonal variation expresses the maximum difference between the average 
highest intake/score (peak) and average lowest intake/score (nadir). Seasonal variation adjusted for cosinor terms, age, sex, 
cohort, physical activity, smoking behaviour, body mass index, comorbidities, education, and kilocalories/day.  
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Appendix 14. Characteristics of the study population stratified by participants with a lower, intermediate, and higher diet 
quality score 
Covariate 
Diet score below 1SD of 
average* (<6.145) 
n=2,071 
Diet score between -1 SD 
and + 1 SD of average* 
n=8,549 
Diet score above 1SD of 
average* (>7.302) 
n=1,969 
Median (IQR) Median (IQR) Median (IQR) 
Age (years) 65.9 (59.7 -  71.9) 66.8 (59.8 - 73.9) 63.4 (57.3 - 75.12) 
Physical activity (MET-
hours per week) 
43.0 (21 - 70.5) 62.4 (30.3 - 95.1) 85.3 (47.4 – 128.0) 
BMI, kg/m2 27.0 (24.7 - 29.6) 26.6 (24.4 - 29.3) 25.2 (23.2 - 27.6) 
Kilocalories/day 1942 (1589 – 2312) 1946 (1612 – 2336) 2264 (1934 – 2721) 
 n % n % n % 
Sex 
     men 
     women 
 
1,767 
304 
 
85.3 
14.7 
 
3,414 
5,135 
 
39.9 
60.1 
 
125 
1,844 
 
6.4 
93.6 
Education 
     primary 
     lower 
     intermediate  
     higher 
 
276 
854 
748 
178 
 
13.4 
41.5 
36.4 
8.7 
 
1,227 
3,640 
2,363 
1,236 
 
14.5 
43.0 
27.9 
14.6 
 
192 
695 
515 
554 
 
9.8 
35.5 
26.4 
28.3 
Smoking status 
     never 
     ever  
     current 
 
84 
626 
1,359 
 
4.0 
30.3 
65.7 
 
2,671 
4,594 
1,246 
 
31.4 
54.0 
14.6 
 
1,276 
659 
21 
 
65.2 
98.7 
1.1 
Comorbidities  
     no 
     yes 
 
1,566 
505 
 
75.6 
24.4 
 
7,089 
1,460 
 
82.9 
17.1 
 
1,779 
190 
 
90.4 
9.6 
Socioeconomic status  
     lower  
     higher 
 
1,438 
633 
 
69.4 
30.6 
 
6,213 
2,336 
 
72.7 
27.3 
 
1,286 
683 
 
65.3 
34.7 
Living status 
     alone  
     with others 
 
389 
1,682 
 
18.8 
81.2 
 
2,285 
6,264 
 
26.7 
73.3 
 
687 
1,282 
 
34.9 
65.1 
BMI = Body mass index.  IQR = Interquartile range. MET = Metabolic Equivalent of Task. SD = Standard deviation. 
*Predicted average of diet score after adjusted for covariates of Model 2. 
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2.2 Seasonality of health outcomes 
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2.2.1 Influence of lifestyle markers and meteorological factors on the seasonality of 
cardiovascular risk factors: The Rotterdam Study 
 
Magda Cepeda, Josje D. Schoufour, Nicole Erler, Pedro Marques-Vidal, Oscar H. Franco 
 
ABSTRACT 
Introduction: The seasonality of multiple cardiovascular risk factors (CVRF), with peak in 
winter, has been widely described. Nevertheless, it remains unclear the mechanisms underlying 
this variation and if it differs according to age. We examined if lifestyle markers (body mass index 
(BMI) and physical activity) or meteorological factors (daily average of ambient and apparent 
temperature and total sunlight hours and precipitation) explained the seasonality of seven CVRF, 
according to age group [middle-aged (<65 years) vs elderly (≥65 years)]. CVRF were hemodynamic 
(systolic and diastolic blood pressure), metabolic (glucose, total-, high-density, and low-density 
lipoprotein cholesterol), and anthropometric (waist-to-hip ratio). 
 
Methods: Seasonality estimates were obtained using cosinor analysis based on data from a 
prospective population-based Dutch cohort. We analyzed 20,723 observations from 10,405 
participants (57% woman, mean age 68 years) obtained between 1997 and 2014. Meteorological 
factors were obtained from local records, BMI was measured, and physical activity was 
questionnaire-based. Additionally, we estimated the population attributable fraction (PAF) to 
lifestyle markers and meteorological factors for the prevalence of selected CVRF (i.e. high blood 
pressure, high glucose levels, high LDL-cholesterol and high/very high cardiovascular mortality 
risk according to SCORE charts).  
 
Results: CVRF had peak values in winter and autumn in both age groups. Among middle-aged, 
meteorological factors explained the seasonality of systolic and diastolic blood pressure, total-, and 
HDL-cholesterol. Among elderly, meteorological factors explained the seasonality of all CVRF. 
Lifestyle markers explained a modest part of the seasonality of CVRF in both age groups. The 
PAF to ambient temperature for the prevalence of selected CVRF was higher in winter than in 
summer (up to 27.7 percentage points among middle-aged and up to 9.1 percentage points 
among elderly). In contrast, the PAF to lifestyle markers was constant across seasons. The main 
limitation of our analysis is that meteorological factors are local measures which may not reflect 
the exposure of participants. 
 
Conclusions: Our findings suggest that ambient temperature explains most of the seasonality of 
the CVRF, especially among elderly. This provides a plausible mechanism for the winter increase 
of cardiovascular mortality and health risks associated to meteorological factors within climate 
change. 
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INTRODUCTION 
Seasonality of cardiovascular risk factors (CVRF) has been widely described.5,28-33 Compared to 
summer, a higher systolic (SBP), diastolic (DBP) blood pressure, and glucose levels and a more 
unfavorable lipid profile have been reported in winter.5,28-33 Several factors can explain the 
seasonality of CVRF. For example, most CVRF are associated with lifestyle markers, such as 
physical activity and body mass index (BMI), which have been reported to have a seasonal 
pattern.17,34 Also, some CVRF have been associated with meteorological factors, like ambient 
temperature, precipitation and sunlight hours;7-15 thus, the prevailing adverse meteorological 
conditions in winter could explain the increase of cardiovascular risk in this season.  
However, it remains unclear if meteorological factors, lifestyle markers, or both, explain 
the seasonality of the CVRF. Moreover, it has not been addressed whether the impact of lifestyle 
markers and meteorological factors in the seasonality of CVRF differs according to age. Age-
related differences are expected as physical activity and dietary patterns change with age,59,137 as 
well as thermoregulation response.138 Understanding the mechanisms underlying the seasonality 
of CVRF is of relevance to identify interventions that are most likely to impact this phenomenon, 
also in preparation for the projected effects of climate change in global health. 
In this study, we examined the role of lifestyle markers and meteorological factors on the 
seasonality of seven CVRF: (hemodynamic (SBP and DBP), metabolic (serum levels of total, high-
density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and glucose), and 
anthropometric (waist-to-hip ratio (WHR)), stratified by age (middle-aged (<65 years) vs elderly 
(≥65 years)). We also calculated the population attributable fraction (PAF) to lifestyle markers and 
meteorological factors for the seasonal prevalence of cardiovascular risk.  
 
METHODS 
Study population and selection criteria 
The Rotterdam Study is a population-based prospective cohort initiated in 1989 by inviting all 
elderly people living in the Ommoord district in Rotterdam, the Netherlands.23 The study is 
composed by three cohorts (RS-I: 7,893 participants aged 55 years or above; RS-II: 3,011 
participants aged over 55 years of age or who moved into the district; and RS-III: 3,932 
participants aged 45-54 years). Follow-up visits are performed approximately every 3-4 years. For 
this study, we included the visits third to fifth of RS-I, first to third of RS-II and, first to second of 
RS-III; each visit corresponds to an observation. We excluded the first and second visit of RS-I for 
consistency in measurement procedures. From 24,954 observations (11,939 participants) we 
excluded 4,231 (1,534 participants) with missing data on CVRF of interest (Appendix 15, page 
73).  
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). 
All participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians. 
 
Assessment of cardiovascular risk factors 
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Data collection included a standardized home interview and two visits to the research center for 
clinical examination and blood sampling. Hemodynamic CVRF were SBP and DBP (mm Hg), 
corresponding to the average of two measurements obtained after a resting period of 5 minutes. 
Metabolic CVRF were total-, HDL-, LDL-cholesterol, and glucose (mmol/L), obtained from 
fasting blood drawn during the examination at the research center. Anthropometric CVRF was 
WHR, which was calculated as waist circumference divided by hip circumference. The SCORE 
risk was calculated according to the SCORE (Systematic COronary Risk Evaluation) charts for 
low-risk countries were used to define high or very high 10-year risk of fatal cardiovascular 
events.139 Details on measurement procedures are provided in Appendix 16 (page 74).  
 
Assessment of lifestyle markers 
BMI (kg/m2) was calculated as weight divided by height squared. Height and weight were 
measured with the participants standing without shoes and heavy outer garments, and with 
emptied out pockets, breathing out gently. Physical activity was assessed using a validated adapted 
version of the Zutphen Physical Activity Questionnaire 140 on RS-I-3 and RS-II-1, and the LASA 
Physical Activity Questionnaire (LAPAQ) on RS-I-5, RS-II-3 and RS-II-2.117 Physical activity is 
expressed in MET-hours/week.116 Details on questionnaires are provided on Appendix 16, page 
74. To account for the heterogeneity between the questionnaires, we estimated a z-score per 
follow-up visit and cohort. Because physical activity was not measured for RS-I-4 and RS-II-2, we 
estimated for each participant the best-linear unbiased prediction using a mixed model with the 
observed zMET-hours/week as outcome, adjusted for age, sex, date of visit, date squared, cohort, 
systolic and diastolic blood pressure, glucose, BMI and WHR, and using the individual id as 
clustering variable. 
 
Assessment of meteorological factors 
Mean ambient temperature (˚C), relative humidity (%), accumulated precipitation (mm) and 
total sunlight hours in Rotterdam, at participants’ blood sampling date and the six days before, 
were obtained from the Koninklijk Nederlands Meteorologisch Instituut (KNMI, Royal Dutch 
Meteorological Institute).67 The monitor is located approximately at 8km from Ommoord district 
(coordinates: 51° 58' N. 04° 27' E). Apparent temperature (˚C) was calculated using the formula: 
−2.653 + 0.994𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 + 0.00153𝐷𝑒𝑤𝑃𝑜𝑖𝑛𝑡2,141 where 𝐷𝑒𝑤𝑃𝑜𝑖𝑛𝑡 =
(
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 ℎ𝑢𝑚𝑖𝑑𝑖𝑡𝑦(%)
100
)
1
8⁄
∗ (112 + 0.9𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒) + 0.1𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 − 112. Visit and 
blood sampling dates were classified in seasons according to the light definition, centered at 
equinoxes (winter: November 6 to February 4, spring: February 5 to May 6, summer: May 7 to 
August 5, autumn: August 6 to November 5).32  
 
Statistical analysis 
All analyses were stratified by age at visit date: middle-aged (<65 years) vs. elderly (≥65 years). This 
corresponds to the age of retirement in The Netherlands; retirement explains part of the age-
related variation of physical activity.142-144 General characteristics at the visit date are presented 
using descriptive statistics. Categorical variables are described in absolute frequencies and 
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percentages. Continuous variables are described as median and interquartile range (25th and 75th 
percentile). Differences in the distribution of general characteristics according to age group were 
tested with Chi2-test for categorical and Mann Whitney U-test for continuous variables. 
To account for potential bias associated with missing data, we used multiple imputation 
procedures (n=5 imputations) to impute missing values of covariates. We applied sequential 
multiple imputation using chained equations with outcomes and covariates as predictors (a full 
description of the imputation procedure is provided in Appendix 16 (page 74)). General 
characteristics of the population according to age-group and season on the imputed dataset are 
presented using descriptive statistics. Categorical variables were described with absolute frequency 
and percentage; the distribution was compared using Chi-squared test. Continuous variables were 
described with median and interquartile range (25th and 75th percentile); the distribution was 
compared using the Kruskal-Wallis test. For all analyses, we used Stata version 14.1 SE 
(StataCorp, College Station, Texas, USA).72 
First, CVRF seasonality was examined using linear mixed models, to account for 
repeated measurements per participant. Glucose seasonality was modelled using generalized linear 
mixed model with a log link, due to its skewed distribution. CVRF were assumed to have a 
sinusoidal seasonality with a period of one-year 5 and, accordingly, a crude model was fitted with 
the cosinor terms of visit or blood sampling date.69 A model 1 was fitted with covariates: sex; age 
(years); self-reported use of antihypertensive, statin or anti-diabetic medication; self-reported 
smoking behavior (never, current, former); living situation [community-dweller vs. other (i.e., 
service flat, nursing home)]; monthly household income at baseline visit, categorized as <1,700 
(<1,890), ≥1,700 to <3,000 (≥1,890 to <3,336), ≥3,000 to <4200 (≥3,336 to <4,670) and ≥4200 € 
(≥4,670 U.S. dollars); cohort; and date and date squared to account for long-term patterns. All 
covariates, except income, were obtained at visit date. Confounders were chosen on the basis of 
literature and model fit, according to the lowest Akaike’s information criterion (AIC) value. 
CVRF seasonality was reported as the seasonal variation, which corresponds to the distance 
between peak and nadir levels throughout the annual period. Procedures to estimate the seasonal 
variation and standard error are described elsewhere.17,69  
To examine the influence of lifestyle markers and meteorological factors on the 
seasonality of CVRF, we first fitted a Lifestyle markers model, by adding BMI (kg/m2) and 
physical activity (z-score of MET-hours/week) in the model 1 (these were included as cubic splines 
with 2 degrees-of-freedom), and then we fitted a set of Meteorological factor models, by adding to 
model 1 the meteorological factors at the visit date and six previous days. To account for changes 
in the strength of the association at increasing lagged days, we applied one constraint between day 
0 and day lag 1 and another between day lag 2 to 6. The influence of either lifestyle markers and 
meteorological factors on the seasonality of the CVRF was operationalized as the relative 
difference of the seasonal variation, which was calculated as 
(𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛𝑀𝑜𝑑𝑒𝑙 2 𝑜𝑟 3 − 𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛𝑀𝑜𝑑𝑒𝑙 1) 𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛𝑀𝑜𝑑𝑒𝑙 1⁄  
Finally, we examined the proportion of the seasonal prevalence of selected CVRF that 
could be attributed to the lifestyle markers and the meteorological factors. First, selected CVRF 
(blood pressure, LDL cholesterol, glucose) and the SCORE risk calculated for each participant 
were dichotomized, i.e. high-very high SCORE (≥5%), high blood pressure (SBP ≥140 and/or 
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DBP ≥90mm Hg), high LDL cholesterol (≥1.8, ≥2.6 and ≥3.0 mmol/L for participants with very 
high (≥10%), high (≥5%), and low to moderate (<5%) SCORE risk), and high glucose 
levels(fasting glucose ≥7.0 mmol/L).145 Then, we fitted fully adjusted Poisson mixed models to 
calculate the relative risk of the association of lifestyle markers (BMI and physical activity) and 
each meteorological factor (first and second constraint) with these dichotomized outcomes. Each 
exposure was included in the model stratified into its deciles. Then, we calculated the PAF per 
season of each exposure using the formula 𝑃𝐴𝐹𝑠𝑒𝑎𝑠𝑜𝑛 = 1 − ∑
𝑝𝑑𝑖
𝑅𝑅𝑖
𝑘
𝑖=0  
146, where 𝑝𝑑𝑖  corresponds 
to the proportion of cases that fall within each exposure category per season and 𝑅𝑅𝑖 corresponds 
to the relative risks obtained from the Poisson model. Finally, to calculate the combined PAF of 
the lifestyle markers, according to season, we used the formula 𝑃𝐴𝐹𝑙𝑖𝑓𝑒𝑠𝑡𝑦𝑙𝑒𝑠𝑒𝑎𝑠𝑜𝑛 = 1 −
(1 − 𝑃𝐴𝐹𝐵𝑀𝐼𝑠𝑒𝑎𝑠𝑜𝑛=𝑖) ∗ (1 − 𝑃𝐴𝐹𝑝ℎ𝑦𝑠𝑖𝑐𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑠𝑒𝑎𝑠𝑜𝑛). The same formula was used to combine 
the PAF of the first and second constraint of each meteorological factor. 95% confidence 
intervals were calculated with the delta method, using the command nlcom from Stata. 
 
RESULTS 
General characteristics 
We included 20,723 observations belonging to 10,405 participants. Overall, elderly participants 
(aged 65 years and over) were more frequently former smokers, reported more often the use of 
antihypertensive, antidiabetic and statins medication, and were less frequently community-dweller 
(Table 9, page 68). No large differences were observed in the distribution of population 
characteristics according to season (Appendix 17, page 75). The seasonal patterns of the CVRF 
are shown in Figure 4, page 71. Seasonal patterns of meteorological factors and lifestyle markers 
are shown in Appendix 18 and Appendix 19 (pages 76 and 77). 
 
Effect of lifestyle markers and meteorological factors on cardiovascular risk factors 
SBP and DBP showed a clear seasonal variation with a peak in early-January (SBP=4.61mmHg 
(95%CI 3.69, 5.52)/4.17 mmHg (3.24, 5.11) and DBP=2.91 mmHg (2.38, 3.45) /1.69 mmHg 
(1.18, 2.20) among middle-aged and elderly participants, respectively; Table 10 (page 69)). The 
amplitude was mainly explained by ambient and apparent temperature.  
Total cholesterol had a larger seasonal variation among middle-aged (0.11mmol/L 
(95%CI=0.06, 0.16) than among elderly adults (0.04mmol/L (0.00, 0.07)). Precipitation 
explained part of the pattern in both groups. Sunlight hours also explained the pattern among 
the middle-aged. LDL-cholesterol had a larger seasonality among the middle-aged (0.10mmol/L 
(0.05, 0.15)) than among the elderly (0.05mmol/L (0.00, 0.10)). The pattern was partly explained 
by ambient and apparent temperature among the elderly. The seasonal variation of HDL-
cholesterol was not significant in any age group. 
Glucose levels were higher in mid-Spring among the middle-aged (0.01mmol/L (0.00-
0.02)). The variation was partly explained by lifestyle markers. Among elderly participants, peak 
levels of glucose were observed in early-December (0.01mmol/L (0.00-0.02)), and the pattern was 
mostly explained by ambient temperature, followed by lifestyle markers and apparent 
temperature. 
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WHR seasonality was similar in both age groups, with values around 0.01 higher in 
summer than in winter. Ambient and apparent temperature and sunlight hours explained the 
pattern among elderly participants. All estimates were similar in the non-imputed analysis 
(Appendix 20, page 78). 
Analyses according to sex were similar for most CVRF. Nevertheless, there were 
differences in LDL-cholesterol, which seasonality among elderly was not explained by ambient or 
apparent temperature; HDL-cholesterol, which seasonality was explained by lifestyle markers 
among elderly men and by ambient temperature among middle-aged men; and glucose, which 
seasonality was not explained by ambient temperature among elderly men neither lifestyle 
markers among middle-aged women and elderly men (Appendix 22, page 80).  
 
Population attributable fraction to lifestyle markers and meteorological factors of the seasonal prevalence of 
selected CVRF 
The PAF to ambient and apparent temperature was higher in winter than in summer between 2.4 
and 27.7 percentage points (pp) among middle-aged and up to 9.1pp among elderly, for the 
seasonal prevalence of the selected CVRF. In contrast, the PAF to lifestyle markers was consistent 
across seasons. The PAF to ambient temperature was higher than that of lifestyle markers for the 
winter prevalence of high blood pressure (middle-aged=6.1pp, elderly=11.7pp), high HDL-
cholesterol (middle-aged=1.6pp, elderly=7.8pp), and high/very high SCORE risk (middle-aged = 
13.8pp, elderly = 14pp). No lifestyle or meteorological factor had a significant PAF to the seasonal 
prevalence of high LDL-cholesterol (Figure 5, page 72). Procedures and PAF estimations are 
provided in the Appendix 23 (page 82). 
 
DISCUSSION 
In this cohort of middle-aged and elderly participants, CVRF had a seasonal variation and most 
CVRF had peak values towards winter/autumn. Lifestyle markers explained a modest proportion 
of the seasonality of glucose in both age groups and of DBP among the elderly. Among middle-
aged participants, ambient and apparent temperature explained the seasonality of SBP and DBP. 
Among the elderly, ambient and apparent temperature explained the seasonality of SBP, DBP, 
glucose, LDL-cholesterol, and WHR. The PAF to meteorological factors, especially ambient and 
apparent temperature, for the seasonal prevalence of the selected CVRF and of high/very high 
SCORE risk was higher in winter. Additionally, PAF to lifestyle markers was constant throughout 
the year. Our findings suggest that exposure to low ambient and apparent temperature explains 
most of the seasonality of the CVRF, especially among elderly, and provides a plausible 
mechanism for the winter increase of cardiovascular mortality. 
The seasonality of SBP and DBP was explained by ambient and apparent temperature in 
both age groups. Ambient and apparent temperature have been associated with blood pressure 
through endothelium-dependent mechanisms and sympathetic activation.7,9,147,148 In contrast, the 
seasonality of glucose, LDL-cholesterol, and WHR was explained by ambient and apparent 
temperature only among the elderly. Previous studies have reported a negative association 
between exposure to low ambien temperature and glucose 149 and LDL-cholesterol levels.13 These 
findings can be attributed to the seasonal variation of insulin resistance 150 and the increase of 
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insulin resistance and energy expenditure under exposure to low ambient temperature.151 It has 
been also suggested that glucose, WHR, and lipid profile can be modified through the activation 
of brown adipose tissue under exposure to low ambient temperature,152,153 although our findings 
do not support this hypothesis, probably because our population is older and have more 
comorbidities than in previous evidence. The specific influence of ambient and apparent 
temperature among elderly but not among middle-aged participants suggests that elderly are more 
sensitive to the exposure to low ambient and apparent temperature, probably due to the age-
related impairment of thermoregulation mechanisms.138 
HDL- and total-cholesterol seasonality was partly explained by sunlight hours and 
precipitation. Precipitation may explain the seasonality of total-cholesterol by modifying the air 
moisture,12,154-156 which may induce changes in plasma volume and hemodilution, with a 
consequent apparent reduction of cholesterol levels.32 Sunlight exposure may influence total-
cholesterol seasonality through vitamin D levels.157 
We found a discrete influence of lifestyle markers in the seasonality of CVRF, as BMI 
and physical activity only explained part of the seasonality of DBP and total cholesterol. It is 
possible that the seasonality of lifestyle markers is not large enough to have a major influence on 
the other CVRF. For example, it has been shown that the seasonality of physical activity is not 
large enough to induce changes in physical fitness 76 that would link the seasonality of physical 
activity with the seasonality of blood pressure.158 Additionally, our study population would be less 
likely to change their lifestyle behavior on a seasonal basis, because we included overall 
population taking statins. Indeed, we observed in our sensitivity analysis according to sex that the 
seasonality of lifestyle markers was larger among men than among women, thus lifestyle markers 
were more likely to explain the seasonality of SBP, DBP, HDL-cholesterol, and glucose among 
men than among women. The influence of lifestyle markers in the seasonality of DBP among 
elderly and of glucose in both age groups suggests that these CVRF may be more senstive to the 
even small seasonal variation of the lifestyle markers. 
We additionally examined the proportion of CVRF prevalence that can be attributed to 
high BMI and low physical activity or to adverse climatic conditions, per season. In agreement 
with our previous findings, the proportion of CVRF prevalence that can be attributed to 
exposure to low ambient temperature was larger in winter, suggesting that the increase of CVRF 
prevalence in winter can be attributed to low ambient and apparent temperature. In contrast, 
whereas a substantial proportion of the CVRF prevalence was attibutable to high BMI and low 
physical activity, this proportion was constant across seasons. A counterintuitive finding was the 
higher PAF to both lifestyle markers and meteorological factors among middle-aged than among 
elderly. However, this finding can be explained by the higher prevalence of participants taking 
medication (antihypertensive, antidiabetic and statins) among the elderly population, what may 
have contributed to counter the influence of lifestyle markers and meteorological factors. 
Nevertheless, these findings suggest that the achievement of therapeutic targets may be lower and 
the prevalence of CVRF may increase in winter time, mostly due to the adverse climatic 
conditions of the season. 
Our findings have several relevant implications, both for clinical and public health 
perspectives. From the clinical perspective, it is likely that the accumulation of peak levels of most 
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CVRF in winter time has effects on the well-stablished seasonality of cardiovascular mortality,6 
and people would benefit of accounting for exposure to adverse climatic conditions as a 
cardiovascular risk factor. From a public health perspective, our findings provide evidence of the 
substantial contribution of meteorological factors in the seasonality and prevalence of CVRF, in 
preparation for the challenges ahead due to climate change. Although it has been projected an 
increase in the health risks associated to climate change due to heat waves, it is also expected that 
without adaption, irrespective of the increasing average temperature the burden of low ambient 
temperature will remain high, partly due to the worldwide ageing trend.159 Elderly people are 
among the most vulnerable population under the projected scenarios of climatic change, partly 
due to the age-related impairment of thermoregulation, what may alter the perception of ambient 
temperature and increase the risk of sustained exposure to adverse climatic conditions.160,161 Such 
impairment of thermoregulation has also been associated with increased insulin resistance and 
endothelial dysfunction.162 Therefore, the public health adaption aimed to mitigate the influence 
of meteorological factors on global health should include sustainable and affordable policies for 
building design and urban planning standards to reduce heat islands and efficiently maintain 
indoors temperature, and strong surveillance and warning systems to increase awareness under 
adverse climatic conditions.163,164 Furthermore, a better understanding of the mechanisms of 
exposure to such climatic conditions is required, to better identify vulnerable population. For 
example, despite the substantial proportion of CVRF prevalence that was attributable to ambient 
temperature in our study, we do not have information about the actual exposure of our 
participants. Although high blood pressure has been previously correlated with improper clothing 
at outdoor excursions in winter 7 and poor housing isolation,11,165,166 the Netherlands has fared 
relatively well, compared to other European countries, in housing standards and measures of fuel 
poverty related with relative excess of winter mortality.167 Additionally, although our elderly 
population was more likely to report baseline household income below 1,700eur than the middle-
aged, all our estimates were adjusted per income and no differences were observed in the 
distribution of income across seasons. Therefore, future studies are urgently required to have a 
better understanding of the susceptibility and mechanisms of exposure to adverse climatic 
conditions, in order to efficiently address their influence in the seasonality of cardiovascular risk 
and to identify strategies to mitigate the upcoming effects of climate change on global health. 
 
Strengths and limitations 
Our study has several strengths. First, using repeated measurements reduced the variability of 
CVRF levels between participants. Second, we adjusted for a broad range of confounders to avoid 
spurious seasonal patterns due to participants attending the research center not at random 
throughout the year (crude vs. model 1).  
However, some limitations deserve attention. First, the seasonality of the metabolic 
CVRF was smaller than in previous studies,5,29,32,33,168 what can be explained because a sizeable 
proportion was taking antihypertensive, antidiabetic, and statins medication. Additionally, about 
two third of our participants was overweight or obese and predominantly of European descent. 
Therefore, our findings might not be generalizable and should be confirmed in other settings. 
Second, we were unable to evaluate the effect of diet quality, which might have provided a more 
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comprehensive understanding of the effect of lifestyle markers on CVRF seasonality.169 Third, 
physical activity was measured with two different questionnaires, and the physical activity not 
measured in one of the visits of two cohorts was assumed to be reflected by the data of other 
visits, which led to a heterogeneous seasonality of physical activity.  Also, our elderly population 
exhibited peak values of physical activity in winter. Although more physical activity in winter has 
been observed among elderly population,17,170-173 objective measurements are necessary to confirm 
this pattern.  Fourth, we calculated our PAF estimates using stratified levels of the exposures, 
what may reduce the power of the calculations. Finally, the meteorological factors used in the 
analyses are derived from locally obtained measurements, which may not necessarily represent the 
individual exposure to adverse climatic conditions, nor account for other environmental factors 
that might be involved, such as air pollution. 
 
Conclusion 
The CVRF examined had a seasonal variation, leading to a worsened cardiovascular risk profile 
worsened in winter/autumn, when most CVRF had peak values. The worsening of the 
cardiovascular risk in winter is largely attributable to the exposure to low ambient and apparent 
temperature and is likely to have a role in the well-described seasonality of cardiovascular 
mortality. Therefore, population may benefit of a close monitoring when elevated levels of CVRF 
are observed, both to confirm the diagnosis during summer and to address the excess of burden 
during winter. In preparation for the projected health effects of climate change, future research is 
required to improve our understanding about the mechanisms of exposure to adverse 
meteorological factors, to efficiently address its effect as risk factors for cardiovascular risk.  
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Table 9. Distribution of general characteristics of participants at visit date 
Covariates 
Middle-aged (<65 years) 
 (n=8,263 observations) 
 
Elderly (≥65 years) 
(n=12,460 observations) p-value 
Median IQR  Median IQR 
Age (years) 59.7 56.0 62.2  73.3 68.8 78.5  
Physical activity (zMETs-hours/week) -0.1 -0.7 0.5  -0.1 -0.6 0.4 0.09 
Body mass index, kg/m² 26.9 24.5 29.8  26.9 24.6 29.6 0.56 
Hemodynamic risk factors (mmHg)        
     Systolic blood pressure 133.0 121.0 146.0  147.0 134.0 162.0 <0.01 
     Diastolic blood pressure 81.0 73.5 88.0  79.0 72.0 87.0 <0.01 
Metabolic risk factors (mmol/L)        
     Total-cholesterol 5.7 5.0 6.3  5.6 4.9 6.3 <0.01 
     Low-density lipoprotein cholesterol‡ 3.6 2.9 4.2  3.5 2.8 4.1 <0.01 
     High-density lipoprotein cholesterol 1.4 1.1 1.7  1.4 1.1 1.7 0.15 
     Glucose 5.4 5.1 5.9  5.6 5.2 6.1 <0.01 
Anthropometric risk factor        
     Waist-to-hip ratio 0.9 0.8 1.0  0.9 0.8 1.0 0.84 
 n %    n %     
Sex*         
     Men 43.7 3,613   42.8 5,334  0.19 
     Women 56.3 4,650   57.2 7,126   
Medication intake         
     Antihypertensive         
     No 72.8 6,015   51.4 6,402  <0.01 
     Yes 27.2 2,248   48.6 6,058   
     Antidiabetic         
     No 95.3 7,871   91.5 11,405  <0.01 
     Yes 4.7 3,92   8.5 1,055   
     Statin         
     No 81.8 6,758   76.6 9,547  <0.01 
     Yes 18.2 1,505   23.4 2,913   
Living situation         
     Community-dweller 99.9 8,256   98.9 12,323  <0.01 
     Non-community dweller 0.1 7   1.1 137   
Smoking status         
     Never 30.3 2,507   31.4 3,916  <0.01 
     Current 25.0 2,066   14.2 1,771   
     Former 44.7 3,690   54.4 6,772   
Monthly household income at baseline*,†        
     <1,700 euros 7.7 634   24.0 2,988  <0.01 
     1,700-3000 euros 12.3 1,015   24.9 3,100   
     3,000-4,200 euros 21.6 1,786   28.1 3,496   
     >4,200 euros 58.4 4,829   23.1 2,875   
Body mass index categories         
     Normal/underweight (<25kg/m²) 30.5 2,519   29.2 3,638  0.57 
     Pre-obesity (25-29.9kg/m²) 46.4 3,833   48.5 6,041   
     Obesity (≥30kg/m²) 23.1 1,911   22.3 2,781   
zMET: score of Metabolic Equivalent of Task. IQR = Interquartile risk (25th to 75th percentile) *Sex and income are 
constant during follow-up visit and are summarized at baseline visit. †Categories are <1,890; ≥1,890 to <3,336; ≥3,336 to 
<4,670 and ≥4,670 U.S. dollars. ‡ Sample sizes for LDL-cholesterol estimates: 7,178 observations among 5,387 middle-
aged participants and 8,174 observations among 6,769 elderly participants 
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Figure 4. Seasonal variation of cardiovascular risk factors 
 
Adjusted monthly levels of CVRF. Adjusted for cosinor terms, age, sex, smoking status, intake of antihypertensive, statin 
and antidiabetic medication, income categories, living situation, cohort, date and date squared. 
  
Seasonality of health outcomes | 72 
 
Figure 5. Population attributable fraction to meteorological factors of prevalence per season of 
selected cardiovascular risk factors 
 
Full circles: Middle-aged. Hollow circles: Elderly. CVRF: Cardiovascular risk factor. High blood pressure: SBP ≥ 140 
and/or DBP ≥ 90 mmHg; high LD-cholesterol: ≥1.8, ≥2.6, ≥3.0 mmol/L for population with very high (≥10%) high (≥5%) 
or low to moderate (<5%) 10-year cardiovascular fatal event according to SCORE chart, respectively; high glucose levels: 
≥7 mmol/L, high/very high SCORE risk: 10-year cardiovascular fatal event according to SCORE charts higher than ≥5%. 
Exposure categories are decile containing BMI ≤24kg/m2, physical activity ≤0 zMET-hours/week, lowest deciles of 
ambient and apparent temperature and sunlight hours and highest deciles of precipitation. PAF are adjusted for cosinor 
terms, age, sex, smoking status, intake of antihypertensive, statin and antidiabetic medication, income categories, living 
situation, cohort, date and date squared. 
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SUPPLEMENTARY MATERIAL 
Appendix 15. Flow chart of selection of participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* All observations from the cohort are 28,154 among 14,926 participants. However, we excluded the visits from RS-I-1 and 
RS-II-2 (2,987 participants [3,185 observations]) for consistency in measurements. Thus, RS-I-3 is considered baseline. 
Thirteen participants who attended in RS-I-1 or RS-I-2 did not attend in RS-I-3, but did attend in further follow-up visits. 
†These exclusions are due to missing values for any of the CVRF in a single visit, except LDL-cholesterol, which were 
missing for RS-I-4 and RS-II-2 because triglycerides levels were not available. Therefore, the sample sizes for LDL-
cholesterol estimates are 7,178 observations among 5,387 middle-aged participants and 8,174 observations among 6,769 
elderly participants. 
 
 
  
Baseline (n=11,728) 
RS-I-3 (1997-1999) = 
4,785 
RS-II-1 (2000-2001) = 
Excluded = 1,534 
participants  
 †
Selected = 10,405 
participants  
(20,723 observations) 
First follow-up (n=9,186) 
RS-I-4 = 3,558 
RS-II-2 = 2,506 
RS-III-2 = 3,122 
Second follow-up 
(n=4,040) 
RS-I-5 = 2,147 
RS-II-3 = 1,893 
Included = 
11,939participants 
 (24,954 observations) 
RS-I* (1989-1993) 
n=7,983 
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Appendix 16. Measurement procedures of cardiovascular risk factors, physical activity, and body mass index and 
imputation procedures 
 
Procedures 
Hemodynamic risk factors: Blood pressure was measured twice after a resting period of 5 minutes in a single visit using a 
random-zero sphygmomanometer (cuff size of 32×17 cm) on the right arm of participants in sitting position. The average 
of the measurements was used in the analyses. 
 
Metabolic risk factors: Fasting blood was drawn during the examination at the research center, and the serum was stored 
at −80°C. Glucose was measured within one week of sampling using the glucose hexokinase method.174 Lipid profile 
measurement were conducted using an automated enzymatic procedure 175 (Hitachi analyzer, Roche Diagnostics, 
Washington, DC, USA). LDL-cholesterol was calculated using the Friedewald formula 176 [LDL-cholesterol=total-
cholesterol–HDL-cholesterol–(0.45*triglycerides)]; 137 observations were excluded because triglycerides was > 
4.5mmol/L.139 LDL-cholesterol were missing for RS-I-4 and RS-II-2, because triglycerides levels were not available. 
 
Anthropometric risk factors: Height, weight and waist circumference were measured with the participants standing 
without shoes and heavy outer garments, and with emptied out pockets, breathing out gently. Waist circumference was 
measured at the level midway between the lower rib margin and the iliac crest, hip circumference was recorded as the 
maximum circumference over the buttocks. Height was measured with a wall-mounted stadiometer, recorded to the 
nearest 0.1cm; weight was measured with an electronic floor scale, recorded to the nearest 0.1kg; waist and hip 
circumference were measured using a non-stretchable tape and recorded to the nearest 0.1cm. 
 
Physical activity: Physical activity on RS-I-3 and RS-II-1 was assessed using a validated adapted version of Zutphen Physical 
Activity Questionnaire,140 and expressed in METhours/week.177 Questions on housekeeping activities were added to the 
original questionnaire that already included questions on walking, cycling, gardening, hobbies, and diverse sports. The 
LASA Physical Activity Questionnaire (LAPAQ) 117 was used on RS-I-5, RS-II-3 and RS-II-2, which contains questions 
regarding the frequency and duration of walking, cycling, sports, gardening and housework. 
 
Imputation procedures 
Sequential multiple imputation using chained equations was performed to impute missing values of covariates. This 
approach has been shown to work well in the context of complex longitudinal data, as in the Rotterdam Study.178 The 
predictors used to impute the covariates were sex, age, cohort, visit, date, date squared, systolic and diastolic blood 
pressure, total and HDL-cholesterol, glucose, waist-to-hip ratio, intake of antihypertensive, antidiabetic and statins 
medication, body mass index, smoking status, physical activity and housing status. To impute dichotomous variables 
(statin intake, antihypertensive medication intake, antidiabetic medication intake and housing status) we used a logit 
function. To impute ordered categorical variables (income) we used an ordered logit function. To impute categorical non-
ordered variables (smoking behavior) we used a multinomial logit function. To impute continuous variables (physical 
activity and body mass index), we used a linear function. To ensure reproducibility, we used a random seed (2005). We 
created five imputed datasets, which were used in all the analysis. Covariates with missing values were: physical activity: 
2,159 missing, body mass index: 140 missing, antihypertensive medication intake: 356 missing, antidiabetic medication 
intake: 250 missing, statins intake: 259 missing; housing: 119 missing, income: 2,140 missing; smoking behavior: 137 
missing. Imputations were performed using the mi impute command of Stata software. 
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Appendix 18. Annual pattern of meteorological factors 
 
 
Monthly mean and confidence interval of meteorological factors during study period 
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Appendix 19. Seasonality of lifestyle markers according to age-group 
 
Seasonal variation of BMI = middle-aged: 0.16 kg/m2 (95%CI 0.04 to 0.28, peak=11-Feb), elderly: 0.20 kg/m2 (95%CI 
0.10 to 0.30, peak=12-Jan). Seasonal variation of physical activity = middle-aged: 0.02 zMET-hours/week (95%CI -0.03 to 
0.07, peak=16-Apr), elderly: 0.09 zMET-hours/week (95%CI 0.05 to 0.12, peak=29-Jan). Adjusted monthly levels of 
CVRF. Adjusted for sine and cosine terms, age, sex, smoking status, intake of antihypertensive, statin and antidiabetic 
medication, income categories, living situation, cohort, date and date squared. Shade area corresponds to 95% confidence 
interval 
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Appendix 21. Seasonality and effect of lifestyle markers and meteorological factors on the seasonality of the cardiovascular 
risk factors, according to sex and age groups 
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Appendix 23. Procedures and PAF estimations 
 
Example of PAF estimations procedure 
 pd(W) pd(S) pd(Su) pd(A) RR p-value 
Deciles BMI 
 High blood pressure 
0 9.5 10.6 11.5 11.4 1.6 0.0 
1 9.0 9.0 8.3 8.2 1.6 0.0 
2 10.9 9.1 10.3 11.0 1.5 0.0 
3 11.1 10.9 11.2 11.2 1.4 0.0 
4 10.5 10.0 9.7 9.0 1.3 0.0 
5 11.2 11.9 9.5 10.1 1.2 0.0 
6 10.6 8.8 9.8 8.9 1.1 0.1 
7 9.0 10.4 10.8 10.1 Ref  
8 9.0 9.9 9.9 10.7 0.9 0.0 
9 9.1 9.6 8.9 9.5 0.9 0.1 
PAF 16.3 15.6 15.8 15.6    
PAF Total 17.2 16.8 17.0 16.5     
 
pd(Seasoni): Proportion of cases that fell on each exposure category, per season. In the example, the numbers below the 
header “pd(W)” correspond to the percentage of participants with high blood pressure at each category of body mass 
index during the winter season, among all participants with high blood pressure in winter season. 
 
RR: Corresponds to the adjusted relative risk for each exposure category. In the example, the RR corresponds to the 
relative risk for each category of body mass index compared to the reference category, which for BMI is at the decile 7, 
which contained the cut-off of BMI for obesity (24kg/m2) 
 
Ref: Reference category. Exposure categories are decile containing BMI ≤24kg/m2, physical activity ≤0 zMET-hours/week, 
lowest deciles of ambient and apparent temperature and sunlight hours and highest deciles of precipitation. 
 
p-value: Significance of the RR at a confidence level of 95% of the relative risk. 
 
PAF: Population attributable fraction of each of the categories of the exposure. It is calculated as 1 − ∑
𝑝𝑑𝑖
𝑅𝑅𝑖
𝑘
𝑖=0   .
146 For 
example, for winter, it would be calculated as 1-((9.5/1.6)+(9.0/1.6)+(10.9/1.5)….) 
 
PAF Total: Population attributable fraction of the exposures considered in each model (either lifestyle markers or 
meteorological factors). For the lifestyle markers model, it is calculated as 1 − (1 − 𝑃𝐴𝐹𝐵𝑀𝐼𝑠𝑒𝑎𝑠𝑜𝑛=𝑖) ∗
(1 − 𝑃𝐴𝐹𝑝ℎ𝑦𝑠𝑖𝑐𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑠𝑒𝑎𝑠𝑜𝑛). For the meteorological factors model, it is calculated as 1 − (1 −
𝑃𝐴𝐹𝑀𝑒𝑡𝐹𝑎𝑐𝐿𝑎𝑔0−1𝑠𝑒𝑎𝑠𝑜𝑛=𝑖) ∗ (1 − 𝑃𝐴𝐹𝑀𝑒𝑡𝐹𝑎𝑐𝐿𝑎𝑔2−6𝑠𝑒𝑎𝑠𝑜𝑛).
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2.2.2 Seasonality of insulin resistance, glucose, and insulin among middle-aged and elderly 
population 
 
Magda Cepeda, Taulant Muka, M. Arfan Ikram, Oscar H. Franco, Josje D. Schoufour 
 
Adapted from Journal of Clinical Endocrinology and Metabolism 2018;103(3):946-55. 
 
ABSTRACT 
Introduction: There are discrepancies in the seasonality of insulin resistance (IR) across the 
literature, probably due to age-related differences in the seasonality of lifestyle factors and 
thermoregulation mechanisms. 
 
Objective: To estimate the seasonality of IR according to the homeostatic model assessment-
insulin resistance (HOMA-IR), glucose, and insulin levels; and to examine the role of lifestyle 
markers (body mass index (BMI) and physical activity) and meteorological factors, according to 
age. 
 
Methods: Seasonality was examined using cosinor analysis among middle-aged (45 to 65 years) 
and elderly (≥65 years) participants of a population-based Dutch cohort. We analyzed 13,622 
observations from 8,979 participants (57.6% women) without diagnosis of diabetes and fasting 
glucose <7mmol/L. BMI was measured, physical activity was evaluated using a validated 
questionnaire, and meteorological factors (daily mean ambient temperature, mean relative 
humidity, total sunlight hours, and total precipitation) were obtained from local records. 
Seasonality estimates were adjusted for confounders. 
 
Results: Among the middle-aged, seasonal variation estimates were: 0.11units (95%CI 0.03, 0.20) 
for HOMA-IR, 0.28µIU/mL (-0.05, 0.69) for insulin, and 0.05mmol/L (0.01, 0.09) for glucose. 
These had a summer peak and lifestyle markers explained the pattern. Among the elderly, 
seasonal variations were: 0.29units (0.21, 0.37) for HOMA-IR, 0.96µIU/mL (0.58, 1.28) for 
insulin, and 0.01mmol/L (-0.01, 0.05) for glucose. These had a winter peak and ambient 
temperature explained the pattern. 
 
Conclusion: Impaired thermoregulation mechanisms could explain the winter peak of IR among 
elderly people without diabetes. The seasonality of lifestyle factors may explain the seasonality of 
glucose.  
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INTRODUCTION 
The seasonal winter peak of glucose, glycosylated hemoglobin, and type 1 diabetes diagnosis has 
been widely described in several populations.5,179,180 In contrast, there are discrepancies in the 
seasonality of insulin resistance or insulin levels, which could be attributed to age differences 
across populations studied. For example, studies reporting a seasonal variation of insulin 
resistance were more likely to include elderly people,181-186 whereas those reporting no seasonal 
variation were performed mostly in middle-aged and young populations.187,188 
Differences between age groups in the seasonality of insulin resistance can be explained 
by age-related differences of underlying mechanisms, including lifestyle and environmental 
factors. Lifestyle factors (e.g. diet and physical activity) and lifestyle markers (e.g. body 
composition and body mass index (BMI)) have a well-described seasonal variation.5,169 However, 
factors that change with age, such as marital status, onset of comorbidities, and housing status 
(community dweller versus other) could lead to different patterns in the seasonality of physical 
activity 17 and diet.169 Additionally, the elderly are more susceptible to thermal challenges, such as 
exposure to low ambient temperature, due to age-related impairment of thermoregulation 
mechanisms 138,189, some of which are related to insulin resistance.162 In consequence, age-related 
differences in the seasonality of lifestyle and in the influence of meteorological factors could lead 
to different seasonal patterns of insulin resistance. 
Nevertheless, to our knowledge, no previous study has evaluated the role of individual 
and environmental factors in the seasonality of insulin resistance with an age-specific approach. 
Therefore, we examined the seasonal variation of insulin resistance, according to the homeostatic 
model assessment-insulin resistance (HOMA-IR), and that of glucose and insulin levels, among 
middle-aged and elderly participants of a Dutch population-based cohort. Additionally, we 
examined the role of lifestyle markers and of meteorological factors in the seasonal patterns. 
 
METHODS 
Study design 
This study is a cross-sectional analysis based on the Rotterdam Study, a population-based 
prospective cohort comprised in 1989 inviting all elderly people living in the Ommoord district 
in Rotterdam, the Netherlands.23 The Rotterdam Study aims to investigate factors that determine 
the occurrence of cardiovascular, neurological, ophthalmological, endocrinological, and 
psychiatric disease in elderly population. The study is composed by three cohorts (RS-I: 7,893 
participants aged 55 years or above; RS-II: 3,011 participants aged over 55 years of age or who 
moved into the district; and RS-III: 3,932 participants aged 45 years and over). Follow-up visits 
are performed every five years.23 The Rotterdam Study has been approved by the Medical Ethics 
Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study). All participants provided written informed consent to participate in the study 
and to obtain information from their treating physicians. 
Out of 40,846 visits obtained from 14,926 participants, fasting insulin and glucose levels 
were determined in 15,928 visits (10,259 participants) (Appendix 25, page 103). We further 
excluded those with diabetes diagnosis or taking medication for diabetes at the time of a visit, and 
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those with glucose levels above 7mmol/L. Analyses were performed with data obtained in 13,622 
visits (observations) among 8,979 participants (Appendix 25, page 103). 
 
Assessment of HOMA-IR, glucose and insulin 
HOMA-IR was estimated with the formula 𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝜇𝐼𝑈
𝑚𝐿
)−𝐺𝑙𝑢𝑐𝑜𝑠𝑒(
𝑚𝑚𝑜𝑙
𝐿
)
22.5
 .190 The 
HOMA-IR has been shown to correlate well with the euglycemic hyperinsulinemic clamp 
method,191 which is the gold standard for insulin resistance. Fasting blood serum was drawn 
during the examination at the research center. Blood collection was performed by venipuncture 
at the center and the blood was stored at -80˚C in 5mL aliquots. Glucose was measured within 
one week of sampling using the glucose hexokinase method.174 Serum insulin levels were 
determined in samples that had been kept frozen from baseline (1997–2001) until usage in 2008 
and were measured on a Roche Modular Analytics E170 analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany) by electrochemiluminescence immunoassay technology. From 2009 
onwards, fasting insulin and glucose levels were measured using a COBAS 8000 Modular 
Analyzer (Roche Diagnostics). Clinical chemistry measurements were done at the Erasmus MC 
AKC laboratory. 
 
Assessment of meteorological factors 
Average ambient temperature (˚C), average relative humidity (%), accumulated precipitation 
(mm) and total sunlight hours in Rotterdam, at participants’ blood sampling date and the five 
days before, were obtained from the Koninklijk Nederlands Meteorologisch Instituut (KNMI, 
Royal Dutch Meteorological Institute).67 The monitor is located approximately at 8km from 
Ommoord district (coordinates: 51° 58' North latitude 04° 27' East longitude). Date of blood 
sampling was classified in seasons according to the light definition, centered at equinoxes (winter: 
November 6 to February 4, spring: February 5 to May 6, summer: May 7 to August 5, autumn: 
August 6 to November 5).32 
 
Assessment of lifestyle markers 
Physical activity was assessed on the third visit of RS-I and on the first visit of RS-II using a 
validated adapted version of Zutphen Physical Activity Questionnaire,140 and expressed in 
metabolic equivalent of task (MET)-hours/week.116 Questions on housekeeping activities were 
added to the original questionnaire that already included questions on walking, cycling, 
gardening, hobbies, and diverse sports. The LASA (Longitudinal Aging Study Amsterdam) 
Physical Activity Questionnaire (LAPAQ) 117 was used on the fifth visit of RS-I, the third visit of 
RS-II, and the first and second visit of RS-III, which contains questions regarding the frequency 
and duration of walking, cycling, sports, gardening and housework. BMI was calculated as weight 
divided by height squared (kg/m2). Height and weight were measured with participants standing 
without shoes and heavy outer garments and with emptied out pockets, breathing out gently. 
Height was measured with a wall-mounted stadiometer and recorded to the nearest 0.1 cm. 
Weight was measured with an electronic floor scale and recorded to the nearest 0.1 kg. 
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Assessment of covariates 
Data on covariates were collected through home interviews or measured in the Rotterdam Study 
research center by trained research assistants.23 History of cardiovascular disease, chronic 
obstructive pulmonary disease, and cancer at the visit date was obtained from medical records. 
Smoking behavior was requested via questionnaires and categorized as never, current or former. 
Housing condition was classified as community-dweller vs. non-community-dweller (i.e., service 
flat, nursing home). Alcohol intake was obtained using the AUDIT tool91 and was categorized as 
<2.5, 2.5-4.4, and ≥4.5 glass/day. Blood pressure was measured twice after a resting period of five 
minutes in a single visit using a random-zero sphygmomanometer (cuff size of 32×17 cm) on the 
right arm of participants in sitting position; the average of the measurements was used in the 
analyses. Lipid profile measurement were conducted using an automated enzymatic procedure 175 
(Hitachi analyzer, Roche Diagnostics, Washington, DC, USA). Waist circumference was 
measured at the level midway between the lower rib margin and the iliac crest using a non-
stretchable tape and recorded to the nearest 0.1cm. 
Fat mass index (FMI) was determined by dividing total fat mass by height squared in 
meters (grams/m2). Total fat mass was available for 7,182 participants and was assessed by DXA 
using a Prodigy TM total body-fan beam densitometer (GE Lunar Corp, Madison, WI, USA) 
following manufacturer protocols; scans were analyzed with enCORE software V13.6 using pre-
determined regions of interest. Data on diet quality were available for 8,766 participants and is 
expressed as the adherence to 2015 Dutch dietary guidelines for fourteen food groups.108,109 Diet 
quality data was obtained using a self-administered semi-quantitative food frequency 
questionnaire (FFQ) with 170 food items among participants of the first visit of RS-II 108 and with 
an extended FFQ based on 389 self-administrated food items among remaining participants.103,104 
Participants were classified as having metabolic syndrome if they had two out of four of 
the following factors, modified from Alberti et al:192 abdominal obesity (waist circumference ≥88 
among men or ≥102cm among women), hypertriglyceridemia (triglycerides ≥1.7mmol/L or taking 
statins), low HDL-cholesterol (HDL-cholesterol ≤1.3 among women or ≤1.0 among men, or 
taking statins), and hypertension (systolic blood pressure ≥130mmHg, diastolic blood pressure 
≥85mmHg, or taking antihypertensive medication). 
 
Statistical methods 
All analyses are stratified as follows: middle-aged below <65 years-old and elderly above ≥65 years-
old. To account for potential bias associated with missing data, we used multiple imputation 
procedures (n=5 imputations) to impute missing values of covariates. We applied sequential 
multiple imputation using chained equations with outcomes and covariates as predictors (a full 
description of the imputation procedure is provided in the Appendix 26 (page 104)). General 
characteristics of the population according to age-group and season on the imputed dataset are 
presented using descriptive statistics. Categorical variables were described with absolute frequency 
and percentage; the distribution was compared using Chi-squared test. Continuous variables were 
described with median and interquartile range (25th and 75th percentile); the distribution was 
compared using the Kruskal-Wallis test. 
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We examined the seasonality of HOMA-IR, glucose, and insulin using generalized linear 
mixed model with log link, due to their skewed distribution. Seasonality was examined with 
cosinor analysis using the date of blood sampling as time parameter. We assumed a sinusoidal 
seasonal variation with a period of one year. Model 1 (crude model) included the cosinor terms 
and the date (linear and quadratic, to account for long-term temporal trends). Model 2 (adjusted 
model) additionally included age, sex, visit, smoking behavior, alcohol intake, housing status, 
prevalence of cardiovascular disease, comorbidities, antihypertensive and statin intake, systolic 
blood pressure (mmHg), and total cholesterol (mmol/L). The cosinor terms were used to calculate 
the seasonal variation, which corresponds to the peak-to-nadir variation of the outcome 
throughout the annual period. The percentage of seasonal variation compared to the adjusted 
average (POA) was calculated as (seasonal variation/adjusted average)*100. Procedures for 
estimation of the seasonal variation are provided elsewhere.5,69 Confidence intervals around 
seasonal variation were calculated under the assumption of normality, using bootstrap (100 
samples).  
Additional models were fitted to estimate the effect of BMI and physical activity (Model 
3, lifestyle model) and of meteorological factors (Model 4, meteorological factors models) on the 
seasonality of the outcomes. The effect was operationalized as the reduction of the seasonal 
variation of Model 3 and Model 4, separately, compared to the seasonal variation in Model 2, and 
was expressed in percentage. BMI was included as a cubic spline with three degrees-of-freedom. 
Meteorological factors at the blood sampling date and the five days before were included in the 
models with one constraint between day 0 (sampling day) and day 1 and other between day 2 to 
day 5. 
To test for possible effect modification, we repeated our main analysis according to age 
groups and sex. We examined the seasonality of HOMA-IR, glucose, and insulin according to 
metabolic syndrome (yes vs. no) and obesity (BMI < vs. ≥ 30kg/m2). Two sensitivity analyses were 
performed in subsamples of the population with available data of dietary patterns (kilocalories 
intake and diet quality) and of FMI, separately, by examining the change of the seasonal variation 
after including these covariates. A third sensitivity analysis was performed by excluding 
participants with one or more comorbidities. For all analysis, we used Stata version 14.1 SE 
(StataCorp LP, College Station, Texas).72 
 
RESULTS 
Age and sex distribution was 58.9 years (IQR=55.3, 61.7) and 57% women among the middle-
aged, and 73.1 years (IQR=68.6, 78.2) and 59% women among the elderly. Table 11 (page 98) 
shows the characteristics of participants at date of visit according to season and age-group. 
Median systolic blood pressure was significantly higher in winter than in summer both among 
middle-aged (133 vs. 129mmHg, p<0.001) and elderly participants (147 vs. 143.8mmHg, 
p<0.001). Elderly community-dweller participants were more likely to attend the study in winter 
than in summer, compared to non-community dweller (91.2% vs. 82.8%, p<0.001). 
 
Seasonality of HOMA-IR, glucose, and insulin 
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Among middle-aged participants, HOMA-IR was 0.11 units (95%CI 0.03, 0.20) higher in 
summer than in winter, representing about 10.5% of the average HOMA-IR. Among elderly, 
HOMA-IR was 0.29 units (95% CI 0.21, 0.37) higher in winter than in summer, representing 
about 29.2% of the average HOMA-IR (Figure 6 (page 101), (Table 12 (page 100)). These patterns 
were reflected by the increment of insulin by 0.28 µIU/mL in summer (95%CI -0.05, 0.69; 
POA=11.8%) among the middle-aged and 0.96 µIU/mL in winter ((95%CI 0.58, 1.28), 
POA=41.2%) among the elderly. Glucose was stable throughout the year, although the seasonality 
was somewhat larger among middle-aged than among elderly participants (0.05mmol/L (0.01, 
0.09; POA=3.2%) vs. 0.01 (-0.01, 0.05; POA=0.8%)) (Table 12 (page 100)). 
 
Effect of lifestyle and meteorological factors on the seasonality of HOMA-IR, glucose, and insulin 
Lifestyle markers explained most of the seasonality of HOMA-IR among middle-aged participants 
(seasonal variation change= -39%). Among elderly, ambient temperature explained the largest part 
of the seasonality of HOMA-IR (-88%), followed by sunlight hours (-24%) and lifestyle markers (-
20%). Among the middle-aged, glucose seasonality was explained by relative humidity (-56%), 
followed by lifestyle markers (-18%); whereas insulin seasonality was partly explained by lifestyle 
markers (-23%). Among the elderly, glucose seasonality was not influenced by lifestyle markers or 
meteorological factors; whereas insulin seasonality was mostly explained by ambient temperature 
(-89%), followed by sunlight hours (-24%), lifestyle markers (-16%), and relative humidity (-13%). 
Analyses based on the non-imputed dataset are shown on Appendix 26 (page 104). 
 
Stratified and sensitivity analyses 
Middle-aged men had a larger seasonal variation than middle-aged women for HOMA-IR (0.22 vs. 
0.10units), glucose (0.07 vs. 0.05mmol/L), and insulin (0.87 vs. 0.41µIU/L). Lifestyle factors 
explained a smaller part of HOMA-IR seasonality among middle-aged men (-30%) than among 
women (-48%). Lifestyle markers and relative humidity explained a larger part of glucose 
seasonality among middle-aged men (-23% and -62%) than among women (-12% and -41%). 
Among elderly, seasonality estimates were similar according to sex for HOMA-IR (men=0.30 vs 
women=0.27units), glucose (0.03 vs 0.02mmol/L), and insulin (0.98 and 0.91µIU/L). Lifestyle 
markers explained a larger part of HOMA-IR seasonality among elderly men (-33%) than among 
women (-8%), but the influence of ambient temperature and sunlight hours was larger among 
elderly women (-72% and -37%) than among men (-49% and -10%) (Appendix 27, page 106). 
No large differences in the seasonality of HOMA-IR, glucose, and insulin levels were 
observed in the stratified analysis according to metabolic syndrome or obesity. Among the 
middle-aged, the seasonality of glucose was partly explained (-12%) by diet quality, but not by 
FMI. None modified the seasonality estimates among elderly. Among the middle-aged, seasonality 
estimates remained similar after the exclusion of participants with comorbidities, except for 
insulin that increased to 0.36µIU/L (POA=15.1%). Among the elderly, HOMA-IR seasonality 
remained the same, but glucose seasonality increased to 0.03mmol/L (POA=1.8%) and insulin 
seasonality increased to 1.04 (POA=44.7%). (Appendix 28 (page 108) and Appendix 29 (page 
109)) 
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DISCUSSION 
In this large population-based Dutch cohort, seasonality of insulin resistance according to 
HOMA-IR was larger among elderly than among middle-aged participants. Among the elderly, 
the seasonality of HOMA-IR reflected that of insulin, with peak in winter, and ambient 
temperature mostly explained the pattern. In contrast, among the middle-aged, the modest 
seasonality of HOMA-IR reflected that of glucose, with peak in summer, and lifestyle markers 
mostly explained the pattern. Age-related differences in thermoregulation could explain the 
winter peak of insulin resistance among the elderly. 
The winter peak of insulin resistance among the elderly was mostly explained by ambient 
temperature. This finding agrees with previous studies showing that sustained exposure to lower 
ambient temperature increases energy expenditure and insulin resistance.189,193 Nevertheless, this 
finding was not observed in middle-aged participants. This could be explained by the age-related 
impairment of thermoregulation, which may alter the cold perception among elderly, exposing 
them more frequently to sustained exposure to low ambient temperature.160,161 Consequently, the 
winter peak of insulin resistance may reflect a sustained cold exposure, probably due to the failure 
to undertake preventive behavioral measures, like proper thermal isolation in buildings and 
clothing. In addition, the nature of the thermoregulation impairment among elderly may 
systematically magnify the insulin resistance under cold exposure. Indeed, exposure to low 
ambient temperature activates physiological thermoregulation mechanisms aimed to produce and 
preserve heat.138 These mechanisms involve the sympathetic nervous system and local signaling 
pathways. However, for reasons not completely understood, the sympathetic pathway is 
diminished among elderly, creating a discrepancy that in the long term may reduce the NO 
bioavailability.138 The reduced NO bioavailability creates a state of insulin resistance, as insulin 
uses NO to induce vasodilation in insulin sensitive tissues,194 some of which are involved in heat 
preservation through skin vasoconstriction and blood flow redistribution. Therefore, an impaired 
response to cold exposure would elicit a reactive hyperinsulinemia.195 Moreover, the ability of 
thermoregulation mechanisms to cope with the seasonal variation of ambient temperature may be 
further hampered by the higher prevalence of comorbidities and of medication intake among the 
elderly. 
Among middle-aged participants, the seasonality of insulin resistance reflected the 
seasonality of glucose, which was explained by lifestyle markers, i.e. BMI and physical activity, in 
agreement with previous evidence.181 We found that relative humidity also explained a large part 
of the seasonality of glucose among the middle-aged. We hypothesize that relative humidity may 
influence the seasonality of glucose through diet behavior. For example, low levels of relative 
humidity during summer, when ambient temperature increases, may explain the summer peak of 
sugar-containing beverages, ice-creams, and alcohol intake.169 Indeed, diet quality explained about 
12% of the seasonality of glucose among the middle-aged in our sensitivity analysis and the 
seasonality of diet quality was explained by relative humidity in both age-groups (results not 
shown). We are not aware of studies addressing the role of meteorological factors in diet 
behavior, but these are required to examine this association. The fact that relative humidity did 
not explain the glucose seasonality among the elderly suggests that its potential influence was 
outweighted by the large seasonality of insulin, which contributed to maintain constant levels of 
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glucose.181  Additionally, the influence of lifestyle factors on the seasonality estimates was smaller 
among elderly, reflecting the smaller seasonality of their lifestyle factors. Similarly, lifestyle factors 
had a smaller influence on the seasonality estimates among women than among men. This 
finding can be attributed to the higher prevalence of comorbidities among elderly and a healthy 
behavior consciousness both among elderly and women, which would make them less prone to 
changes in lifestyle behavior on a seasonal basis. 
Our findings have multiple relevant implications. First, the winter peak of insulin 
resitance among the elderly provide a plausible mechanism for the seasonality of cardiovascular 
risk and of proinflamatory and pro-coagulant factors 5,196,197 and, arguably, also of cardiovascular 
mortality.6,32,198 Indeed, the reactive winter hyperinsulinemia has been associated with a 
phenomenon of selective insulin resistance, which may worsen the endothelial dysfunction162 and 
increase the production of proinflamatory and prothrombotic mediators,195 such as endothelin-
1.162 Future studies are required to confirm this hypothesis among susceptible population, such as 
elderly. Second, fact that ambient temperature did not influence the seasonality of glucose in our 
population contradicts previous evidence suggesting that low ambient temperature exposure 199 
could modify glucose metabolism through brown adipose tissue (BAT) activation.200,201 However, 
it is possible that under non-experimental conditions, factors such as diet counteract the effect of 
BAT activation. Therefore, population-based studies addressing the role of BAT on glucose 
metabolism are required to weight its therapeutic value to prevent and control diabetes. Third, 
although we were unable to determine the actual mechanisms of exposure to low ambient 
temperature, our findings suggest that ambient temperature is a leading cause of the winter-
related insulin resistance in susceptible population. Clinicians and clinical guidelines should 
address the exposure to low ambient temperature by recommending and pursuing measures to 
warrant proper thermal isolation in home buildings and in clothing. Nevertheless, our 
understanding of the mechanisms to low ambient temperature exposure needs to be improved to 
account for the clustering of associated factors, such as energetic poverty and frailty. Finally, our 
findings suggest that season-led recommendations on dietary patterns and physical activity would 
contribute to reduce the burden of seasonal hyperglycaemia. 
Our study has several strenghts. First, in contrast with previous studies, we had up to two 
measurements for most of our participants, which contributes to reducing the random variability 
of the outcomes across seasons. Second, we adjusted for several counfounders, which reduces the 
seasonality that could be explained by the non-random participation of the cohort population. 
Third, to our knowledge, we are the first to examine the efect of lifestyle markers and 
meteorological factors in the seasonality of HOMA-IR, glucose and insulin. However, we also 
have to acknowledge several limitations. First, because our population was predominantly an 
European white population with high levels of physical activity, comorbidities, and high BMI, our 
findings must be confirmed in other settings. Second, lifestyle markers did not modify the 
seasonality of HOMA-IR and insulin among middle-aged participants when we replicated the 
analysis in the non-imputed dataset. This discrepancy can be explained because HOMA-IR and 
insulin levels were higher in the population with missing data on BMI and/or physical activity 
than in those with complete data. HOMA-IR and insulin at lower levels could be less susceptible 
97 | Chapter 2.2 
 
 
to the variation of BMI and physical activity than at higher levels, and consequently, the influence 
of these lifestyle markers could be underestimated in the non-imputed dataset. 
 
Conclusion 
In this large population-based Dutch cohort, seasonality of insulin resistance, according to 
HOMA-IR, was larger among elderly than among middle-aged participants. Among middle-aged 
participants, the modest seasonality of insulin resistance reflected that of glucose, with a summer 
peak, and lifestyle factors explained the pattern. Among elderly, the seasonality of insulin 
resistance reflected that of insulin, with a winter peak, and ambient temperature explained the 
pattern. Insulin resistance seasonality among elderly appears susceptible to adverse climatic 
conditions, due to increased exposure to low ambient temperature and age-related impairment of 
thermoregulation, thus providing a plausible mechanism for the winter peak of cardiovascular 
risk through endothelial dysfunction. Taking into account that susceptible population is rising 
given the worldwide ageing trend, it is an urgent matter from the clinical and public health 
perspective to address environmental risk factors, such as exposure to low ambient temperature, 
as a relevant mechanism of insulin resistance, with potential implications on cardiovascular risk. 
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Figure 6. Seasonal pattern of HOMA-IR, glucose and insulin according to age group 
(a) HOMA-IR    (b) Glucose
  
(c) Insulin 
 
The solid line corresponds to the seasonal pattern among middle-aged participants and the dashed line the seasonal 
pattern among elderly participants. The range around estimates corresponds to 95% confidence intervals. The patterns 
are adjusted for cosinor terms, date (linear and quadratic), age, sex, visit, smoking behavior, alcohol intake, housing status, 
prevalent cardiovascular disease, comorbidities (chronic obstructive pulmonary disease, cancer), medication intake 
(antihypertensive and statin), cholesterol levels and systolic blood pressure. 
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SUPPLEMENTARY MATERIAL 
 
Appendix 24. Overview of the Rotterdam Study 
Sub-cohort  Visits 
RS-I 
1 
n=7,983 
2 
n=6,315 
3 
n=4,785 
4 
n=3,558 
 
5 
n=2,147 
     2 
RS-II 
  
 1 
n=3,011 
2 
n=2,506 
 
3 
n=1,893 
   1    
RS-III 
  
 
  
1 
n=3,932 
2 
n=3,122 
     2 2 
Timeline -> 1989-1993 1993-1995 1996-2001 2002-2005 2006-2008 2009-2013 
RS: Rotterdam Study 
Included visits 
Not included visits 
Overall study population 
Population of sensitivity analysis 
      Fat mass index data 
     1 Diet quality data, assessed with 170 food items FFQ 
     2 Diet quality data, assessed with 339 food items FFQ 
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Appendix 25. Flowchart of data selection 
 
 
  
40,846 observations 
(14,926 participants) 
15,928 observations 
(10,259 participants) 
13,731 observations 
(9,014 participants) 
13,622 observations 
(8,979 participants) 
109 observations (35 participants) with glucose 
levels ≥7mmol/mL 
 
2,197 observations (1,245 participants) with 
diabetes diagnosis or taking medication for diabetes 
24,918 observations (4,667 participants) without 
data of glucose/insulin 
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2.2.3 Seasonality of cognitive performance in the general population: the Rotterdam Study 
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ABSTRACT 
Objective: To assess the seasonality of cognitive performance in the general population. 
 
Methods: Within the prospective, population-based Rotterdam Study, we assessed cognitive 
performance in 8,560 participants free from dementia at baseline and subsequent visits between 
1999 and 2016. Using multiple measurements in cosinor linear mixed models, we assessed the 
annual seasonality of global cognition. Cognition was constructed with principal component 
analysis based on four different cognitive tests in 16,707 observations. In addition, we assessed 
seasonality patterns for each standardized test separately.  
 
Results: In this study, the median age was 67.1 years and 57.2% were women. Global cognition 
had a significant annual seasonal variation (SV) with lowest values in winter and highest values in 
summer months (3.2 times lower in winter than in summer, SV: 0.04 standard deviation (SD), 
95% confidence interval (CI): 0.01 to 0.06). Individual tests with large SV were: manual dexterity 
test (1.35 times lower in winter than in summer, 0.11 SD, 95%CI: 0.08 to 0.15), and verbal 
fluency test (1.29 times lower in early-spring than in autumn, 0.04 SD, 95%CI: 0.01 to 0.07). 
These SVs were less pronounced for the Stroop interference task (0.03 SD, 95%CI: 0.00 to 0.06) 
and the letter digit substitution test (0.02, 95%CI: -0.01 to 0.05). Largest variations in seasonality 
were seen for individuals with a higher score on global cognition, those with higher Mini-Mental 
State Examination (MMSE) scores and those with higher educational levels. 
 
Conclusions: Cognitive performance shows an annual seasonal variation pattern in the general 
population, characterized by lower performance during winter and higher performance during 
summer. Larger seasonal variation in cognitive performance may be a sign of preserved cognitive 
function while ageing, yet future studies are warranted to confirm these observations. 
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INTRODUCTION 
With ageing populations worldwide, reliable assessment of cognitive performance is becoming 
increasingly important to detect subsequent decline. Cognitive performance is largely determined 
by an individual’s educational attainment, although vascular and lifestyle factors also play an 
important role.202-206 More recently, several clinical conditions and environmental factors that 
influence cognitive performance have been identified,35 some of which could express their effects 
depending on the season. For instance, seasonal affective and bipolar disorders207 and allergies208 
are associated with lower cognitive performance during their symptomatic periods of the seasonal 
pattern. Among the most widely studied environmental factors influencing cognition are ambient 
temperature and sunlight. Both low and high temperature are associated with lower Mini-Mental 
Score Examination (MMSE) score209 whereas sunlight may harbor indirect effects on cognition via 
mood disorders207 and vitamin D insufficiency 210,211 
However, regardless of extensive evidence on these seasonal factors influencing 
cognition, less is known about the seasonal variation of cognitive function in the general 
population.36,37 Some studies have shown differences in attention and information 
processing212,213 during winter, however these findings come from studies with 100 or less 
participants 36,212-214 or were performed in selected populations (i.e., individuals with bipolar 
disorder).207 A seasonal variation in cognitive function could help to better understand the 
influence of environmental determinants of cognition, as well as the interpretation of cognitive 
tests across seasons in the general population. In this large cohort study, we studied the 
seasonality of cognitive functioning among community-dwelling individuals. 
 
METHODS 
Study design 
This study was embedded in the Rotterdam Study, a population-based prospective cohort 
conducted in the Ommoord district in Rotterdam, the Netherlands.23 Briefly, the first cohort of 
this study comprised of 7,983 participants aged 55 years old and above, between 1997 and 1999. 
Between 2000 and 2001, 3,011 new participants who were 55 years and older or moved into the 
district since the start of the study, were included in a second cohort (RS-II). A third cohort (RS-
III) was comprised between 2006 and 2008 with 3,932 new participants aged 45 and above. The 
overall response rate across cohorts was 72%. Study participants were invited at the research 
center every three to four years. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). 
All participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians. 
 
Study population 
For this study, we used baseline and follow-up visits of all three cohorts. A cognitive test battery 
was implemented in the study protocol in 1997. We therefore considered the third visit of the 
first cohort (RS-I) as baseline. We excluded participants who did not provide informed consent to 
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access medical records or hospital discharge letters (compromising 184 observations on cognitive 
tests from 121 participants). We further excluded participants who were not or insufficiently 
screened at baseline for dementia or suffered from dementia while performing the cognitive test 
(n=896 observations, from 587 participants). We finally excluded observations from individuals 
with insufficient data on the subsequent tests to calculate a global cognition score (n=9,760 
observations from 2,683 participants) (the flowchart of population selection is provided in 
Appendix 37 (page 142)). 
 
Assessment of cognitive performance 
Both at baseline and during follow-up, participants underwent the Mini-Mental State 
Examination (MMSE) during home interviews and an extensive cognitive test battery at the 
research center. This cognitive test battery consisted of the following four tests: Letter-Digit 
Substitution Task (LDST, participants have to write down as many numbers underneath the 
corresponding letters as possible in 60 seconds), Stroop test (reading task of printed words, task of 
naming colours and interference task, which combines both: participants are asked to name the 
colors of color names printed in incongruous ink color), Verbal Fluency Test (VFT, animal 
categories), and Purdue Pegboard Test (PPT, placing as many as possible metal pins into one of 
the 25 holes in a pegboard in 30 seconds). In 3,313 individuals with 18,173 visits, 15-Word 
Learning Tests (15-WLT; including three immediate trials to remember these words (mean used 
for analysis), a 10-minute delayed retrieval task and a recognition task) were additionally obtained.  
 
Covariates 
Data collection for each research visit included a standardized home interview and two visits at 
the research center for clinical examination and blood sampling. Sex, age and ethnicity were 
obtained during the baseline home-interview, ethnicity was categorized as Caucasian or non-
Caucasian. Participants’ level of education and monthly household income at baseline were 
assessed by trained interviewers. Level of education was categorized as low (primary education), 
low/intermediate (lower/intermediate general education or lower vocational education), high 
general (intermediate vocational or higher general education) and university (higher vocational 
education or university). Participants were screened for depressive symptoms using the Center for 
Epidemiology Studies Depression Scale (CES-D Scale).90 Alcohol intake was obtained using the 
AUDIT tool91 in grams/day. Smoking behavior was categorized as never, current or former and 
requested via questionnaires. Housing condition was classified as community-dweller and non-
community-dweller (i.e., service flat, nursing home). History of cardiovascular disease at the visit 
date was obtained from medical records. At the research center, height and weight were measured 
with the participants standing without shoes and heavy outer garments, and with emptied 
pockets, breathing out gently. Height was measured with a wall-mounted stadiometer, recorded to 
the nearest 0.1cm; weight was measured with an electronic floor scale, recorded to the nearest 0.1 
kg. Participants were categorized as having a normal weight or being underweight (<25 kg/m2), 
overweight (25-30 kg/m2) and obese (≥30 kg/m2). Systolic blood pressure was measured twice 
after a resting period of five minutes during a single visit using a random-zero 
sphygmomanometer on the right arm of participants in sitting position. The average of the 
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measurements was used in the analyses. Cholesterol and high-density lipoprotein cholesterol 
(HDL) levels were measured using an automated enzymatic procedure.175 Glucose was measured 
within one week of blood sampling using the glucose hexokinase method.174  Because only 
housing status was readily available at analysis date at the sixth visit of RS-I and the fourth of RS-
II, we assumed that the remaining covariates did not change with respect to the previous visit. 
Alcohol intake was assumed to be the arithmetic mean of the previous visits, as long as there were 
three data points for estimation. 
 
Data analyses 
We used 5-fold multiple imputation with chained equations to impute missing covariates, using 
both covariates and outcomes as predictors. A full description of imputation procedures is shown 
in Appendix 37 (page 142). To examine the influence of imputation procedures on main 
analyses, we also performed a full-case analysis (shown in Appendix 35 (page 140)). General 
characteristics of the population in the imputed dataset are presented in absolute frequency and 
percentage for categorical variables and as median and interquartile range (25th and 75th 
percentile) for continuous variables. Additionally, we compared the general characteristics of the 
participants according to their season of examination. Continuous variables were compared with 
the Kruskal-Wallis test. Categorical variables were compared with Chi-squared test. Seasons were 
classified according to the light definition, centered at equinoxes:32 winter (November 6th to 
February 4th), spring (February 5th to May 6th), summer (May 7th to August 5th), and autumn 
(August 6th to November 5th). 
We calculated global cognition as the first compound of an unrotated principal 
component analysis (PCA) that incorporates tasks from all four cognitive function tests (LDST, 
Stroop, VFT, and PPT). Although three Stroop subtasks are available, we only used data from the 
most complicated task of the Stroop to prevent highly correlated tasks distorting factor loadings 
in the PCA when calculating the g-factor of global cognition. We examined the seasonality of this 
g-factor and of the standardized score (z-score) of each component of the factor (log-Stroop 
interference (because of non-normal distribution), LDST, VFT, PPB both hands) using linear 
mixed model with random intercept for each participant to account for the correlation between 
visits. Date of study visit was included in the model transformed into its cosinor terms (i.e. sine 
and cosine)101,119 with an assumed annual seasonality. The coefficients of the cosinor terms were 
used to calculate the seasonal variation, which corresponds to the maximal difference between the 
highest level (peak) and the lowest level (nadir) of the levels of the corresponding outcome 
throughout the annual period.119 Detailed descriptions to estimate the seasonal variation are 
provided elsewhere.101,119 Confidence intervals around seasonal variation were calculated using 
the delta-method.215  
In all of the following analyses, we adjusted seasonality estimates for non-random 
participation of study population throughout the year. We constructed two models for analyses. 
First, we fitted a crude model, which contained age, sex, and cosinor terms. In additional model, 
we selected several potential confounders based on the basis of literature, including education 
level, systolic blood pressure, total cholesterol levels, HDL-cholesterol levels, glucose levels, use of 
antihypertensive, antidiabetic or statin medication, depressive symptoms, body mass index, 
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smoking behavior, alcohol intake, housing status, number of follow-up visit, date of the visit, and 
date of visit squared.  
We repeated all analyses using as outcome the g-factor that included the delayed WLT 
test in the principal analysis calculation (n=13,826 observations) and the delayed WLT test itself. 
Next, we examined if the fit of the model was improved by flexibilizing the annual variation 
assumption, by including in the model cosinor terms for a biannual variation (biannual 
harmonics). The fit of the models (annual seasonality and annual seasonality with biannual 
harmonics) was compared for each outcome using the Bayesian Information Criterion (BIC). A 
priori, we considered the fit as significantly improved if it was reduced by more than 10 units.216 
We also tested to what extent each component of the g-factor influenced seasonality, by 
re-calculating the g-factor while excluding one of the components at a time and the seasonality of 
the remainder was estimated. 
In stratified analyses, we examined potential effect modification by age (middle-aged (>65 
years), young-elderly (65-75 years), old-elderly (≥75 years), sex, presence or absence of 
cardiovascular disease (defined as at least one of the following: history of cardiovascular disease or 
use of antihypertensive, statin or diabetes medication), depressive symptoms (CES-D scale ≥16), 
education (primary, low/intermediate, high general, and university), MMSE (< 26 or ≥26), low or 
high g-factor (below or above zero), and working status (occupied or not occupied).  
Finally, we conducted a number of sensitivity analyses to test the robustness of our 
findings. First, we excluded participants who were diagnosed with dementia within five years after 
the study visit. Second, we calculated the seasonality of the g-factor and components of the g-
factor only in the years with the most extreme variations of the average monthly ambient 
temperature to test the potential influence of ambient temperature on the seasonality of the g-
factor. Ambient temperature was obtained from the Royal Dutch Meteorological Institute 
(KNMI).67 The monitor is located approximately at 8km from the study district. Third, we visually 
inspected the annual variation of all outcomes without pre-specifying any seasonality 
assumptions, as is done with the use of cosinor terms (such as annual or bi-annual patterns). To 
do this, we converted the date of visit of each participant into the day of the year of the 
corresponding year. Next, we repeated the analyses using flexible splines with seven knots over 
the year,217 instead of the cosinor terms. The obtained predicted values of the outcome and the 
average predicted value per week were plotted. All analyses were performed in Stata version 14.1 
SE (StataCorp LP, College Station, Texas).72  
 
RESULTS 
Characteristics of the overall population at study visit are provided in Table 13 (page 120). 
Median age was 67.1 years (interquartile range (IQR): 60.0-75.2). There were more women (57%) 
than men and most of the participants attained low to intermediate education (41.1%) level of 
education. Participants who attended the research center in winter were on average less than one 
year older than those in summer (68.1 vs. 66.9 years, p<0.01).  Other covariates were largely 
similar across seasons when attending the corresponding examination round ( 
Appendix 30 (page 125)). 
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Seasonality of global cognitive functioning 
Global cognition constructed with factor analysis had an annual seasonal variation with lowest 
values observed in early February, (seasonal variation (SV): 0.04 standard deviation, 95% 
confidence interval (CI): 0.02 to 0.07) (Table 14 (page 121) and Figure 7 (page 123)). This 
variation was also observed in middle-aged participants, among whom the seasonality was larger 
than among the overall population (SV: 0.07 SD, 95%CI: 0.04 to 0.10), with nadir in late 
October (Table 14 (page 121)). Overall, participants with a higher g-factor had a larger seasonality 
of the score than their respective counterparts, such as women (0.05 SD, 0.02 to 0.08, nadir in 
mid-January), participants with low CES-D scale (0.04 SD, 0.01 to 0.06, nadir in mid-January), 
with a g-factor above the average (0.03 SD, 0.01 to 0.06, nadir in late-January), and those with an 
MMSE score of 26 and above (0.05 SD, 0.02 to 0.07, nadir in early-February) (Table 14 (page 
121)). Compared to the age and sex adjusted model, the SV of the g-factor was smaller in the fully 
adjusted model (SV: 0.07 SD, 95%CI: 0.05 to 0.01 vs. 0.04 SD, 95%CI: 0.02 to 0.07), indicating 
that up to 64.6% of the observed seasonality of the g-factor was explained by confounders 
included in the full model (Appendix 31 (page 127)). 
Within a subsample of the observations in which the delayed WLT test was obtained 
(n=13,833, 83%), we recalculated the g-factor, showing similar seasonal variation to that of the g-
factor without the test (SV: 0.04 SD, 95% CI: 0.02 to 0.06), although the nadir was shifted from 
early-February to late-October (Appendix 32 (page 128)). The seasonality of the delayed WLT test 
itself was small and non-significant (SV: 0.02 SD, 95%CI: -0.01 to 0.06). 
According to the BIC value, there is no evidence of better model fit for any of the 
cognitive tests when we included the biannual harmonics in the annual models (Appendix 33 
(page 138)). The seasonality of Stroop Interference and Color naming test and LDST in the crude 
model was largely explained by the covariates, as the seasonal variation was significantly smaller 
when covariates were included in the model (Appendix 31 (page 127)). 
 
Stratified analyses 
The PPT both hands test had a significant seasonality in every subgroup examined, except in the 
old-elderly population and in those with working status occupied (Appendix 32 (page 128)). The 
magnitude of the seasonality was higher among those with a higher g-factor. The VFT also 
showed a significant seasonality among most of the subgroups analyzed, except among old-elderly, 
those with primary and intermediate-high education, g-factor above the average, and MMSE score 
equal or above 26.  
 
Seasonality of cognitive function based on individual tests 
The seasonality of the g-factor was mostly driven by the seasonality of the PPT for both hands, 
which showed the largest variation with lowest values in early January (SV: 0.08 SD, 95%CI: 0.05 
to 0.11) and the VFT, which had the lowest value in late January (SV: 0.04 SD, 0.01 to 0.07) 
(Table 15 (page 122) and Figure 7 (page 123)). Indeed, after excluding the PPB for both hands 
from the g-factor calculation, the seasonality of the g-factor was smaller (SV: 0.03 SD, 95%CI: 
0.01 to 0.06) (Appendix 34 (page 139)).  
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Sensitivity analyses 
First, after excluding participants with a dementia diagnosis within the first five years after their 
last visit, the g-factor seasonality remained largely unchanged and statistically apparent (SV: 0.04, 
95%CI: 0.02 to 0.07) (Table 14 (page 121)). The seasonality of the cognitive tests also remained 
similar after excluding these participants (Appendix 32 (page 128)). Second, in analyses among 
participants who attended the years with the most extreme variations in monthly average ambient 
temperature, the seasonality of the VFT test becomes smaller, whereas the seasonality of 
immediate, delayed and recognition tests becomes larger and significant, all with nadir in late-
February (Appendix 36 (page 141)). Third, we found no evidence of substantial differences in the 
seasonal variation between the model using flexible splines and the annual plus harmonics test 
(Appendix 38 (page 143)). 
 
DISCUSSION 
In this study, we found an annual seasonality pattern of cognitive performance with up to three 
times lower global cognition in winter compared to summer among community-dwelling 
individuals. In addition, a lower seasonal variation was consistently observed among those 
individuals who had lower global cognition, attained lower levels of education and had lower 
MMSE score. These findings highlight the potential role of seasonal factors on cognitive 
performance and suggest that a smaller seasonal variation in cognitive performance may yield 
information on cognitive deterioration. 
To our knowledge, this is the first study to examine the seasonality of cognitive function 
in middle-aged and elderly individuals from a large, population-based cohort. So far, few studies 
have examined the seasonality of cognitive function, reporting heterogeneous results. For 
instance, among 80 healthy cognitively unimpaired individuals from the United States (US) 
(mean age 20.9 years SD = 2.0) who underwent cognitive tests at different times of the year while 
measuring brain activity using electroencephalographic (EEG) P300 waves, a higher activity was 
observed during spring and summer compared to autumn and winter.212 The P300 wave is an 
electroencephalographic measure of brain response under processes of decision making.218,219 In 
contrast, another study from the US, among 32 healthy participants (mean age 26.2 years SD = 
5.1), showed that auditory and visual P300 and visual slow waves were highest in winter or spring. 
These participants were also measured at two different seasons.213 More recently, a cross-sectional 
fMRI study in young healthy adults showed that brain areas involved in attention tasks had a 
stronger brain activity in summer than in winter.214 Also, brain areas involved in working memory 
tasks had a seasonal variation, which was slightly smaller and shifted about three months later 
than those in involved in attention tasks.214 Nevertheless, they did not observe seasonality in a 
visual psychomotor vigilance task (sustained attention). Among 100 community-dwelling people 
from Tromso, about 300 kilometers above the Arctic Circle, no seasonality was observed in the 
performance of cognitive tests such as Stroop, time estimation, short-term memory (Sternberg 
task), or face recognition.36 However, they found a better performance in speed of reaction task, 
dot numerosity, mapping, and word memory during winter and in fluency during summer.36  In a 
longitudinal study with allergic patients, these had a slight reduction in the speed of cognitive 
processing and some individuals had difficulties in working memory, whereas no variation was 
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observed in non-allergic individuals during the ragweed season.208 These findings may suggest that 
brain pathways involved in cognitive functioning are influenced by different environmental 
conditions depending on the season, leading to seasonal variation in some cognitive tests, but not 
in others. 
In this study, the seasonal variation of cognitive function was mostly explained by a lower 
performance in a manual dexterity test (the Purdue Pegboard Task) and in a verbal fluency test 
during winter. Mechanistic and biological mechanisms can explain these findings. Among 
mechanistic, cold exposure may explain the lower test performance on the Purdue Pegboard Task 
in winter. For this test, as many as possible cylindrical metal pins have to be put into small holes 
on a board within 30 seconds – an effort that may be affected by ambient temperature, such as 
having cold hands. It is unlikely that ambient temperature also influences the test performance 
on the VFT test, where individuals have to come up with as many as possible animal names 
within one minute. However, evidence coming from 594 elderly men within the Veterans Affairs 
Normative Aging Study showed a decreased risk of low MMSE score when ambient temperature 
was between 10-15oC, whereas the risk increased at temperatures above and below this range.209 
As such, it is possible that when ambient temperature is too low or too high, participants may feel 
themselves uncomfortable and subsequently become inattentive, what could influence the test 
performance.209 Among biological mechanisms, one study found higher activation of frontal, 
dorsolateral, prefrontal and parietal cortex under warmer temperatures during sustained 
attention task among patients with multiple sclerosis.220 It is also suggested that ambient 
temperature may influence brain functions (e.g. learning and memory) through alterations on 
hippocampal neural activities.209 Unfortunately, we did not have information on indoor 
temperature. This would be useful to disentangle the contribution of either mechanism because, 
for example, the potential influence of ambient temperature may be affected by the use of heaters 
and air conditioning inside the visit center building. Therefore, future studies examining the 
influence of temperature in cognitive performance while controlling for indoor temperature and 
thermal adaptation are required to test these hypotheses. 
Other potential mechanisms explaining the seasonality of cognition could be sunlight 
exposure and seasonal mood changes. The circadian rhythm associated to sunlight exposure may 
underlie the seasonality of cognition.214 However, no association was observed between the 
seasonality of EEG P300 wave length amplitude and sunlight time.213 The vitamin D insufficiency 
has been associated with lower cognition performance,210,211 thus, the seasonality of vitamin D 
might also relate the seasonal variation of sunlight exposure with cognition seasonality. 
Nevertheless, it is unclear if vitamin D levels could influence the cognition performance on a 
short-term basis or the extent at what the levels should fluctuate to induce such seasonality on 
cognition. Changes in mood may also contribute to the seasonality of cognition, as these are 
highly influenced by seasonal factors.221,222 For instance, a case-control study among bipolar 
patients, their first-degree relatives, and unrelated controls,207 found that individuals from 
families of patients performed worse during winter compared to controls on measures of visual 
and verbal attention, working memory, verbal ability, verbal fluency and executive functioning. In 
a study aimed to test the seasonality of cognitive function among participants with seasonal 
affective disorder, the patients showed improved attention during summer, when compared to 
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controls.37 However, one study performed in Turkey among hemodialysis patients did not observe 
seasonality in MMSE score, but they found a significant seasonality in depression symptoms and 
quality of life.223 We observed a seasonal variation of cognition independently of mood status, but 
it was statistically significant only among those who did not report the presence of depressive 
symptoms; thus, further studies are required to specifically address this potential mechanism. 
Larger seasonal variation was consistently observed among participants with higher 
cognitive performance. We hypothesize this could be a sign of healthier or better preserved 
cognitive function, where healthy participants may have a better capability to cope with 
environmental changes across seasons.224,225 Cognitively impaired individuals also exhibited a 
seasonal variation in cognition, but of smaller amplitude. Additionally, we observed that the 
inclusion of covariates in the statistical model had a larger impact in the magnitude of the 
seasonal variation among those more cognitively impaired than among the unimpaired. The 
inclusion of covariates in the model is aimed to account for the uneven distribution of 
participants’ characteristics across the year, what may lead to a spurious seasonal variation of 
cognition. This finding is in concert with our hypothesis that among cognitively impaired 
individuals, the cognitive performance remains relatively stable on their pathophysiological 
(neurodegenerative) level throughout the year, whereas cognitively more unimpaired individuals 
could be able to fluctuate across seasons, relying on their cognitive reserve. 
Because decline in cognition may lead to poor decision- making ability and executive 
functioning,226,227 a seasonal variation in cognitive function could help to understand the nature 
of other seasonality phenomena among ageing populations. For example, the winter increase of 
cardiovascular disease5 and the mortality excess related to heat waves could be partly attributed to 
reduced awareness of cool or warm feeling and execution of preventive measures. Our findings 
underscore the potential effects of seasonality on cognition and highlight that lack of seasonality 
across cognitive tests may be indicative for potential cognitive decline. Yet, as this is the first 
attempt to generalize findings from small and cross-sectional studies to the general population 
using a large cohort study, further studies are required to examine whether the effect estimates 
have a direct translation to clinical practice. It would be interesting to further study the potential 
role of seasonality effects involved in physiological pathways that constitute cognitive performance 
and maintain cognitive reserve. 
Strengths of this study include the repeatedly and consistent cognitive test assessments in 
a large sample size of community-dwelling individuals. This reduces the between-subject 
heterogeneity that could explain the seasonal patterns. Additionally, we took a large set of 
potential confounders into consideration and we examined several sensitivity analyses to test the 
robustness of findings. Additionally, we also provided evidence that participants do not attend 
the research at random independently of the season, because up to 60% of the crude seasonal 
variation of the g-factor was explained by participants’ characteristics. Nevertheless, some 
limitations deserve attention. First, we were not able to examine the seasonality of the cognition 
performance for the same individual at different seasons, because these volunteers attend the 
center at their best convenience during the year. For instance, individuals who had a demanding 
job may have visited the research center more often during holidays (e.g., summer times). These 
cognitively active individuals may have subsequently performed better on their cognitive tests, 
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confounding our results. However, there were no large differences in the proportion of occupied 
participants attending the research center across seasons, in fact, those who were occupied tended 
to attend the center more often in winter compared to summer (76.5% vs. 74.6%, p = 0.10). 
Moreover, results were unaffected after adjusting for several covariates, including educational 
level, household income and cardiovascular risk factors, yet we cannot exclude any further 
residual confounding. Second, by design, the generalizability of our findings is limited to white 
middle-aged and elderly population and may not generalizable to settings with smaller 
environmental differences across seasons, such as ambient temperature and sunlight hours. 
In conclusion, we observed a seasonal variation in cognitive function, with lowest values 
in winter months. This pattern is largely explained by the seasonality of a manual dexterity and a 
verbal fluency test. These findings were more pronounced among individuals with higher 
cognitive functioning; indicating that seasonal variation in cognitive performance may provide 
information about healthy brain function ageing. Future studies are warranted to better 
understand the potential influence of the seasonality on cognitive performance, and to establish 
whether the season of a cognitive assessment may be of clinical importance. 
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Table 13. Characteristics of the participants at date of study visit 
Covariates  Median IQR 
Age, years  67.1 60.0 75.2 
Depression (CES-D scale)  10.0 2.0 13.0 
Alcohol intake, grams/day  6.4 1.0 14.0 
Systolic blood pressure, mmHg  142.0 128.0 157.0 
Total cholesterol, mmol/L  5.6 4.9 6.3 
HDL-cholesterol, mmol/L  1.4 1.2 1.7 
Glucose, mmol/mL  5.5 5.1 6.0 
    
  n % 
Sex     
     Men  7,156 42.8 
     Women  9,551 57.2 
Ethnicity    
     Other  678 4.1 
     White  16,029 95.9 
Living situation    
     Community-dweller  16,654 99.7 
     Non-community dweller  53 0.3 
Education    
     Low  1,433 8.6 
     Low/intermediate  6,872 41.1 
     High general  5,022 30.1 
     University  3,381 20.2 
Smoking status    
     Never  5,162 30.9 
     Current  2,935 17.6 
     Former  8,611 51.5 
Body mass index    
     <25 kg/m2  4,782 28.6 
     25-30 kg/m2  8,006 47.9 
     ≥30 kg/m2  3,919 23.5 
History of cardiovascular disease    
     No  14,804 88.6 
     Yes  1,903 11.4 
Medication use    
Antihypertensive    
     No  10,006 59.9 
     Yes  6,701 40.1 
Antidiabetic    
     No  15,530 93.0 
     Yes  1,177 7.0 
Statin     
     No  12,781 76.5 
     Yes  3,926 23.5 
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Table 14. Seasonality of g-factor in overall population and stratified 
Strata Observations 
Average  
g-factor 
 Seasonal 
variation 
95% CI Nadir 
 
All 16,707 -0.01  0.04 0.02 0.07 1-Feb 
Age-group        
     Middle-aged 7,123 0.34  0.07 0.04 0.10 28-Oct 
     Young-elderly 5,310 0.06  0.05 0.00 0.09 5-Mar 
     Old elderly 4,274 -0.69  0.04 -0.02 0.10 6-Mar 
Sex        
     Men 7,156 -0.08  0.04 0.00 0.07 29-Feb 
     Women 9,551 0.04  0.05 0.02 0.08 15-Jan 
CES-D        
     <16 14,357 0.02  0.04 0.01 0.06 20-Jan 
     ≥16 2,155 -0.16  0.07 -0.01 0.16 22-Apr 
Education        
     Low 1,412 -0.78  0.01 -0.09 0.10 2-Jun 
     Low/intermediate 6,788 -0.12  0.07 0.03 0.10 24-Jan 
     High general 4,966 0.04  0.05 0.01 0.09 11-Mar 
     University 3,346 0.46  0.03 -0.01 0.08 7-Dec 
g-factor        
     Below average 7,826 -0.83  0.02 -0.02 0.05 13-Mar 
     Above average 8,881 0.72  0.03 0.01 0.06 28-Jan 
MMSE        
     ≥26 13,723 0.14  0.05 0.02 0.07 1-Feb 
     <26 2,933 -0.73  0.04 -0.03 0.12 15-Feb 
Dementia diagnosis < 5 years        
     Excluded 16,354 0.02  0.04 0.02 0.07 3-Feb 
Working status        
     Occupied 2,806 0.37  0.04 -0.04 0.12 19-Oct 
     Not occupied 8,751 -0.26  0.04 0.00 0.07 24-Nov 
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Table 15. Seasonality of cognitive tests 
Cognitive tests* Observations 
Average  
g-factor 
 Seasonal 
variation 
95% CI Nadir 
 
  
g-factor 16,707 -0.01  0.04 0.02 0.07 1-Feb  
LDST 16,707 -0.01  0.02 -0.01 0.04 10-May  
log-Stroop Interference 16,707 0.01  0.04 0.02 0.07 5-Mar  
VFT 16,707 0.00  0.04 0.01 0.07 28-Jan  
PPT - both hands 16,707 -0.01  0.08 0.05 0.11 0-Jan  
         
g-factor + delayed WLT 13,833 -0.04  0.04 0.02 0.06 26-Oct  
g-factor of participants with WLT 13,833 0.03  0.04 0.02 0.07 20-Oct  
Delayed WLT 13,833 -0.02  0.02 -0.01 0.06 19-Dec  
         
Immediate WLT 13,837 -0.02  0.04 0.01 0.08 13-Jan  
Recognition WLT 13,930 -0.01  0.03 -0.01 0.07 29-Jan  
log-Stroop Color naming 16,706 0.01  0.04 0.01 0.07 15-Feb  
log-Stroop Reading 16,704 0.01  0.02 -0.01 0.05 26-Dec  
*All cognitive tests, except g-factor, are standardized. LDST: Letter-Digit Substitution Task; VFT: Verbal Fluency Test; 
PPT: Purdue Pegboard Task; WLT: 15-Word Learning Test 
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Figure 7. Seasonal variation of g-factor and standardized cognitive tests 
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LDST: Letter-Digit Substitution Task; VFT: Verbal Fluency Test; PPT: Purdue Pegboard Task; WLT: 15-Word Learning 
Test. Annual + H means annual variation plus biannual harmonics. Monthly averages are adjusted for cosinor terms, age 
(linear and quadratic), ethnicity, SBP, cholesterol, HDL-cholesterol, glucose, antihypertensive, antidiabetic, statins intake, 
CES-D scale, BMI (categories), smoking behavior, alcohol intake, housing status, education, cohort, date (linear and 
quadratic). 
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Appendix 33. Selection of variation according to AIC and BIC 
Cognitive test 
AIC  BIC 
Annual variation 
Annual + harmonic 
variation 
 Annual variation 
Annual + harmonic 
variation 
g-factor 40731.25 40732.40  40777.59 40794.18 
LDST 104392.90 104396.53  104439.24 104458.32 
Stroop Reading -13446.32 -13448.48  -13399.98 -13386.69 
Stroop Color naming -13744.78 -13748.14  -13698.44 -13686.35 
Stroop Interference 5287.89 5291.31  5334.23 5353.10 
VFT 101222.17 101225.17  101268.51 101286.96 
PPB both hands 65166.18 65164.06  65212.53 65225.85 
g-factor + delayed WLT 34334.57 34324.82  34379.78 34385.10 
Delayed WLT 66046.18 66049.79  66091.39 66110.07 
Immediate WLT 90101.48 90098.95  90146.69 90159.23 
Recognition WLT 57522.05 57526.03  57567.30 57586.36 
Bold values are lowest AIC or BIC, respectively. LDST: Letter-Digit Substitution Task; VFT: Verbal Fluency Test; PPT: 
Purdue Pegboard Task; WLT: 15-Word Learning Test 
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Appendix 34. Seasonality of g-factor recalculated after excluding one component at a time (n=16,307) 
Strata Average 
 Annual seasonal variation  Annual + harmonics seasonal variation 
 
Seasonal 
variation 
95% CI Nadir  
Seasonal 
variation 
95% CI Nadir 
Excluding LDST -0.01  0.06 0.04 0.09 25-Jan  0.05 0.01 0.09 28-Mar 
Excluding VFT -0.01  0.04 0.02 0.06 3-Feb  0.03 0.00 0.07 9-Apr 
Excluding PPT  
     both hands 
-0.01  0.03 0.01 0.06 29-Aug  0.04 0.01 0.08 18-Nov 
Excluding Stroop  
     interference 
-0.01  0.05 0.02 0.07 19-Jul  0.03 -0.01 0.07 22-Jul 
 
LDST: Letter-Digit Substitution Task; VFT: Verbal Fluency Test; PPT: Purdue Pegboard Task 
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Appendix 37. Flowchart of data selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Missing LDST = 3,847 observations; missing Stroop 3= 4,555 observations; missing VFT = 3,844 observations; missing 
PPB-both hands = 8,586 observations. 
 
Imputation procedures: Sequential multiple imputation using chained equations was performed to impute missing values 
of covariates. This approach has been shown to work well in the context of complex longitudinal data, as in the 
Rotterdam Study.178 The predictors used to impute the covariates were previous CVD, sex, age, cohort, visit, month, 
Stroop interference, VFT, LDST, date, date squared, systolic blood pressure, total-cholesterol, HDL-cholesterol, glucose, 
intake of antihypertensive, antidiabetic or statin medication, CES-D scale, body mass index (categories), smoking 
behavior, alcohol intake, physical activity (z-score of MET-hours/week), education, and housing status. To impute 
dichotomous variables (intake of antihypertensive, diabetic, or statin medication, and housing status) we used a logit 
function. To impute ordered categorical variables (education and body mass index (categories)) we used an ordered logit 
function. To impute categorical non-ordered variables (smoking behavior) we used a multinomial logit function. To 
impute continuous variables (physical activity and alcohol intake) we used a linear function. To ensure reproducibility, we 
used a random seed (2005). We created five imputed datasets, which were used in all the analysis. Covariates with missing 
values were: systolic blood pressure: 167 missing, HDL-cholesterol: 389 missing, total cholesterol: 382 missing, glucose: 
383 missing, CES-D scale: 195 missing, physical activity: 4,402 missing, alcohol intake: 1,599 missing, intake of 
antihypertensive: 89 missing, antidiabetic intake: 85 missing, statin intake: 88 missing, housing status: 100 missing, 
education: 195 missing, body mass index: 130 missing, smoking behavior: 110 missing. Imputations were performed using 
the mi impute command of Stata software.  
27,527 observations 
(11,948 participants) 
27,343 observations 
(11,827 participants) 
26,474 observations 
(11,239 participants) 
16,709 observations 
(8,560 participants) 
9,765 observations (2,679 participants) with 
incomplete data of neuropsychological tests* 
869 observations (588 participants) with diagnosis 
of dementia at visit date 
184 observations (121 participants) who did not 
provide informed consent for follow-up or who 
attended only before the cognitive test battery was 
added to the core protocol 
 
16,707 observations 
(8,560 participants) 
2 observations because of unreliable data in Stroop 
Interference test 
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Appendix 38. Seasonality of cognitive tests – using flexible spines 
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LDST: Letter-Digit Substitution Task; VFT: Verbal Fluency Test; PPT: Purdue Pegboard Task; WLT: 15-Word Learning 
Test 
 
  
145 | Chapter 2.2 
 
2.2.4 Seasonality of antimicrobial resistance in critically important bacteria that pose a great 
threat to public health: A systematic review and meta-analysis 
 
Evelyn Pamela Martinez*, Magda Cepeda*, Marija Jovanoska, Wichor M. Bramer, Josje D. 
Schoufour, Marija Glisic, Annelies Verbon, Oscar H. Franco 
*These authors have contributed equally to this paper. 
 
ABSTRACT 
Introduction: There is a perception that antimicrobial resistance (AMR) may display seasonal 
variation due to an increase use of antibiotics because seasonal outbreaks of infectious diseases. 
We aim to assess seasonality of AMR in five bacteria that imposed higher risk to public health.  
 
Methods: Six online databases (Embase.com, Medline Ovid, Cochrane CENTRAL, Web of 
Science Core Collection, Biosis Ovid, and Google Scholar) were searched until September 2017. 
We selected observational studies describing resistant rates of Campylobacter spp., Salmonella spp., 
Escherichia coli, Streptococcus pneumoniae, and Haemophilus influenza at least in two different seasons, 
independently of sample source at any setting (e.g. humans and animals) and geographical region. 
Two authors appraised studies independently. Primary outcome measures were pooled odds 
ratios (OR) of seasonal AMR rates and 95% confidence intervals per bacteria type, antibiotic 
class, geographical region, and sample source. Pooled OR were calculated by using a random-
effects meta-analysis. 
 
Results: We included 32 references, of which 28 were meta-analyzed. AMR rates of S. pneumoniae 
and H. influenzae against penicillins and cephalosporines were lower in other seasons than in 
winter (OR = 0.72, 95% CI=0.66-0.78). AMR rates of E. coli were lower in other seasons than in 
summer, but these were heterogeneous according to sample source, geographical regions, and 
antibiotic classes (OR=0.70, 95%CI= 0.54-0.79). Multidrug-resistant rates of S. pneumoniae and E. 
coli were higher in winter and spring. No significant seasonal AMR rates were observed for 
Salmonella spp. and Campylobacter spp.  
 
Conclusion: AMR rates of S. pneumoniae, H. influenzae, and Escherichia coli exhibit a seasonal 
variation, explained by seasonality of infectious diseases and to antibiotic use. There is need to 
increase awareness on rational antibiotic use and to strengthen stewardship to efficiently detect 
and address increasing AMR rates.  
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INTRODUCTION 
The World Health Organization (WHO) published a list of critically important resistant bacteria 
that impose a high burden for public health. 228 This list includes bacteria such as Streptococcus 
pneumoniae, Haemophilus influenzae, Escherichia coli, Campylobacter spp., and Salmonella spp. 228 
Globally, these bacteria are responsible for 550 million respiratory and foodborne infections 
among humans, and 230.000 deaths every year. 229-231 In addition, almost 50% of all women will 
experience at least one episode of urinary tract infections (UTI’s) caused by E. coli during their 
lifetime, leading to increased hospital stay and higher health care costs. 232,233 
As antimicrobial resistance (AMR) is increasing globally, the morbidity and mortality 
related to resistant infections are also expected to increase. Indeed, it has been estimated that 
AMR will be responsible for an extra 10 million of deaths in 2050.234 The increase of AMR rates 
has been linked to antimicrobial use in human and in veterinary medicine.41,44,234-236 Nevertheless, 
the use of antibiotics differs according to geographical region, mostly due to local practices and 
regulations regarding the use of antibiotics and husbandry practices in food-producing 
animals.39,44,236-241 Moreover, such differences appear to also be determined by environmental 
factors, which in light of the increasing burden imposed by climate change, may influence the 
occurrence of diseases and higher prevalence of infections with resistant bacteria.242   
Emerging evidence suggests that AMR rates vary with seasons because of the seasonal 
incidence of infectious diseases and the accompanying antimicrobial use. 39-45 In Europe and the 
USA, the use of antibiotics such as penicillins and cephalosporins increase in winter, along with 
the increase of respiratory infections caused by S. pneumoniae and H. influenza. 39-41,45,243  In 
humans, higher resistance rates of Campylobacter spp. to fluoroquinolones and macrolides have 
been reported in winter.244,245 In contrast, high resistance rates of urinary E. coli to nitrofurantoin 
and sulphamides have been reported in summer. 246 In animals and carcasses, foodborne bacteria 
(e.g. Salmonella spp., Campylobacter spp., and E. coli) were shown to have peak resistance rates to 
fluoroquinolones, macrolides, and tetracyclines in summer and autumn, when the incidence of 
enteric diseases is also high.247-249 
There is a large variability in the seasonal patterns of AMR across the literature. Such 
variability can be attributed to differences in methodological approaches across studies, 
antimicrobial prescription settings in human and veterinary medicine, geographical regions and 
the incidence of infectious diseases. In this era of increasing AMR, it is pivotal to understand all 
phenomena contributing to the selection of antimicrobial resistant bacteria. Nevertheless, to the 
best of our knowledge, no previous effort has been made to systematically review evidence that 
addresses seasonal AMR and to assess the heterogeneity across the literature. Here, we 
systematically reviewed relevant published studies to assess seasonal AMR variation in the most 
important foodborne bacteria and respiratory bacteria, both in humans and in animals. 
 
METHODS 
Search strategy  
We performed a systematic review of all published studies describing the seasonal variation in 
AMR of Campylobacter spp., Salmonella spp., Escherichia coli, Streptococcus pneumoniae, and 
Haemophilus influenzae. The search of relevant studies was performed until September 27th, 2017.  
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Embase.com, Medline Ovid, Cochrane CENTRAL, Web of Science Core Collection, Biosis 
Ovid, and Google Scholar databases were used to identify published observational studies.  
There was no publication date or language restriction. The search was performed by 
using combined terms related to antibiotic resistance (e.g. "penicillin resistance") and bacteria (e.g. 
"'Campylobacter OR campylobacteriosis") with seasonality terms (e.g. "winter OR cold").  
Additional studies were searched by reviewing the references list from the full-text retrieved 
studies and by contacting authors via e-mail. The full search strategy is available (Appendix 39, 
page 163).  
 
Selection criteria and quality assessment 
Studies were included if they presented resistance rates at least in two different seasons of 
Campylobacter spp., Salmonella spp., Escherichia coli, Streptococcus pneumoniae, and Haemophilus 
influenzae, from human and animal sources. Studies evaluating vaccination programs, literature 
reviews, abstracts, reports, thesis, and protocols were excluded. By working independently, all 
studies were reviewed by title and abstracts by four independent authors. Titles selected were full-
text retrieved and read independently by two authors to identify those that fulfilled the selection 
criteria (Appendix 39, page 163), with a third investigator available in case of disagreement. 
A modified version of the Newcastle-Ottawa Scale (NOS) was used to assess the quality of 
included studies (Appendix 39, page 163). We used as main quality criteria the representativeness 
of sample source, the length of follow-up, comparability of the population within the study 
period, reliability measure of antibiotic sensitivity and clear description of the outcome.  
 
Data extraction and statistical analysis 
From each study, relevant data were extracted and registered on a purposely designed 
form. We extracted general information (e.g. year, study design), bacteria type, antibiotic class, 
and season definition (Appendix 39, page 163). Furthermore, we extracted the frequency and the 
percentage of resistant and (if available) intermediate resistant bacteria per antibiotic class, and 
the total number of bacteria described. Frequency and percentage of multidrug-resistant (MDR) 
bacteria (i.e. bacteria resistant to two or more antibiotics) was also extracted.  
Seasons were defined as winter (December to February), summer (June to August), 
autumn (September to October), spring (March to April). Depending on the geographical region 
of the study, and information provided by the authors, we also used the season definition as cold 
(November to April), warm (May to October), wet (Jun to September), and dry (October to May). 
Country of the studies were categorized into regions according to the WHO Member States 
regions to Eastern Mediterranean, Europe, America, South East Asia, and Western Pacific. 
Antibiotic drugs were categorized into classes as aminoglycosides, penicillins, cephalosporins, 
phenicols, fluoroquinolone, macrolides, nitrofurans, sulphamides, trimethoprim, and 
tetracyclines ((Appendix 39, page 163).  
We performed several analyses to compare seasonal AMR per bacteria type, antibiotic 
class, sample source and geographical region. First, for each study, we calculated the resistance 
rates per season, stratified according to bacteria type, antibiotic class, and sample source, using as 
numerator the number of resistant isolates and as denominator the total number of isolates 
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tested per season. If the denominator (total number of isolates per season) was not available, we 
assumed that the sampling was equally distributed across the full length of the study. Thus, we 
calculated the denominator by dividing the overall number of isolates tested in the study by the 
number of seasons included in the study (i.e. dividing by four if the study presented resistance 
rates for four seasons). In addition, for studies in which monthly resistance rates were provided, 
resistance rates were pooled according to season category within each bacteria type and antibiotic 
class. Finally, for studies in which monthly resistance rates were provided per month and per year, 
we first pooled the monthly resistance rates per year into season category, and then seasonal 
resistance rates were calculated by dividing the sum of resistant isolates per month of the four 
months of the corresponding season by the sum of the isolates examined per month of the four 
months of the corresponding season.  These rates were calculated per antibiotic class and sample 
source.  
Second, using the rates calculated for each study in the previous step, we calculated the 
ratio of resistance rates between any season vs. winter, which was the reference category. The 
ratios were calculated stratified by bacteria type, antibiotic class, and sample source. For those 
studies that only compared spring and autumn, spring was the reference group. For the studies in 
which seasons were defined as cold and warm, or wet and dry, cold and wet were the reference 
groups, respectively. In addition, for the studies in which resistance rates were presented 
comparing June – August vs. other nine months of the year, June-August was defined as summer 
and was the reference group.  
Finally, we carried out random-effects meta-analyses to calculate pooled odd ratios (OR) 
for each comparison (any season vs. winter), stratified according to bacteria type, antibiotic class, 
bacteria, and sample source. As a subgroup analysis, we recalculated the meta-analyses according 
to study region. We calculated 95% confidence intervals for each pooled odds ratio. 
Heterogeneity was measured using the I-squared test. We examined publication bias for each 
comparison by examining asymmetry funnel plots and using Egger's test. All tests were two-tailed 
and p-values ≤ 0.05 were significant. All analysis was carried out using the statistical software Stata 
MP 14 and R Studio.  
 
RESULTS  
Study selection and main characteristics 
A total of 3,261 studies were identified through database searching, of which 211 studies 
were selected for full-text assessment. After the final appraised, 32 studies were included for the 
qualitative synthesis, of which 28 studies were quantitative analyzed (see Figure 8 (page 159) for 
reasons of exclusion). No additional studies were identified by either manual research or contact 
to authors. 18 of 32 studies reported a random recruitment of data across seasons (at least two 
seasons), and 13 of 32 adjusted prevalence resistant rates by season (Appendix 40, page 168). 
For the calculation of seasonal AMR, in 8 studies, 238,245,246,249-254 the denominator was 
imputed by dividing the overall number of isolates by the number of seasons. In other 8 studies, 
41,44,45,244,255-258 for the denominator was necessary to pooled monthly resistance rates by season 
first, and the seasonal AMR were calculated. In 3 studies, 239,251,259 monthly resistance rates per 
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year were firstly categorized by season, and then seasonal AMR were calculated as previously 
described.  
In addition, for the meta-analysis winter was mainly the reference group, however, cold 
season was the reference group in 3 studies, 250,256,260 wet season in other 3 studies, 243,256,261 and 
summer (June-August) was the reference group in two studies. 258,262  
Most of the studies were cross-sectional (n=23) and performed in human samples (n=23). 
Studies were mainly performed in Europe (n=14) and reported resistance rates of E. coli (n=13). 
In humans, E. coli was isolated in patients with UTI´s (n=6), whereas in animals, E. coli originated 
from the gut (n=4) (Table 16, page 155). In humans, the highest resistance rates were found 
against penicillins, cephalosporins and macrolides in both respiratory bacteria (S. pneumoniae and 
H. influenzae). The highest resistance rate for urinary E. coli was against nitrofurantoins, 
aminoglycosides and cephalosporins. In animals, antibiotic resistance in foodborne bacteria (E. 
coli, Salmonella spp, and Campylobacter spp.) was most commonly against fluoroquinolones, 
macrolides and tetracyclines (Table 16, page 155). Additional characteristic of included studies is 
available (see Appendix 41, page 169).   
 
Seasonal variation in antimicrobial resistance of S. pneumoniae and H. influenzae  
Included studies mainly described resistance rates of S. pneumoniae and H. influenzae causing 
respiratory infections in children. The AMR rates in S. pneumoniae were lower in other seasons 
than in winter (pooled OR = 0.72, 95% CI=0.66-0.78, I2=17.9%, Egger’s P=0.11) (Figure 9, page 
160). In addition, AMR rates were lower in dry and warm months and in autumn (see Appendix 
42, page 172).  
Lower resistance rates in other seasons than in winter were observed for penicillins (OR= 
0.69, 95% CI=0.62-0.77) cephalosporins (OR= 0.78, 95% CI=0.66-0.92), and MDR isolates 
(OR= 0.75, 95% CI=0.50-1.13) (Figure 9, page 160). Only one study examined the seasonality of 
AMR rates in H. influenzae to penicillins and it was not significant (Table 17, page 157). The 
seasonal AMR rates both in H. influenzae and S. pneumoniae were similar after stratifying by 
geographical region (Table 17, page 157). We identified relative relatively low heterogeneity 
(I2<60 %) (Figure 9, page 160), and no evidence of publication bias according to Egger´s test and 
by visual inspection of funnel plots (Table 17, page 157 and Appendix 43, page 173).  
 
Seasonal variation in antimicrobial resistance of E. coli  
The AMR rates in urinary E. coli were lower in other seasons than in winter (pooled OR= 0.96, 
95%CI=0.89-1.03, I2=56.0%, Egger’s P= 0.23) (Figure 10, page 161). Based on two studies, 258,262 
resistance rates were lower in the other nine months of the year compared to summer (pooled 
OR=0.70, 95%CI= 0.54-0.79, I2=68%, Egger's P=0.12) (Appendix 44, page 174).  
Higher AMR rates were observed in summer than in winter to nitrofurans (OR= 1.41, 
95% CI=1.06-1.88) and tetracyclines (OR= 2.02, 95% CI=1.30-3.13) (Figure 10, page 161). Also, 
resistance to sulphamides, tetracyclines and multidrug-resistance occurred at higher rates in spring 
and winter (Figure 10, page 161). 
Additionally, seasonal AMR rates varied according to geographical region. In Europe, 
resistance rates were lower in winter, whereas in Western Pacific and American countries these 
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were higher in summer (Table 18, page 158).  We identified medium heterogeneity (I2 >50%) and 
no evidence of publication bias for these meta-analyses (Table 18, page 158 and Appendix 43, 
page 173). 
In animals, included studies mainly described resistance rates of commensal E. coli from 
healthy food-producing animals and carcasses. The seasonal antimicrobial resistance rate was 
higher in other seasons than in winter (pooled OR=1.14, 95% CI=1.02-1.28, I2=75.3%, Egger’s 
P= 0.30) (Figure 11, page 162). Resistance to phenicols and macrolides occurred at higher rates in 
summer than in winter, and resistant to sulphonamides occurred at higher rates in winter and 
spring (Figure 11, page 162). Furthermore, seasonal AMR rates varied by geographical region. In 
Europe, resistant rates were lower in other seasons than in winter, whereas in Eastern 
Mediterranean and American countries these were higher in summer (Table 18, page 158). We 
identified high heterogeneity (I2 >80%), and evidence of publication bias in some meta-analyses 
(Table 18, page 158 and Appendix 43, page 173). 
 
Seasonal variation in antimicrobial resistance of Salmonella spp. and Campylobacter spp.  
No significant seasonality was observed in AMR of Salmonella spp.  and Campylobacter spp.  from 
humans with foodborne diseases or from healthy food-producing animals and carcasses. In one 
study performed in humans, 245 the resistance rates of Campylobacter spp. to fluoroquinolones and 
macrolides were lower in summer than in winter (OR= 0.86, and 95% CI=0.73-1.01). In one 
study performed in humans, 261 the occurrence of multidrug- resistant Salmonella spp. was similar 
in dry vs. wet seasons (OR= 1.01, and 95% CI=0.51-1.98).  
In animals, resistance rates of Campybolacter spp. were higher in autumn than in spring, 
although the difference was not statistically significant (pooled OR =1.52, 95%CI=0.97-2.39, 
I2=76.6%, Egger’s P= 0.48). Similar findings were observed for AMR to fluoroquinolones, 
macrolides, and tetracyclines (Appendix 45, page 175).  One study performed with chicken 
carcasses 247 showed higher rates of AMR of Salmonella spp. in summer than in winter, although 
the difference was not statistically significant (OR= 2.48, and 95% CI=0.55-11.11, I2=26.6%, 
Egger’s P= 0.01 ) (Appendix 45, page 175). 
 
DISCUSSION  
Our systematic review and meta-analysis suggests there is seasonality in the AMR rates of S. 
pneumoniae, H. influenzae and E. coli. For Salmonella spp. and Campylobacter spp. there is no 
evidence of seasonal variation in AMR rates. AMR rates of S. pneumoniae and H. influenzae were 
higher in winter. AMR rates of E. coli in patients with urinary tract infections were higher in 
summer, as well as in E. coli isolates from food-producing animals. 
Based on the available evidence, two main determinants may be dynamically 
contributing to the seasonality of AMR rates. First, the seasonality of antibiotic use secondary to 
the seasonal variation of the incidence of infectious diseases may exert a selective pressure that 
results in a seasonal variation of AMR rates.41,43-45,235 Indeed, under the continued selective 
pressure exerted by antibiotic use, bacteria can develop different co-selective mechanisms such as 
co-resistance (i.e. various resistant determinants in the same genetic element such as plasmid) and 
cross-resistance (i.e. same genetic determinant responsible for resistance to all antibiotics from the 
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same class), which may furthermore lead to a resistance to a broad spectrum of antibiotics (i.e. 
multidrug-resistance).263 Second, the seasonal variation of the incidence of infectious diseases, per 
se, may contribute to the increment of circulating resistant strains, what not only contributes to 
the seasonality of the AMR rates, but also to the increasing need for antibiotics of second and 
third line treatment options.42,238,243,250,252 These factors should be closely analyzed in future 
studies to fully understand its role in the dynamics of the seasonality of AMR rates. 
Nevertheless, our results need to be interpreted with caution as large heterogeneity was 
observed in the seasonal variation of AMR rates, especially in E. coli isolates (I2>80%). Part of the 
heterogeneity is attributable to the specific characteristics of the study population (e.g. age, sex, 
presence of comorbidities). However, a large part of the heterogeneity may also be explained by 
the geographical regions where the studies were conducted underscoring the influence of local 
factors modifying the patterns of antibiotic use and, consequently, of AMR occurrence. For 
example, it has been observed that differences in drug regulations and the structure of the 
pharmaceutical market across countries may lead to differences in the seasonality of AMR rates.235 
This includes also the regulation on antimicrobial prescription at various levels of the healthcare 
system (e.g. primary and secondary care).44,45,249 Furthermore, within the same country, socio-
cultural determinants and educational level can influence the patient demands and the proclivity 
of medical doctors for prescribing antibiotics.242,264  Besides, climate variability according to 
regions has been linked to health consequence such as outbreaks of food-borne diseases and air 
pollution, and therefore changes in antibiotic use and further resistance.242 Finally, emerging 
evidence suggests that region differences in animal-farming practices,246,253 including the 
antimicrobial use, may also influence the seasonality of AMR rates. These findings indicate the 
importance of developing national surveillance and monitoring programs of antimicrobial use 
and resistance to fully understand local determinants of use and, therefore, the underlying 
selective pressure of AMR occurrence.  
 
Seasonality of AMR rates in humans 
The AMR rates of S. pneumoniae and H. influenzae showed a marked winter-peak seasonal 
variation. This pattern is expected as respiratory infections exhibit a clear seasonal pattern with 
peak in cold-months, thus leading to an increase in antibiotic use. 41,45,235,243,250,254 The antibiotic 
use was between 24% and 38% higher in winter than in summer, 39,40 most of which 
corresponded to the increase of penicillins and cephalosporins, which are broadly used for 
respiratory infections. 235,238,256,265,266 Other studies have reported a winter peak in other antibiotics 
used for respiratory infections, such as amoxicillin, amoxicillin-clavulanic acid, macrolides, and 
quinolones. 246,267 These overlapping patterns would correspond to periods of multidrug-resistant 
respiratory bacteria around winter. 41  One potential explanation is that under the continued 
pressure of antibiotic use during the winter, the multidrug-resistant strains become more 
prevalent in the community.  
AMR rates of E. coli tended to be higher in summer than in other seasons, as has been 
described in other studies. 42,268 Nevertheless, this trend was highly heterogeneous according to 
geographical region and antibiotic classes. On one hand, resistance rates from Western Pacific 
(e.g. Australia) and American countries (e.g. USA) were rather high in winter unlike those from 
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Europe (e.g. Norway and England), where the rates were higher in summer. It is possible that this 
geographical cluster can be attributed to region-specific patterns of antimicrobial prescription. 
44,251,268,269 On the other hand, we found that resistance rates to sulphamides and tetracyclines 
were higher in spring and winter, respectively. This pattern might be attributable to previous use 
of these antibiotic classes to treat diseases such as skin infections, respiratory infections and 
UTI’s. 44 Additionally, previous studies have shown a 1 to 2 month-lag between the increase of 
use of a particular antibiotic class such as quinolone and -lactams and the increase of AMR of E. 
coli to these antibiotics. 44,45 It might be argued that this phenomenon occurs also with other 
antibiotic classes. 
 
Seasonality of AMR rates in animals 
We did not find consistent seasonality of AMR rates for samples obtained from animals, probably 
due to the large heterogeneity in the seasonal patterns observed across studies. The studies 
reporting a seasonal variation in AMR rates in animal samples suggested as potential explanation 
the different husbandry practices of food-producing animals. 236,239,240 On one hand, resistance 
strains of Campylobacter spp., E. coli and Salmonella spp. has been described by keeping animals 
outdoors in summer, probably because this practice increases the risk of contact with other AMR 
bacteria sources, such as farm pets, 270 wild animals, 271 and contaminated farm water and soil. 272 
On the other hand, the intensive housing, commonly used in colder months, may increase the 
effective transmission of resistant and non-resistant bacteria due to crowding. 240 Such mechanism 
was explained for the spring-peak of AMR rates of E. coli to -lactams, sulphamides, tetracyclines, 
and trimethoprim. 240,253,259 Similarly, the summer-peak of respiratory and enteric infections with 
E. coli and Campylobacter spp. in pigs and poultry has been related to a summer increase of 
resistance to fluoroquinolones and macrolides. 236,249 Previous studies suggested a decrease of 
resistant rates in E. coli strains from food-producing animals after the reduction of antimicrobial 
use, together with good farming practices. 273 
The seasonality of resistant bacteria among food-producing animal poses special treat to 
public health, highlighting the potential role of animal sources in the transmission and spread of 
AMR bacteria to humans through the food-chain. 245,274-276 For example, resistant E. coli has been 
described as a reservoir of resistance genes for potentially pathogens bacteria that can be 
transmitted to humans. 259 A higher consumption of chicken meat in winter may be the 
underlying mechanism of the winter-peak of human Campylobacteriosis resistant to 
fluoroquinolones and macrolides in the winter. 244,245 Additionally, higher rates of multidrug-
resistant Salmonella spp. strains have been isolated in summer from chicken carcasses. 247,261 
 
Strengths and limitations 
To our knowledge, this is the first comprehensive systematic review and meta-analysis addressing 
seasonal variation in AMR in humans and animals of critically important bacteria for the public 
health. We have addressed, across the evidence, the multiples sources of heterogeneity emerging 
from differences factors underlying the seasonal patterns according to antibiotic type, bacteria, 
geographical region and sample source. However, some limitations need to be acknowledged. 
First, we could not systematically examine the role of potential explicative factors of the observed 
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seasonal patterns, such as antimicrobial prescriptions and infections incidence, because it was not 
systematically examined in the studies included in this review and because it fell beyond the scope 
of our study. However, our results coincide with the well-known seasonality of infections caused 
by S. pneumonia 238,243,250,252 and urinary E. coli. 251 Consequently, these patterns appear as relevant 
determinants contributing to the observed seasonal variation in AMR rates.  
Second, because of incomplete reporting of the findings in eight studies included in our 
review, we assumed that the sampling of the isolates for resistance determination was at random 
throughout the year. Nevertheless, if the sample procedure is not at random throughout the year, 
a spurious seasonality can occur if, for example, more isolates are taken in peak-periods of 
infection in a population who are more likely to have resistant infections and higher exposure to 
antibiotics. 41 Finally, although we found evidence of publication bias in only a few comparisons, 
we cannot rule out its influence on our results. Indeed, because most of the studies included in 
our review were performed in European and North American countries, the potential variation 
that could occur in countries with different seasonal incidence of infections and antibiotic use 
could be underrepresented in our meta-analyses. The same holds true for seasonal variation in 
AMR of Campylobacter spp. and Salmonella spp.  
 
Implications  
Our study shows that the seasonality of AMR is more consistent for respiratory infections than 
for infections caused by food-borne bacteria. This finding has multiple implications. First, the fact 
that respiratory infections have a more consistent seasonality, thus leading to a more consistent 
seasonal variation of AMR of these bacteria could be attributed both to the increase of resistant 
strains, and to the newly-generated resistance as a consequence of increased use of antibiotics in 
winter. In clinical settings, and from a public health perspective, these findings highlight the need 
for a proactive preparation for the seasonal increase of bacterial infections and it subsequent 
antibiotic use, which may mostly affect susceptible population, such as elderly and children. 
Additionally, active surveillance and reaction protocols are required in order to rapidly identify 
and address outbreaks of AMR rates. These are required as the burden imposed by climate 
change through extreme climatic conditions may favor outbreak of infections, and therefore the 
need to increase antibiotic use. Additionally, the international collaboration may be fundamental 
in reducing the heterogeneity in the practices of antibiotic prescription through enhancing 
stewardship programs in hospitals, what may contribute to reduce practices of unnecessary 
antibiotic use and further spread of MDR strains.  
Second, we found a large heterogeneity in the seasonality of AMR rates in food-
producing animals, which can be largely attributed to the fact that all studies were performed to 
screen resistance in commensal E. coli. In spite of this, the patterns identified within the studies 
consistently identified the husbandry practices, including antibiotic use, as the main determinant 
of seasonal AMR variation. Because of the risk that poses for public health, it remains a priority 
to handle the practices of food-producing animals and to implement antimicrobial stewardship 
on farms promoting rational antibiotic use, and therefore helping to reduce risk of transmission 
of resistant bacteria to humans through the food-chain.  
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Finally, studies included in our systematic review suggested that periods of MDR can 
occur due to the accumulation of resistance strains of respiratory bacteria and potentially, of 
infections caused by food-borne bacteria. This may induce complicated infections accompanied 
with higher risk of mortality, higher cost of treatment and longer length of stay in hospitals, 233,277 
especially in developing countries, where certainly the impact of AMR is much higher. 278 This 
longer occupancy in bed might be taken into consideration in the planning of availability of beds 
in hospitals. Furthermore, governments should consider implementing strong politics for 
surveillance and increased the response against AMR and the factors that underlay its seasonality, 
which may be worsen the upcoming challenges of climate change. 241 
 
Conclusion 
In this comprehensive systematic review, seasonality of AMR was more consistent in respiratory 
infections caused by S. pneumoniae and H. influenzae, whereas seasonality of AMR in E. coli was 
rather heterogeneous according to sample source, geographical region and antibiotic class. Due to 
few available studies in humans, we could not find significant seasonal variation of AMR in 
Salmonella spp. and Campylobacter spp, however, seasonal fluctuations of these bacteria can occur in 
relation with husbandry practices in animals. Based on the available evidence, the seasonal 
variation in AMR among bacteria depends on the seasonal fluctuation of antibiotic use due to 
the incidence of infectious disease. Since emerging evidence associated the occurrence of diseases 
with environmental changes and its impact to the public health, future studies are required to 
better understand the factors underlying the seasonality of AMR. Resources are required to global 
standardization of stewardship programs for antibiotics in hospitals and farms.  
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Table 17. Comparison of antimicrobial resistance rates in respiratory bacteria between seasons 
according to geographical regions (n=28). Winter and spring were reference groups  
 
  
Geographical region Antibiotic Class n studies OR 95% CI I2 (%) Egger's p-value 
 All seasons vs Winter   
Streptococcus pneumoniae 
Europe  
All classes 4 0.72 0.65 - 0.79* 29.6 
0.10 
Penicillins 3 0.69 0.60 - 0.78* 37.8 
Cephalosporines 1 0.78 0.66 - 0.92* 23.2 
Multidrug-resistant 1 0.75 0.50 - 1.13 10.4 
America Penicillins 2 0.66 0.44 - 1.00 0.0 0.85 
 Autumn vs Spring   
Streptococcus pneumoniae 
Europe 
All classes  5 0.92 0.80 – 1.06 0.0 
0.10 Penicillins 4 0.93 0.77 – 1.11 0.0 
Cephalosporines 1 0.96 0.65 – 1.42 48.7 
America Penicillins 3 0.52 0.08 – 3.47 89.3 0.85 
Haemophilus influenzae 
Europe Penicillins 1 0.55 0.27 – 1.11 - 0.67 
Seasonality of health outcomes | 158 
 
Table 18.  Comparison of antimicrobial resistance rates of urinary E. coli (isolates from humans) 
and commensal E. coli (isolates from animals) between seasons according to geographical regions 
(n=28). Winter was reference group. 
 
  
Geographical region Antibiotic Class Studies (n) OR 95% CI I2 (%) Egger's p-value 
 All seasons vs Winter 
Escherichia coli from patients with urinary tract infections  
Europe All classes 2 1.05 0.85 - 1.29 72.1 
0.80 
Penicillins 1 0.61 0.37 - 1.01 78.2 
Fluoroquinolones 1 1.23 0.77 - 2.12 48.0 
Nitrofurans 2 1.44 1.12 - 1.88* 0.0 
Sulphamides 2 0.98 0.77 - 1.23 65.0 
Tetracycline 1 1.41 0.85 - 2.34 72.0 
Western Pacific All classes 1 0.97 0.92 - 1.03 0.0 
0.73 
Aminoglicosides 1 1.11 0.86 - 1.45 60.7 
Penicillins 1 1.13 0.94 - 1.35 0.0 
Cephalosporins 1 0.98 0.87 - 1.11 0.0 
Fluoroquinolones 1 0.81 0.67 - 0.98 0.0 
Nitrofurans 1 1.13 0.89 - 1.44 0.0 
Tri/sulpha 1 0.92 0.79 - 1.06 0.0 
Trimethoprim 1 0.91 0.81 - 1.01 0.0 
America Cephalosporins 1 0.84 0.72 - 0.97 59.9 0.12 
Escherichia coli from food-producing animals and carcasses  
Eastern Mediterranean All classes 1 1.21 0.92 - 1.59 71.5 
0.44 
Aminoglicosides 1 0.71 0.25 - 2.00 39.6 
Fenicoles 1 2.79 1.71 - 4.56* 45.3 
Fluoroquinolones 1 1.02 0.82 - 1.28 0.0 
Macrolides 1 1.14 0.28 - 4.61 84.3 
Tetracycline 1 1.54 0.88 - 2.70 71.8 
Tri/sulpha 1 0.47 0.24 - 0.94* 69.1 
Europe All classes 2 0.45 0.83 - 1.09 66.0 
0.00 
Aminoglicosides 1 0.91 0.76 - 1.09 40.4 
Penicillins 1 0.89 0.74 - 1.08 0.0 
Fluoroquinolones 1 5.41 0.85 - 34.47 78.1 
Tetracycline 1 1.1 0.89 - 1.35 47.1 
Sulphamides 1 0.78 0.65 - 0.93* 34.0 
America Multidrug-resistant 1 1.26 1.06 - 1.50* 82.0 0.00 
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Figure 8. Study selection process flow-diagram (PRISMA flow chart). 
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Figure 9. Forest plot of overall seasonality of antimicrobial resistance in Streptococcus pneumoniae 
from patients with respiratory infections. 
 
Solid line, refers to no difference in seasonal AMR between the two groups. Winter season was the reference group = 1. 
n/N = number of included studies in that comparison/total number of included studies. OR, pooled odds ratio of 
seasonal AMR with 95% Confidence intervals. 
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Figure 10. Forest plot of overall seasonality of antimicrobial resistance of urinary E. coli from 
inpatients and outpatients.
 
Solid line, refers to no difference in seasonal AMR between the two groups. Winter season was the reference group = 1. 
n/N = number of included studies in that comparison/total number of included studies. OR: pooled odds ratio of 
seasonal AMR with 95% Confidence intervals. 
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Figure 11. Forest plot of overall seasonal variation in antimicrobial resistance of E. coli from food-
producing animals. 
 
Solid line, refers to no difference in seasonal AMR between the two groups. Winter season was the reference group = 1. 
n/N = number of included studies in that comparison/total number of included studies. OR: pooled odds ratio of 
seasonal AMR with 95% Confidence intervals. 
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SUPPLEMENTARY MATERIAL 
 
Appendix 39. Review protocol 
1) Databases search strategy and terms 
 
Embase.com: ('antibiotic sensitivity'/exp OR 'antibiotic agent'/exp/dd_ad OR 'penicillin resistance'/de OR (('drug resistance'/de OR 'drug sensitivity'/de) AND 
'antiinfective agent'/exp) OR 'multidrug resistance'/exp OR (((antibiotic* OR antibacter* OR anti-biotic* OR antiinfect* OR anti-infect* OR anti-bacter* OR 
antimicrob* OR anti-microb* OR penicillin* OR aminoglycosid* OR lactam* OR cephalosporin* OR fenicole* OR fluorochinono* OR macrolide* OR 
trimethoprim* OR tetracyclin* OR sulphamide* OR abyssomicin* OR acetomycin* OR actinorhodine* OR aditoprim* OR agglomerin* OR alafosfalin* OR 
aldecalmycin* OR alisamycin* OR allicin* OR ambruticin* OR ansamitocin* OR ansamycin* OR aplasmomycin* OR aristeromycin* OR asukamycin* OR 
atpenin* OR auricularum* OR aurograb* OR avilamycin* OR bafilomycin* OR baliz* OR baquiloprim* OR beroline* OR betafectin* OR betamipron* OR 
boromycin* OR borrelidin* OR brilacidin* OR butalactin* OR cadazolid* OR calcimycin* OR carbadox* OR carbazomycin* OR chloramphenicol* OR ciadox* 
OR cinoquidox* OR citrinin* OR concanamycin* OR coumamycin* OR cryptosporin* OR cycloheximide* OR dalfopristin* OR dealanylalahopcin* OR 
dioxidine* OR echinomycin* OR edeine* OR efepristin* OR emimycin* OR endusamycin* OR eperezolid* OR epetraborole* OR epiderstatin* OR epiroprim* 
OR ethylhydrocupreine* OR evernimicin* OR everninomicin* OR flopristin* OR fosmidomycin* OR furaquinocin* OR furazidin* OR furazolium* OR 
fusafungine* OR fusidate-sodium* OR fusidic-acid* OR gepotidacin* OR grisein* OR hatomamicin* OR hedamycin* OR heliomycin* OR hidamicin* OR 
hymeglusin* OR iclaprim* OR ikarugamycin* OR inostamycin* OR kalafungin* OR kelfiprim* OR kidamycin* OR kinamycin* OR kinamycin* OR lactacystin* 
OR lactivicin* OR laidlomycin* OR lanopepden* OR lasalocid* OR lavanducyanin* OR lenoremycin* OR linezolid* OR linopristin* OR lonomycin* OR 
lotilibcin* OR lydicamycin* OR lysocellin* OR macrolide* OR malyngolide* OR manumycin* OR methylenomycin* OR mikamycin* OR monensin* OR 
monensin* OR mureidomycin* OR mycolog* OR myxothiazol* OR narasin* OR negamycin* OR nybomycin* OR olaquindox* OR paldimycin* OR patulin* OR 
pentalenolactone* OR platensimycin* OR pluramycin* OR polyactin* OR polyfungin* OR posizolid* OR pristinamycin* OR prothracarcin* OR pseudomonic-
acid* OR pyrroxamycin* OR quinomycin* OR quinupristin* OR radezolid* OR radicicol* OR ranbezolid* OR simaomicin* OR simocyclinone* OR 
spectinomycin* OR squalamine* OR streptogramin* OR streptovitacin* OR tedizolid* OR terdecamycin* OR tetracycline* OR tetronasin* OR tetronomycin* OR 
tetroxoprim* OR thiolactomycin* OR tibezonium-iodide* OR tizoxanide* OR toyocamycin* OR toyocamycin* OR trichostatic-acid* OR trichostatin* OR 
trimethoprim* OR trimethoprim* OR triostin* OR trospectomycin* OR tuftsin* OR tuftsin* OR tutofusin* OR urdamycin* OR validamycin* OR vernamycin* 
OR virginiae-butanolide* OR virginiamycin* OR volpristin* OR zibrofusidic-acid* OR zorbamycin* OR fluoroquinolon* OR quinolon* OR multidrug* OR multi-
drug* OR methicillin* OR ticarcillin* OR ampicillin* OR ciprofloxacin* OR cefprozil* OR cefaclor* OR amoxicillin* OR streptomycin*) NEAR/10 (sensitiv* OR 
susceptib*)) OR resistan*):ab,ti) AND ('Campylobacter'/exp OR 'campylobacteriosis'/exp OR 'Salmonella'/exp OR 'salmonellosis'/de OR 'Escherichia coli'/exp 
OR 'Escherichia coli infection'/exp OR 'Streptococcus pneumoniae'/exp OR 'pneumococcal infection'/exp OR 'Haemophilus influenzae'/exp OR 'Haemophilus 
infection'/exp OR 'bacterial meningitis'/exp OR 'bacterial pneumonia'/exp OR 'otitis media'/de OR 'acute otitis media'/de OR (Campylobacter* OR Salmonell* 
OR 'Escherichia coli' OR e-coli OR (Streptococc* NEAR/3  pneumon*) OR (Haemoph* NEAR/3  (influen* OR meningit*)) OR ((respirator* OR food-born* OR 
foodborn*) NEAR/3  pathogen*) OR ((enteric* OR typhoid*) NEAR/3 fever*) OR pneumococc* OR (bacteri* NEAR/3 meningit*) OR (otitis NEAR/3 (media 
OR infect*)) OR ((Communit* OR bacter*) NEAR/3 pneumonia*)):ab,ti) AND ('temporal analysis'/exp OR 'meteorological phenomena'/exp OR ((time NEAR/3 
series*) OR season* OR Autumn* OR spring OR summer* OR winter* OR meteorolog* OR weather* OR climate* OR ((temporal* OR month* ) NEAR/6 
(variat* OR higher* OR lower* OR compar* OR divers* OR risk OR fluctuat* OR peak OR pattern* OR dynamic* OR trend* OR monitor* OR decline* OR 
decrease* OR increase* OR incline* OR change* OR associat*)) OR (throughout NEAR/3 year) ):ab,ti) 
 
Medline Ovid: (exp "Drug Resistance, Microbial"/ OR (("Drug Resistance"/ ) AND exp "Anti-Infective Agents"/) OR "Drug Resistance, Multiple"/ OR (((antibiotic* 
OR antibacter* OR anti-biotic* OR antiinfect* OR anti-infect* OR anti-bacter* OR antimicrob* OR anti-microb* OR penicillin* OR aminoglycosid* OR lactam* 
OR cephalosporin* OR fenicole* OR fluorochinono* OR macrolide* OR trimethoprim* OR tetracyclin* OR sulphamide* OR abyssomicin* OR acetomycin* OR 
actinorhodine* OR aditoprim* OR agglomerin* OR alafosfalin* OR aldecalmycin* OR alisamycin* OR allicin* OR ambruticin* OR ansamitocin* OR ansamycin* 
OR aplasmomycin* OR aristeromycin* OR asukamycin* OR atpenin* OR auricularum* OR aurograb* OR avilamycin* OR bafilomycin* OR baliz* OR 
baquiloprim* OR beroline* OR betafectin* OR betamipron* OR boromycin* OR borrelidin* OR brilacidin* OR butalactin* OR cadazolid* OR calcimycin* OR 
carbadox* OR carbazomycin* OR chloramphenicol* OR ciadox* OR cinoquidox* OR citrinin* OR concanamycin* OR coumamycin* OR cryptosporin* OR 
cycloheximide* OR dalfopristin* OR dealanylalahopcin* OR dioxidine* OR echinomycin* OR edeine* OR efepristin* OR emimycin* OR endusamycin* OR 
eperezolid* OR epetraborole* OR epiderstatin* OR epiroprim* OR ethylhydrocupreine* OR evernimicin* OR everninomicin* OR flopristin* OR fosmidomycin* 
OR furaquinocin* OR furazidin* OR furazolium* OR fusafungine* OR fusidate-sodium* OR fusidic-acid* OR gepotidacin* OR grisein* OR hatomamicin* OR 
hedamycin* OR heliomycin* OR hidamicin* OR hymeglusin* OR iclaprim* OR ikarugamycin* OR inostamycin* OR kalafungin* OR kelfiprim* OR kidamycin* 
OR kinamycin* OR kinamycin* OR lactacystin* OR lactivicin* OR laidlomycin* OR lanopepden* OR lasalocid* OR lavanducyanin* OR lenoremycin* OR 
linezolid* OR linopristin* OR lonomycin* OR lotilibcin* OR lydicamycin* OR lysocellin* OR macrolide* OR malyngolide* OR manumycin* OR 
methylenomycin* OR mikamycin* OR monensin* OR monensin* OR mureidomycin* OR mycolog* OR myxothiazol* OR narasin* OR negamycin* OR 
nybomycin* OR olaquindox* OR paldimycin* OR patulin* OR pentalenolactone* OR platensimycin* OR pluramycin* OR polyactin* OR polyfungin* OR 
posizolid* OR pristinamycin* OR prothracarcin* OR pseudomonic-acid* OR pyrroxamycin* OR quinomycin* OR quinupristin* OR radezolid* OR radicicol* OR 
ranbezolid* OR simaomicin* OR simocyclinone* OR spectinomycin* OR squalamine* OR streptogramin* OR streptovitacin* OR tedizolid* OR terdecamycin* 
OR tetracycline* OR tetronasin* OR tetronomycin* OR tetroxoprim* OR thiolactomycin* OR tibezonium-iodide* OR tizoxanide* OR toyocamycin* OR 
toyocamycin* OR trichostatic-acid* OR trichostatin* OR trimethoprim* OR trimethoprim* OR triostin* OR trospectomycin* OR tuftsin* OR tuftsin* OR 
tutofusin* OR urdamycin* OR validamycin* OR vernamycin* OR virginiae-butanolide* OR virginiamycin* OR volpristin* OR zibrofusidic-acid* OR zorbamycin* 
OR fluoroquinolon* OR quinolon* OR multidrug* OR multi-drug* OR methicillin* OR ticarcillin* OR ampicillin* OR ciprofloxacin* OR cefprozil* OR 
cefaclor* OR amoxicillin* OR streptomycin*) ADJ10 (sensitiv* OR susceptib*)) OR resistan*).ab,ti.) AND (exp "Campylobacter"/ OR exp "Campylobacter 
Infections"/ OR exp "Salmonella"/ OR exp "Salmonella Infections"/ OR exp "Escherichia coli"/ OR exp "Escherichia coli Infections"/ OR exp "Streptococcus 
pneumoniae"/ OR exp "Pneumococcal Infections"/ OR exp "Haemophilus influenzae"/ OR exp "Haemophilus Infections"/ OR exp "Meningitis, Bacterial"/ OR 
exp "Pneumonia, Bacterial"/ OR "otitis media"/ OR (Campylobacter* OR Salmonell* OR "Escherichia coli" OR e-coli OR (Streptococc* ADJ3  pneumon*) OR 
(Haemoph* ADJ3  (influen* OR meningit*)) OR ((respirator* OR food-born* OR foodborn*) ADJ3  pathogen*) OR ((enteric* OR typhoid*) ADJ3 fever*) OR 
pneumococc* OR (bacteri* ADJ3 meningit*) OR (otitis ADJ3 (media OR infect*)) OR ((Communit* OR bacter*) ADJ3 pneumonia*)).ab,ti.) AND ("Climate"/ OR 
Seasons/ OR Weather/ OR ((time ADJ3 series*) OR season* OR Autumn* OR spring OR summer* OR winter* OR meteorolog* OR weather* OR climate* OR 
((temporal* OR month* ) ADJ6 (variat* OR higher* OR lower* OR compar* OR divers* OR risk OR fluctuat* OR peak OR pattern* OR dynamic* OR trend* 
OR monitor* OR decline* OR decrease* OR increase* OR incline* OR change* OR associat*)) OR (throughout ADJ3 year) ).ab,ti.) 
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Cochrane: ((((antibiotic* OR antibacter* OR anti-biotic* OR antiinfect* OR anti-infect* OR anti-bacter* OR antimicrob* OR anti-microb* OR penicillin* OR 
aminoglycosid* OR lactam* OR cephalosporin* OR fenicole* OR fluorochinono* OR macrolide* OR trimethoprim* OR tetracyclin* OR sulphamide* OR 
abyssomicin* OR acetomycin* OR actinorhodine* OR aditoprim* OR agglomerin* OR alafosfalin* OR aldecalmycin* OR alisamycin* OR allicin* OR 
ambruticin* OR ansamitocin* OR ansamycin* OR aplasmomycin* OR aristeromycin* OR asukamycin* OR atpenin* OR auricularum* OR aurograb* OR 
avilamycin* OR bafilomycin* OR baliz* OR baquiloprim* OR beroline* OR betafectin* OR betamipron* OR boromycin* OR borrelidin* OR brilacidin* OR 
butalactin* OR cadazolid* OR calcimycin* OR carbadox* OR carbazomycin* OR chloramphenicol* OR ciadox* OR cinoquidox* OR citrinin* OR 
concanamycin* OR coumamycin* OR cryptosporin* OR cycloheximide* OR dalfopristin* OR dealanylalahopcin* OR dioxidine* OR echinomycin* OR edeine* 
OR efepristin* OR emimycin* OR endusamycin* OR eperezolid* OR epetraborole* OR epiderstatin* OR epiroprim* OR ethylhydrocupreine* OR evernimicin* 
OR everninomicin* OR flopristin* OR fosmidomycin* OR furaquinocin* OR furazidin* OR furazolium* OR fusafungine* OR fusidate-sodium* OR fusidic-acid* 
OR gepotidacin* OR grisein* OR hatomamicin* OR hedamycin* OR heliomycin* OR hidamicin* OR hymeglusin* OR iclaprim* OR ikarugamycin* OR 
inostamycin* OR kalafungin* OR kelfiprim* OR kidamycin* OR kinamycin* OR kinamycin* OR lactacystin* OR lactivicin* OR laidlomycin* OR lanopepden* 
OR lasalocid* OR lavanducyanin* OR lenoremycin* OR linezolid* OR linopristin* OR lonomycin* OR lotilibcin* OR lydicamycin* OR lysocellin* OR 
macrolide* OR malyngolide* OR manumycin* OR methylenomycin* OR mikamycin* OR monensin* OR monensin* OR mureidomycin* OR mycolog* OR 
myxothiazol* OR narasin* OR negamycin* OR nybomycin* OR olaquindox* OR paldimycin* OR patulin* OR pentalenolactone* OR platensimycin* OR 
pluramycin* OR polyactin* OR polyfungin* OR posizolid* OR pristinamycin* OR prothracarcin* OR pseudomonic-acid* OR pyrroxamycin* OR quinomycin* 
OR quinupristin* OR radezolid* OR radicicol* OR ranbezolid* OR simaomicin* OR simocyclinone* OR spectinomycin* OR squalamine* OR streptogramin* 
OR streptovitacin* OR tedizolid* OR terdecamycin* OR tetracycline* OR tetronasin* OR tetronomycin* OR tetroxoprim* OR thiolactomycin* OR tibezonium-
iodide* OR tizoxanide* OR toyocamycin* OR toyocamycin* OR trichostatic-acid* OR trichostatin* OR trimethoprim* OR trimethoprim* OR triostin* OR 
trospectomycin* OR tuftsin* OR tuftsin* OR tutofusin* OR urdamycin* OR validamycin* OR vernamycin* OR virginiae-butanolide* OR virginiamycin* OR 
volpristin* OR zibrofusidic-acid* OR zorbamycin* OR fluoroquinolon* OR quinolon* OR multidrug* OR multi-drug* OR methicillin* OR ticarcillin* OR 
ampicillin* OR ciprofloxacin* OR cefprozil* OR cefaclor* OR amoxicillin* OR streptomycin*) NEAR/10 (sensitiv* OR susceptib*)) OR resistan*):ab,ti) AND 
((Campylobacter* OR Salmonell* OR 'Escherichia coli' OR e-coli OR (Streptococc* NEAR/3  pneumon*) OR (Haemoph* NEAR/3  (influen* OR meningit*)) 
OR ((respirator* OR food-born* OR foodborn*) NEAR/3  pathogen*) OR ((enteric* OR typhoid*) NEAR/3 fever*) OR pneumococc* OR (bacteri* NEAR/3 
meningit*) OR (otitis NEAR/3 (media OR infect*)) OR ((Communit* OR bacter*) NEAR/3 pneumonia*)):ab,ti) AND (((time NEAR/3 series*) OR season* OR 
Autumn* OR spring OR summer* OR winter* OR meteorolog* OR weather* OR climate* OR ((temporal* OR month* ) NEAR/6 (variat* OR higher* OR lower* 
OR compar* OR divers* OR risk OR fluctuat* OR peak OR pattern* OR dynamic* OR trend* OR monitor* OR decline* OR decrease* OR increase* OR 
incline* OR change* OR associat*)) OR (throughout NEAR/3 year) OR 'periodicity'):ab,ti) 
 
Web of science : TS=(((((antibiotic* OR antibacter* OR anti-biotic* OR antiinfect* OR anti-infect* OR anti-bacter* OR antimicrob* OR anti-microb* OR penicillin* 
OR aminoglycosid* OR lactam* OR cephalosporin* OR fenicole* OR fluorochinono* OR macrolide* OR trimethoprim* OR tetracyclin* OR sulphamide* OR 
abyssomicin* OR acetomycin* OR actinorhodine* OR aditoprim* OR agglomerin* OR alafosfalin* OR aldecalmycin* OR alisamycin* OR allicin* OR 
ambruticin* OR ansamitocin* OR ansamycin* OR aplasmomycin* OR aristeromycin* OR asukamycin* OR atpenin* OR auricularum* OR aurograb* OR 
avilamycin* OR bafilomycin* OR baliz* OR baquiloprim* OR beroline* OR betafectin* OR betamipron* OR boromycin* OR borrelidin* OR brilacidin* OR 
butalactin* OR cadazolid* OR calcimycin* OR carbadox* OR carbazomycin* OR chloramphenicol* OR ciadox* OR cinoquidox* OR citrinin* OR 
concanamycin* OR coumamycin* OR cryptosporin* OR cycloheximide* OR dalfopristin* OR dealanylalahopcin* OR dioxidine* OR echinomycin* OR edeine* 
OR efepristin* OR emimycin* OR endusamycin* OR eperezolid* OR epetraborole* OR epiderstatin* OR epiroprim* OR ethylhydrocupreine* OR evernimicin* 
OR everninomicin* OR flopristin* OR fosmidomycin* OR furaquinocin* OR furazidin* OR furazolium* OR fusafungine* OR fusidate-sodium* OR fusidic-acid* 
OR gepotidacin* OR grisein* OR hatomamicin* OR hedamycin* OR heliomycin* OR hidamicin* OR hymeglusin* OR iclaprim* OR ikarugamycin* OR 
inostamycin* OR kalafungin* OR kelfiprim* OR kidamycin* OR kinamycin* OR kinamycin* OR lactacystin* OR lactivicin* OR laidlomycin* OR lanopepden* 
OR lasalocid* OR lavanducyanin* OR lenoremycin* OR linezolid* OR linopristin* OR lonomycin* OR lotilibcin* OR lydicamycin* OR lysocellin* OR 
macrolide* OR malyngolide* OR manumycin* OR methylenomycin* OR mikamycin* OR monensin* OR monensin* OR mureidomycin* OR mycolog* OR 
myxothiazol* OR narasin* OR negamycin* OR nybomycin* OR olaquindox* OR paldimycin* OR patulin* OR pentalenolactone* OR platensimycin* OR 
pluramycin* OR polyactin* OR polyfungin* OR posizolid* OR pristinamycin* OR prothracarcin* OR pseudomonic-acid* OR pyrroxamycin* OR quinomycin* 
OR quinupristin* OR radezolid* OR radicicol* OR ranbezolid* OR simaomicin* OR simocyclinone* OR spectinomycin* OR squalamine* OR streptogramin* 
OR streptovitacin* OR tedizolid* OR terdecamycin* OR tetracycline* OR tetronasin* OR tetronomycin* OR tetroxoprim* OR thiolactomycin* OR tibezonium-
iodide* OR tizoxanide* OR toyocamycin* OR toyocamycin* OR trichostatic-acid* OR trichostatin* OR trimethoprim* OR trimethoprim* OR triostin* OR 
trospectomycin* OR tuftsin* OR tuftsin* OR tutofusin* OR urdamycin* OR validamycin* OR vernamycin* OR virginiae-butanolide* OR virginiamycin* OR 
volpristin* OR zibrofusidic-acid* OR zorbamycin* OR fluoroquinolon* OR quinolon* OR multidrug* OR multi-drug* OR methicillin* OR ticarcillin* OR 
ampicillin* OR ciprofloxacin* OR cefprozil* OR cefaclor* OR amoxicillin* OR streptomycin*) NEAR/9 (sensitiv* OR susceptib*)) OR resistan*)) AND 
((Campylobacter* OR Salmonell* OR "Escherichia coli" OR e-coli OR (Streptococc* NEAR/2  pneumon*) OR (Haemoph* NEAR/2  (influen* OR meningit*)) 
OR ((respirator* OR food-born* OR foodborn*) NEAR/2  pathogen*) OR ((enteric* OR typhoid*) NEAR/2 fever*) OR pneumococc* OR (bacteri* NEAR/2 
meningit*) OR (otitis NEAR/2 (media OR infect*)) OR ((Communit* OR bacter*) NEAR/2 pneumonia*))) AND (((time NEAR/2 series*) OR season* OR 
Autumn* OR spring OR summer* OR winter* OR meteorolog* OR weather* OR climate* OR ((temporal* OR month* ) NEAR/5 (variat* OR higher* OR lower* 
OR compar* OR divers* OR risk OR fluctuat* OR peak OR pattern* OR dynamic* OR trend* OR monitor* OR decline* OR decrease* OR increase* OR 
incline* OR change* OR associat*)) OR (throughout NEAR/2 year) OR "periodicity"))) 
 
Biosis Ovid: ((((antibiotic* OR antibacter* OR anti-biotic* OR antiinfect* OR anti-infect* OR anti-bacter* OR antimicrob* OR anti-microb* OR penicillin* OR 
aminoglycosid* OR lactam* OR cephalosporin* OR fenicole* OR fluorochinono* OR macrolide* OR trimethoprim* OR tetracyclin* OR sulphamide* OR 
abyssomicin* OR acetomycin* OR actinorhodine* OR aditoprim* OR agglomerin* OR alafosfalin* OR aldecalmycin* OR alisamycin* OR allicin* OR 
ambruticin* OR ansamitocin* OR ansamycin* OR aplasmomycin* OR aristeromycin* OR asukamycin* OR atpenin* OR auricularum* OR aurograb* OR 
avilamycin* OR bafilomycin* OR baliz* OR baquiloprim* OR beroline* OR betafectin* OR betamipron* OR boromycin* OR borrelidin* OR brilacidin* OR 
butalactin* OR cadazolid* OR calcimycin* OR carbadox* OR carbazomycin* OR chloramphenicol* OR ciadox* OR cinoquidox* OR citrinin* OR 
concanamycin* OR coumamycin* OR cryptosporin* OR cycloheximide* OR dalfopristin* OR dealanylalahopcin* OR dioxidine* OR echinomycin* OR edeine* 
OR efepristin* OR emimycin* OR endusamycin* OR eperezolid* OR epetraborole* OR epiderstatin* OR epiroprim* OR ethylhydrocupreine* OR evernimicin* 
OR everninomicin* OR flopristin* OR fosmidomycin* OR furaquinocin* OR furazidin* OR furazolium* OR fusafungine* OR fusidate-sodium* OR fusidic-acid* 
OR gepotidacin* OR grisein* OR hatomamicin* OR hedamycin* OR heliomycin* OR hidamicin* OR hymeglusin* OR iclaprim* OR ikarugamycin* OR 
inostamycin* OR kalafungin* OR kelfiprim* OR kidamycin* OR kinamycin* OR kinamycin* OR lactacystin* OR lactivicin* OR laidlomycin* OR lanopepden* 
OR lasalocid* OR lavanducyanin* OR lenoremycin* OR linezolid* OR linopristin* OR lonomycin* OR lotilibcin* OR lydicamycin* OR lysocellin* OR 
macrolide* OR malyngolide* OR manumycin* OR methylenomycin* OR mikamycin* OR monensin* OR monensin* OR mureidomycin* OR mycolog* OR 
myxothiazol* OR narasin* OR negamycin* OR nybomycin* OR olaquindox* OR paldimycin* OR patulin* OR pentalenolactone* OR platensimycin* OR 
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pluramycin* OR polyactin* OR polyfungin* OR posizolid* OR pristinamycin* OR prothracarcin* OR pseudomonic-acid* OR pyrroxamycin* OR quinomycin* 
OR quinupristin* OR radezolid* OR radicicol* OR ranbezolid* OR simaomicin* OR simocyclinone* OR spectinomycin* OR squalamine* OR streptogramin* 
OR streptovitacin* OR tedizolid* OR terdecamycin* OR tetracycline* OR tetronasin* OR tetronomycin* OR tetroxoprim* OR thiolactomycin* OR tibezonium-
iodide* OR tizoxanide* OR toyocamycin* OR toyocamycin* OR trichostatic-acid* OR trichostatin* OR trimethoprim* OR trimethoprim* OR triostin* OR 
trospectomycin* OR tuftsin* OR tuftsin* OR tutofusin* OR urdamycin* OR validamycin* OR vernamycin* OR virginiae-butanolide* OR virginiamycin* OR 
volpristin* OR zibrofusidic-acid* OR zorbamycin* OR fluoroquinolon* OR quinolon* OR multidrug* OR multi-drug* OR methicillin* OR ticarcillin* OR 
ampicillin* OR ciprofloxacin* OR cefprozil* OR cefaclor* OR amoxicillin* OR streptomycin*) ADJ10 (sensitiv* OR susceptib*)) OR resistan*).ab,ti.) AND 
((Campylobacter* OR Salmonell* OR "Escherichia coli" OR e-coli OR (Streptococc* ADJ3 pneumon*) OR (Haemoph* ADJ3 (influen* OR meningit*)) OR 
((respirator* OR food-born* OR foodborn*) ADJ3  pathogen*) OR ((enteric* OR typhoid*) ADJ3 fever*) OR pneumococc* OR (bacteri* ADJ3 meningit*) OR 
(otitis ADJ3 (media OR infect*)) OR ((Communit* OR bacter*) ADJ3 pneumonia*)).ab,ti.) AND (" Climatology"/ OR ((time ADJ3 series*) OR season* OR 
Autumn* OR spring OR summer* OR winter* OR meteorolog* OR weather* OR climate* OR ((temporal* OR month*) ADJ6 (variat* OR higher* OR lower* OR 
compar* OR divers* OR risk OR fluctuat* OR peak OR pattern* OR dynamic* OR trend* OR monitor* OR decline* OR decrease* OR increase* OR incline* 
OR change* OR associat*)) OR (throughout ADJ3 year) ).ab,ti.) 
 
Google scholar: "antibiotic|antibacterial|biotic sensitivity|susceptibility|resistance" Campylobacter|Salmonella|"Escherichia|e 
coli"|Streptococca|Haemophilae|"respiratory|foodborne pathogens" "time series"|season|seasonal|weather|climate|"temporal variation|fluctuation" 
 
Additional searching: Reference review off all included studies (pulled for possible inclusion). The search was done independently by both PM and MJ. Any study felt 
suitable by either of the authors was included for further examination. Contact of authors via e-mail. The search was done by PM, authors from included (good 
qualify) studies were contacted via e-mail looking for suggestions of suitable studies.  
 
2) Selection criteria 
The appraised by tittle of all studies found by search on online database was done by PM, MC, MJ, JS, MG authors. Final 
selection of included studies by reviewing tittle and abstract was done by PM and MJ, and disagreements were discussed 
with MC.  
 
The detail inclusion/exclusion criteria considered for this study is below: 
a. Inclusion criteria 
*Design: Include all studies (cross-sectional, cohorts, case-control, time-series, surveillance) that evaluated seasonal 
incidence and/or prevalence of antibiotic resistance or antibiotic susceptibility in any of the following bacteria 
Campylobacter spp. Salmonella spp. Escherichia coli, Streptococcus pneumoniae and Haemophilus influenza. independently from 
the type of disease caused.   
*Population: Include all studies that measured antibiotic resistant/susceptibility criteria in any of the following sample 
sources: soil, water, humans, animals or animal products. 
*Outcome: Include studies that measured antibiotic resistance/susceptibility through objective determination on isolated 
bacteria strains, for example:  
- Dilution method,  
- Disk-diffusion method, 
- E-test, 
- Automated methods, 
- Genotypic methods such as PCR and DNA hybridization methods, 
- Minimal inhibitory concentration (MIC) 
*Include studies that measured any type of resistance genes to any of the bacteria under study.  
b. Exclusion criteria 
*Exclude literature reviews, abstracts, congress information, reports, thesis, meta-analysis, and protocols. 
*Exclude studies that obtained antibiotic resistant patter based on surveys.  
*Exclude studies that has been conducted only in one season (e.g. only in winters). 
*Exclude studies that has measured antibiotic-resistant patterns having as main objective evaluated vaccination programs. 
 
3) Quality assessment 
Quality assessment was based on a adapted version from the Newcastle-Ottawa Quality Assessment Scale for cross-
sectional studies by  2811. The three factors considered were: 
 
Sample selection criteria (maximum 4 points):  
1- Representativeness of the sample/sample size 
a. Truly representative of the average in the target population (random sampling) and justified sample size 
based on population characteristics (i.e. farms production, hospitals, slaughter houses, river length). ** 
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b. Somewhat representative of the average in the target population (convenience sampling or other 
sampling method), justified sample size based on population characteristics. *  
c. No description of the sampling strategy/sample size not justified.  
 
2- Study time period  
a. The time period was satisfactory (i.e. monthly observations) making possible the categorization of the 
four seasons (summer, winter, spring and autumn) ** 
b. The time period was partly satisfactory making possible the categorization of two seasons (including cold 
and warm seasons). * 
c. The time period was unsatisfactory making difficult the categorization of seasons.  
 
Comparability on the basis of the design or analysis (maximum 2 points): 
3- Comparability of the population (control of confounders): 
a. Population is comparable throughout the time period of study (have the same characteristics) and 
adjusted for at least an important factor (i.e. seasonal prevalence of resistant strains, population, year). ** 
b. Population is not comparable throughout the time period of study (different characteristics) but adjusted 
for at least an important factor. * 
c. Population is not comparable and not adjusted.  
 
Outcome (maximum 2 points): 
4- Assessment of the exposure: 
a. Medical records or laboratory assessment with a validated antimicrobial susceptibility testing and 
interpretation method based on standard minimal concentration break points* 
b. Self-report (i.e. survey, questionnaire). 
c. No description of antimicrobial susceptibility testing and interpretation method. 
 
5- Data analysis and statistical test: 
a. Total number of samples, frequencies and proportion of susceptible and non-susceptible strains are 
clearly described, as well as the statistical test used to analyze the data including p-values. * 
b. The data described is incomplete, the statistical test is not appropriate or not well describe. 
1Modesti, P. A., G. Reboldi, F. P. Cappuccio, C. Agyemang, G. Remuzzi, S. Rapi, E. Perruolo, G. Parati and E. S. H. W. 
G. o. C. R. i. L. R. Settings (2016). "Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-
Analysis." PLOS ONE 11(1): e0147601. 
 
4) Data extraction and statistical analysis 
Data extraction: PM extracted the data from included studies. MC did a review of the data extracted. Data was recorded 
in a proper excel sheet, including: author, published year, study design, country, follow-up time period, sample source 
(animal, human), sample origin (e.g. cattle, poultry, hospital, care center), number of total isolates tested in the study, 
sampling method, previous use of antibiotics, culture isolation method, biochemical testing, antimicrobial susceptibility 
testing method, bacteria type, bacteria serotype, season definition, antibiotic class tested in the study, antibiotic type, 
number of resistant isolates per antibiotic class, resistant rates (%) per bacteria and per antibiotic class, number of 
susceptible isolates per antibiotic class, susceptible rates (%) per bacteria and per antibiotic class, number of intermediate 
resistant isolates per antibiotic class, intermediate resistant rates (%) per bacteria and per antibiotic class 
 
5) Statistical analysis 
All statistical analysis was carry on by PM and supported by MC. For the statistical analysis was necessary to categorized 
variables as follows: 
 
Geographical regions: All countries included in each category are listed below: 
-Eastern Mediterranean: Iran. 
-Europe: Czech Republic, Denmark, England, Finland, France, Israel, Italy, Lithuania, Norway, Poland, Spain, Netherlands 
and Turkey. 
-America: Canada, Costa Rica and United States. 
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-South East Asia: Thailand and India. 
-Western Pacific: Australia, China, Japan and Korea.  
 
Antibiotic classes: All antibiotic types included in each category are listed below: 
-Aminoglycosides: Amikacin, Gentamicin, Kanamycin and Streptomycin. 
-Penicillins: Amoxycillin/clavulanic acid, Amoxycillin, Ampicillin, Penicillin, Carbenicillin, Piperacillin. 
-Cephalosporines: Cefaclor, Cefalexin, Cefazolin, Cefepime, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Ceftiofur, 
Ceftriaxone, Cefuroxime, Cefaloridine, Cefalothin, Cefaxolin. 
-Phenicols: Chloramphenicol and Florfenicol. 
-Fluoroquinolones/Quinolones: Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Levofloxacin, Norfloxacin, Ofloxacin, 
Nalidixic acid.  
-Macrolides: Azithromycin, Carithromycin, Doxycycline, Erythromycin and Tylosin. 
-Nitrofurans: Nitrofurantoin and Furazolidone. 
-Sulphamides: Sulfadiazine, Sulfamethazine, Sulphamethoxazole and Sulphonamide. 
-Trimethoprim: Trimethroprim. 
-Tetracyclines: Tetracycline, Chlortetracycline, Doxycycline, Liquamycin, Oxytetracycline. 
 
Sample source: The variables included in each category are listed below: 
-Animals: cats, cattle, dog, poultry, sheep, and swine. 
-Human: samples at population level, hospitals, and sewage water. 
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Appendix 40. Quality assessment of included studies (n=32). 
 
A cut-off of NOS score of 7 or more to considered as “good quality” was used. This criterion was based on (see 
McPheeters et al. 2012*; see Appendix G page 103-104 in http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049229/). 
Bold letter indicate author that were contacted for additional search studies.  
No. First autor 
Study 
year 
Sample Criteria Comparability Outcome 
Total 
score 
Quality  
assessment 
interpretation 
Representativeness 
of the sample 
Study 
time 
period 
Control of 
confounders 
Assessment 
of the 
exposure 
Data 
analysis 
and 
statistical 
testing 
1 Vorland 1985 * * ** * * 6 Fair quality 
2 Stacevičiene et al. 2016 * ** ** * * 7 Good quality 
3 Rao et al. 2010 ** * ** * * 7 Good quality 
4 Baquero et al. 1999 * ** * * * 7 Good quality 
5 Sulonen et al. 2007 ** * - * - 4 Low quality 
6 Usui et al. 1973 - ** - - * 3 Low quality 
7 Boken et al. 1995 * * * * * 5 Fair quality 
8 Talebiyan et al. 2014 * ** * * * 6 Fair quality 
9 Vardhan et al. 2003 ** ** - * - 5 Fair quality 
10 Taylor et al. 2009 * * ** * * 6 Fair quality 
11 Fasugba et al. 2016 * ** ** * * 7 Good quality 
12 Siripongpreeda et al. 2010 * ** * * * 6 Fair quality 
13 Albanese et al. 2001 * * ** * * 6 Fair quality 
14 Alali et al. 2008 ** ** ** * * 8 Good quality 
15 Dar et al. 1992 * ** - * - 4 Low quality 
16 Hashida et al. 2008 * * * * * 5 Fair quality 
17 Wormald et al. 1971 - ** - * * 4 Low quality 
18 Hoberman et al. 2005 * ** ** * * 7 Good quality 
19 Gow et al. 2008 ** * ** * * 7 Good quality 
20 Andrzejewska et al. 2013 * * - * - 3 Low quality 
21 Lee et al. 2016 ** * - * * 5 Fair quality 
22 van Hees et al. 2006 ** ** - - * 5 Fair quality 
23 Abatih et al. 2009 ** ** ** * * 8 Good quality 
24 Talsma et al. 1999 ** ** - * - 5 Fair quality 
25 Guevara et al. 2008 ** * * * * 6 Fair quality 
26 Tam et al. 2015 * ** * - * 5 Fair quality 
27 Marchisio et al. 2001 ** * * * * 6 Fair quality 
28 Sun et al. 2012 * ** ** - * 6 Fair quality 
29 Dagan et al. 2008 ** ** ** * * 8 Good quality 
30 Gencay 2014 ** * * * * 6 Fair quality 
31 Marco et al. 2000 * * * * * 5 Fair quality 
32 Meumann et al. 2015 ** ** ** * * 8 Good quality  
*McPheeters, M.L., Kripalini, S., Peterson, N.B., Idowu, R.T. et al. (2012). Quality Improvement Interventions To 
Address Health Disparities. Evidence Report/ technology Assessment. Rockville (MD): Agency for Healthcare Research 
and Quality (US). http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049222/pdf/TOC.pdf
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Appendix 42. Forest plot of seasonal resistance variation in S. pneumoniae and H. influenza isolates. 
 
Solid line, refers to no difference in seasonal AMR between the two groups. Winter, wet and spring seasons were the 
reference groups = 1. n/N = number of included studies in that comparison/total number of included studies. OR, 
pooled odds ratio of seasonal AMR with 95% CIs. 
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Appendix 43. Analysis of publication bias: Funnel plots 
a) Funnel plots of S. pneumonia comparisons considering all antibiotic classes:   
 
A1: All-seasons vs Winter    A2: Autumn vs Spring  
  
  
b) Funnel plots of urinary E. coli in humans comparisons considering all antibiotic classes:   
B1: All-seasons vs Winter   B2: Autumn vs Spring  
 
 
c) Funnel plots of E. coli from animals comparisons considering all antibiotic classes: 
C1: All-seasons vs Winter   C2: Autumn vs Spring  
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Appendix 44. Forest plot of seasonal resistance variation in urinary E. coli. 
 
Solid line, refers to no difference in seasonal AMR between the two groups. Summer and spring seasons were the 
reference groups = 1. n/N = number of included studies in that comparison/total number of included studies. OR: 
pooled odds ratio of seasonal AMR with 95% CIs. 
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Appendix 45. Forest plot of seasonal antimicrobial resistance variation in Campylobacter spp. and Salmonella spp. isolates 
from healthy animals.  
 
 
Solid line, refers to no difference in seasonal AMR between the two groups. Spring and winter seasons were the reference 
groups = 1. n/N = number of included studies in that comparison/total number of included studies. OR: pooled odds 
ratio of seasonal AMR with 95% CIs. 
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Chapter 3 Air pollution exposure and health effects in aging 
population 
3.1 Exposure to air pollution among commuters according to mode of 
transport 
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3.1.1 Exposure to carbon monoxide, nitrogen dioxide, black carbon, fine and coarse particles 
according to mode of transport: systematic review and meta-analysis 
 
Magda Cepeda, Josje D. Schoufour, Rosanne Freak-Poli, Chantal Koolhaas, Klodian Dhana, 
Wichor M. Bramer, Oscar H. Franco 
 
Adapted from The Lancet Public Health 2016; 2 (1), e23-e34 
 
ABSTRACT 
Introduction: Controversy exists about the differences in air pollution exposure and inhalation 
dose between mode of transport. We aimed to review air pollution exposure and inhaled dose 
according to mode of transport and pollutant and their effect in terms of years of life expectancy 
(YLE) 
 
Methods: In this systematic review, we searched ten online databases from inception to April 13, 
2016, without language or temporal restrictions, for cohort, cross-sectional, and experimental 
studies that compared exposure to carbon monoxide, black carbon, nitrogen dioxide, fine and 
coarse particles in active commuters (pedestrian or cyclist) and commuters using motorized 
transport (car, bus, massive motorized transport (MMT, i.e. train, subway or metro)) commuters. 
We excluded studies that measured air pollution exposure exclusively with biomarkers or on the 
basis of simulated data, reviews, comments, consensuses, editorials, guidelines, in-vitro studies, 
meta-analyses, ecological studies, and protocols. We extracted average exposure and commuting 
time per mode of transport and pollutant to calculate inhaled doses. We calculated exposure and 
inhaled dose ratios using active commuters as the reference and summarized them with medians 
and IQRs. We also calculated differences in YLE due to fi ne particle inhaled dose and physical 
activity 
 
Results: We identified 4037 studies, of which 39 were included in the systematic review. Overall, 
car commuters had higher exposure to all pollutants than did active commuters in 30 (71%) of 
42 comparisons (median ratio 1.22 [IQR 0.90–1.76]), followed by those who commuted by bus in 
57 (52%) of 109 (1.0 [0.79–1.41]), by motorcycle in 16 (50%) of 32 (0.99 [0.86–1.38]), by a car 
with controlled ventilation settings in 39 (45%) of 86 (0.95 [0.66–1.54]), and by MMT in 21 
(38%) of 55 (0.67 [0.49–1.13]). Overall, active commuters had higher inhalation doses than did 
commuters using motorized transport (median ratio car with controlled ventilation settings 0.16 
[0.10–0.28]; car 0.22 [0.15–0.30]; motorcycle 0.38 [0.26–0.78]; MMT 0.49 [0.34–0.81]; bus 0.72 
[IQR 0.50–0.99]). Commuters using motorized transport lost up to 1 year in YLE more than did 
cyclists. 
 
Conclusion: Proximity to traffic and high air interchange increased the exposure to air pollution 
of commuters using motorized transport. Larger inhalation rates and commuting time increased 
inhaled dose among active commuters. Benefits of active commuting from physical activity are 
larger than the risk from an increased inhaled dose of fine particles. 
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INTRODUCTION 
Worldwide, air pollution exposure is a public health issue associated with various health effects, 
including cardiovascular and respiratory disease, cancer, pregnancy complications, and adverse 
birth outcomes. 282 Air pollution exposure can be considered a function of the concentration of 
pollutants in a microenvironment and the time spent by individuals in that microenvironment. 
283 Traffic emissions contribute the major part of air pollution in traffic-related 
microenvironments. 46 Commuters are exposed to the highest levels of pollutants,47 which often 
do not meet air quality standards. 
Findings from two previous systematic reviews 48,49 suggested that commuters using 
motorized transport (i.e., private or public car, train, metro, tram, bus, or subway) have a higher 
exposure to air pollution than do active commuters (i.e., pedestrian or cyclist). However, if the 
higher breathing parameters and trip time of an active commute than of a motorized commute 
are considered, inhaled and deposited doses of pollutants become higher among cyclists and 
pedestrians than among commuters using motorized transport.284-287. Authors of a systematic 
review 288 of health impact assessment studies concluded that consensus exists that despite the 
increased health risks associated with the higher inhaled dose of traffic-related pollutants among 
active commuters than among commuters using motorized transport, the benefits of physical 
activity from active commuting remain larger. Nevertheless, to our knowledge, no previous review 
of a modal comparison of air pollution exposure has systematically addressed the differences in 
inhaled dose of pollutant per mode of transport or the differential effect on years of life 
expectancy (YLE). 
Therefore, we aimed to systematically review studies that compared air pollution 
exposure by mode of transport to examine differences in inhaled dose according to mode of 
transport and pollutant. Furthermore, we estimated the trade-off in YLE while taking into 
account the inhaled dose of fi ne particles and physical activity levels according to transportation  
 
METHODS 
Search strategy and selection criteria 
In this systematic review, we searched ten databases (Embase, MEDLINE, Cinahl, the 
Cochrane Library, Web of Science, Scopus, PubMed, Google Scholar, ProQuest, and Scielo) in 
cooperation with a medical information specialist (WMB) to identify relevant studies that 
compared air pollution exposure between modes of transport among adult commuters from 
inception to April 13, 2016, with no language or temporal restrictions. We combined terms 
related to air pollution (e.g., “air pollution”) or specific air pollutants (e.g., “PM10”, “PM2.5”, or 
“CO”) with terms related to mode of transport (e.g., “traffic”, “subway”, “car”, “bicycle”, or 
“walk”). Full search strategies are provided in the  
Appendix 46 (page 194). 
We included all studies (cohort, cross-sectional, and experimental) that measured 
personal air pollution exposure while commuting by at least one active and one motorized mode 
of transport. We excluded studies that measured air pollution exposure exclusively with 
biomarkers or on the basis of simulated data, reviews, comments, consensuses, editorials, 
guidelines, in-vitro studies, meta-analyses, ecological studies, and protocols. We selected data only 
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for carbon monoxide (CO), black carbon (BC), nitrogen dioxide (NO2), fine (particulate matter 
of ventilation settings (windows closed, air conditioning on or off, or air recirculation modes on 
or off) and those without controlled ventilation settings. 
Working in pairs, three authors (MC, CMK, and KD) reviewed titles and abstracts of the 
entire list of studies identified by the search to select those that fulfilled the selection criteria. 
After initial appraisal, we retrieved full texts of selected titles. Full texts were appraised 
independently by two authors (MC and RF-P) to select those that fulfilled the selection criteria. 
Disagreements were solved through discussion and with consultation with a third independent 
author (OHF). We reviewed reference lists of the retrieved articles and previous systematic 
reviews for additional publications. We contacted experts in the field to identify additional 
references that should be considered. Selection criteria and study selection procedures, data 
extraction and quality assessment are described in detail in Appendix 47 (page 196) and 
Appendix 48 (page 197).  
 
Statistical analysis 
We registered extracted data from each article in a purposely designed form, including for study 
design, measurement period, modes of transport, monitoring device, commuting time, and 
number of measurements. We extracted summary and dispersion measurements of exposure 
according to mode of transport and pollutant. If available, we extracted summary measurements 
stratified by season, day, period of monitoring, type of route, and city. If more than one summary 
measurement was reported for the same stratum, we preferably extracted arithmetic means, then 
geometric means, and, finally, medians. We extracted summary measurements of inhalation and 
uptake dose (per h or trip), the model, and the parameters used for the estimation. We used the 
most complete report when multiple papers of the same study were available. We addressed 
quality of the studies in terms of the comparability of the exposure measured between mode of 
transport (i.e., time and route standards), external validity (i.e., background and meteorological 
conditions and commuting standards), measurement standardization, and data reporting. We 
used a modified version of the Newcastle-Ottawa Scale for assessing the quality of observational 
studies (Appendix 48, page 197). 
To uniformly summarize the exposure data extracted, we standardized the units of 
concentrations by applying standard conversion factors.289 We calculated the median and IQR of 
averages of exposure concentration per mode of transport and pollutant and the percentage of 
exposure averages above the European Union ambient air quality standards 290 (except for BC, 
because there is no standard defined). Within each study, we calculated the exposure ratio 
according to mode of transport using cyclists’ exposure as the reference. We summarized 
exposure ratios as medians and IQRs per mode of transport and pollutant and calculated the 
percentages of ratios above 1. Also, we meta-analyzed exposure ratios using random-effects 
models.291 We assessed heterogeneity with I² 292. We assessed variability within studies by 
estimating the SE from the variance for ratios of the mean. 291 We visually inspected publication 
bias with funnel plots and used Egger’s tests to assess asymmetry. All tests were two-tailed and we 
considered p values of 0.05 or less significant. For 13 studies that did not include cyclists, we used 
pedestrians’ exposure as the reference (reported separately to the studies that included cyclists). 
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For two additional studies, we used pedestrians’ exposure as the reference because for some 
comparisons in these studies only comparisons with pedestrians were possible. 
We calculated inhaled doses of pollutants (inhaled amount per trip) as the average 
exposure concentration (reported by authors) multiplied by minute ventilation (m³/h) multiplied 
by trip time (min; reported by authors) multiplied by a conversion factor, if applicable. We used 
minute ventilation as suggested by the US Environmental Protection Agency 293 for each mode of 
transport (Appendix 49, page 198). Then, we calculated the inhalation dose ratio between mode 
of transport using the inhaled dose of cyclists (or pedestrians, accordingly) as the reference. We 
summarized ratios as medians and IQRs. 
Finally, we estimated the trade-off in YLE due to fine particle inhaled dose and physical 
activity, according to mode of transport. We used fine particles because it has the most consistent 
evidence for all-cause mortality risk.294 We calculated the loss or gain of YLE due to fine particle 
inhaled dose and physical activity levels for a person commuting by a given mode of transport. 
We based calculations on fine particle exposure and a set of assumptions regarding weekly levels 
of physical activity per mode of transport (Appendix 49, page 198). We built the assumptions for 
a given scenario where one hypothetical person spends 7 days in four microenvironments: at 
work, at home, sleeping, and commuting by one of the modes of transport over a 7 km route 
twice a day. We did a sensitivity analysis for the person commuting over a 3.5 km route. We 
calculated the net gains or losses by comparing each mode of transport to a reference scenario 
(cyclists or pedestrians, accordingly) and summarizing them as medians and IQRs. A detailed 
description of the procedures is provided in the Appendix 50 (page 199). All analyses were 
performed in Stata (version 14.0).72 
 
RESULTS 
After screening 4,037 potentially relevant studies, we retrieved and assessed 228 full 
texts, of which 54 fulfilled the initial selection criteria and 39 reported on exposure to the 
pollutants of interests and were included in the systematic review (Table 19 (page 185) and Figure 
12 (page 190)); we excluded three duplicate studies from the systematic review but included them 
in the table of study characteristics). The studies were done in European (n=24), west Pacific 
(n=11), American (n=3), and Southeast Asian (n=1) countries. Further characteristics are 
provided in the Appendix 51 (page 200). 
Irrespective of pollutant, car commuters had higher air pollution exposure than did 
active commuters in 30 (71%) of 42 comparisons (median 1.22 [IQR 0.90–1.76]), followed by 
those who commuted by bus in 57 (52%) of 109 (1.0 [0.79–1.41]), by motorcycle in 16 (50%) of 
32 (0.99 [0.86–1.38]), by a car with controlled ventilation settings in 39 (45%) of 86 (0.95 [0.66–
1.54]), and by MMT in 21 (38%) of 55 (0.67 [0.49–1.13]). (Appendix 53-54, pages 215-216). We 
observed differences in exposure ratio per mode of transport and pollutant (Figure 13, page 191 
and Appendix 55, page 217). We obtained similar estimations by meta-analyzing the exposure 
ratios, but we identified a large heterogeneity (higher than 90% in most comparisons; Appendix 
56 (page 220)). We did not find evidence of publication bias (Appendix 60, page 232). 
Inhalation or uptake pollutant dose was available in 12 of the studies included in the 
systematic review (Appendix 57, page 222). Uptake dose was estimated as the deposition of 
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pollutants in the airway. VE as breathing parameter was heterogeneous across studies. Cyclists 
followed by pedestrians had the highest uptake dose of pollutants. Minute ventilation as a 
breathing parameter was heterogeneous across studies. Five studies 284,286,287,295,296 used surrogates 
of activity intensity to derive minute ventilation, whereas the remaining studies 297-302 used 
published parameters. In Figure 14 (page 192), we compare the distribution of exposure and 
inhaled dose ratios on the basis of our calculation of inhalation dose. For all motorized modes of 
transport, the median of the inhaled dose ratio was lower than the exposure ratio. Active 
commuters had a higher inhalation dose of pollutants than did commuters who used motorized 
transport (median ratio car with controlled ventilation settings 0.16 [IQR 0.10–0.28]; car 0.22 
[0.15–0.30]; motorcycle 0.38 [0.26–0.78]); MMT 0.49 [0.34–0.81]; bus 0.72 [0.50–0.99]) due to 
increased respiratory parameters. A ratio of inhaled dose lower than the ratio of exposure, with 
respect to the y axis, suggests that the relative inhaled dose of pollutant among cyclists, in the 
denominator, is higher than their relative exposure. We observed small differences between 
exposure and inhaled dose ratios for the comparison of pedestrians with cyclists. 
Figure 15 (page 193) shows the difference in YLE due to fine particle exposure and 
physical activity per mode of transport. Median losses in YLE were up to 1 year larger among 
commuters using motorized transport than among cyclists because of less physical activity, despite 
the lower inhaled dose of fine particles (Appendix 58, page 228) using motorized transport 
compared with cyclists because of the longer commuting time of pedestrians than of cyclists. In a 
sensitivity analysis, we tested varying commuting times and consistently observed YLE gains in 
favor of active transport (Appendix 59, page 230), as the difference between life-years lost due to 
fine particle exposure and life-years gained due to physical activity remained roughly the same for 
a 3.5 km route as for a 7 km route with the relative risk of physical activity of 0.80303 (age 20–30 
years: median –1.50 years [IQR –1.69 to –1.08]; age 40–64 years: –1.26 [–1.44 to –0.77]; age ≥65 
years: –0.59 [–0.82 to –0.26]). 
Regarding quality of studies, comparability of exposure between mode of transport was 
high (at least three stars according to the Newcastle-Ottawa Scale) in 16 experimental studies 
(Appendix 52, page 214). We noted a very low comparability in 13 experimental studies (two or 
fewer stars). Ten studies were observational, which aimed to measure rather than compare 
exposure between modes of transport. Irrespective of pollutant, exposure levels to CO, NO₂, and 
fine and coarse particles were above ambient air quality standards 290 among cyclists in 50 (56%) 
of 89 exposure averages, among pedestrians in 22 (46%) of 48, among those who commuted by 
car in 22 (55%) of 40, among those who commuted by a car with controlled ventilation settings 
in 45 (52%) of 87, among those who commuted by MMT in 25 (48%) of 52, and among those 
who commuted by motorcycle in 24 (65%) of 37. The distribution of pollutant exposure level per 
mode of transport is shown in the appendix. Fine particles were more frequently above ambient 
air quality standards than were the other pollutants (155 [83%]) of 187 exposure averages). 
Detailed information about ascertainment of air pollution exposure was provided in 33 (85%) 
studies. Sample size or dispersion measurements were not reported in four (10%) studies. 
Complete reporting of background and meteorological conditions was found in 21 (54%) studies. 
Standardization of all modes of transport measured and reporting of it was found in 20 (51%) 
studies. 
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DISCUSSION 
Car and bus commuters had the highest levels of air pollution exposure, followed by those 
commuting by a car with controlled ventilation settings, cyclists, and pedestrians, whereas the 
lowest was experienced by MMT commuters and motorcyclists. Cyclists, followed by pedestrians, 
had the highest inhalation and uptake dose of pollutants because of increased minute ventilation 
and trip time. Compared with people commuting by car, by a car with controlled ventilation 
settings, and by motorcycle, the negative effect on YLE of increased inhaled dose did not 
overcome the positive effect of physical activity when commuting actively. Commuter exposure 
can be reduced by increasing the distance from traffic emissions, reducing air exchange with use 
of ventilation settings in motorized mode of transport, and choice of routes with l ow emissions 
and high dispersion of pollutants (e.g., parks), as well as eff orts to reduce local and regional 
emissions. We observed a large heterogeneity across the evidence. Further research should 
consider inhaled and uptake dose while commuting to address air pollution effects on health. 
In agreement with previous systematic reviews 48,49 the differences in air pollution 
exposure between mode of transport in this study can be explained mainly by the position of the 
commuter with respect to the gradient of pollutant concentration 285,295,299,301,304-307 and the 
commuter’s microenvironment sensitivity to surrounding pollutant concentration. The gradient 
of pollutant concentration depends on the rate of emissions and the dispersion and decay of 
pollutants in the air,282,308 which is influenced, among others, by meteorological309,310 and route 
295,301,310 attributes. The close contact of commuters using motorized transport to the traffic line 
explains their higher levels of air pollution exposure than those for active commuters.48,49,302 
Indeed, bus commuters and cyclists have lower exposure when they travel via separated bus lanes 
or cycle routes or travel close to kerb than when they do not.48,283,295,302,306 Also, pedestrians, who 
usually travel on the pavement, have a lower exposure than do cyclists.49,306 We observed the 
lowest exposure among MMT commuters, except for exposure to BC, most probably because they 
often travel on railways or through tunnels separated from ground traffic.297 The main sources of 
exposure for MMT commuters involve walking stages, when approaching the stations, 304 and 
while waiting inside the stations.48,301,311 Commuters using ground motorized transport (i.e., car 
and bus) on overcongested routes with high emission levels had high pollutant exposure because 
of high emissions, long trip time, and frequent idling.48,49,300 Additionally, canyon-like street 
configuration reduces the dispersive and catalytic action of environmental and meteorological 
factors, thus trapping the pollutants.285,301,312 
Commuters’ microenvironment sensitivity to surrounding pollutants depends on the 
rate of air interchange of the microenvironment. Active commuters, and commuters using 
motorized transport with open windows, have a high rate of air interchange, increasing their 
exposure to high pollutant concentrations 301,311,313 and pollutants hotspots like intersections and 
traffic lights.297,301,313-316 This leads to a pattern of concentration peaks in active commuters’ 
exposure, whereas commuters using motorized transport have a constant concentration exposure. 
Physical barriers like controlled ventilation settings in cars help to extract and filter fine and 
coarse particles from the vehicle microenvironment.311,313,317,318 Moreover, physical barriers make a 
large difference in highly contaminated environments,300 where both commuters using motorized 
transport and active commuters have similar exposure levels to fi ne and coarse particles.300,318,319 
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Nevertheless, people commuting with a car with controlled ventilation settings had an increased 
exposure to CO,287,300,302,306,317,320 attributed to self-pollution due to filtration of surrounding 
emissions and products from engine combustion. 
Commuters’ microenvironment sensitivity to traffic related air pollution is largely 
determined by built environment attributes that increase their proximity to traffic emissions, by 
an absence of physical barriers like ventilation settings, and by increased respiratory parameters 
leading to increased airway deposition of pollutants. Therefore, active commuters might benefit 
from air pollution forecasting and on-road advice to actively protect themselves from exposure—
e.g., by choosing uncongested routes. Incentives to shift from private motorized to active and 
public transport should be accompanied by urban planning standards and policies, such as 
dedicated lanes, separated cycle routes and pavements, improved ventilation in vehicles and at 
stops and stations for public transport, a boosted transition to environmentally friendly vehicles, 
and other eff orts aimed to reduce both combustive and non-combustive traffic-related 
emissions.46 Moreover, large societal benefits are obtained from an active commuter-friendly 
environment, which affects additional traffic-related risk factors, like noise, traffic injuries, quality 
of life, and social cohesion, among others.321,322 
By contrast with overall exposure, the inhaled dose of pollutants was higher among active 
commuters than among commuters using motorized transport. This finding is mainly explained 
by the increased minute ventilation, leading to increased air volume and frequency of breathing, 
deeper inhalation, and larger inhalation of pollutants in active commuters than in commuters 
using motorized transport.284 Active commuters, especially pedestrians, also have a longer trip 
time than do commuters using motorized transport and thereby have increased exposure 
time.284,285,296,300,318 
In agreement with previous studies,288 the large losses in YLE among commuters using 
motorized transport due to less physical activity than in active commuters were not offset by the 
modest gains due to lower inhaled fi ne particles. YLE losses of commuting by car, by a car with 
controlled ventilation settings, and by motorcycle were larger than were the losses observed 
among public transport commuters (bus and MMT). This finding can be explained by the 
contribution of physical activity during the active stages of the trip, like when approaching 
stations or stops, despite additional sources of air pollution inhalation.286,295,296,323 
To our knowledge, this study is the first systematic review of air pollution exposure and 
inhaled dose according to mode of transport. Our findings are in agreement with the systematic 
review by Mueller and colleagues,288 which included 30 studies that assessed the net health 
benefits of active transport through health impact assessment, 17 of which addressed the negative 
effect of air pollution exposure. Nevertheless, none of the studies included by Mueller and 
colleagues 288 were included in our study as they did not comply with our selection criteria and 
research question. Also, all but one study analyzed by Mueller and colleagues 288 were done with 
data from European countries, the USA, New Zealand, and Australia, with mostly indirect air 
pollution exposure levels, and with heterogeneous assumptions and modelling frameworks. By 
contrast, we used fine particle exposure levels purposely measured for modal comparison in 23 
studies and applied standard assumptions for inhaled and physical activity doses. Also, because of 
our selection criteria, we included further settings, also adding Asian and west Pacific cities, with 
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higher ambient air pollution than in the USA and most European countries. Under very high air 
pollution concentrations, the trade-off between air pollution exposure risks and active transport 
benefits has been suggested to not benefit active transport anymore.324 Yet, our findings are 
consistently in favor of active transport. 
Limitations of our analyses deserve attention. First, the external validity of the studies 
included in this report was affected by the heterogeneity of settings and methodological 
approaches. Nevertheless, on the basis of the observed heterogeneity, this systematic review 
encompasses various environmental conditions and makes our findings generalizable. Second, 
despite our comprehensive search, only eight studies were done in countries other than European 
and North American countries (China,300,301,311,314 India,325 Taiwan,326 or Vietnam,317 and 
Chile304). Although we did not find evidence of publication bias, these regions are under-
represented in our review. Third, we did not take into account the additional toxicity of other 
pollutants. However, fine particle levels are a strong marker of traffic related air pollution, and we 
found that fine particles were more frequently above ambient air quality standards than were the 
other pollutants. Fourth, we assumed a rather unlikely scenario of pedestrians commuting daily 
for longer than 2 h. Walking is an important source of physical activity, and a large proportion of 
active commuters are pedestrians.327 With a sensitivity analysis, we tested varying commuting 
times and consistently observed YLE gains in favor of active transport. Fifth, we focused on the 
long-term mortality effect of physical activity and fine particle exposure. However, examination of 
other short-term and long-term health effects would be beneficial, as well as other exposures, like 
noise and traffic injuries. Findings from previous studies suggest that regardless of the expected 
increment of traffic injuries along the shift from motorized to active commuting, the reduction in 
motorized traffic volume and the increment of an active commuter friendly environment would 
contribute to a reduction of the burden of traffic incidents.288 Finally, we assumed a total 
replacement of mode of transport at each scenario modelled and a linear association of fine 
particle exposure and physical activity with mortality, by contrast with previous findings.288,303,321 
However, our approximation is intended to build on previous efforts to summarize air pollution 
exposure according to mode of transport to examine the effect of commuting parameters on 
inhaled doses and potential population-level effects. Health benefits strongly depend on specific 
local attributes,288,321 such as the offer of mode of transport, apportionment of emissions, and 
built environment attributes, besides local policies and normative behavior. Decision making 
based on health impact assessment should take into account such local attributes. 
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Figure 12. Study selection 
 
 
 
 
  
Screened references n = 2,566 
Duplicate references n = 1,471 
Selected references by title and abstract 
screening (retrieved) 
n = 228 
Excluded references n=2,338 
Full text articles selected=54 
References detected by search terms used on 
search engines 
n =3,953 
Excluded articles 
n=174 
Study design=14 
Only motorized transport=24 
Only active transport=3 
Not commuting=13 
Biomarkers=1 
Conference proceedings=20 
Not relevant=93 
Full text not available=6 
 
References detected by manual search on 
references list and experts suggestions 
n = 84 
Included in the systematic review = 42 
 
 
Articles where are not reported measures of 
pollutants of interest for this review  
n = 12 
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Figure 13. Distribution of ratio of pollutants exposure level among modes of transport, compared 
to (A) cyclists or (B) pedestrians’ exposure 
(A) Reference: Cyclists   (B) Reference: Pedestrians 
  
The squares size is weighted according to the number of comparisons used to calculate the median. The exact values of 
median and interquartile range are provided in Appendix 53 (page 215). 🚲 Cyclists 🚶 Pedestrians Car: Car driven 
without controlled ventilation settings Car[V] Car driven with controlled ventilation settings MMT: Massive motorized 
transport CO: Carbon monoxide, BC: Black carbon, Coarse: Coarse particles. Fine: Fine particles. NO2: Nitrogen 
dioxide. Bicycle/Walk (HT) Comparison is cyclists/pedestrians in high traffic route (HT) vs. cyclists/pedestrians in low 
traffic route. 
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Figure 14. Comparison of ratio of exposure vs. ratio of inhaled dose to pollutants according to 
MT and pollutant (reference is cyclists) 
a) BC     b) CO 
 
c) Coarse particles    d) Fine particles 
 
e) NO2 
 
Numbers in top of bars correspond to median of exposure/inhaled dose ratios. 🚲 Cyclists 🚶 Pedestrians 🚗 Car driven 
without controlled ventilation settings 🚗 [V] Car driven with controlled ventilation settings 🚌 Bus 🚉 Massive motorized 
transport 🚲 [M] Motorcycle.  
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Figure 15. Gains of years of life expectancy per age-group due to air pollution exposure and 
physical inactivity, compared between any MT vs. bicycle (A) or walk (B) commuting of a 7km 
route per week* 
 
YLE: Years of life expectancy. 🚲 Cyclists 🚶 Pedestrians 🚗 Car driven without controlled ventilation settings 🚗 [V] Car 
driven with controlled ventilation settings 🚌 Bus 🚉 Massive motorized transport 🚲 [M] Motorcycle.  Values of medians 
(bars) and interquartile ranges are provided in Appendix 58 (page 228). 
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SUPPLEMENTARY MATERIAL 
 
Appendix 46. Search terms per search engine 
Ten databases were searched in cooperation with a medical information specialist to identify relevant studies 
(Embase.com, Medline (Ovid), Cinahl (EBSCOhost), the Cochrane Library, Web of Science, Scopus, PubMed, Google 
Scholar, ProQuest and Scielo) 
 
Embase.com: ('air pollution'/de OR 'air pollutant'/exp OR 'air pollution indicator'/de OR 'environmental exposure'/de OR 'exhaust gas'/de OR acetylene/de OR 
benzene/de OR '1, 3 butadiene'/de OR 'carbon monoxide'/de OR dust/de OR ethane/de OR ethylbenzene/de OR ethylene/de OR 'airborne particle'/de OR 
'nitrogen dioxide'/de OR 'particulate matter'/de OR toluene/de OR xylene/de OR 'polycyclic aromatic hydrocarbon'/exp OR combustion/de OR 'black 
carbon'/de OR 'volatile organic compound'/de OR ((air NEAR/3 (clean*)) OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR 
microenvironment* OR exhaust* OR emission* OR acetylene* OR benzene* OR butadiene* OR (carbon NEXT/1 monoxide*) OR co OR carbonmonoxide* OR 
Coarse OR dust OR ethane OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEXT/1 dioxide*) OR pm1 
OR 'pm2 5' OR pm10 OR 'pm 1' OR 'pm 2 5' OR 'pm 10' OR soot OR toluene* OR xylene* OR ufp* OR 'black carbon' OR (polycyclic NEAR/3 (hydrocarbon* 
OR carbon*)) OR pah OR pahs OR combust* OR (volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex):ab,ti) AND ('traffic and 
transport'/de OR 'motor vehicle'/exp OR 'railway'/de OR traffic/de OR bicycle/de OR 'car driving'/exp OR 'motorized transport'/de OR walking/de OR 
travel/de OR pedestrian/de OR (traffic* OR subway* OR tram OR tramway* OR streetcar OR metro OR underground OR tube OR train OR car OR cars OR 
rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* OR vehicle* OR 
((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR driver*):ab,ti) AND (commut* OR 
telecommut* OR ((travel) NEAR/3 (work*))) 
 
Medline (OvidSP): ("air pollution"/ OR exp "Air Pollutants"/ OR "environmental exposure"/ OR "Vehicle Emissions"/ OR acetylene/ OR benzene/ OR "Benzene 
Derivatives"/ OR "butadienes"/ OR "carbon monoxide"/ OR dust/ OR ethane/ OR ethylenes/ OR "nitrogen dioxide"/ OR "particulate matter"/ OR toluene/ 
OR "Polycyclic Hydrocarbons, Aromatic"/ OR ((air ADJ3 (clean*)) OR ((environment* OR personal) ADJ3 expos*) OR pollut* OR microenvironment* OR 
exhaust* OR emission* OR acetylene* OR benzene* OR butadiene* OR (carbon ADJ monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane 
OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* ADJ3 matter*) OR (nitro* ADJ dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" 
OR "pm 2 5" OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR "black carbon" OR (polycyclic ADJ3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR 
combust* OR (volatile ADJ3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex).ab,ti.) AND ("Transportation"/ OR exp "Motor Vehicles"/ OR 
"railroads"/ OR Bicycling/ OR walking/ OR travel/ OR (traffic* OR subway* OR tram OR tramway* OR streetcar OR metro OR underground OR tube OR train 
OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* OR 
vehicle* OR ((commut*) ADJ3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR driver*).ab,ti.) AND (commut* 
OR telecommut* OR ((travel) ADJ3 (work*))) 
 
Cinahl (ebsco): (MH "air pollution+" OR MH "Air Pollutants+" OR MH "environmental exposure+" OR MH "Benzene Derivatives+" OR MH "carbon monoxide+" 
OR MH dust+ OR MH ethylenes+ OR MH "particulate matter+" OR MH toluene+ OR MH "Polycyclic Hydrocarbons, Aromatic+" OR ((air N3 (clean*)) OR 
((environment* OR personal) N3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR acetylene* OR benzene* OR butadiene* OR 
(carbon N1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* 
N3 matter*) OR (nitro* N1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR 
"black carbon" OR (polycyclic N3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR (volatile N3 compound*) OR VOCs OR voc OR tVOCs OR 
tvoc OR btex)) AND (MH "Transportation+" OR MH "Motor Vehicles+" OR MH "railroads+" OR MH cycling+ OR walking+ OR travel+ OR (traffic* OR subway* 
OR tram OR tramway* OR streetcar OR metro OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR 
cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* OR vehicle* OR ((commut*) N3 (mode OR type OR way OR public OR strateg*)) 
OR travel* OR pedestrian* OR passenger* OR driver*)) AND (commut* OR telecommut* OR ((travel) N3 (work*))) 
 
Cochrane: (((air NEAR/3 (clean*)) OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR 
acetylene* OR benzene* OR butadiene* OR (carbon NEXT/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR 
ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEXT/1 dioxide*) OR pm1 OR 'pm2 5' OR pm10 OR 'pm 1' OR 'pm 2 5' OR 
'pm 10' OR soot OR toluene* OR xylene* OR ufp* OR 'black carbon' OR (polycyclic NEAR/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR 
(volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex):ab,ti) AND ((traffic* OR subway* OR tram OR tramway* OR streetcar OR 
metro OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR 
buses OR foot OR bike OR transport* OR vehicle* OR ((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR 
passenger* OR driver*):ab,ti) AND (commut* OR telecommut* OR ((travel) NEAR/3 (work*))) 
 
Web-of-science: TS=((((air NEAR/3 (clean*)) OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* 
OR acetylene* OR benzene* OR butadiene* OR (carbon NEAR/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* 
OR ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEAR/1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" 
OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR "black carbon" OR (polycyclic NEAR/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* 
OR (volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ((traffic* OR subway* OR tram OR tramway* OR streetcar OR metro 
OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses 
OR foot OR bike OR transport* OR vehicle* OR ((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR 
passenger* OR driver*)) AND (commut* OR telecommut* OR ((travel) NEAR/3 (work*)))) 
 
Scopus: TITLE-ABS-KEY((((air W/3 (clean*)) OR ((environment* OR personal) W/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR 
acetylene* OR benzene* OR butadiene* OR (carbon W/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR 
ethylene* OR ethene* OR particle* OR (particul* W/3 matter*) OR (nitro* W/1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 10" 
OR soot OR toluene* OR xylene* OR ufp* OR "black carbon" OR (polycyclic W/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR (volatile 
W/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ((traffic* OR subway* OR tram OR tramway* OR streetcar OR metro OR 
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underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR 
foot OR bike OR transport* OR vehicle* OR ((commut*) W/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR 
driver*)) AND (commut* OR telecommut* OR ((travel) W/3 (work*)))) 
 
PubMed: ("air pollution"[mh] OR "Air Pollutants"[mh] OR "environmental exposure"[mh] OR "Vehicle Emissions"[mh] OR acetylene[mh] OR benzene[mh] OR 
"Benzene Derivatives"[mh] OR "butadienes"[mh] OR "carbon monoxide"[mh] OR dust[mh] OR ethane[mh] OR ethylenes[mh] OR "nitrogen dioxide"[mh] OR 
"particulate matter"[mh] OR toluene[mh] OR "Polycyclic Hydrocarbons, Aromatic"[mh] OR ((air AND (clean*[tiab])) OR ((environment*[tiab] OR personal) AND 
expos*[tiab]) OR pollut*[tiab] OR microenvironment*[tiab] OR exhaust*[tiab] OR emission*[tiab] OR acetylene*[tiab] OR benzene*[tiab] OR butadiene*[tiab] OR 
(carbon ADJ monoxide*[tiab]) OR co OR carbonmonoxide*[tiab] OR Coarse OR dust OR ethane OR ethylbenzene*[tiab] OR ethylene*[tiab] OR ethene*[tiab] 
OR particle*[tiab] OR (particul*[tiab] AND matter*[tiab]) OR (nitro*[tiab] ADJ dioxide*[tiab]) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 
10" OR soot OR toluene*[tiab] OR xylene*[tiab] OR ufp*[tiab] OR "black carbon" OR (polycyclic AND (hydrocarbon*[tiab] OR carbon*[tiab])) OR pah OR pahs 
OR combust*[tiab] OR (volatile AND compound*[tiab]) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ("Transportation"[mh] OR "Motor Vehicles"[mh] 
OR "railroads"[mh] OR Bicycling[mh] OR walking[mh] OR travel[mh] OR (traffic*[tiab] OR subway*[tiab] OR tram OR tramway*[tiab] OR streetcar OR metro 
OR underground OR tube OR train OR car OR cars OR rail*[tiab] OR automobile*[tiab] OR bicycle*[tiab] OR motorcycle*[tiab] OR cycling OR walk*[tiab] OR 
bus OR busses OR buses OR foot OR bike OR transport*[tiab] OR vehicle*[tiab] OR ((commut*[tiab]) AND (mode OR type OR way OR public OR 
strateg*[tiab])) OR travel*[tiab] OR pedestrian*[tiab] OR passenger*[tiab] OR driver*[tiab])) AND (commut*[tiab] OR telecommut*[tiab] OR ((travel) AND 
(work*[tiab]))) AND publisher[sb]  
 
Google Scholar: Pollution|pollutant|pollutants|exhaust|"particulate matter|pah|pahs|combustion|"black carbon"|vacs 
traffic|vehicle|railway|bicycle|car|driving|motorized|walking|pedestrian|pedestrians|subway|metro|underground|train|cycling 
commuters|commuting|commuter 
 
Proquest: (ti(Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black carbon" OR vac OR vacs OR 
carbonmonoxide OR Coarse OR dust OR btex) OR ab(Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black 
carbon" OR vac OR vacs OR carbonmonoxide OR Coarse OR dust OR btex)) AND (ti( traffic OR vehicle OR railway OR bicycle OR car OR driving OR 
motorized OR walking OR pedestrian OR pedestrians OR subway OR metro OR underground OR train OR cycling) OR ab( traffic OR vehicle OR railway OR 
bicycle OR car OR driving OR motorized OR walking OR pedestrian OR pedestrians OR subway OR metro OR underground OR train OR cycling) ) AND 
(ti(commuter*) OR ab(commuter*)) 
 
Scielo: (Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black carbon" OR vac OR vacs OR carbonmonoxide 
OR Coarse OR dust OR btex) AND ( traffic OR vehicle OR railway OR bicycle OR car OR driving OR motorized OR walking OR pedestrian OR pedestrians OR 
subway OR metro OR underground OR train OR cycling) AND (commuter*)  
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Appendix 47. Selection criteria and study selection procedures, data extraction and quality assessment 
 
Study selection and eligibility criteria 
We included studies only in human adults. We excluded studies that measured AP exposure exclusively by biomarkers or 
based on simulated data, reviews, comments, consensuses, editorials, guidelines, in vitro studies, meta-analyses, ecological 
studies and protocols. We did not consider language or temporal limits. 
Working in pairs, three authors reviewed titles and abstracts of the entire list of references to select those that 
fulfilled the selection criteria. After initial appraisal, full texts of selected titles were retrieved. Full texts were appraised 
independently by two authors to select those that fulfilled the selection criteria. Disagreements were solved through 
discussion, and upon consultation with a third independent author. Reference lists of the retrieved articles and previous 
systematic reviews were reviewed for additional publications. Experts in the field were contacted to identify additional 
references that should be considered. 
 
Data extraction and quality assessment of the evidence 
Extracted data from each article were registered in a form purposely designed, including study design, measurement 
period, MT, monitoring device, commuting time and number of measurements performed. Summary and dispersion 
measurements of exposures were extracted, according to MT and pollutant. If available, we extracted summary 
measurements stratified by season, day, period of monitoring, type of route and city. If more than one summary 
measurements were reported for the same strata, we extracted preferably arithmetic means, then geometric means and 
finally, medians. We extracted summary measurements of inhalation and uptake dose (per hour and/or per trip), model 
and parameters used for the estimation. We used the most complete report when multiple papers of the same study were 
available. 
Quality of the studies was addressed in terms of the comparability of the exposure measured between MT, and 
the information provided to assess comparability. We used a modified version of the Newcastle-Ottawa scale for assessing 
the quality of observational studies (Appendix 48 (page 197)).  
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Appendix 48. Adjusted Newcastle-Ottawa Quality Assessment Scale 
 
Selection (Maximum, four stars) 
-1) Modal comparison 
-a. Experimental [E] 
-b. Observational [O] 
-2) Background concentration and meteorological conditions 
-a. Background concentration of ultrafine particles and meteorological conditions were provided/used for 
measurements standardization ** 
-b. Either background concentration of pollutants or meteorological conditions are provided but not used for 
standardization* 
-c. Not measured or not provided 
-3) Sources of heterogeneity 
-a. Sources of heterogeneity for all modes of transport were standardized during measurements [i.e. for 
motorized modes, ventilation standards, type of car and fuel type; and for active modes, position in the road or 
in the sideway] ** 
-b. Standards were used in some modes of transport * 
-c. No description or not standardized 
Comparability (Maximum, four stars) 
-1) Commuting time standards (start time and iterations) 
-a. All modes of transport were measured at the same time ** 
-b. Not all the modes were measured at the same time, but the sampling time was standardized * 
-c. No description or not standardized 
-2) Route(s) standardized (same route followed by all the modes) 
-a. Fixed route(s) followed by all the modes of transport ** 
-b. The fixed route(s) were not followed by all the modes, but were standardized * 
-c. No description or not standardized 
Outcome (Maximum, three stars) 
-1) Ascertainment of exposure 
-a. Sampling, device operation and analysis of the samples were standardized for all modes of transport ** 
-b. Sampling, device operation and analysis of the samples were standardized only for some modes of transport 
*  
-c. No description or not standardized 
-2) Sample size and dispersion measurements 
-a. Average or total trip time and/or number of trips and dispersion data for summary measurements reported 
for all modes of transport * 
-b. Incomplete reporting of trip time or number of trips for all modes of transport  
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Appendix 49. Parameters for estimation of gains in life expectancy by commuting over a 7km route by any MT vs. bicycle 
or walking during a week 
Issue Parameter Values Hours per day Hours per week 
Time (hours) Motorized transport, except public 
transport 
 0.63 4.43 
 Walk  2.50 17.50 
 Bicycle  1.00 7.00 
 Public transport  1.33 9.33 
 Indoor (Sleep)  8.00 56.00 
 Indoor (Work)  8.00 56.00 
 Indoor (Home if motorized scenario)  7.37 51.57 
 Indoor (Home if walk scenario)  5.50 38.50 
 Indoor (Home if pedestrian scenario)  7.00 49.00 
 
Indoor (Home if public transport 
scenario) 
 6.67 46.67 
Air pollution 
Background AP factor† 0.74   
Minute ventilation (m3/hour)    
Sleep 0.30   
Home/Work 0.74   
Trip: Motorized 0.28   
Trip: Public transport 0.94   
Trip: Walk 1.59   
Trip: Bicycle 1.59   
RR all-cause mortality per 10µg/m3 of 
increment in PM2.5 concentration 
1.06   
Physical activity 
MET mode – Motorized 1.5   
MET mode – Public transport‡ 2.0   
MET mode – Walk 4.5   
MET mode – Bicycle 4.5   
MET sleep 1.0   
MET home 2.25   
MET work 2.25   
RR all-cause mortality of seven hours 
per week of moderate physical activity 
vs 0 hours per week of moderate 
physical activity 
0.76   
†This factor was used to estimate the background concentration of PM2.5 in those studies where it was not provided. The 
factor was estimated as the average of the ratio between background PM2.5 measured in fixed monitoring sites vs 
cyclists/pedestrians (if cyclists not measured), as reported in 25 studies included in the systematic review. ‡ This MET is 
assumed, taking into account that most trips made by public transport include approach stages, usually made by walking; 
thus, we assumed that 20 out of the 40 minutes of each public transport trip were approach stages of the trip made by 
walking. 
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Appendix 50. Procedures for estimation of gains in life expectancy by commuting over a 7-km route by any MT vs. bicycle 
or walking during a week 
 
1. Scenarios: Within each study (n=25), we constructed a scenario for one hypothetical person spending seven days on 
four microenvironments: at work, at home, sleeping and commuting by one of the MT measured over a 7km route, twice 
a day (e.g., if cyclists and car commuters were measured, we built one scenario where the person commutes only by bicycle 
and other where the person commutes only by car). For each scenario, we calculated the weekly doses of physical activity 
and of inhaled fine particles. We assumed that at work and sleeping time were equal in all scenarios. The commuting time 
for each MT was calculated for a 7km route. At home time varied depending on the scenario to complete 24 hours.  
 
2. Air pollution dose estimation: First, we estimated the daily inhaled fine particles dose of each scenario by adding the 
inhaled dose at each of the four activities, which were calculated applying the formula [1]: Inhaled dose [inhaled 
amount/trip]= Average exposure concentration (reported by the authors) x VE (m3/hr.) x activity time (min), using the 
reported average exposure and standard VE depending on the activity293, and weighted by the daily time spent at each 
activity.  
 
3. Physical activity dose estimation: Second, we estimated the daily physical activity dose in MET-hours/week of each 
scenario by adding the energy expenditure weighted by the daily time spent at each activity. Both daily inhaled fine 
particles dose and physical activity dose were multiplied by seven. 
 
4. Scenarios comparison: We calculated a weighted ratio of weekly inhaled fine particles dose and of physical activity dose 
by dividing the weekly inhaled fine particles dose and the weekly physical activity dose of each scenario by the 
corresponding weekly doses of the cyclists (or pedestrians) scenario. 
 
5. Risk estimation between scenarios: We used the weighted ratio to calculate an adjusted dose-related all-cause mortality 
risk ratio (RR), derived from the RR for all-cause mortality estimated in previous meta-analyses. For fine particles exposure 
(1.06 per 10µg/m3 change in fine particles concentration) 294 and for physical activity (0.76 for seven hours/week of 
moderate physical activity, compared to 0 hours/week).303 Details of the procedures are explained in detail by de Hartog et 
al.342 
 
6. Life-expectancy impact: The weighted RR were used to calculate the all-cause mortality rate per age group (20-39, 40-64 
and +65 years) of the alternative scenarios mDxA at each study, by applying the formula [2] mDxA=mDxR*RR, where mDxR is 
the mortality rate of the reference scenario (cyclist or pedestrian). As mDxR we used the all-cause mortality rates per age 
group provided by the Global Burden of Disease for 2013343 for the corresponding country of the study. The mortality 
rates were used to calculate the life expectancy at each scenario, using standard life tables.7. Summary: We calculated the 
difference of years of life expectancy between the alternative and the reference scenarios at each study. The differences 
were summarized in medians and interquartile ranges. The Appendix 50 (page 199) shows the assumptions used for the 
estimations. 
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Appendix 52. Quality of the studies¶ 
Author, year 
(Reference) 
Modal 
comparison 
Background 
factors 
Heterogenei
ty 
Same time – 
All modes 
Same route – 
All modes 
Ascertain
ment 
of 
exposure 
Sample 
size and 
dispersion  
Adams, 2001 307 
Adams, 2002 328 
E ** ** * ** ** * 
Boogaard, 2009 305 E ** * *  ** * 
Brauer, 1999 329 E * *   ** * 
Briggs, 2008 318 E ** ** ** ** ** * 
Chertok, 2004 330 O ** NA * NA *  
De Bruin, 2004 331 O * NA NA NA * * 
de Nazelle, 2012 295 E ** ** * ** ** * 
Dirks, 2012 297 O  NA * * ** * 
Dons 2011 298 
Dons 2012299 
O ** * NA NA ** * 
Dor, 1995 320 E  **   **  
Duci, 2003 332 E **  * * ** * 
Farrar, 2001 312 O * * NA NA **  
Gee, 1999 333 E/O * * ** * ** * 
Georgoulis, 2002 
334 
O * NA NA NA *  
Goel 2015 325 E ** *  * ** * 
Gulliver, 2004 319 E ** ** ** ** ** * 
Gulliver, 2007 313 E ** ** ** ** ** * 
Huang, 2012 300 E ** *  ** ** * 
IntPanis, 2010 284 E ** ** * ** ** * 
Kaur, 2005 306 
Kaur, 2009 310 
E ** ** ** * ** * 
Kingham 2013 335 E * ** ** ** ** * 
Li, 2015 301 E ** ** * ** ** * 
Liu, 2015 326 O * * ** NA * * 
McNabola, 2008 285 E * ** * ** ** * 
Morabia, 2009 336 E ** **   * * 
Moreno 2015 337 E * * * * ** * 
Nyhan, 2014 286 O ** ** * NA ** * 
Onat, 2013 316 E * * * * ** * 
Ramos 2016 302 E  *  ** * * 
Rank, 2001 338 E ** ** ** ** ** * 
Saksena, 2008 317 E * ** * ** ** * 
Suárez, 2014 304 E ** ** * ** ** * 
Van Wijnen, 1995 
287 
E * ** ** ** ** * 
Vellopolou, 1998 
339 
O * * * NA ** * 
Vouitsis, 2014 340 E ** * * ** ** * 
Williams 2016 341 O  * NA NA ** * 
Wu, 2013 311 E ** ** *  ** * 
Yan, 2015 314 E * **  * ** * 
Zuurbier, 2010 296 E ** ** * * ** * 
E: Experimental. O: Observational ¶ Details of the tool used for the assessment is provided in Appendix 48 (page 197). 
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Appendix 56. Meta-analysis of ratio of pollutants exposure level according to MT 
MT Pollutant Ratio 95% CI I2 Comparisons* References 
Reference category: Cyclists  
🚲 (HT) 
Coarse 1.04 0.88 1.23 100% 1 296 
Fine 1.01 0.53 1.91 100% 1 296 
🚌 
BC 1.29 0.95 1.75 96% 6 299,301,340,341 
CO 1.40 1.12 1.74 63% 7 300,302,306 
Coarse 1.12 0.75 1.67 93% 18 286,296,302,340 
Fine 1.05 0.94 1.19 90% 22 285,286,296,300,302,304,306,311,325,340 
NO2 1.53 1.27 1.85 0% 2 312 
🚗 
BC 1.38 1.15 1.65 91% 7 299,301,340,341 
CO 1.07 0.83 1.38 0% 2 306 
Coarse 0.92 0.64 1.34 94% 3 333,340 
Fine 1.05 0.89 1.25 80% 5 306,340 
NO2 0.68   100% 1 312 
🚗 [V] 
BC 1.32 0.13 13.25 99% 2 302,340,341 
CO 2.85 2.53 3.22 57% 10 287,300 
Coarse 0.71 0.55 0.91 88% 18 284,296,302,340 
Fine 0.95 0.84 1.07 95% 30 284,285,296,300,302,304,305,311,340 
NO2 0.77 0.48 1.25 88% 3 287 
🚉 
BC 1.04 0.67 1.60 99% 6 299,301,341 
CO 1.00 0.21 4.74 0% 4 302 
Coarse 0.70 0.59 0.83 0% 11 286,302 
Fine 0.73 0.46 1.14 85% 8 286,302,304,311 
🚲 [M] 
CO 3.00 0.53 16.96 0% 4 302 
Coarse 0.75 0.55 1.04 0% 10 302 
Fine 0.84 0.79 0.90 0% 8 302,311,325 
🚶 
BC 0.92 0.81 1.03 79% 5 299,301,341 
CO 0.91 0.78 1.05 0% 3 287,306 
Coarse 0.83 0.67 1.03 100% 1 286 
Fine 0.82 0.71 0.94 66% 7 285,286,306,311,325 
NO2 1.12 0.79 1.58 100% 1 287 
Reference category: Pedestrians  
🚌 
BC 1.04 0.55 1.95 100% 1 337 
CO 0.92 0.86 0.99 74% 21 317,331,332,337 
Coarse 0.66 0.45 0.98 86% 2 317,326 
Fine 0.90 0.76 1.06 79% 10 314,316,325,326 
🚗 
CO 1.77 1.64 1.92 36% 7 331,332 
Fine 0.77   100% 1 325 
 
🚗 [V] 
CO 2.18 0.03 141.99 100% 1 317 
Coarse 0.66 0.47 0.95 97% 6 317-319,326 
Fine 0.54 0.39 0.73 95% 9 316,318,319,325,326 
🚉 
BC 1.32 0.73 2.39 100% 1 337 
CO 0.48 0.34 0.70 97% 7 331,332,337 
Coarse 0.63 0.61 0.65 100% 1 326 
Fine 0.58 0.45 0.74 70% 7 314,316,325,326 
🚲 [M] 
CO 1.75 1.22 2.52 47% 2 317,331 
Coarse 1.17 0.94 1.46 100% 1 317 
Fine 0.97 0.86 1.11 0% 4 325 
🚶 (HT) 
BC 1.26 0.82 1.92 72% 3 337 
CO 1.33 1.10 1.61 32% 3 337 
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🚲/🚶 (HT) Cyclists/pedestrians exposure over a high traffic route, the reference is low traffic route. 🚶 Pedestrians 🚗 Car 
driven without controlled ventilation settings [V] Car driven with controlled ventilation settings 🚌 Bus 🚉 Massive 
motorized transport 🚲 [M] Motorcycle.  BC: Black carbon. CO: Carbon monoxide. NO2 Nitrogen dioxide. 95% CI: 95% 
level confidence interval. IQR: Interquartile range (between 25th and 75th percentiles) I2 describes the percentage of 
variation across comparisons that corresponds to heterogeneity rather than chance292. The highest the I2 indicates a higher 
heterogeneity. *Some meta-analyses were performed with less comparisons that the corresponding exposure ratios, because 
of incomplete reporting of sample size and variance, required for estimation of pooled ratios. 
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Appendix 60. Funnel plots for publication bias assessment, according to mode of transport and 
pollutant 
a) BC 
 
b) CO 
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c) Coarse particles 
 
d) Fine particles 
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e) NO2 
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3.1.2 Exposure and inhaled dose of ultrafine particles according to mode of transport: 
systematic review 
 
Magda Cepeda, Josje D. Schoufour, Rosanne Freak-Poli, Chantal Koolhaas, Klodian Dhana, 
Mònica Guxens, Oscar H. Franco 
 
ABSTRACT 
Introduction: There is increasing interest concerning the toxicity of ultrafine particles, however 
differences in exposure to ultrafine particles according to mode of transport and differences in 
inhalation dose remain unclear.  In this systematic review we aimed to compare the exposure to 
ultrafine particles according to mode of transport, calculate the potential differences in the 
inhalation and dose, and examine if these differences differed according to World Health 
Organization (WHO) region. 
 
Methods: We searched ten online datasets from inception to January 27th 2018 without language 
or temporal restrictions. We searched for cohort, cross-sectional, and experimental studies that 
compared the exposure to ultrafine particles was measured in at least one motorized (car, massive 
motorized transport (MMT), tram, bus) and at least one active (pedestrian and cyclist) mode of 
transport. We excluded studies that measured air pollution exposure exclusively with biomarkers, 
or on the basis of simulated data, reviews, comments, consensuses, editorials, guidelines, in-vitro 
studies, meta-analyses, ecological studies, and protocols. We extracted average exposure and 
commuting time per mode of transport. Within each study, we calculated exposure ratios using 
active commuters as reference categories. We also calculated potential inhalation of ultrafine 
particles per mode of transport and the corresponding inhalation ratios per study. The exposure 
and inhalation ratios were summarized as medians and interquartile ranges, for all studies and 
stratified according to WHO region. 
 
Results: Out of 2,277studies identified, we included 28 studies. Car and bus commuters were 
more likely to exhibit higher exposure to ultrafine particles than active commuters (median 
ratio=1.23 [interquartile range (IQR)=0.72, 1.46] and 1.11 [IQR=0.72, 1.46], respectively), while 
MMT and tram commuters were less likely to exhibit higher exposure (0.86 [IQR=0.45, 1.48] and 
0.62 [0.38, 0.79]). Reducing air interchange through closed windows and air conditioning 
reduced the exposure among car commuters (0.79 [IQR=0.47, 1.08]). However, active commuters 
(i.e. those walking or biking) inhaled a larger dose of ultrafine particles than motorized 
commuters, due to higher breathing rate and commuting time. 
 
Conclusions: Car and bus commuters are exposed to more ultrafine particles, but active 
commuters inhaled more pollutants. However, the inhalation of ultrafine particles was larger 
among active commuters. 
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INTRODUCTION 
The negative health effects of exposure to particulate matter with a diameter below 10 and 2.5µm 
have been widely documented.282,344  Nevertheless, within the complex mixture of air pollution, 
particles of smaller size, such as ultrafine particles (diameter < 0.1µm),345 may have a toxicity 
independent of the effects of larger particles. Such toxicity is partly attributed to its enhanced 
deposition efficiency, given its small size, what contributes to reach more organs and tissues in the 
body.346 Additionally, because ultrafine particles account for up to 80% of the particulate matter 
number,347-349 these have a larger interaction surface carrying toxic components.345 Most of the 
ultrafine particles are known as accumulation mode (size about 0.03-0.5µm), which are mostly 
produced in traffic during the combustion of diesel and petrol engines.345,347,348 Ultrafine particles 
can also be found as nucleation mode particles (size below 0.03µm),347 which are mostly generated 
in the environment under warm and dry conditions and high concentration of sulfur 
dioxide.347,349 The concentration of ultrafine particles is strongly determined by traffic 
characteristics,50,350 and up to 50% of the daily exposure occurs in proximity to traffic, for 
example while commuting.345,351 
Ultrafine particles besides having a high deposition efficiency are also slowly cleared and 
retained longer than coarser particles, leading to chronic tissue damage under repeated 
exposure.345. However, it remains unclear if the mode of transport confers any advantage in terms 
of exposure to ultrafine particles. For example, car and bus commuters would be more exposed to 
freshly emitted particles given their position in the traffic line.50 However, since pedestrians and 
cyclists have a higher respiratory rate than motorized transport commuters, they would inhale 
more particles. Previously, we showed that the mortality risk due to the increased exposure to air 
pollutants with a diameter of less than 2.5 micrometers (PM2.5) would be offset by the benefits of 
increased physical activity 352 and a meta-analysis of health impact assessment studies identified 
that the gains of active commuting were driven mostly by physical activity.353 Also, de Nazelle et al 
performed a systematic review comparing the exposure to ultrafine particles,50 but they did not 
examine the potential differences in inhalation dose and it was limited to studies performed in 
Europe. Therefore, we performed a systematic review with the aim to compare the exposure to 
ultrafine particles according to mode of transport and calculated the potential differences in the 
inhalation and dose. 
 
METHODS 
Search strategy  
We conducted a systematic review of studies that compared the exposure to ultrafine particles 
between modes of transport among adult commuters. Ten databases (Embase, Medline, Cinahl, 
Cochrane, Web of science, Scopus, PubMed, Google Scholar, Proquest, and Scielo) were 
searched in cooperation with a medical information specialist to identify relevant studies; the 
search was last conducted on January 27th 2018. Terms related to air pollution (e.g. “air 
pollution”) or key terms of a detailed list of air pollutants (e.g. “ufp”, “particulate matter”, etc.) 
were combined with key terms of mode of transport (e.g. “traffic” “subway”, “car”, “bicycle”, 
“walk”). Full search strategies are provided in Appendix 61 (page 250). 
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Selection criteria 
We selected all studies, independently of study design (observational and experimental) where 
personal ultrafine particle air pollution exposure was measured while commuting by at least one 
active and at least one motorized mode of transport. Ultrafine particles were defined as particles 
size below 0.01µm. Modes of transport were defined as walking, cycling, bus, massive motorized 
transportation (MMT, i.e. subway, metro and train), car (private or public). The mode of 
transport ‘car’ was stratified in two categories: “car[V]” for those that reported controlled 
ventilation settings (windows closed, air conditioning (A/C) on or off and/or air recirculation 
modes on or off) and “car” for those without controlled ventilation settings or not specified. 
Furthermore, we selected studies conducted among healthy human adults. We excluded 
studies where exposure was measured exclusively by biomarkers or studies solely based on 
simulated data. We also excluded reviews, comments, consensuses, editorials, guidelines, in vitro 
studies, meta-analyses, ecological studies and protocols. We include all studies independently of 
language or temporal limits. 
 
Study selection 
All titles and abstracts were reviewed by two independent investigators to select those that would 
fulfill the selection criteria. Then, we retrieved the full text of all studies selected in this initial 
appraisal. Two authors reviewed independently the full text, to select those studies that fulfilled 
the selection criteria. We solved disagreements through discussion and consulting a third 
independent author. We also extracted the references of all the selected studies and of previous 
systematic reviews to find other potentially relevant references. Finally, we contacted experts in 
the field to identify further relevant references to consider. 
 
Data extraction and quality assessment of the evidence 
Data from each article was extracted in a purposely designed form. Data extracted included 
overall study design, measurement period, modes of transport, monitoring devices and range of 
detection, commuting time and number of measurements performed, city and country of the 
study. Additionally, we extracted the levels of exposure to ultrafine particles, according to mode 
of transport. If available, we extracted the most disaggregated summary and dispersion measures 
by season, day of measurement campaign, day period of monitoring (e.g. morning vs. afternoon), 
and type of route. If more than one summary measure was provided per strata, we extracted 
preferably arithmetic means, then geometric means, and then median. If available, we also 
extracted the summary and dispersion measures of inhalation dose and deposition (per hour or 
per trip), along with the model or procedures for calculation and the parameters used for the 
estimation. If more than one article was available for one study, we extracted data from the most 
complete report.  
We also assessed the study quality in terms of comparability of the exposure measured 
between modes of transport, and the information provided to assess such comparability. We used 
a modified version of the Quality Newcastle-Ottawa scale of the studies for assessing the quality of 
observational studies (Appendix 48 (page 197)). 
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Statistical analysis 
In order to improve the comparability of the exposure to ultrafine particles according to mode of 
transport across the selected studies, we calculated exposure ratios according to mode of transport 
within each study. The exposure ratios were calculated using the exposure measurements 
provided for each mode of transport, using the exposure of active commuters’ (pedestrian or 
cyclists) as the reference. When both cyclists and pedestrians were measured, we used cyclists’ as 
the reference. We prioritized the calculation of exposure ratios between modes over the same 
route, when more than one route was measured. Nevertheless, if no active commuter was 
measured in a given route, we used as reference the exposure of the active commuter with the 
highest exposure, as long as it was in the same city and in approximate the same period of time. 
We summarized the exposure ratios as medians and interquartile ranges per mode of transport, 
and we calculated the percentage of exposure ratios that were above one.  
We also calculated inhalation ratios, using inhalation doses estimated with the exposure 
levels extracted from each study. The inhalation ratios were calculated for the same comparisons 
as in the previous step, except for two studies,335,354 where no exposure levels were provided, but 
only exposure ratios. The inhaled doses were calculated using the formula: average exposure 
concentration (reported by authors; #/m3) x minute ventilation (VE) (m3/hr). We used VE 
suggested by U.S. EPA 2011293 for each mode of transport. The inhalation ratios were also 
summarized as medians and interquartile range, according to mode of transport. To account for 
the different time that commuters of each mode of transport would require to complete the same 
route, we performed a sensitivity analysis recalculating the inhalation dose with the following 
formula: average exposure concentration (reported by authors; #/m3) x minute ventilation (VE) 
(m3/hr) x trip time (hour). To derive trip times per mode of transport we used Google Maps to 
calculate the time that would take to complete a route of approximately 3km in Rotterdam, the 
Netherlands. The calculated route can be followed by any mode of transport, except by bus, but 
we assumed the same time as MMT. The inhalation doses were also summarized as explained 
above. 
We performed a subgroup analysis, in order to assess whether the exposure and 
inhalation ratios would differ according to the geographic region were the study were performed; 
we plotted the exposure and inhalation ratios using different vignettes for the region according to 
the WHO.355 We also summarized the exposure and inhalation ratios according to WHO region. 
Finally, we meta-analyzed the exposure ratios using random effect models;291 
heterogeneity was assessed with I2, which describes the percentage of the variation across 
comparisons that is due to heterogeneity rather than chance 292. We used funnel plots and Egger’s 
test to assess publication bias. All tests were two- tailed and p-values below 0.05 were considered 
statistically significant. All analyses were performed in Stata (version 15.0).72 
 
RESULTS 
Overall studies characteristics and reporting quality 
We included 28 studies in this systematic review (Figure 16 (page 244)). Six studies were 
performed in four American countries (AMR), 18 studies in nine European countries (EUR) and 
four studies in four West Pacific Region countries (WPR) (Table 20 (page 247)). No studies from 
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other WHO regions were identified. Bus commuting was examined in 18 studies, car commuting 
in 25 studies (in 10 without standard ventilation settings and in 19 with standard ventilation 
settings), MMT commuting in 9 studies, tram commuting in 4 studies, pedestrians’ in 17 studies, 
and cyclists’ in 17. In one study cyclists and pedestrians’ exposure was merged in one category 356 
and in other the exposure of all motorized commuters was merged in one category.357 In one 
study motorcyclists were included, but no data on ultrafine particles was reported.358 Overall 
exposure was highest among car commuters, followed by bus, cyclists, MMT, car [V], and tram 
commuters (Appendix 64 (page 254)). Pedestrians experienced the lowest exposure. 
The study design was experimental in 24 studies and observational or mixed in the 
remaining. The experimental studies consisted in planned commutes where exposure was 
measured, with scripted routes and/timing. Observational studies consisted in measures obtained 
from volunteers during their regular commutes. Complete information about commuting 
standards was provided in 18 studies (Appendix 65 (page 255) and Appendix 66 (page 256)). The 
same routes were followed by all commuters in 13 studies and in four all commuters started the 
commute at the same time, whereas in 19 the commuters started around the same time frame or 
consecutively.  
 
Comparison of exposure and inhaled dose of ultrafine particles according to mode of transport 
Car commuters were more likely to experience higher exposure to ultrafine particles than active 
commuters (14/20 comparisons; median (IQR): 1.23 (0.98-1.61)), followed by bus (15/26; 1.11 
(0.72-1.46)), and MMT commuters (5/11; 0.86 (0.45-1.48)) (Figure 17 (page 245) and Appendix 
67 (page 266)). Car [V] and tram commuters were less likely to experience higher exposure to 
ultrafine particles than active commuters (15/44 comparisons (0.79 (0.47-1.08)) and 0/4 
comparisons (0.62 (0.38-0.79)), respectively). Nevertheless, active commuters were more likely to 
inhale more ultrafine particles than car, car [V], and tram commuters in all comparisons. In 
20/26 comparisons active commuters inhaled more particles than bus commuters (0.69 (0.42-
0.86)) and in 10/11 than MMT commuters (0.51 (0.26-0.87)). 
Pedestrians commuting in low traffic routes experienced a higher exposure to ultrafine 
particles than pedestrians commuting in high traffic routes or cyclists in 10/39 comparisons (0.83 
(0.63-1.00)) (Figure 17 (page 245) and Appendix 67 (page 266)). Cyclists commuting in high 
traffic routes experienced higher exposure than cyclists commuting in low traffic routes in 2/2 
comparisons (0.63 (0.45-0.81)). 
Inhalation ratios while taking into account the time that would take the commuters to 
complete the same route were similar to those of the main analysis, as long as the reference mode 
of transport was cyclists (Appendix 68 (page 267)). When the reference was pedestrians, the 
inhalation ratio is farther from one, as pedestrians inhaled more particles due to their larger 
commuting time (about 30 minutes per trip) than motorized commuters (about 15 minutes). 
 
Exposure ratios according to WHO region 
Bus commuters were more likely to experience higher exposure than active commuters and the 
magnitude of the exposure ratio was larger in studies performed in AMR countries (median ratio 
= 1.93 (IQR = 1.11, 2.85), 4 studies) than in studies performed in EUR countries (0.91 (IQR = 
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0.72, 1.14), 11 studies) and WPR countries (1.3 (0.62, 1.57), 4 studies) (Appendix 68 (page 267)). 
Additionally, whereas most of the studies that measure car commuter exposure were performed 
in EUR and AMR (9/10 studies), car [V] commuters exposure was mostly measured in EUR 
studies (12/18 studies). 
 
Meta-analysis and publication bias 
The heterogeneity of meta-analyzed exposure ratios was close to 100% in all comparisons; 
compared to the median of exposure ratios, the direction was similar in all comparisons. Given 
the large heterogeneity observed we provide these findings only for informative purposes 
(Appendix 62 (page 252) and Appendix 63 (page 253)). We found evidence of publication bias 
for the comparison car [V] vs. active transport (p<0.001), car vs. active transport (p=0.005), walk 
vs. active transport (p=0.041) (Appendix 62 (page 252) and Appendix 63 (page 253)). 
 
DISCUSSION 
In general, car and bus commuters not using standard ventilation settings (i.e. windows closed 
and air conditioning on) had higher exposure to ultrafine particles than active commuters, while 
massive motorized transport (MMT) and tram commuters had lower exposure. Exposure ratios 
according to mode of transport were heterogeneous, due to factors that affect the emission rates, 
including local traffic load, speed, and fleet composition; factors of the built environment that 
affect the proximity to traffic, such as availability of cycle-routes; and factors that affect the 
dispersion, such as attributes of the built environment and meteorological factors. Nevertheless, 
under a hypothetical scenario of commuting over a standard route, active commuters inhaled 
more ultrafine particles than motorized commuters, due to higher breathing rate and commuting 
time.  
Differences in exposure according to mode of transport were mostly determined by the 
proximity to traffic,50,318 explained by the fast decay of ultrafine particles concentration once 
emitted. Consequently, the emissions of surrounding traffic explain the higher exposure of car 
and bus commuters.359 In contrast, MMT exposure was generally lower than that of active 
commuters because they usually ride underground.304,337,360,361 However, public transport 
commuters (i.e. bus, MMT, and tram) experienced high exposure levels while approaching and 
waiting at stations and stops. Car [V] commuters had a lower exposure ratio than car commuters 
by reducing the rate of air interchange between cabin and on-road by closing windows and 
turning on the air conditioning.356,362 However, the largest reduction of car [V] commuters 
exposure was when using air recirculation and particulates filters, since these features contribute 
to remove ultrafine particles filtered inside the cabin at a low but steady rate from products of 
combustion 284 or surrounding emissions,335,350 or rapidly filtering when bus doors were opened at 
stops.314,363  Enclosed bus stops reduced the exposure to idling buses emissions.358 Poorly 
ventilated MMT stations increased the exposure 314 to particles filtered from above-ground or 
generated in the abrasion of wheels, rails, and breaks. 314,360,364,365 
Exposure among active commuters was characterized by concentrations peaks 364 in 
proximity to highly emitting sources, either mobile, such as passing vehicles and 
mopeds,305,359,360,363 especially in high traffic routes;296 or static, such as construction dust, 
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restaurants or smoking by the curbside.314,358,364 Cyclists and pedestrians had increased exposure 
when rode along to the motorized traffic due to lack of separate cycle routes and at intersections 
and elevated crossings.305,358 Choosing alternative less trafficked routes reduced the exposure of 
active commuters (about 19% among pedestrians and 37% among cyclists; (Appendix 67 (page 
266))).305,354,356 
Local attributes and methodological characteristics explained part of the heterogeneity in 
the comparison of ultrafine particles’ exposure according to mode of transport. Among local 
attributes, traffic, meteorological factors, and built environment influenced the concentration of 
ultrafine particles in the commuter microenvironment. Among meteorological factors, the 
exposure was high during rush traffic hours and around midday, especially in summer time, due 
to photochemical nucleation events 314,356 that occur under high sunlight and temperature and 
low relative humidity.314,363 The exposure was also high under low ambient temperature, which 
favors the formation of particles at vehicle exhausts 363 and the persistence of the particles by low 
mixing heights and temperature inversions 356,363 and under high wind speed, which favors the 
dispersion and dilution of particles,363 but also its resuspension.347 Among built environment 
attributes, the exposure was high in canyon-like routes, where both accumulation mode and 
precursors of nucleation mode particles were trapped.366 Methodological characteristics that 
influenced the heterogeneity of the comparisons were mainly the comparability of exposure 
between commuters and the range of particles size detected by the devices used to measure the 
exposure. First, the exposure comparability between commuters was low in the studies included 
in this review, because only two studies compared all modes of transport in the same route and 
commuting time and in 19 studies all commuters started the commute in the same time frame. 
The large temporal and geographical variability of ultrafine particles concentrations reduce the 
comparability of exposure between commuters when these are not measured in almost similar 
time and space. Nevertheless, these differences may also reflect real life scenarios, such as active 
commuters choosing quieter or shorter routes. Second, the lower limit of particles size detected 
by the devices used in 14 studies was 0.01µm, which is more sensitive to detect particles generated 
in nucleation events than devices with lower limit of 0.02µm, which were used in the remaining 
studies. This feature may become a source of bias in settings with frequent nucleation events.347,363 
Although particles generated by diesel and gasoline combustion are mostly larger than 0.02µm,363 
particles generated in nucleation events are smaller and may remain unnoticed in some 
commuters microenvironment as these coagulate and grow,345 to become detectable only among 
commuters traveling by the curbside.347 
The inhalation ratios were less heterogeneous; as active commuters would inhale more 
ultrafine particles than motorized in all regions. Our estimations of inhaled dose based on 
standard assumptions were in agreement with those calculated in nine studies.284,285,295,302,340,367-370 
(Appendix 70 (page 270)) Also, according to our assumptions, public transport commuters would 
inhale some more particles than private transport commuters due to the slightly higher breathing 
rate attributed to account for the active period while approaching the stations and stops. We also 
accounted in our sensitivity analysis for the larger time that would take pedestrians to complete 
route compared to motorized commuters and cyclists. As a consequence, the inhalation rates 
where pedestrians’ inhalation was reference were farther from one than those where cyclists’ 
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inhalation was reference. Nevertheless, the inhalation dose of cyclists may be underestimated in 
our analysis because it is usually assumed that pedestrians and cyclists have the same breathing 
rate, corresponding to moderate intensity activity. However, recent studies suggest that cyclists’ 
breath rate may be higher than that of pedestrians, especially in routes with a high physical 
demand.358,371  
A key feature of the toxicity of ultrafine particles is its high deposition efficiency, 
depending on its particle size and composition.348,372 However, it also depends on individuals 
characteristics, such as water uptake, density, breathing pattern (oral vs. nasal), and lung 
morphology,349,373 among others.345 In six studies that examined the deposition of ultrafine 
particles, bus commuters,337,356,374 pedestrians,284,360 and cyclists 375 experienced the highest 
deposition, what is partly explained because they were exposed to smaller particles. Nevertheless, 
differences according to mode of transport may also vary depending on the particles size that 
predominates in the microenvironment. For example, active commuters over highly trafficked 
routes were exposed to bigger ultrafine particles, probably accumulation mode particles, what 
implied a lower lung deposited surface area than among active commuters over low trafficked 
routes.356 Moreover, Kumar et al 348 suggested than in spite the exposure to ultrafine particles is 
higher in Asia; the relative deposition would be higher in Europe. This, because the nucleation 
mode particles are more prevalent in Europe, whereas the accumulation mode particles 
predominate in Asia. These differences in particles size could be partly explained by European 
regulations to reduce the emission of accumulation mode particles, which absorb the precursors 
of accumulation mode particles.348 Differences in the toxicity potential of particles due to 
particles size and composition reduces the external validity between epidemiological studies 
performed in regions with diverse modal distribution of ultrafine particles 376 and could explain 
the large heterogeneity in the association of ultrafine particles with health outcomes.  
Our findings suggest there might be differences in exposure ratios of car and bus 
commuters according to the WHO region of the study. Such differences could be attributed to 
lack of maintenance and access to cleaner and newer vehicle technologies that reduce the 
emission of ultrafine particles 377 and the unequal reduction of Sulphur from diesel fuel and 
lubricant oils.347 However, it is unclear if the characteristics of the vehicles used in the studies 
contributed to explain these differences, because the reporting of ventilation settings standards in 
buses was heterogeneous. Although we aimed for a comprehensive review of the literature by 
including studies irrespective of study region, 18 out of 28 studies were performed in EUR, 
whereas six were performed in AMR and four in WPR. Therefore, our findings not only 
underrepresent regions outside Europe, but may also not be generalizable to regions such as 
African, South-East Asian, or Eastern Mediterranean. The observed evidence of publication bias, 
according to the funnel plots, may have reflected such lack of generalizability. Future studies and 
international collaboration are required to better understand the exposure determinants and the 
health consequences of exposure to ultrafine particles in other regions. Additionally, given the 
large heterogeneity of the studies, the meta-analysis of exposure ratios is provided only for 
informative purposes. Nevertheless, we aimed to provide a comprehensive assessment of the 
available evidence; therefore, the observed sources of heterogeneity should be accounted for local-
wise policies. 
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Previous studies concluded that air pollution exposure is not the most important reason 
to select a route among active commuters (e.g. the fastest route is of higher importance 378). 
Additionally, active commuter’s exposure is not constant even if travelling in less trafficked 
routes,371 as the exposure increases in proximity to highly emitting hotspots.378 Therefore, while 
pursuing to increase the shift from motorized to active commuting, policies in urban 
infrastructure should prioritize pedestrian and cyclists’ corridors separated from highly trafficked 
roads and hotspots. Additionally, improving the attractiveness and safety perception of active 
transport not only contributes to reduce the exposure to air pollution, but also contributes to 
reduce the risks of accidents and enhances health by increasing levels of physical activity,353,379 
what might lead to further health benefits including increases in life expectancy and reduction of 
mortality.353,380 Other societal gains of corridors include reduced noise exposure, increased 
exposure to green environments, and enhanced self-efficacy and social cohesion, among 
others.353,380,381 As for the future, it is uncertain whether the contribution of new fuels, such as 
biodiesel and ethanol and electric, and vehicle technologies will reduce the emissions of ultrafine 
particles.345 Therefore, it may be insufficient to aim for a reduced proximity of active commuters 
to traffic,371 as stakeholders could aim for a higher efficiency in the use of public space with 
policies aimed to also reduce the preference for the use of private motorized transport. 
In conclusion, car and bus commuters had a higher exposure to ultrafine particles than 
active commuters while MMT commuters were more likely to exhibit a lower exposure. Use of 
ventilation settings that reduced the air interchange between in-vehicle and on-road contributed 
to reduce the exposure of car and bus commuters. However, active commuters would inhale a 
larger dose of ultrafine particles, independently of the differences in exposure between active and 
motorized commuters. Although the burden of commuting actively due to exposure to traffic-
related air pollution may not be larger than the advantages of added physical activity,352 it is 
necessary to grant active commuters with urban environment that reduces their proximity to 
traffic emissions. Reducing emissions of ultrafine particles require strategies aimed to reduce the 
reliance on private motorized transport. 
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Figure 16. Flowchart of the systematic review 
 
 
 
 
  
Screened references n = 2,717 
Duplicate references n = 2,122 
Selected references by title and abstract 
screening (retrieved) 
n = 218 
Excluded references n=2,499 
Full text articles selected = 77 
References detected by search terms 
used on search engines 
n =4,756 
Excluded articles 
n=141 
Study design=9 
Only motorized transport=22 
Only active transport=3 
Not commuting=13 
Biomarkers=1 
Conference proceedings=22 
Not relevant=65 
Full text not available=6 
 
References detected by manual search 
on references list 
n = 83 
Included in the systematic review  
n = 28 
 
Articles where no ultrafine particles exposure is 
measured 
n = 49 
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Figure 17. Ratio of exposure and dose inhaled of ultrafine particles according to motorized 
modes of transport 
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Full symbols correspond to exposure ratios. Hollow symbols correspond to dose ratios. All ratios are calculated using bicycle as reference, 
unless stated otherwise with labels in the ratio as follows: W: Walk as reference, A: Active transport as reference (the authors combined 
walk and bicycle exposure). Car [V]: Car driven under standard ventilation conditions. MMT: Massive motorized transport. AT: Active 
transport (bicycle or walk). Study region: EUR: European countries, AMR: American countries, WPR: Western Pacific Region countries. 
IQR: Interquartile range (25th to 75th percentiles). 
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SUPPLEMENTARY MATERIAL 
 
Appendix 61. Search terms per search engine 
 
Embase.com: ('air pollution'/de OR 'air pollutant'/exp OR 'air pollution indicator'/de OR 'environmental exposure'/de OR 'exhaust gas'/de OR acetylene/de OR 
benzene/de OR '1, 3 butadiene'/de OR 'carbon monoxide'/de OR dust/de OR ethane/de OR ethylbenzene/de OR ethylene/de OR 'airborne particle'/de OR 
'nitrogen dioxide'/de OR 'particulate matter'/de OR toluene/de OR xylene/de OR 'polycyclic aromatic hydrocarbon'/exp OR combustion/de OR 'black 
carbon'/de OR 'volatile organic compound'/de OR ((air NEAR/3 (clean*))  OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR 
microenvironment* OR exhaust* OR emission* OR acetylene* OR benzene* OR butadiene* OR (carbon NEXT/1 monoxide*) OR co OR carbonmonoxide* OR 
Coarse OR dust OR ethane OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEXT/1 dioxide*) OR pm1 
OR 'pm2 5' OR pm10 OR 'pm 1' OR 'pm 2 5' OR 'pm 10' OR soot OR toluene* OR xylene* OR ufp* OR 'black carbon'  OR (polycyclic NEAR/3 (hydrocarbon* 
OR carbon*)) OR pah OR pahs OR combust* OR (volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex):ab,ti) AND ('traffic and 
transport'/de OR 'motor vehicle'/exp OR 'railway'/de OR traffic/de OR bicycle/de OR 'car driving'/exp OR 'motorized transport'/de OR walking/de OR 
travel/de OR pedestrian/de OR (traffic* OR subway* OR tram  OR tramway* OR streetcar OR metro OR underground OR tube OR train OR car OR cars OR 
rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* OR vehicle* OR 
((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR driver*):ab,ti) AND (commut* OR 
telecommut* OR ((travel) NEAR/3 (work*))) 
 
Medline (OvidSP): ("air pollution"/ OR exp "Air Pollutants"/ OR  "environmental exposure"/ OR "Vehicle Emissions"/ OR acetylene/ OR benzene/ OR "Benzene 
Derivatives"/ OR "butadienes"/ OR "carbon monoxide"/ OR dust/ OR ethane/ OR ethylenes/ OR "nitrogen dioxide"/ OR "particulate matter"/ OR toluene/ 
OR "Polycyclic Hydrocarbons, Aromatic"/ OR ((air ADJ3 (clean*))  OR ((environment* OR personal) ADJ3 expos*) OR pollut* OR microenvironment* OR 
exhaust* OR emission* OR acetylene* OR benzene* OR butadiene* OR (carbon ADJ monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane 
OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* ADJ3 matter*) OR (nitro* ADJ dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" 
OR "pm 2 5" OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR "black carbon"  OR (polycyclic ADJ3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR 
combust* OR (volatile ADJ3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex).ab,ti.) AND ("Transportation"/ OR exp "Motor Vehicles"/ OR 
"railroads"/ OR Bicycling/ OR walking/ OR travel/ OR (traffic* OR subway* OR tram  OR tramway* OR streetcar OR metro OR underground OR tube OR 
train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* 
OR vehicle* OR ((commut*) ADJ3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR driver*).ab,ti.) AND 
(commut* OR telecommut* OR ((travel) ADJ3 (work*))) 
 
Cinahl  (ebsco): (MH "air pollution+" OR MH "Air Pollutants+" OR  MH "environmental exposure+" OR  MH "Benzene Derivatives+" OR MH "carbon 
monoxide+" OR MH dust+ OR MH ethylenes+ OR MH "particulate matter+" OR MH toluene+ OR MH "Polycyclic Hydrocarbons, Aromatic+" OR ((air N3 
(clean*))  OR ((environment* OR personal) N3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR acetylene* OR benzene* OR 
butadiene* OR (carbon N1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR ethylene* OR ethene* OR particle* 
OR (particul* N3 matter*) OR (nitro* N1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 10" OR soot OR toluene* OR xylene* OR 
ufp* OR "black carbon"  OR (polycyclic N3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR (volatile N3 compound*) OR VOCs OR voc OR 
tVOCs OR tvoc OR btex)) AND (MH "Transportation+" OR MH "Motor Vehicles+" OR MH "railroads+" OR MH cycling+ OR walking+ OR travel+ OR (traffic* 
OR subway* OR tram  OR tramway* OR streetcar OR metro OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR 
motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR foot OR bike OR transport* OR vehicle* OR ((commut*) N3 (mode OR type OR way OR 
public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR driver*)) AND (commut* OR telecommut* OR ((travel) N3 (work*))) 
 
Cochrane: (((air NEAR/3 (clean*))  OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR 
acetylene* OR benzene* OR butadiene* OR (carbon NEXT/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR 
ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEXT/1 dioxide*) OR pm1 OR 'pm2 5' OR pm10 OR 'pm 1' OR 'pm 2 5' OR 
'pm 10' OR soot OR toluene* OR xylene* OR ufp* OR 'black carbon'  OR (polycyclic NEAR/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR 
(volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex):ab,ti) AND ((traffic* OR subway* OR tram  OR tramway* OR streetcar OR 
metro OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR 
buses OR foot OR bike OR transport* OR vehicle* OR ((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR 
passenger* OR driver*):ab,ti) AND (commut* OR telecommut* OR ((travel) NEAR/3 (work*))) 
 
Web-of-science: TS=((((air NEAR/3 (clean*))  OR ((environment* OR personal) NEAR/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* 
OR acetylene* OR benzene* OR butadiene* OR (carbon NEAR/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* 
OR ethylene* OR ethene* OR particle* OR (particul* NEAR/3 matter*) OR (nitro* NEAR/1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" 
OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR "black carbon"  OR (polycyclic NEAR/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR 
combust* OR (volatile NEAR/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ((traffic* OR subway* OR tram  OR tramway* OR streetcar 
OR metro OR underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses 
OR buses OR foot OR bike OR transport* OR vehicle* OR ((commut*) NEAR/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* 
OR passenger* OR driver*)) AND (commut* OR telecommut* OR ((travel) NEAR/3 (work*)))) 
 
Scopus: TITLE-ABS-KEY((((air W/3 (clean*))  OR ((environment* OR personal) W/3 expos*) OR pollut* OR microenvironment* OR exhaust* OR emission* OR 
acetylene* OR benzene* OR butadiene* OR (carbon W/1 monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR 
ethylene* OR ethene* OR particle* OR (particul* W/3 matter*) OR (nitro* W/1 dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 10" 
OR soot OR toluene* OR xylene* OR ufp* OR "black carbon"  OR (polycyclic W/3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR (volatile 
W/3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ((traffic* OR subway* OR tram  OR tramway* OR streetcar OR metro OR 
underground OR tube OR train OR car OR cars OR rail* OR automobile* OR bicycle* OR motorcycle* OR cycling OR walk* OR bus OR busses OR buses OR 
foot OR bike OR transport* OR vehicle* OR ((commut*) W/3 (mode OR type OR way OR public OR strateg*)) OR travel* OR pedestrian* OR passenger* OR 
driver*)) AND (commut* OR telecommut* OR ((travel) W/3 (work*)))) 
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PubMed: ("air pollution"[mh] OR "Air Pollutants"[mh] OR  "environmental exposure"[mh] OR "Vehicle Emissions"[mh] OR acetylene[mh] OR benzene[mh] OR 
"Benzene Derivatives"[mh] OR "butadienes"[mh] OR "carbon monoxide"[mh] OR dust[mh] OR ethane[mh] OR ethylenes[mh] OR "nitrogen dioxide"[mh] OR 
"particulate matter"[mh] OR toluene[mh] OR "Polycyclic Hydrocarbons, Aromatic"[mh] OR ((air AND (clean*[tiab]))  OR ((environment*[tiab] OR personal) AND 
expos*[tiab]) OR pollut*[tiab] OR microenvironment*[tiab] OR exhaust*[tiab] OR emission*[tiab] OR acetylene*[tiab] OR benzene*[tiab] OR butadiene*[tiab] OR 
(carbon ADJ monoxide*[tiab]) OR co OR carbonmonoxide*[tiab] OR Coarse OR dust OR ethane OR ethylbenzene*[tiab] OR ethylene*[tiab] OR ethene*[tiab] 
OR particle*[tiab] OR (particul*[tiab] AND matter*[tiab]) OR (nitro*[tiab] ADJ dioxide*[tiab]) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 
10" OR soot OR toluene*[tiab] OR xylene*[tiab] OR ufp*[tiab] OR "black carbon"  OR (polycyclic AND (hydrocarbon*[tiab] OR carbon*[tiab])) OR pah OR pahs 
OR combust*[tiab] OR (volatile AND compound*[tiab]) OR VOCs OR voc OR tVOCs OR tvoc OR btex)) AND ("Transportation"[mh] OR "Motor Vehicles"[mh] 
OR "railroads"[mh] OR Bicycling[mh] OR walking[mh] OR travel[mh] OR (traffic*[tiab] OR subway*[tiab] OR tram  OR tramway*[tiab] OR streetcar OR metro 
OR underground OR tube OR train OR car OR cars OR rail*[tiab] OR automobile*[tiab] OR bicycle*[tiab] OR motorcycle*[tiab] OR cycling OR walk*[tiab] OR 
bus OR busses OR buses OR foot OR bike OR transport*[tiab] OR vehicle*[tiab] OR ((commut*[tiab]) AND (mode OR type OR way OR public OR 
strateg*[tiab])) OR travel*[tiab] OR pedestrian*[tiab] OR passenger*[tiab] OR driver*[tiab])) AND (commut*[tiab] OR telecommut*[tiab] OR ((travel) AND 
(work*[tiab]))) AND publisher[sb] 
 
Google Scholar: Pollution|pollutant|pollutants|exhaust|"particulate matter|pah|pahs|combustion|"black carbon"|vacs  
traffic|vehicle|railway|bicycle|car|driving|motorized|walking|pedestrian|pedestrians|subway|metro|underground|train|cycling 
commuters|commuting|commuter 
 
Proquest: (ti(Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black carbon" OR vac OR vacs  OR 
carbonmonoxide OR Coarse OR dust OR btex) OR ab(Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black 
carbon" OR vac OR vacs  OR carbonmonoxide OR Coarse OR dust OR btex)) AND (ti( traffic OR vehicle OR railway OR bicycle OR car OR driving OR 
motorized OR walking OR pedestrian OR pedestrians OR subway OR metro OR underground OR train OR cycling)   OR ab( traffic OR vehicle OR railway OR 
bicycle OR car OR driving OR motorized OR walking OR pedestrian OR pedestrians OR subway OR metro OR underground OR train OR cycling) ) AND 
(ti(commuter*) OR ab(commuter*)) 
 
Scielo: (Pollution OR pollutant OR exhaust OR "particulate matter" OR pah OR pahs OR combustion OR "black carbon" OR vac OR vacs  OR carbonmonoxide 
OR Coarse OR dust OR btex) AND ( traffic OR vehicle OR railway OR bicycle OR car OR driving OR motorized OR walking OR pedestrian OR pedestrians OR 
subway OR metro OR underground OR train OR cycling)   AND (commuter*)  
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Appendix 62. Meta-analysis of exposure ratios according to mode of transport and WHO region 
Mode of 
transport 
WHO 
region 
Ratio (95% CI) I2 S C 
Bus EUR 0.95 (0.75 - 1.20) 93.1 6 7 
 AMR 1.78 (1.42 - 2.24) 99.5 4 8 
 WPR 1.24 (0.45 - 3.46) 98.0 3 4 
 Total 1.30 (0.99 - 1.70) 99.9 13 19 
       
Car EUR 1.14 (0.87 - 1.50) 72.5 2 3 
 AMR 1.75 (1.48 - 2.06) 73.3 3 6 
 WPR 0.73 (0.14 - 3.73) 97.0 1 2 
 Total 1.26 (1.00 - 1.57) 92.3 6 11 
       
Car [V] EUR 0.80 (0.70 - 0.93) 97.3 9 31 
 AMR 0.38 (0.21 - 0.69) 86.7 3 5 
 WPR 0.15 (0.03 - 0.72) 98.7 2 2 
 Total 0.68 (0.57 - 0.80) 98.1 14 38 
       
MMT EUR 0.53 (0.31 - 0.92) 99.6 3 3 
 AMR 1.09 (0.39 - 3.05) 90.1 2 2 
 WPR 0.85 (0.24 - 3.01) 99.3 2 3 
 Total 0.74 (0.49 - 1.12) 99.4 7 8 
       
Tram EUR 0.51  100.0 1 1 
 AMR 0.25  100.0 1 1 
 WPR -     
 Total 0.37 (0.18 - 0.74) 87.7 2 2 
       
Walk EUR 0.80 (0.69 - 0.92) 94.5 5 25 
 AMR 1.00 (0.96 - 1.04) 0.0 2 4 
 WPR 0.40 (0.23 - 0.71) 95.6 1 8 
 Total 0.70 (0.61 - 0.81) 95.7 8 37 
S = Number of studies; C = Summary data extracted per study for comparisons 
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Appendix 63. Funnel plots and evaluation of publication bias according to meta-analyses 
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Appendix 64. Exposure to ultrafine particles according to mode of transport and WHO region (units: particles/cm3) 
Mode of 
transport 
WHO 
region 
Median IQR S C 
Bus EUR 31,451   14,055 – 52,300  11 18 
 AMR 89,950   25,328 – 139,500  4 8 
 WPR 22,471   15,211 – 44,990  4 4 
 Total  31,451   15,000 – 66,845  19 30 
      
Car EUR 58,950   40,000 – 87,545  5 10 
 AMR 31,495   13,200 – 38,348  4 6 
 WPR 13,966   4,456 – 23,476  1 2 
 Total 39,174   23,476 – 78,000  10 18 
      
Car [V] EUR 21,639   9,159 – 29,722  13 39 
 AMR 7,830   3,500 – 7,900  3 5 
 WPR 7,672   911 – 14,433  3 2 
 Total 16,515   8,848 – 25,000  19 46 
      
MMT EUR 10,804   6,857 – 26,500  5 8 
 AMR 42,250   42,000 – 42,500  2 2 
 WPR 19,405   12,542 – 21,740  2 3 
 Total 19,405   8,609 – 30,000  9 13 
      
Tram AMR 13,312   11,783 – 18,818  3 5 
 WPR 5,500   5,500 – 5,500  1 1 
 Total   -     
 EUR 12,547   10,008 – 18,818  4 6 
      
Walk EUR 13,400   9,300 – 27,400  11 43 
 AMR 20,470   12,700 – 28,400  3 6 
 WPR 9,490   4,335 – 13,924  3 11 
 Total 12,450   9,300 – 25,700  17 60 
S = Number of studies; C = Summary data extracted per study for comparisons 
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Appendix 65. Quality of the studies included in the systematic review 
Author, year 
(Reference) 
Modal 
comparison 
Backgro
und 
factors 
Heteroge
neity 
Same time – 
All modes 
Same route – 
All modes 
Ascertainment 
of exposure 
Sample 
size and 
dispersion  
Boogaard, 2009 305 E ** * * - ** * 
Briggs, 2008 318 E ** ** ** ** ** * 
Cattaneo, 2009 382 E * * * * * * 
Dirks 2016 383 E - * ** ** ** * 
Good 2015 354 E/O ** NA * * ** * 
Ham 2017 374 O - NA * NA ** * 
Huang 2017 360 E ** ** * ** ** * 
Int Panis, 2010 284 E ** ** * ** ** * 
Isley 2017 384 E ** * - - * * 
Kaur, 2005 306 
Kaur, 2009 310 
E ** ** ** * ** * 
Kingham 2013 335 E * ** ** ** ** * 
De Kluizenar 2017 
357 
O NA - NA NA ** * 
Lonati 2010 385 E - - - - ** * 
Morales 2017 358 E ** * * * ** * 
Moreno 2015 337 E * - * * ** * 
de Nazelle, 2012 295 E ** ** * ** ** * 
Okokon 2017 359 E - ** * ** ** * 
Ozgen 2016 361 E * ** * ** ** * 
Quiros 2013 387 E ** * * ** ** * 
Ragettli 2013 362 E ** ** * ** ** * 
Rivas 2017 388 E ** ** - - ** * 
Spinazzè 2015 356 E ** * * - ** * 
Strasser 2017 375 E ** ** * ** - * 
Suárez, 2014 304 E ** ** * ** ** * 
Vouitsis, 2014 340 E ** * * ** ** * 
Weichenthal 2008 
363 
E/O ** * * * ** * 
Yan, 2015 314 E * ** - * ** * 
Zuurbier, 2010 296 E ** ** * * ** * 
E: Experimental. O: Observational 
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Appendix 67. Summary of exposure and inhalation ratios according to mode of transport and WHO region 
Mode of 
transport 
WHO 
region 
Exposure ratios  Inhalation ratios 
Median (IQR) S C 
Ratios above 1  
Median (IQR) C S 
Ratios above 1 
# (%)  # (%) 
Bus EUR 0.91 (0.72, 1.14) 11 14 5 (36)  0.53 (0.42, 0.67) 14 11 0 (0) 
 AMR 1.83 (1.11, 2.85) 4 8 7 (88)  1.08 (0.65, 1.68) 8 4 4 (50) 
 WPR 1.3 (0.62, 1.57) 4 5 3 (60)  0.64 (0.34, 1.85) 4 3 1 (25) 
 Total 1.11 (0.72, 1.46) 19 27 15 (56)  0.64 (0.42, 0.86) 26 18 5 (19) 
           
Car EUR 1.11 (0.95, 1.48) 5 8 5 (63)  0.2 (0.17, 0.26) 8 5 0 (0) 
 AMR 1.38 (1.2, 2) 4 10 8 (80)  0.25 (0.18, 0.36) 6 3 0 (0) 
 WPR 0.99 (0.32, 1.66) 1 2 1 (50)  0.18 (0.06, 0.3) 2 1 0 (0) 
 Total 1.23 (0.98, 1.61) 10 20 14 (70)  0.21 (0.17, 0.27) 16 9 0 (0) 
           
Car [V] EUR 0.83 (0.7, 1.09) 12 36 13 (36)  0.15 (0.12, 0.19) 36 12 0 (0) 
 AMR 0.33 (0.25, 0.36) 3 5 0 (0)  0.06 (0.04, 0.06) 5 3 0 (0) 
 WPR 0.33 (0.06, 1.1) 3 3 1 (33)  0.03 (0.01, 0.06) 2 2 0 (0) 
 Total 0.79 (0.47, 1.08) 18 44 14 (32)  0.14 (0.07, 0.19) 43 17 0 (0) 
           
MMT EUR 0.67 (0.45, 1.03) 5 6 2 (33)  0.39 (0.26, 0.61) 6 5 0 (0) 
 AMR 1.29 (0.67, 1.91) 2 2 1 (50)  0.76 (0.39, 1.12) 2 2 1 (50) 
 WPR 1.39 (0.28, 1.56) 2 3 2 (67)  0.82 (0.17, 0.92) 3 2 0 (0) 
 Total 0.86 (0.45, 1.48) 9 11 5 (45)  0.51 (0.26, 0.87) 11 9 1 (9) 
           
Tram EUR 0.73 (0.51, 0.86) 3 3 0 (0)  0.43 (0.3, 0.5) 3 3 0 (0) 
 AMR 0.25 (0.25, 0.25) 1 1 0 (0)  0.15 (0.15, 0.15) 1 1 0 (0) 
 WPR -     -    
 Total 0.62 (0.38, 0.79) 4 4 0 (0)  0.37 (0.22, 0.47) 4 4 0 (0) 
           
Walk EUR 0.85 (0.66, 1.02) 7 27 8 (30)  0.85 (0.66, 1.02) 27 7 8 (30) 
 AMR 0.95 (0.89, 1.1) 2 4 2 (50)  0.95 (0.89, 1.1) 4 2 2 (50) 
 WPR 0.5 (0.27, 0.71) 1 8 0 (0)  0.5 (0.27, 0.71) 8 1 0 (0) 
 Total 0.83 (0.63, 1) 10 39 10 (26)  0.83 (0.63, 1) 39 10 10 (26) 
           
Bicycle EUR 0.81 (0.81, 0.81) 1 1 0 (0)  0.81 (0.81, 0.81) 1 1 0 (0) 
 AMR -     -    
 WPR 0.45 (0.45, 0.45) 1 1 0 (0)  -    
 Total 0.63 (0.45, 0.81) 2 2 0 (0)  0.81 (0.81, 0.81) 1 1 0 (0) 
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Appendix 68. Ratio of exposure and dose inhaled and dose inhaled over a standardized route of ultrafine particles 
according to motorized modes of transport 
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Full symbols correspond to exposure ratios. Hollow symbols correspond to dose ratios. Hollow gray symbols correspond to dose ratios over a standard route 
(sensitivity analysis). All ratios are calculated using bicycle as reference, unless stated otherwise with labels in the ratio as follows: W: Walk as reference, A: Active 
transport as reference (the authors combined walk and bicycle exposure). Car [V]: Car driven under standard ventilation conditions. MMT: Massive motorized 
transport. AT: Active transport (bicycle or walk). Study region: EUR: European countries, AMR: American countries, WPR: Western Pacific Region countries. 
IQR: Interquartilic range (25th to 75th percentiles). 
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Appendix 69. Mean diameter and lung deposited surface area of ultrafine particles 
Author Study place Mode of transport Exposure (#/cm3) 
Mean diameter 
(nm) 
LDSA (mm2/m3) 
Ham et al 374 Sacrament (USA) Car [V] 7,900 ± 4,700  11 (2-21) 1 
  Light rail 5,500 ± 3,000  14 (13-15) 1 
  Bus 13,000 ± 4,400  38 (35-40.5) 1 
  Bicycle 22,000 ± 11,000  30.5 (25-40) 1 
  Train 42,000 ± 49,000  37 (30-59) 1 
Huang et al 360 Beijing (China) MMT 12,542 ± 2,577  83 ± 21 
  Car [V] 14,433 ± 3,790  115 ± 39 
  Bus 23,135 ± 14,079  116 ± 30 
  Pedestrians 44,038 ± 6,142  134 ± 23 
Moreno et al 337 Barcelona (Spain) MMT 23,000 ± 4,000 90 ±13 94 ± 27 
  Tram 30,000 ± 10,000 66 ± 9 92 ± 27 
  Pedestrians   101 ± 20 
  Outer Diagonal 37,000 ± 6,000 66 ± 9  
  Inner Diagonal 59,000 ± 13,000 56 ± 9  
  Central gridplan 54,000 ± 18,000 54 ± 6  
  Diagonal to La Rambla 54,000 ± 20,000 67 ± 7  
  Bus 54,000 ± 16,000 64 ± 8 125 ± 39 
Ragettli et al 362 Basel (Switzerland) Bus 14,055 ± 7,951 50 (44-59) 1  
  Tram 18,818 ± 8,120 49 (42.5-52) 1  
  Pedestrian 19,481 ± 11,705 51 (40-55) 1  
  Bicycle 22,000 ± 0 45 (40-51) 1  
  Car 31,784 ± 25,555 47 (41-52) 1  
Spinazze et al 356 Como (Italy) Car [V] 9,159 ± 9,048 72.5 ± 17.3 33.5 ± 27.6 
  
Active commuters 
(low traffic) 
12,091 ± 9,176 70.1 ± 19.4 66.2 ± 44.8 
  
Active commuters 
(high traffic) 
21,778 ± 18,302 64 ± 20.1 41.9 ± 23.2 
  Bus 24,819 ± 13,673 60 ± 12.6 78.2 ± 36.5 
Strasser 2017 375 Vienna (Austria)  C1 C2 C3  C1 C2 C3 
  Subway 7,233.3 6,480.5 8,608.9  3.56 5.99 4.00 
  Car [V]  8,848.4    3.33  
  Tram 11,783.2 10,008.2 13,311.5  5.01 5.01 7.49 
  Bus 12,296.0 10,598.3 13,129.9  5.05 6.46 6.32 
  Bicycle   18,199.6    35.47 
1Median and IQR [Approximate, extracted from figure]. 
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3.2 Description of air pollution exposure in the Rotterdam Study 
 
Magda Cepeda, Frank van Rooij, Josje D. Schoufour, Oscar H. Franco, Mònica Guxens 
 
INTRODUCTION 
Traffic-related air pollution exposure is a high public health problem, associated with increased 
mortality and morbidity and shortened life expectancy. 390 The Global Burden of Disease 
estimated the effects of long-term exposure to ambient particulate matter of size 2.5 or smaller 
(PM2.5) contributed to a loss of 103.1 million (95% uncertainty interval (UI) 90.8 to 115.1) 
disability-adjusted life years (DALY) and 4.2 million (95% UI 3.7 to 4.8) deaths, which is only 
one of the pollutants associated to traffic emissions, between 1990 and 2015.390 They reported 
that long-term exposure to ambient PM2.5 Long-term exposure to ambient PM2.5 is ranked as the 
most important environmental risk factor and fifth cause of mortality worldwide in 2015, with a 
disproportionate share of the burden borne by population aged 70 years or older. 390 Health 
effects of traffic-related air pollution exposure are multiple including ischemic heart disease, 
stroke, cerebrovascular and chronic obstructive pulmonary disease.390.282 Additionally, an 
increasing body of evidence links air pollution exposure to insulin resistance and diabetes 
mellitus.391-394 
Traffic-related air pollution is a major source of air pollution in urban settings,46 but it is 
only one of the multiple traffic-related pollutants strongly correlated between them.52 For 
example, proximity to traffic also increases the exposure to noise.395 This confounds the 
associations between traffic-related air pollution exposure and several health outcomes, as noise 
and lower proximity to green spaces has been documented to influence physical activity levels but 
also hypertension, vascular disease, diabetes, among others. 381,396-400 In order to tackle the burden 
attributable to air pollution exposure, it is necessary to have a better understanding of the health 
effects of air pollution by addressing these sources of confounding. 
The Rotterdam Study is a large prospective cohort study aimed to examine the incidence 
of risk factors for neurological, cardiovascular, psychiatric, and other chronic diseases. The 
population of the Rotterdam Study is recruited from the Ommoord district, a small very well 
defined geographic area (~4.5 km2). Therefore, we aimed to calculate the individual exposure to 
air pollutants among the participants of the Rotterdam Study. In this chapter I describe the 
assessment of exposures to particulate matter of 1o µm (PM10), 2.5 µm (PM2.5), PM2.5 absorbance, 
nitrogen dioxide (NO2), and nitrogen oxides (NOx) at the Ommoord district, using land use 
regression models developed within the European Study of Cohorts for Air Pollution Effects 
(ESCAPE) project and, for illustrative purposes, I describe the distribution of the exposure levels 
in one specific visit of the cohort, according to participants characteristics at one follow-up visit. 
 
METHODS 
Study design 
The Rotterdam Study is a prospective population-based cohort established in 1990 in Rotterdam, 
the Netherlands,23 inviting all participants aged 45 years or older living in the Ommoord district 
(a scheme of the cohort is provided in Figure 1, page 8). In the first cohort (RS-I), 7,983 
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participants aged ≥55 years were recruited. A second cohort (RS-II) with 3,011 new participants 
aged ≥55 years started in 2000. A third cohort (RS-III) started in 2006 with 3,932 new 
participants aged ≥45 years. Follow-up visits are performed every four to five year approximately, 
so by 2014 were obtained about 41,852 visits among 14,926 participants. For this chapter, we 
used the information of the participants of the fifth visit of RS-I, third of RS-II, and second of RS-
III with updated information of home addresses (n=5,356 out of 7,162 participants). This visit 
was held between 2009 and 2013. 
The Ommoord district is located at the north of Rotterdam, has a land area of 448 
hectares (~4.5 km2). This small district is bounded on the south by a motorway with 3 lanes in 
each direction and maximal velocity of 100km/h, the river Rotte on the north, and residential 
neighborhoods on the east and west.  
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). 
All participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians. 
 
Air pollution exposure assessment 
Air pollution concentrations at the participants’ home address were estimated using land use 
regression models developed within the ESCAPE project.401,402 A multistep procedure was 
followed in order to ensure the confidentiality of the participants. 
 
Geocoding: As all participants were recruited from population living in the Ommoord district, we 
obtained a list of all address in the district (about 13,000 unique addresses) from the municipality 
of Rotterdam and the Rotterdam Study management group. These addresses were geocoded in 
QGIS using the Google Maps geocoder.403 These data did not contain personal identifiers or 
links to the participants of the cohort. About 80% of the addresses were automatically matched 
with high confidence to spatial points corresponding to build rooftops. The remaining addresses 
were located nearby the actual address, thus we assigned manually the spatial points to the closest 
building.  
 
Estimation of air pollution at home’s participant addresses: The concentrations of the pollutants 
were calculated for each geocoded point using the land use regression models for The 
Netherlands/Belgium developed and validated within the ESCAPE project (described below). 
Geographic Information System (GIS) predictors were used to estimate the concentration of each 
pollutant, accordingly, as described below. These calculations were conducted at the Institute for 
Risk Assessment Sciences (IRAS) from the University of Utrecht.  
 
Backwards extrapolation of the air pollution estimates: Because the concentrations were 
calculated for the year of models’ validation (between February 17th 2009 to February 19th 2010 
for The Netherlands/Belgium 404,405), we first assigned the estimated pollutants concentrations to 
the records of the cohort participants using as individual identifier the home address reported by 
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the participant at the follow-up visit. Then, we calculated the exposure for each air pollutant at 
the home’s participant address at the exact day of follow-up visit and fourteen days before that 
visit applying a backward extrapolation method using the concentrations obtained from fixed-
background monitors, according to ESCAPE procedures, also described below.  
To calculate the exposure by means of backward extrapolation, first, we collected the 
daily measurements of the pollutants concentration obtained by seven fixed-background monitors 
located in The Netherlands (obtained from https://www.lml.rivm.nl/gevalideerd/index.php). 
The monitors were selected because these had the lowest number of measurement days with 
missing data among all monitors with available information (monitor 131, 133, 230, 318, 437, 
538, and 722). Second, we calculated the average of the daily measurements within the period of 
the measurement campaigns performed in The Netherland/Belgium (February 17th 2009 to 
February 19th 2010), per pollutant. Third, we calculated the backward extrapolation factors by 
dividing the daily data obtained from the fixed background monitors by the average previously 
calculated, per pollutant. Fourth, we merged the dataset of backward extrapolation factors with 
the dataset of the participants of the Rotterdam Study at the specified visit, using as individual 
identifier the date of follow-up visit. To account for lagged air pollution exposure, we assigned to 
each participant the backward extrapolation factors of fourteen days before the follow-up visit. 
Fifth, we estimated the exposure of the participant at the home address at the date of the follow-
up visit by multiplying the pollutants concentrations estimated with the LUR model times the 
backwards extrapolation factor corresponding to the date of visit. This step was repeated for each 
of the 14-days lags per each pollutant. For this illustrative chapter, we express the exposure as the 
average of the exposure at the day of follow-up and the 14-days lags per pollutant. 
 
Development of the Land Use Regression models by the ESCAPE project: In this section we 
briefly describe the procedures followed in the ESCAPE project to develop the LUR models for 
the pollutants exposure calculated in the Rotterdam Study. First, a measurement campaign of 
particulate matter (PM2.5, PM2.5 absorbance, and PM10) and nitrogen oxides (NO2 and NOx) was 
performed using mobile monitors deployed in 20 European study areas at 20 to 40 sites for 
particulate matter and 40 to 80 sites for NOx, per area, and additional 16 measurement sites for 
NOx; second, a number of GIS predictor variables that would explain the concentration of 
pollutants were calculated at each measurement site; and third, the LUR models were generated 
by linear regression using as outcomes the measurements obtained in the measurements 
campaigns and as predictors the GIS variables, background concentrations of the pollutants and 
the coordinates of the sites monitored, the variable selection followed a predesigned procedure of 
supervised stepwise selection procedure. 
The measurement campaign was performed between October 2008 and April 2011, in 
each study area were selected approximately 20 sampling sites, representing regional background, 
urban background and traffic sites 404,405 Rotterdam was among the measurement sites included in 
the development of the LUR models for The Netherlands/Belgium; the measurement campaigns 
went between February 17th 2009 to February 19th 2010.404,405 Traffic sites were overrepresented 
and the full range of local traffic intensities was included, as more variability was expected 
between streets. Other sites were considered, such as industries and major ports. Each site was 
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measured three times for 14 days in cold, warm, and intermediate seasons. The three 
measurements obtained in each site were averaged to obtain an annual average. A centrally 
located background reference site was operated for a whole year, the measurements obtained 
from this monitor were used to adjust for temporal variation the annual average. 404,405 Harvard 
impactors were used to measure PM2.5 and PM10. The measurements of reflectance on PM2.5 
filters were used to calculate the PM2.5 absorbance.402 Ogawa badges were used for NOx 
measurements.406 
Each measurement site was geocoded with Global Positioning System (GPS) readings at 
each site visit. At each measurement site, a number of GIS predictor variables from European and 
local source data were calculated. Circular buffers around each monitoring site were calculated 
for traffic variables (radii of 25, 50, 100, 300, 500, and 1000 m) and for land use and population 
(100, 300, 500, 1000, and 5000m).401,402 Known dispersion patterns of the pollutants were taken 
into account to select the corresponding buffer size per predictor. The overall sets of European 
GIS data obtained at each monitoring site was road data, land use data (high density residential 
land, low density residential land, industry, ports, urban green and natural land), population 
density data, altitude. Local GIS data included land use, population and household density, 
altitude and study-area specific variables such as distance to the sea. 401,402 
The final LUR models were developed by building a linear regression model using the 
GIS variables as predictors of the pollutants’ concentrations obtained in the measurements 
campaigns, as well as the geographical coordinates of the measurement sites and background 
measurements of the pollutants. The models were built using a supervised stepwise selection 
procedure, to obtain a model that improved the adjusted explained variance (R2), on the basis of 
predefined assumptions of the direction of the association with the outcome, collinearity, and 
model performance (examined by leave-one-out cross validation). A model for each pollutant and 
study area was developed. 401,402 
 
LUR models performance: To estimate air pollution exposure among the participants of the 
Rotterdam Study, we used the LUR models developed for The Netherlands/Belgium region. 
401,402 The covariates, coefficient, and model performance of the LUR model for each air pollutant 
described in the table below. 
 
Pollutant LUR model LUR model performance 
PM2.5
402 9.46  
+ 0.42 × (a regional background concentration estimate (µg/m3))  
+ 0.01 × (road length (m) of major roads within a buffer of 50 meters)  
+ 2.28·10-9 × (total traffic load (vehicles·day-1·m) of major roads within a 
buffer of 1000 meters (sum of (traffic intensity × length of all segments))). 
R2 of the model: 67%  
R2 of the model validation was 61%.  
Forty sites were used for the model 
development 
 
PM2.5 
absorbance402 
0.07  
+ 2.95·10-9 × (total traffic load (vehicles·day-1·m) of all roads within a 
buffer of 500 meters (sum of (traffic intensity × length of all segments)))  
+ 2.93·10-3 × (road length of major roads within a buffer of 50 meters) 
 + 0.85 × (a regional background concentration estimate (10-5/m)) 
+ 7.90·10-9 × (surface area (m2) of all residential land within a buffer of 
5000 meters)  
+ 1.72·10-6 × (total heavy-duty traffic load (vehicles·day-1·m) of all roads ) 
within a buffer of 50 meters (sum of (traffic intensity × length of all 
segments))) 
R2 of the model:  92%  
R2 of the model validation: 89%.  
Forty sites were used for the model 
development 
PM10
402 23.71  R2 of the model:  68%  
R2 of the model validation:  60%.  
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+ 2.16·10-8 × (total traffic load (vehicles·day-1·m) of major roads within a 
buffer of 500 meters (sum of (traffic intensity × length of all segments)))  
+ 6.68·10-6 × (population (N) within a buffer of 5000 meters)  
+ 0.02 × (road length (m) of major roads within a buffer of 50 meters) 
Forty sites were used for the model 
development 
NO2
401 7.80 
+ 1.18 × (a regional background concentration estimate (µg/m3))  
+ 2.30·10-5 ×  (population (N) within a buffer of 5000 meters)  
+ 2.46·10-6 × (total traffic load (vehicles·day-1·m) of all roads within a 
buffer of 50 meters (sum of (traffic intensity × length of all segments)))  
+ 1.06·10-4 × (road length (m) of all roads within a buffer of 1000 meters)  
+ 9.84·10-5 × (total heavy-duty traffic load (vehicles·day-1·m) of all roads in 
a buffer of 25 meters (sum of (heavy-duty traffic intensity × length of all 
segments))  
+ 12.19 × (inverse distance (m-1) to the nearest road of the central road 
network  
+ 4.47·10-7 × (total heavy-duty traffic load (vehicles·day-1·m) of all roads 
within a buffer between 25 and 500 meters (sum of (heavy-duty traffic 
intensity × length of all segments)) 
R2 of the model:  86%  
R2 of the model validation:  81%.  
Eighty sites were used for the model 
development 
NOx
401 3.25 
+ 0.74 ×  (a regional background concentration estimate (µg/m3) 
+ 4.22·10-6 × (total traffic load of all roads within a buffer of 50 meters 
(sum of (traffic intensity × length of all segments)))  
+ 6.36·10-4 × (population (N) within a buffer of 1000 meters)  
+  2.39·10-6 × (total heavy-duty traffic load of all roads within a buffer of 
500 meters (sum of (heavy-duty traffic intensity × length of all segments)))  
+ 71.65 × (inverse distance (m-1) to the nearest major road) 
+ 0.21 × (road length of major roads in a buffer of 25 meters) 
R2 of the model:  87%  
R2 of the model validation:  82%. 
Eighty sites were used for the model 
development 
 
Statistical analysis 
We conducted descriptive analyses of each pollutant. First, we describe the distribution of each 
pollutant for the Ommoord district as estimated with the LUR models; we calculated the median, 
mean, range, and the distribution by dividing the range times the mean and multiplying by 100. 
We compared this distribution to the distribution of the pollutants obtained in the ESCAPE 
project measurement campaigns for the Netherlands/Belgium region, as reported by Eeftens et al 
404 and Cyrys et al 405. Second, we calculate the correlation between the pollutants at the 
Ommoord district, using the Pearson correlation coefficient. These are also compared to those 
estimated in the ESCAPE measurement campaigns. 404,405 Third, we examined the annual 
distribution of the pollutants calculated among the participants of the Rotterdam Study; we fitted 
a generalized linear model with a log link to account for the no-linear distribution of the 
pollutants, using as predictors a natural cubic spline with 7 degrees-of-freedom of the month of 
follow-up and the year of visit. Then, we plotted the fitted values of the pollutants over date. 
Finally, we estimated the median and interquartile range of the pollutants according to 
characteristics of the participants. We tested the distribution according to the following 
characteristics: age (<60, 60-70, 70-80 and ≥80), sex (men vs. women), season (winter, spring, 
summer, autumn), income (<2100eur, 2100-3000eur, 3000 to 4200eur, ≥4200eur), education 
levels (lower general vs. intermediate higher), occupation (yes vs. no), community dwelling (yes vs. 
no), body mass index (normo-weight (<25kg/m2), overweight (25-30 kg/m2) and obese 
(≥30kg/m2)), smoking behavior (never, current, former), and medication intake (antihypertensive, 
statin or antidiabetic). We also stratified in quartiles physical activity (MET-hours/week), systolic 
and diastolic blood pressure (mmHg), total cholesterol (mmol/L), HDL-cholesterol (mmol/L), 
glucose (mmol/L), insulin (µIU/mL), and HOMA-IR. For all characteristics, we tested the 
differences with the U-Mann Whitney test and Kruskal-Wallis test if more than two categories. 
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For ordered categories, we tested the trend with the p for trend. All analyses were performed 
using Stata version 14.1 SE (StataCorp LP, College Station, Texas).72 
 
RESULTS 
Table 21 (page 281) shows the distribution of air pollutants concentrations estimated for the 
Ommoord district and the distribution of pollutants reported for the measurements obtained 
within ESCAPE project in the Netherlands/Belgium region. Overall, median exposure was 
similar between the Ommoord district and the Netherlands/Belgium region, but the dispersion 
of the distribution was smaller. As observed in the Netherlands/Belgium region, the dispersion of 
NOx and NO2 is larger than that of particulate matter, Also, the correlation between pollutants 
was similar compared to the Netherlands/Belgium region, although the correlation of PM2.5 
absorbance with the remaining pollutants was stronger (Table 22 (page 282)). The spatial 
distribution of air pollutants concentrations estimated for the Ommoord district is shown in 
Figure 18 (page 288). It shows a larger variability for NO2 and NOx, which follows the pattern of 
the traffic network in the district.  
In Figure 19 (page 289) we show the distribution of the 14-days lag average exposure 
average at the home address of the participants of the Rotterdam Study. The exposure had a 
substantial temporal variation, with higher values around winter time, which was slightly shifted 
towards spring for particulate matter. Also, the exposure exhibited a long-term trend towards a 
reduction of the average levels, which was steeper around 2011 for particulate matter. 
Additionally, we show the distribution of the 14-days lag average exposure at home 
address among participant to PM10, PM2.5 and PM2.5 absorbance (Table 23 (page)) and NO2 and 
NOx (Table 24 (page 286)), according to participants characteristics at the visit date. The exposure 
to all pollutants was higher among older participants, among participants with lower general 
education level, with lower levels of physical activity, and higher systolic and diastolic blood 
pressure. Specifically, NO2 exposure was higher among participants with higher insulin and 
HOMA-IR levels. 
 
DISCUSSION 
In this chapter we describe the methods used to estimate the air pollution exposure in one large 
population-based cohort located in Rotterdam, using the LUR models developed within the 
ESCAPE project for the region of the Netherlands/Belgium. We found that the dispersion of the 
distribution of the pollutants was smaller in the Ommoord district than in the region of The 
Netherlands/Belgium.404,405 Nevertheless, there were a substantial spatial variation of the 
pollutants, particularly of NO2 and NOx, probably as a consequence of the traffic emissions. 
Moreover, when we attributed the concentrations at the home address of the participants of the 
Rotterdam Study, we observed that the 14-days lag average exposure exhibited a large temporal 
variation, with higher levels of air pollution exposure in winter time.  
These findings highlight the issue of a gradient of air pollution exposure, even within 
relatively small areas, as a consequence of the proximity to roads and avenues. Moreover, these 
findings are in agreement with the notion that relying on ecologic measures of air pollution 
exposure, such as single background monitoring stations, may underestimate the influence of 
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traffic-related air pollution.405 Consequently, the health effects of air pollution exposure may be 
biased and confounded, because the actual contribution of traffic to the individual’s exposure 
may not be captured by such background measures. Indeed, air pollutants such as NO2 and NOx 
usually exhibit a large spatial variation, because these rapidly undergo chemical and physical 
processes in the atmosphere. Therefore, the measures obtained with background monitoring 
stations may underestimate the actual levels of exposure given the proximity to traffic emitting 
sources. This is in contrast to PM10 and PM2.5 concentrations, which are often much more stable 
in the environment and are better correlated to background measures of particulate matter 
concentrations. Therefore, the estimation of air pollution exposure in the Rotterdam Study, 
along with the detailed measurements of biomarkers, genomics, and proteomics data obtained in 
each visit, will likely contribute to the understanding of the health effects of traffic-related air 
pollution exposure.  
There were differences in the concentrations of pollutants according to certain 
characteristics of the participants. Overall, the concentration of the pollutants increased as the 
age and the blood pressure of the participants increased and the education and physical activity 
levels decreased. Furthermore, the exposure was higher during winter and spring than during 
summer or autumn. These findings have several interpretations. It is possible that the increase of 
air pollution exposure according to age, physical activity levels, blood pressure, and insulin-
resistance are confounded by a non-random distribution of the participants throughout the year. 
Indeed, we observed in previous chapters of this thesis that elderly participants were more likely 
to attend the study center in winter than in summer. Nevertheless, we did not find differences in 
the distribution of the pollutants according to other variables which are also related to age and 
age-related comorbidities, such as medication intake. Therefore, we cannot rule out that, at least 
in part, different levels of air pollution exposure according to participants’ characteristics may 
confound the association between air pollution exposure and relevant health outcomes. 
Therefore, these characteristics need to be accounted for when exploring the health effects of air 
pollution exposure in our population. Finally, the fact that exposure levels were higher in winter 
than in other seasons, as well as the exposure was higher in the highest concentrations of blood 
pressure and insulin resistance levels, supports the notion of the influence of air pollution 
exposure in the seasonal pattern of these outcomes. 
The LUR models have shown a high ability to detect intra urban contrasts.405 The choice 
of the LUR models enhances the prediction of the spatial contrast due to traffic emissions 
contributing to the air pollution exposure.407 The oversampling of traffic sites, as well as the 
detailed selection of measurement sites in the monitoring campaign and the availability of better 
GIS data contributed to improve the performance of the LUR models.402 This also explains the 
enhanced ability of these models to detect a relatively substantial spatial variation of air pollution 
exposure in a small area, such as the Ommoord district. Regarding the temporal variation, the 
models are designed to estimate long-term exposure; thus, the estimations obtained for the 
Rotterdam Study population are yet to be performed in the full cohort. In this chapter, we aimed 
for a description of the findings in one follow-up visit that includes population from all the 
cohorts, as an exploratory effort. Thus, future efforts include the assessment of exposure in the 
remaining visits and the estimation of other relevant geographic covariates, such as noise. 
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One potential limitation of this estimation is the fact that the exposure is only at home 
address. It has been shown that the estimation of air pollution exposure at the home-address may 
lead to an attenuation bias of the health effects estimations of NO2 exposure up to 12% (95%CI 
11-14%), compared to including the work/school exposure.408 Nevertheless, taking into account 
that about half of our population was aged 70 years of more in the visit examined in this chapter, 
the home-address exposure may be more accurate to represent their exposure, compared to 
younger working/studying population. Nevertheless, it would be valuable, in the future, to at 
least have information on the time-space-activity patterns of the cohort participants, in order to 
determine the potential of exposure misclassification as a consequence of not taking into account 
non-home address exposure. Especially, because a new cohort is currently being recruited, by 
inviting people aged 40 years and older, for whom not accounting for work/study exposure may 
be a source of exposure misclassification.408 Another potential limitation of our approach is that, 
because the estimations of the exposure are made only in addresses from the Ommoord district, 
we lose information of participants who move out of the district. Indeed, in spite this population 
is followed for incident events or until death and may participate in follow-up visits if the 
participant agrees to, this information cannot be taken into account since the estimation 
procedure only accounts for the exposure at the Ommoord district home address.  
 
Conclusion 
We have shown that there is a relatively high variation of the exposure to air pollution among the 
participants of the Rotterdam Study, as estimated with land use regression models developed and 
validated within the ESCAPE project. These estimations can be used in future epidemiological 
studies aimed to disentangle the role of traffic-related air pollution exposure in a mostly elderly 
population living in the small and well-defined district. The detailed measurements obtained 
during each visit, including genetics, imaging and biomarkers, along with these estimations of air 
pollution exposure, will allow broadening the scope of the risk factors examined within the 
Rotterdam Study. 
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Table 21. Distribution of air pollution concentrations estimated in the Ommoord district 
compared to the adjusted annual average concentrations obtained in the ESCAPE study for The 
Netherlands/Belgium*  
 
Air pollutant 
Ommoord district  ESCAPE (The Netherlands/Belgium) 
Median (Range) Mean 
Range/ 
Mean (%) 
 Median (Range) Mean 
Range/ 
Mean (%) 
PM10 25.6 (24.9 - 31.5) 26 26  n.a. 27.1 56 
PM2.5 16.7 (16.3 - 19.8) 16.7 21  n.a. 17.7 50 
PM2.5 absorbance 1.5 (1.3 - 2.4) 1.5 73  n.a. 1.7 123 
NOx 41.8 (31.6 - 106.7) 45.5 165  44.3 (17.5 - 130.8) n.a. 219 
NO2 31.9 (26.3 - 47.7) 32.7 65   30.2 (12.8 - 61.5) n.a. 157 
 
The estimations obtained in the ESCAPE The Netherlands/Belgium region were obtained from Eeftens et al 404 and 
Cyrys et al 405  
n.a. Not available. 
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Table 22. Correlation of air pollutants estimated with LUR models in the Ommoord district 
compared to the correlations obtained in the ESCAPE study for The Netherlands/Belgium* 
 Ommoord district  ESCAPE  (The Netherlands/Belgium) 
 PM10 PM2.5 
PM2.5 
absorbance 
NOx NO2  PM10 PM2.5 
PM2.5 
absorbance 
NOx NO2 
PM10 1.00      1.00     
PM2.5 0.73 1.00     0.72 1.00    
PM2.5 absorbance 0.96 0.83 1.00    0.74 0.71 1.00   
NOx 0.94 0.65 0.89 1.00   n.a. n.a. n.a. n.a.  
NO2 0.74 0.61 0.74 0.83 1.00  0.74 0.57 0.86 0.92 1.00 
 
The estimations obtained in the ESCAPE The Netherlands/Belgium region were obtained from Eeftens et al 404 and 
Cyrys et al 405  
n.a. Not available 
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Table 24. Distribution of NOx and NO2 according to the characteristics of the participants of the 
Rotterdam Study 
Covariate n (%)  
NOx (µg/m
3)  NO2 (µg/m
3) 
Median (IQR) p-value p-trend  Median (IQR) p-value p-trend 
Age (years)          
     <60 960 (17.9)  58.43 (43.48, 78.82) Ref   40.99 (33.24, 54.06) Ref  
     60-70 1,986 (37.1)  58.49 (42.72, 78.66) 0.97 0.08  42.64 (33.42, 55.12) 0.04 <0.01 
     70-80 1,684 (31.4)  63.44 (45.57, 86.36) <0.01   46.18 (35.00, 56.50) <0.01  
     ≥80 726 (13.6)  59.15 (43.58, 80.27) 0.69   45.12 (35.04, 54.74) <0.01  
Sex          
     Male 2,285 (42.7)  59.79 (43.18, 81.56) Ref   43.58 (33.65, 55.17) Ref  
     Female 3,071 (57.3)  60.4 (43.83, 80.43) 0.56 -  43.86 (34.29, 55.41) 0.67 - 
Season of follow-up visit          
     Winter 1,304 (24.3)  81.14 (62.81, 109.48) Ref   56.21 (46.73, 65.57) Ref  
     Spring 1,664 (31.1)  70.07 (55.97, 88.06) <0.01 -  51.35 (43.63, 58.85) <0.01 - 
     Summer 1,083 (20.2)  38.16 (33.36, 46.82) <0.01   30.63 (27.49, 34.41) <0.01  
     Autumn 1,305 (24.4)  51.68 (41.26, 65.73) <0.01   38.11 (32.52, 44.58) <0.01  
Income category (euros)          
     <2100 555 (10.4)  60.29 (42.74, 79.82) Ref   45.08 (34.03, 55.92) Ref  
     2100-3000 772 (14.4)  59.84 (45.15, 79.27) 0.83 0.7  45.54 (35.59, 55.55) 0.71 <0.01 
     3000-4200 1,183 (22.1)  62.2 (44.01, 83.58) 0.32   44.82 (34.45, 56.15) 0.82  
     ≥4200 2,325 (43.4)  59.38 (43.44, 80.83) 0.61   42.06 (33.54, 54.98) <0.01  
     Missing 521 (9.7)  58.92 (42.61, 79.33) 0.55   43.94 (34.02, 53.98) 0.4  
Education levels          
     Lower general 2,545 (47.5)  61.33 (43.58, 80.33) Ref   44.79 (34.45, 55.72) Ref  
     Intermediate Higher 2,754 (51.4)  59.12 (43.63, 81.27) 0.03 0.35  42.71 (33.66, 54.9) <0.01 0.01 
     Missing 57 (1.1)  58.45 (43.22, 79.34) 0.56   43.94 (33.73, 51.9) 0.78  
Community dwelling          
     Yes 5,335 (99.6)  60.17 (43.62, 80.91) Ref   43.81 (34.02, 55.31) Ref  
     No 11 (0.2)  44.19 (39.02, 67.34) 0.16 -  34.46 (28.58, 50.24) 0.19 - 
     Missing 10 (0.2)  54.34 (43.24, 83.02) 0.62   43.33 (36.09, 58.06) 0.95  
Body mass index (kg/m2)          
     <25 1,558 (29.1)  60.03 (42.72, 81.5) Ref   42.82 (33.53, 55.72) Ref  
     25-30 2,537 (47.4)  59.87 (43.83, 80.64) 0.9 0.38  43.86 (34.06, 55.02) 0.16 0.25 
     ≥30 1,258 (23.5)  61.04 (44.54, 80.83) 0.48   44.79 (34.43, 55.31) 0.03  
     Missing 3 (0.1)  60.78 (59.4, 192.41) 0.97   50.68 (43.03, 92.78) 0.56  
Smoking behavior          
     Never 1,741 (32.5)  61.38 (44.05, 82.82) Ref   44.62 (34.57, 56.04) Ref  
     Currently 815 (15.2)  58.12 (42.33, 79.77) 0.04 0.16  42.34 (32.97, 55.35) 0.02 0.19 
     Former 2,790 (52.1)  59.84 (43.68, 79.66) 0.18   43.85 (33.96, 54.89) 0.28  
     Missing 10 (0.2)  52.84 (43.24, 54.38) 0.48   39.05 (36.09, 45.28) 0.46  
Physical activity  
     (MET-hours/week)* 
         
     0.12 – 15.5 1,161 (21.7)  60.95 (44.43, 81.39) Ref   44.77 (34.45, 55.68) Ref  
     15.5 – 39.3 1,143 (21.3)  61.02 (44.23, 83.58) 0.97 <0.01  43.81 (34.17, 56.21) 0.31 <0.01 
     39.4 – 76.9 1,152 (21.5)  58.59 (42.88, 77.55) 0.12   42.69 (33.37, 54.41) 0.03  
     77.0 – 224.8 1,151 (21.5)  57.82 (42.01, 79.56) 0.04   42.04 (33.51, 54.09) <0.01  
     Missing 749 (14)  63.86 (45.15, 82.96) 0.09   46.67 (35.56, 56.43) 0.07  
Systolic blood pressure 
    (mmHg)* 
         
     86 – 128 1,386 (25.9)  57.46 (42.08, 78.04) Ref   41.45 (32.97, 54.47) Ref  
     129 – 142 1,342 (25.1)  59.38 (44.05, 81.17) 0.17 <0.01  43.35 (34.13, 55.31) 0.02 <0.01 
     143 – 158 1,306 (24.4)  60.42 (44.18, 81.14) 0.04   44.76 (34.29, 55.28) <0.01  
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     159 – 241 1,269 (23.7)  62.57 (44.39, 83.98) <0.01   45.54 (35.04, 56.45) <0.01  
     Missing 53 (1)  62.5 (45.56, 79.91) 0.33   44.22 (35.17, 56.5) 0.35  
Diastolic blood pressure  
     (mmHg)* 
         
     50 – 76 1,470 (27.4)  57.24 (41.13, 77.44) Ref   41.56 (32.96, 54.3) Ref  
     77 – 83 1,316 (24.6)  61.38 (45.48, 82.88) <0.01 <0.01  44.81 (34.83, 55.46) <0.01 <0.01 
     84 – 91 1,322 (24.7)  61.11 (43.29, 80.95) <0.01   44.52 (34.51, 55.73) <0.01  
     92 – 133 1,195 (22.3)  61.13 (44.16, 83.32) 0.01   44.41 (34.29, 56) <0.01  
     Missing 53 (1)  62.5 (45.56, 79.91) 0.30   44.22 (35.17, 56.5) 0.40  
Total cholesterol (mmol/L)*          
     1.7 – 4.7 1,399 (26.1)  60.55 (44.3, 81.27) Ref   44.54 (34.74, 55.47) Ref  
     4.8 – 5.5 1,430 (26.7)  61 (44.71, 81.24) 0.75 0.1  44.32 (34.46, 55.68) 0.81 0.02 
     5.6 – 6.2 1,248 (23.3)  59.1 (42.31, 80.09) 0.32   42.69 (33.39, 54.8) 0.04  
     6.3 – 12.4 1,238 (23.1)  59.82 (43.18, 81.14) 0.61   42.84 (33.59, 55.27) 0.07  
     Missing 41 (0.8)  60.06 (44.71, 71.58) 0.93   40.09 (34.43, 51.98) 0.23  
HDL-cholesterol (mmol/L)*          
     0.40 – 1.18 1,350 (25.2)  60.78 (44.05, 81.45) Ref   44.24 (34.14, 55.26) Ref  
     1.19 – 1.43 1,333 (24.9)  58.75 (42.89, 79.51) 0.15 0.89  43.09 (33.37, 54.52) 0.21 0.9 
     1.44 – 1.74 1,326 (24.8)  60.42 (44.17, 82.46) 0.80   43.85 (34.02, 55.86) 0.67  
     1.75 – 4.03 1,306 (24.4)  61.11 (43.63, 80.87) 0.81   44.12 (34.66, 55.27) 0.89  
     Missing 41 (0.8)  60.06 (44.71, 71.58) 0.90   40.09 (34.43, 51.98) 0.27  
Glucose (mmol/L) *          
     3.0 – 5.1 1,432 (26.7)  62.81 (44.52, 82.59) Ref   44.92 (34.45, 55.79) Ref  
     5.2 – 5.5 1,363 (25.4)  59.68 (41.91, 80.33) 0.03 0.13  42.95 (33.41, 55.17) 0.03 0.70 
     5.6 – 6.1 1,314 (24.5)  58.69 (43.78, 81.16) <0.01   43.21 (34.04, 55.56) 0.06  
     6.2 – 201 1,206 (22.5)  59.68 (44.05, 79.56) 0.03   44.15 (34.21, 54.47) 0.40  
     Missing 41 (0.8)  60.06 (44.71, 71.58) 0.64   40.09 (34.43, 51.98) 0.20  
Insulin levels (µIU/mL) *          
     0.1 – 7.5 1,381 (25.8)  57.99 (42.12, 79.06) Ref   41.98 (33.06, 54.62) Ref  
     7.6 – 10.7 1,328 (24.8)  62.05 (44.16, 82.33) <0.01 0.04  44.14 (34.51, 55.86) 0.01 0.01 
     10.8 – 15.4 1,279 (23.9)  59.59 (43.65, 80.87) 0.26   44.02 (33.78, 55.73) 0.02  
     15.6 – 595.4 1,322 (24.7)  61.39 (44.52, 81.27) 0.02   44.93 (34.59, 54.82) <0.01  
     Missing 46 (0.9)  60.06 (43.18, 84.71) 0.71   40.09 (34.45, 54.96) 0.58  
HOMA-IR*          
     0.02 – 1.75 1,332 (24.9)  58.79 (42.69, 80.27) Ref   42.34 (33.2, 55.17) Ref  
     1.76 – 2.62 1,321 (24.7)  60.21 (43.56, 81.16) 0.33 0.11  43.37 (34.4, 55.05) 0.25 0.03 
     2.62 – 4.08 1,326 (24.8)  59.93 (43.43, 80.87) 0.44   43.94 (33.73, 55.73) 0.07  
     4.08 – 195.82 1,326 (24.8)  60.96 (44.85, 81.22) 0.14   44.93 (34.69, 55.24) <0.01  
     Missing 51 (1)  60.14 (44.71, 84.71) 0.80   43.72 (34.83, 56.05) 0.67  
Medication intake          
Antihypertensive          
     No 2,859 (53.4)  59.40 (43.48, 81.50) Ref   43.00 (33.78, 55.05) Ref  
     Yes 2,494 (46.6)  60.85 (43.63, 80.64) 0.16 -  44.66 (34.24, 55.63) 0.01 - 
     Missing 3 (0.1)  64.75 (37.31, 72.9) 0.81   38.38 (30.57, 41.42) 0.72  
Statin          
     No 3,869 (72.2)  59.79 (43.26, 81.22) Ref   43.31 (33.72, 55.26) Ref  
     Yes 1,484 (27.7)  60.96 (44.58, 80.46) 0.32 -  44.56 (34.51, 55.47) 0.08 - 
     Missing 3 (0.1)  64.75 (37.31, 72.9) 0.82   38.38 (30.57, 41.42) 0.71  
Diabetic medication          
     No 4,870 (90.9)  60.06 (43.58, 80.81) Ref   43.71 (34.02, 55.28) Ref  
     Yes 483 (9)  60.69 (43.72, 81.94) 0.72 -  44.42 (34.17, 55.86) 0.52 - 
     Missing 3 (0.1)  64.75 (37.31, 72.9) 0.83   38.38 (30.57, 41.42) 0.69  
*Stratified in quartiles 
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Figure 18. Maps illustrating the spatial distribution of air pollutants in the Ommoord district, 
Rotterdam, the Netherlands 
a) NO2 concentration (µg/m3)   b) NOx concentration (µg/m3) 
 
c) PM10 concentration (µg/m3)   d) PM2.5 concentration (µg/m3) 
 
e) PM2.5 absorbance (10-5/m) 
 
The maps show the spatial distribution of the air pollutants concentrations estimated for the Ommoord district, 
Rotterdam, the Netherlands. These concentrations were estimated using land use regression models validated for The 
Netherlands/Belgium and represent the annual concentration in 2008. 
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Figure 19. Annual distribution of the back-extrapolated concentrations of air pollutants among 
participants of the Rotterdam Study  
a) NO2 concentration   b) NOx concentration 
 
 
c) PM10 concentration   b) PM2.5 concentration 
 
 
e) PM2.5 absorbance 
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Chapter 4 General discussion 
 
Throughout this thesis, I examined the influence of environment factors in lifestyle, 
cardiovascular risk, cognition, and antibiotic resistance, which account for a large part of the 
health burden among aging population. The findings are of relevance for several challenges 
related to climate change. First, we showed a seasonal variation of physical activity and diet 
quality. For physical activity, the seasonality was larger among middle-aged than among elderly 
population and was larger for light intensity physical activity than for moderate-to-vigorous 
physical activity, sleep, and sedentary behavior. The seasonal variation of diet quality reflected 
that of legumes and sugar-containing beverages. Second, we showed that seasonality of 
cardiovascular risk factors and insulin resistance was mostly explained by ambient temperature 
and the influence was larger among elderly participants. Third, we showed that cognition had a 
larger seasonal variation among middle-aged than among elderly. A review of the literature also 
showed a seasonal variation of antibiotic resistance, especially of respiratory bacteria, which may 
be attributable to the seasonality of infectious diseases and consequently of antibiotic use. Fourth, 
we found that, across the evidence, active commuters inhale more pollutants than motorized 
commuters, although the health effects of pollutants inhalation could be offset by the physical 
activity health gains. Finally, we described the estimation of the air pollution exposure among the 
population of the Rotterdam Study. The dispersion of the pollutants concentrations was small, 
but there was substantial spatial variation according to the road network of the Ommoord 
district, where the cohort population lives. Also, the distribution of the exposure differed 
according to selected covariates of the population, which need to be accounted for when 
addressing the health effects of air pollution exposure in the Rotterdam Study. 
In this chapter, I aim to put these findings in perspective, first by addressing the 
methodological considerations and second, by addressing the potential meaning of the observed 
findings within the ongoing debate regarding the challenges of environment in health of an aging 
population. 
 
METHODOLOGICAL CONSIDERATIONS 
Studies based on the Rotterdam Study 
There are a few aspects to take into account regarding the internal validity of our results. First, we 
estimated the seasonality of the outcomes of interest including all the population that was 
relevant to the specific research question and the data obtained for all analyses were systematically 
collected and coded by trained interviewers and researchers from participants whom consented to 
participate at each wave of the cohort. Nevertheless, it is possible that the participants who 
remain in the cohort throughout the visits are more health conscious than those who do not 
attend in further visits and, in consequence, may be less likely to change their behavior on a 
seasonal basis. Therefore, it is possible that our estimates of seasonal variation of lifestyle factors 
are underestimated compared to general population. Second, our studies about seasonal variation 
are embedded in a prospective cohort, in which invitations to participate are sent randomly to all 
eligible people throughout the year. In spite of this, we found that a large part of the crude 
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seasonal variation observed for lifestyle factors, cognition, and cardiovascular risk was explained 
by factors such as age and presence of comorbidities. This finding suggests that the observed 
seasonal variation is partly owned to the fact that participants do not attend the research center 
randomly throughout the year and, in consequence, some characteristics are not evenly 
distributed across seasons. Although we addressed this issue by adjusting the seasonality estimates 
by a number of covariates that were unevenly distributed across the year and that could explain 
the observed seasonality, it is possible that our estimates of seasonality are affected by residual 
confounding. For example, at the writing of the studies about seasonality of cardiovascular risk 
and insulin resistance, we did not have complete information about accelerometer-based physical 
activity or diet. Regarding physical activity, we used questionnaire-based physical activity levels, 
which may not account for light physical activity or physical activity for certain domains, such as 
occupational.409 However, according to our findings in chapter 2.1.1, light and occupational 
physical activity may make for a large part of the seasonality of physical activity levels. Therefore, 
it is possible that seasonality of health outcomes that can be explained by the seasonality of 
physical activity is underestimated. Regarding diet, we used body mass index as a proxy. However, 
not only body mass index does not entirely depend on diet, but also there are differences in diet 
patterns according to food component and diet quality (chapter 2.1.2). Therefore, also the 
seasonality of health outcomes that could be attributed to diet may be underestimated. 
Third, an ideal scenario for seasonality estimates would be to measure the same 
individual several times a year, in order to reduce the variability that can be attributed to the 
differences of the population throughout the year. However, such approach is rather intensive 
and could hardly be implemented in about 14,000 individuals; such is the number of participants 
of the Rotterdam Study. Yet, all the studies included in average between two to three visits per 
participant, which helps to reduce the seasonality that could be explained by non-random 
participation. 
In addition, we need to consider several aspects regarding the external validity. First, our 
population was mostly characterized by middle-aged and elderly white European participants, 
with a small mix of ethnicity. Second, we observed that our population reported large levels of 
moderate-to-vigorous physical activity and sedentary behavior; this may explain the low seasonality 
observed in physical activity in our population. Third, the Netherlands is a country characterized 
by large differences in the meteorological factors across seasons, whereas previous studies suggest 
that most of the seasonality of several health events is larger in warmer countries with less 
extreme variation in meteorological factors across seasons. Therefore, it is likely that our findings 
are generalizable only to settings similar to those found in the studies included in this thesis. 
However, our findings could still provide an indication of the potential extent of the influence of 
meteorological factors on the seasonality of cardiovascular risk in a population assumed to be 
adapted to the local conditions. Moreover, it is possible that the seasonal health effects of 
meteorological factors are relevant regardless the geographical region as a consequence of the 
variation of the meteorological factors between seasons, rather than absolute values of the 
meteorological factors in each season. 
There are also statistical considerations to the studies included in this thesis, regarding 
the choice of the cosinor model to examine the seasonal variations. There are several statistical 
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approaches to address the seasonal variation of health outcomes. A frequent and straightforward 
approach is to time variable into months or seasons. However, it implies the assumption of non-
biological jumps between time strata and may reduce the power by increasing the number of 
comparisons and increasing the number of parameters.217 A more mathematically complex 
approach is based on Fourier transformations of the time variable, including the cosinor 
terms.69,217 The cosinor terms are trigonometric transformations of the time variable, which are 
included in the model (e.g. linear, Poisson, logistic) and the coefficients are used to estimate the 
magnitude of the variation of the outcome.69 A frequently mentioned disadvantage of cosinor 
modelling is that it only tests if there is a sinusoidal variation of the outcome of interest and 
assumes a regular seasonal variation across the observation time, e.g. from year to year. 
Nevertheless, the variation can be flexibilized with the inclusion of harmonics, i.e. cosinor terms 
with different periods, as shown in chapter 2.2.3. In spite of this, it is assumed that the variation 
does not change across the entire time of observation, which is an assumption that may not hold. 
A further approach to account for seasonal variation and long-term trends is the use of flexible 
spline functions of the time. The flexibility of this modelling may be used as a hypothesis-free 
approach to address the variation of outcomes for which the pattern of seasonal variation is not 
clear and to account for the long term and seasonal variation in time-series analyses.217 Future 
studies aimed to address the seasonal variation of other outcomes may consider testing 
hypothesis-free variations to test the risk of type II error, if there is a clear indication of a non-
sinusoidal variation.  
 
Systematic reviews 
First, we aimed to enhance the internal validity of our systematic reviews by building comparable 
estimates of the relevant comparisons for each study (either between modes of transport or 
seasons) by calculating ratios of exposure. Regarding the external validity, although we aimed for 
comprehensive and exhaustive reviews of the evidence aimed to include information of several 
settings, most of the evidence was obtained European countries, followed by North American, 
Asiatic and Western Pacific countries. This may have reflected in the observed evidence of 
publication bias. Therefore, it is possible that both the seasonal variation of antibiotic resistance 
(chapter 2.2.4) and the differences in the exposure to air pollution according to mode of 
transport (chapters 3.1.1 and 3.1.2) are underrepresented in our systematic reviews, thus 
potentially reducing the external validity of our findings. Nevertheless, our systematic reviews 
were aimed to also identify sources of heterogeneity, which can be used by stakeholders to adapt 
local-wise policies regarding both the exposure to air pollution according to mode of transport 
and the seasonality of antimicrobial resistance. Yet, further studies are granted to gather evidence 
from such overseen regions, to have a better understanding of the role of local environmental 
factors both in the variation of antimicrobial resistance and in the exposure to air pollution 
among commuters. 
 
MAJOR FINDINGS AND IMPLICATIONS 
Seasonal variation of lifestyle factors 
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Unhealthy lifestyle factors, such as low physical activity, sedentary behavior, and poor diet quality 
are among the most important determinants of worldwide mortality and disability.410 In spite of 
the awareness of its contribution to global health, the burden attributable to these factors is 
increasing. In this context, the fact that these lifestyle factors have a seasonal variation implies 
that there are periods of the year where the population changes their physical activity levels and 
diet. Although it is suggested that meteorological factors have a role, societal schedules may also 
contribute to this seasonality. The seasonal approach is of relevance to understand the factors 
that can be targeted to develop public and health interventions to achieve changes in population-
level lifestyle that are already occurring on a seasonal basis. On the basis of our findings, such 
interventions need to take into account the societal schedules that may drive the variation of 
these lifestyle factors throughout the year, for example working and school schedules, holidays, 
and festivities. Understanding the role of the societal schedules may also be of relevance in 
settings with a smaller variation of meteorological factors according to seasons (e.g., close to the 
Equator), where the societal schedules may also shape the physical activity levels and diet quality 
in different moments of the year. Thus, the seasonal approach may help to spot opportunities to 
improve the physical activity levels and diet quality. 
In chapter 2.1.1 we showed that physical activity was larger for light intensity than for 
moderate-to-vigorous intensity, indicating that the participants may be more likely to increase or 
reduce the physical activity that is less structured. However, such variation was observed only 
among middle-aged (45-64 years) and younger-elderly (65-74 years), but not among older-elderly 
population (≥75 years). This difference may reflect the transition from the schedule-driven activity 
among the working population (middle-aged) to a less structured physical activity routine among 
old-elderly, with less light activity and more sedentary behavior. In addition, the small seasonality 
of sedentary behavior, which was not completely replaced by physical activity in the summer, 
suggests it is a behavior strongly ingrained in the daily routine. In chapter 2.2.2, we found that 
diet quality slightly increased in winter. The seasonal variation was largest among men, obese 
participants, and participants with high socio-economic status than in the corresponding 
counterparts. As these groups also had the lowest diet quality, it is possible that the seasonal 
variation is partly explained by a low consciousness about diet quality, which makes it more 
susceptible for seasonal influences. Additionally, we found that the seasonality of diet quality was 
mostly driven by the winter increase of the intake of legumes and nuts and the summer increase 
of sugar-containing beverages and dairy, which are behaviors that can be explained by the 
preference of Dutch people for legume soups around winter and sugar-containing beverages and 
ice creams in summer while outdoors. Taken together, these findings suggest that efforts to 
improve physical activity and diet quality would require: a) reducing the large bouts of sedentary 
behavior with light-intensity physical activity both indoor and outdoor; and b) enhancing the 
access to healthy food choices around the year, thus creating a healthy food environment tailored 
to the societal schedules of the population. 
 
Seasonal variation of morbidity in an aging population 
A growing body of evidence has shown that mortality is higher in winter than in summer.6,411,412 
Such seasonal variation differs according to geographical region; and a larger seasonality has been 
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observed in countries at mid distance from the equator than in those closer to the poles, where 
more extreme differences in weather conditions are present between seasons.6 The seasonality of 
all-cause mortality appears to be mostly explained by the seasonality of cardiovascular mortality,6 
whereas little evidence supports the seasonality of cancer or non-cardiovascular/non-cancer 
outcomes. Also cardiovascular diseases, such as myocardial infarction and stroke, are more 
frequent in winter than in summer.411,412 Whether this variation is explained by the seasonal 
variation of cardiovascular risk factors is less clear.413 
On the basis of our findings, the seasonality of cardiovascular risk factors (Chapter 2.2.1) 
and insulin resistance (Chapter 2.2.2) are mostly attributable to exposure to low ambient 
temperature, whereas the seasonality of physical activity and diet appeared to be less relevant. The 
influence was larger among the elderly population. This pattern coincides with multiple studies 
that showed an increase of all-cause and cardiovascular mortality following the exposure to low 
ambient temperature, what suggests a role of the seasonality of these factors on mortality 
seasonality.414,415 Nevertheless, other hypotheses suggest that the winter increase of all-cause and 
cardiovascular mortality could also be attributable to the increase in the incidence of influenza, 
the reduction of vitamin D levels due to lower exposure to sunlight, and the increase of exposure 
to air pollution, which is higher in winter due to production of pollutants by heating devices and 
thermal inversion.412 
To further understand the underlying mechanisms driving the increase in mortality and 
morbidity in winter, future studies are required to disentangle the contribution of these factors. 
Specifically, it is necessary to address the patterns of exposure to low ambient temperature among 
elderly population, which would be contribute to size the burden of climate change on health. 
For example, if the burden is higher under sustained exposure to low ambient temperature or at 
cold waves; if the exposure occurs at home or while outdoors; and if the exposure is consequence 
of impaired sensitivity to ambient temperature, non-perceived sense of burden, or vulnerability 
given by energetic poverty or disability; or, most likely, a combination of these. 
 
Climate change and health in aging population 
Several projections suggest that a large part of the burden of the climate change will arise from 
the increase in the average temperature, the increase of the frequency of extreme weather events, 
and conditions that will favor the widespread of infections.4 In all these scenarios, elderly 
populations are among the most susceptible and vulnerable. Therefore, the burden attributable to 
the climate change is magnified by the population aging.  In this section, we discuss the 
implications of our findings within the upcoming challenges of climate change. 
The seasonal approach to examine the factors underlying the variation of lifestyle factors 
(i.e. physical activity and diet quality) on a seasonal basis is of relevance in preparation for climate 
change. First, the fact that the seasonal variation of physical activity was larger in the middle-aged 
population than in elderly provides clues about the activity domains that vary the most across 
seasons, with occupation and transportation physical activity probably explaining the reduction of 
physical activity in winter (chapter 2.1.1). If confirmed in future studies, these findings could be 
used to design effective strategies to improve activity levels while addressing environmental factors 
contributing to climate change. For example, active transportation is an attractive endpoint that 
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contributes to increase physical activity levels;416 to reduce the traffic-related pollution, such as 
heat islands, air pollution, and noise by reducing the amount of circulating traffic; and to 
intervene the build environment in order to increase the cyclists and pedestrians-friendly roads 
and green spaces. Second, the diet quality increased slightly in winter, with different patterns per 
food group. While the factors underlying this variation are less clear, we hypothesize that societal 
schedules partly shape these patterns, because those with lowest diet quality tended to have a 
larger seasonality. This suggests that the diet is most probably influenced by the offer of food 
products at supermarkets, which vary across seasons. Therefore, aiming for a healthy food 
environment may potentially contribute to improve overall diet by partnering with food markets. 
Additional environmental gains can be obtained by increasing the attainment to Dutch diet 
guidelines, as in current diet predominates the intake of red and processed meat, which 
production has a large impact in the environment. These guidelines and others of high income 
countries, with a lower reliance on animal products, have a lower environmental impact in terms 
of green-house emissions, eutrophication and land use compared to other from low and medium 
income countries417 while reducing the risk of all-cause mortality.418 It is less clear if aiming only 
for locally seasonal food reduces the environmental impact of the food industry. As there is no 
evidence that food transport makes a large difference in, for example, greenhouse emissions, it is 
suggested to prioritize the identification of cultural and individual factors that motivate diet 
choice, in order to maximize interventions aimed to improve the environmental and health 
consequences of diet behavior.419 
We found that the winter increase of cardiovascular risk and of insulin resistance was 
mostly explained by exposure to low ambient temperature, especially among elderly participants. 
It is possible that this pattern contributes to explain the well-described seasonality of 
cardiovascular mortality and morbidity.6 Whether the influence of exposure to low ambient 
temperature will be reduced under climate change is less clear. It has been suggested that 
although the burden of heat-related mortality is likely to increase by 256%, the reduction of cold-
related deaths will be of only 2%, what is explained by the increasing of elderly population, what 
in absolute terms, keeps almost unchanged the burden of cold exposure.159 Nevertheless, 
understanding the future health burden of climate change requires disentangling the 
contribution of two phenomena: the burden attributable to persistent exposure to low or high 
ambient temperature and the burden attributable to extreme weather events, such as cold and hot 
waves. Although both phenomena will be aggravated by climate change, there is evidence that the 
pathways of each are distinct. On one hand, mortality and morbidity due to persistent exposure 
to low or high ambient temperature may be explained by the cold-related increase of blood 
pressure, cholesterol, and insulin levels (chapters 2.2.1 and 2.2.2) and, arguably of insulin 
resistance, which may relate to the worsening of endothelial dysfunction. This burden tends to 
accumulate over lags of up to 27 days.415 The age-related impairment of thermoregulation may 
imply a higher burden among elderly population, although poor home insulation and improper 
clothing may contribute to sustain the exposure. Therefore, addressing this burden implies 
structural efforts to reduce the risk of sustained exposure to cold or warm temperature. On the 
other hand, mortality and morbidity attributable to extreme weather conditions, such as heat 
waves, are usually observed in short time periods and lead to mortality displacement through 
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harvesting.415 Harvesting means that those who die first under heat waves are the most susceptible 
and vulnerable populations, thus the pool of susceptible and vulnerable populations deplete after 
three or four days of intense heat.415 This burden is high even in high income countries,420 
although the effect of heat waves would differ across regions, since the thresholds for 
temperature-related mortality depend on the adaptation of the population to local environmental 
weather conditions.421 Nevertheless, unless strong systems of alarm and reaction are deployed, it 
may be more difficult to prevent the casualties related to these extreme events, especially among 
isolated and vulnerable elderly.22 In order to enhance the adaptive capacity of the society, future 
studies are required to disentangle the contribution of persistent exposure to high or low ambient 
temperature and extreme weather events, as both the health effects and alternatives of 
intervention may differ.422  
Another not largely foreseen consequence of the aging of the population under the 
current projections of climate change is the influence of the higher prevalence of cognition 
decline in the population. On the basis of our findings, elderly population have a lower cognitive 
function which fails to adapt to the environmental conditions as observed by a lack of seasonal 
variation of cognitive function, which contrasted with the larger seasonality of cognitive function 
among younger population, who also had a higher cognitive function. Therefore, the adaptive 
capacity that can be built around the prevention of exposure to sustained high or low ambient 
temperature and to extreme weather events would be hampered by this reduced adaptability of 
cognitive function, as well as the increased prevalence of population with cognitive decline. 
Current estimations suggest that the burden of climate change that is attributable to mental 
health considers mostly the acute impact of natural disasters and displacement and the 
physiological responses of exposure to extreme weather events.4 Nevertheless, as a prevailing 
condition among an aging population, future projections should also account for the cognitive 
decline as a contributing factor within the burden attributable to climate change. 
Finally, it is suggested that infectious diseases, especially influenza and other that increase 
during winter time, contribute to the seasonality of all-cause and cardiovascular mortality. 
Potential mechanisms involve the worsening of the underlying vascular disease, such as 
atherosclerosis, or acutely activating the inflammatory and pro-thrombotic states.412 On the basis 
of our findings, it is also possible that the increase of these infections in winter lead to a 
widespread of resistant infections, increasing the burden in the population. Indeed, antimicrobial 
resistance rates of S. pneumoniae and H. influenza were higher in winter than in other seasons. This 
pattern was opposite for antimicrobial resistance rates of E. coli, which had a higher prevalence in 
summer than in other seasons, although the pattern was very heterogeneous. We did not find 
seasonality of antibiotic rates in Campylobacter spp. and Salmonella spp., although available evidence 
suggests that seasonal variations might occur in relation of diseases outbreaks and husbandry 
practices in animals. These findings have several implications for upcoming challenges of climate 
change. First, based on the appraised evidence, the main determinant underlying the seasonality 
of antimicrobial resistance rates is the selective pressure exerted by antibiotic use, which follows a 
seasonal variation along with the seasonality of infectious diseases. Second, the reduced 
responsiveness of their immune system and higher disease burden increase the frequency of 
infectious disease and in consequence, the use of antibiotics among elderly population. Such 
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scenario is expected to worsen under climatic change, as the environmental conditions that will 
favor the spread of infections will be more frequent, such as storms and floods. Third, the fact 
that at least two of the most prevalent respiratory bacteria showed a winter peak of resistance to 
several antibiotics implies that the winter period may also become a season of multi-resistance, 
which is a worrisome scenario under limited effective therapeutic strategies. Therefore, our 
findings should increase the awareness about the potential role of antibacterial resistance in the 
adaptive capacity steps, to enforce the rational use of antibiotics to reduce the widespread of 
resistance and to enhance stewardship on active surveillance and response protocols to efficiently 
detect and address increasing rates of antibiotic rates on a seasonal basis. 
 
Implications of the seasonal approach 
The fact that we found large differences between the crude and adjusted seasonal patterns 
examined has implications for research. First, future studies need to consider that the 
characteristics of the participants attending research centers could differ across the year. On the 
basis of the participation rates in our study, we found that elderly participants were more likely to 
attend in winter months, thus rates of comorbidities prevalence and other age-related factors will 
have a higher prevalence than population recruited in summer. Therefore, there is a risk of 
selection bias while recruiting participants only in a given season of the year. Second, the seasonal 
variation of the factors addressed in this thesis should be accounted for in future studies using 
these variables. Especially, for diet and for physical activity information collected with 
questionnaires, since not only people do change their behavior across seasons, but they also are 
more likely to report their current levels of physical activity and diet as if these were typical levels. 
Therefore, there is a risk of information bias when people are asked by their typical levels of 
physical activity and diet since it could mostly reflect their recent behavior. Third, it is likely that 
accounting for this seasonal variation is even more important in settings with large meteorological 
variations across the year. Nevertheless, the influence of meteorological factors does not fully 
explain the seasonality of physical activity, sedentary behavior or sleep (chapter 2.1.1), and societal 
schedules are likely to play a relevant role in the variation of lifestyle factors. Therefore, because 
the societal schedules are rather constant across countries (e.g. holiday’s season, Christmas, 
summer break), a) further studies may contribute to enhance our understanding about their 
influence in the seasonal pattern of lifestyle factors, b) their influence on potential information 
bias when collecting this information for research should not be ruled out. 
 
Exposure to air pollution exposure according to mode of transport 
One of the strategies suggested to increase physical activity levels is to increase active commuting, 
i.e. walking and cycling, instead of motorized commuting.416 Nevertheless, the advocacy for active 
commuting has raised awareness of several risks that people face while commuting actively under 
the actual distribution of the public commuting space, including the exposure to a large amount 
of air pollutants that are emitted by the traffic. In urban spaces, traffic is the major source of 
several air pollutants. In spite the typical commuting time accounts for a brief portion of the daily 
time, the exposure while commuting accounts for up to 50% of the daily exposure to air 
pollution. Moreover, the exposure while commuting frequently exceeds air quality standards.352 
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Therefore, the actual balance in health outcomes by shifting from motorized to active commuting 
have been under debate. 
In chapters 3.1 and 3.2 we systematically reviewed the literature that examined the 
exposure to air pollutants according to mode of transport. We found that car and bus commuters 
were more often exposed to PM2.5, CO, BC and ultrafine particles. Nevertheless, while taking 
into account that active commuters have an increased breathing rate due to the increased physical 
activity, they would inhale much more pollutants than active commuters. Such difference would 
be even larger when comparing to pedestrians, since they spend more time than motorized 
commuters and cyclists to complete the same route. Furthermore, I examined the potential 
balance between the benefits of physical activity and the risks of inhalation of PM2.5, and found 
that in terms of life expectancy, the gains of the physical activity due to commuting actively were 
larger than the burden of inhaling more PM2.5. Nevertheless, this assessment only accounted for 
the risk of PM2.5 inhalation, but not for other risks, such as noise and traffic accidents. 
Therefore, policies aiming for a shift from motorized to active commuter need to 
account for a street configuration that not only reduces the objective and perceived barriers for 
actively commuting, but also reduces the risks associated to commuting actively, such as the large 
exposure to air pollution. Several studies have demonstrated large public health and societal gains 
by prioritizing the use of the street by pedestrians and cyclists.353,379,381,423 Among them, the 
reduction of the traffic related emissions and the increase of pedestrians and cyclists friendly built 
environment, which contributes to reduce the noise and heat islands, in line with the targets of 
the reduction of the burden of the air pollution and climate change crisis. 
 
Conclusions 
Seasonal factors, not necessarily related to meteorological factors, contribute to explain the 
seasonality of lifestyle factors. Because improving the levels of physical activity and enhancing diet 
quality is of emergency to halt the increasing burden of cardiovascular disease, future studies are 
necessary to improve our understanding of the factors underlying a variation that already occur 
on a seasonal basis, for example to disentangle the role of societal schedules and meteorological 
factors in the observed variation. 
Cardiovascular risk factors and insulin resistance have a seasonal variation that is mostly 
explained by exposure to low ambient temperature. The influence of low ambient temperature 
was larger among elderly population than among middle-aged, probably due to the age-related 
impairment of thermoregulation. These findings are likely to contribute to the well-described 
seasonality of cardiovascular risk. Although it has been suggested that in the face of the upcoming 
challenges of climate change the health burden attributable to cold exposure will be reduced, the 
aging trend of the population and changes in the daily temperature range are likely to keep 
relatively constant the burden attributable to cold exposure. Additionally, the events associated to 
changes of meteorological factors are likely to be different from those related to extreme weather 
conditions. In order to improve the adaptive capacity of the society to climate change, it is 
urgently needed to examine the patterns of exposure to ambient temperature, the role of the 
seasonal variation of cardiovascular risk factors on the seasonality of cardiovascular mortality and 
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morbidity and to disentangle the burden attributable to the variation of average and daily 
temperature range and extreme weather conditions. 
Finally, it is suggested that promoting the shift from motorized to active commuting may 
help to increase the levels of physical activity of the population as well as to reduce the traffic-
related pollution, such as air pollution and noise. Nevertheless, stakeholders need to account for 
the risks while commuting actively, such as higher inhalation of air pollution, in order to increase 
safety. 
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Chapter 5 Summary 
 
Part of the increasing burden of climate change can be attributed to the increase of the 
population with high susceptibility to environmental challenges, due to population ageing trend 
worldwide. This implies that the pool of population with an age-related decline of physiological 
reserve capacity, deteriorated immune system response, and reduced cognitive capacity is 
increasing. Therefore, in order to cope with the upcoming challenges of environmental 
deterioration and climate change, it is necessary to enhance the adaptive capacity of the society. 
This involves improving our understanding of the influence of environmental factors in the 
health of the population, and the susceptibility of population subgroups, such as the elderly. In 
this thesis I examined some of the most urgent health issues that potentially will affect the 
susceptibility of elderly population under the upcoming challenges of climate change. This 
includes the seasonal variation of lifestyle factors, cardiovascular risk factors, cognition, and 
antibiotic resistance and exposure to air pollution.  
First, I examined the seasonal variation and explored potential underlying mechanisms 
of seasonality of lifestyle factors, cardiovascular risk factors, and cognition in the Rotterdam 
Study; as well as the seasonality of antibiotic resistance using a systematic review of the literature. 
Second, I examined the exposure to air pollution according to mode of transport in two 
systematic reviews and described the estimation and preliminary findings of the exposure to air 
pollution among the population of the Rotterdam Study. All but the systematic reviews were 
based in the Rotterdam Study, a prospective Dutch cohort comprised in 1987 with middle-aged 
and elderly population living in the district of Ommoord, in Rotterdam. The cohort is comprised 
by three cohorts, the first one which started in 1987, the second one in 1996 and the third one in 
2006. The age for inclusion in the cohort has moved across the cohorts, with participants being 
recruited at age of 55 in the first cohort and currently, being recruited at age of 45. The 
information from the participants is obtained through dedicated follow-up visits performed every 
four to five years though standardized interviews and questionnaires, physical examination, 
biological samples, and imaging procedures, as well as collected from medical records. In Figure 1 
(page 8) we show an overview of the cohorts and the relevant visits for the studies that compose 
the chapters about the seasonal variation and health effects of air pollution. 
In chapter 2.1.1 we examined the seasonality of the complete 24-hour spectrum, 
including physical activity, sedentary behavior and sleep, measured objectively with 
accelerometers, according to an age-specific approach, while accounting for the influence of 
meteorological factors in the seasonal variation.  We observed that among middle-aged and 
elderly adults, the seasonality of physical activity was larger than that of sedentary behavior and 
nighttime sleep. Moreover, we observed that the seasonality of physical activity was only partly 
explained by meteorological factors. In chapter 2.1.2 we found a seasonal variation of diet quality, 
which was mostly influenced by the seasonality of the intake of legumes and sugar-containing 
beverages. Overall, a larger seasonality was observed among subgroups with lower diet quality, 
such as men and obese population. These findings highlight the role of the seasonal approach to 
address potential targets, in order to improve the overall population lifestyle choices. For 
301 | Chapter 5 
 
 
example, the need to reduce the large bouts of sedentary behavior with light-intensity physical 
activity both indoor and outdoor, and the need to provide a healthy food environment tailored to 
the societal schedules of the population. 
In chapter 2.2 we examined the seasonal variation and potential underlying mechanisms 
of health outcomes in an aging population. In chapters 2.2.1 and 2.2.2 we showed an overall 
winter peak of the cardiovascular risk profile and of insulin resistance, according to HOMA-IR. 
The seasonality patterns were mostly explained by ambient temperature, especially among elderly 
participants. These findings suggest that elderly population may be more susceptible to ambient 
temperature because of the impairment of thermoregulation mechanisms, which may not only 
increase their risk of exposure to sustained low temperature, but also increase the burden of the 
exposure. Additionally, these findings may contribute to explain the winter peak of cardiovascular 
mortality and morbidity. In chapter 2.2.3 we showed a seasonal variation of cognitive 
performance, which lowered around winter time and was larger among population with higher 
cognitive performance. The seasonal variation of cognitive performance among population with 
higher cognitive performance can be interpreted as a sign of healthy aging and needs to be 
addressed in the future to better understand the adaptability of cognitive performance in an aging 
population. In chapter 2.2.4 we performed a systematic review to examine the seasonal variation 
of antimicrobial resistance of bacteria that pose a threat for public health. The antimicrobial 
resistance rate of S. pneumoniae and H. influenza was higher in winter and of E. coli in summer, 
although the pattern was very heterogeneous. No seasonal variation was observed for 
Campylobacter spp. and Salmonella spp. This observed seasonality may be explained by the seasonal 
variation of infectious diseases incidence and the consequent variation of antibiotic use. Our 
findings should increase the awareness about the potential role of antimicrobial resistance in the 
adaptive capacity of the society. 
In chapter 3 we addressed the exposure to air pollution. First, we performed a systematic 
review to examine the exposure to NOx, CO, BC, coarse, and fine particles (chapter 3.1.1) and to 
ultrafine particles (chapter 3.2.2) according to mode of transport. Overall, motorized commuters 
were more often exposed to PM2.5, CO, BC and ultrafine particles. However, because pedestrians 
and cyclists have a higher inhalation rate, they inhaled more pollutants. Nevertheless, the gains in 
life expectancy of cyclists and pedestrians due to physical activity were not overcome by the 
burden of higher inhalation of PM2.5. Large societal gains can be obtained by promoting the shift 
from motorized to active transportation. 
Finally, in chapter 3.2 we describe the methodology to estimate the exposure to NO2, 
NOx, PM10, PM2.5, and PM2.5 absorbance among the participants of the Rotterdam Study, using 
land use regression models developed and validated for the Netherlands/Belgium region by the 
ESCAPE study. We observed a lower dispersion of the pollutants in the Ommoord district 
compared to those observed in the Netherlands/Belgium during the ESCAPE measurement 
campaigns. However, there was substantial spatial variation of the pollutants, particularly of NO2 
and NOx, in relation with the road network of the district, suggesting this is a large source of air 
pollution exposure among the participants of the Rotterdam Study. Additionally, we found a 
winter peak of air pollution exposure, and the distribution of air pollution exposure changed 
with certain characteristics of the participants, such as age and blood pressure. Future studies 
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based on this data will contribute to have a better the health effects of traffic-related air pollution 
exposure in an aging population. 
Finally, in chapter 4 I discuss the methodological implications of our findings and 
discuss the major findings of our study in relation with the seasonality of mortality and 
morbidity, climate change, and air pollution exposure among elderly population. 
In this thesis, I examined some of the most urgent health issues that may affect the 
susceptibility of elderly population under the upcoming challenges of the climate change. 
Lifestyle factors (physical activity and diet quality) had a seasonal variation. The seasonal 
approach may provide clues of factors already influencing the seasonal variation of lifestyle 
choices on a seasonal basis, such as societal schedules. Also, cardiovascular risk factors and insulin 
resistance had a seasonal variation and tended to worsen in winter. The pattern was mostly 
explained by low ambient temperature, especially among elderly. The seasonality of cardiovascular 
risk factors and insulin resistance may contribute to explain the winter peak of cardiovascular 
mortality and morbidity. Also, the seasonality of cognition and antimicrobial resistance can pose 
important threats for the adaptive capacity of the society to the upcoming challenges of climate 
change. The expected burden of these variations can increase, as the susceptibility of the 
population to environmental deterioration and changes in daily temperature rises, as a 
consequence of population aging trend. This trend will increase the pool of population with 
declined physiological reserve capacity, deteriorated immune system response, and reduced 
cognitive capacity. Therefore, to improve the adaptive capacity of the society to climate change, it 
is urgently needed to understand the mechanisms underlying the seasonal variation of these 
health outcomes. Additionally, it is suggested that promoting the shift from motorized to active 
commuting may help to increase the levels of physical activity of the population as well as to 
reduce the traffic-related pollution, such as air pollution and noise. Nevertheless, stakeholders 
need to account for the risks associated to commuting actively, such as higher inhalation of air 
pollution, in order to improve safety. Finally, I described the estimation of air pollution exposure 
in the population of the Rotterdam Study. Futures studies based on these estimations will help to 
elucidate the health effects of traffic-related air pollution exposure in an aging population. 
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Samenvatting 
Er is bewijs dat klimaatveranderingen in toenemende mate problemen kunnen veroorzaken, deels 
omdat het deel van de bevolking dat hier last van kan hebben toeneemt, en deels doordat de 
bevolking wereldwijd steeds ouder wordt. Als een gevolg daarvan is er een toename van het aantal 
mensen met een verminderde fysiologische reserve, een minder goed werkend immuunsysteem en 
een verminderd cognitief vermogen. Om te kunnen omgaan met de komende veranderingen in 
het milieu en het klimaat, is het nodig om het aanpassingsvermogen van de populatie te 
optimaliseren. Hierbij moeten we onze kennis over de invloed van omgevingsfactoren op de 
gezondheid van de populatie verbreden, en moeten we meer te weten komen over de invloed van 
omgevingsfactoren op kwetsbare subgroepen, zoals ouderen. In dit proefschrift heb ik een aantal 
van de meest dringende gezondheidsproblemen onderzocht die mogelijk kunnen voortvloeien uit 
de klimaatveranderingen. Hierbij heb ik onder andere gekeken of leefstijlfactoren, 
cardiovasculaire risicofactoren, cognitie, antibioticaresistentie en blootstelling aan luchtvervuiling 
een seizoensgebonden patroon vertonen. 
Eerst onderzocht ik het seizoensgebonden patroon, en mogelijke onderliggende 
mechanismen, van leefstijlfactoren, cardiovasculaire risicofactoren en cognitie binnen de 
Rotterdam Studie. Ook onderzocht ik het seizoensgebonden patroon van antibioticaresistentie 
aan de hand van een systematische literatuurstudie. Als tweede onderzocht ik in twee 
systematische literatuurstudies of de blootstelling aan luchtvervuiling afhankelijk was van de 
keuze van vervoer en beschreef ik de geschatte luchtvervuiling in de Rotterdam Studie. Met 
uitzondering van de literatuurstudies, is al mijn onderzoek gebaseerd op de Rotterdam Studie, 
een langlopend prospectief bevolkingsonderzoek in Nederland, dat in 1987 is gestart. Deelnemers 
van de Rotterdam Studie zijn van middelbare en oudere leeftijd en zijn woonachtig in de wijk 
Ommoord, in Rotterdam. De Rotterdam Studie bestaat uit drie cohorten, waarvan de eerste is 
gestart in 1987, de tweede in 1996 en de derde in 2006. In de eerste cohort kwamen mensen in 
aanmerking voor deelname als ze 55 jaar of ouder waren, en ondertussen worden mensen 
gerekruteerd die 45 jaar of ouder zijn. Van de deelnemers wordt informatie verzameld via 
bezoeken die elke 4-5 jaar herhaald worden. Hierbij worden gestandaardiseerde interviews en 
vragenlijsten afgenomen, wordt er lichamelijk onderzoek gedaan, wordt er bloed afgenomen en 
worden er verschillende beeldtechnieken gebruikt om gezondheid in kaart te brengen. Tot slot 
wordt er informatie verzameld via medische gegevens van de huisarts en het ziekenhuis. De 
bezoeken waarvan informatie is gebruikt in dit proefschrift verschillen per hoofdstuk, zoals 
weergegeven in Figuur 1 (pagina 8). 
In hoofdstuk 2.1.1 onderzochten we of objectief gemeten fysieke activiteit, sedentair 
gedrag en slaap een seizoensgebonden patroon vertoonden, en of dit afhankelijk was van de 
leeftijd. Hierbij corrigeerden we voor de mogelijke invloed van meteorologische factoren. Bij 
volwassenen van middelbare leeftijd en bij ouderen vonden we dat het seizoensgebonden patroon 
van fysieke activiteit groter was dan het patroon van sedentair gedrag en slaap. We vonden ook 
dat meteorologische factoren maar een kleine invloed hadden op het seizoensgebonden patroon 
van fysieke activiteit. 
In hoofdstuk 2.1.2 vonden we een seizoensgebonden patroon voor de kwaliteit van het 
eetpatroon, dat vooral verklaard kon worden door de inname van peulvruchten en 
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suikerhoudende dranken. Bij volwassenen met een algemeen lagere kwaliteit van het eetpatroon, 
zoals mannen en mensen met obesitas, vonden we een groter seizoensgebonden patroon. Deze 
bevindingen benadrukken dat het belangrijk is om rekening te houden met het seizoen bij het 
identificeren van mogelijkheden om de leefstijlkeuzes van de populatie te beïnvloeden. 
In hoofdstuk 2.2 onderzochten we het seizoensgebonden patroon, en mogelijke 
onderliggende mechanismen, van gezondheidsuitkomsten in een verouderende populatie. In 
hoofdstuk 2.2.1 en 2.2.2 laten we zien dat het cardiovasculaire risicoprofiel de slechtste waarden 
laat zien in de winter. Ook vonden we in de winter de hoogste mate van insulineresistentie, zoals 
gemeten met HOMA-IR. Dit patroon kon vooral worden verklaard door de buitentemperatuur, 
vooral in de oudere deelnemers. Deze bevindingen suggereren dat ouderen gevoeliger zouden 
kunnen zijn voor de buitentemperatuur, doordat hun thermoregulatie minder goed werkt. Ook 
kunnen deze bevindingen bijdragen aan de verklaring waarom er in de winter meer 
cardiovasculaire aandoeningen ontstaan, en de mortaliteit gerelateerd aan cardiovasculaire 
ziekten hoger is. In hoofdstuk 2.2.3 laten we zien dat er een seizoensgebonden patroon is voor 
cognitief presteren, waarbij de laagste scores werden gevonden in de winter. In deelnemers met 
een hogere cognitieve prestatie zagen we een groter seizoensgebonden patroon. Deze laatste 
bevinding kan worden gezien als een teken van gezond ouder worden, en zou in de toekomst 
onderzocht moeten worden om het aanpassingsvermogen van cognitief presteren in een 
verouderende populatie beter te begrijpen. In hoofdstuk 2.2.4 laten we zien dat er in de literatuur 
een hogere antimicrobiële resistentie tegen S. pneumoniae en H. influenza was gevonden in de 
winter en een hogere resistentie tegen E.coli in de zomer, hoewel het patroon erg heterogeen was. 
Voor Campylobacter spp. en Salmonella spp was geen seizoensgebonden variatie geobserveerd. De 
geobserveerde seizoensgebonden patronen zouden kunnen worden verklaard door de variatie van 
infectieziektes gedurende het jaar, en het bijbehorende gebruik van antibiotica. Onze bevindingen 
kunnen het bewustzijn verbeteren met betrekking tot de mogelijke rol van antimicrobiële 
resistentie in het aanpassingsvermogen van de samenleving. 
In hoofdstuk 3 onderzochten we de blootstelling aan luchtvervuiling. Eerst deden we een 
systematisch literatuuronderzoek om erachter te komen of de blootstelling aan NOx, CO, BC, 
grove-, en fijnstof (hoofdstuk 3.1.1) en ultrafijnstof (hoofdstuk 3.1.2) zou verschillen tussen 
verschillende manieren van vervoer. We vonden dat gemotoriseerde weggebruikers vaker 
blootgesteld waren aan PM2.5, CO, BC en ultrafijnstof. Echter, omdat lopende en fietsende 
weggebruikers een hogere ademfrequentie hebben, ademden zij meer verontreinigende stoffen in. 
De nadelige effecten van de hogere opname van PM2.5 tijdens fietsen en lopen zijn echter niet zo 
groot dat ze de positieve effecten van fysieke activiteit op de levensverwachting teniet doen. 
Wanneer er een transitie van gemotoriseerd naar actief transport zou plaatsvinden, zou er op 
grote schaal winst voor de maatschappij behaald kunnen worden. 
In hoofdstuk 3.2 beschrijf ik de methoden om de blootstelling aan NO2, NOx, PM10, 
PM2.5, en PM2.5 te schatten voor deelnemers van de Rotterdam Studie. Hierbij maak ik gebruik 
van landgebruik-regressiemodellen, die door de ESCAPE studie ontwikkeld en gevalideerd zijn 
voor Nederland en België. We vonden een lagere spreiding van luchtvervuilende stoffen in 
Ommoord, vergeleken met Nederlandse en Belgische wijken zoals gemeten in de ESCAPE studie. 
We vonden echter wel substantiële ruimtelijke variatie van de luchtvervuilende stoffen, vooral 
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voor NO2 en NOx, in relatie tot het wegnetwerk van de wijk. Dit suggereert dat NO2 en NOx 
grote bronnen van luchtvervuiling zijn voor deelnemers van de Rotterdam Studie. We vonden 
ook dat de distributie van blootstelling aan luchtvervuilende stoffen afhankelijk was van bepaalde 
karakteristieken van de deelnemers, zoals leeftijd en bloeddruk. Vervolgstudies gebaseerd op deze 
data kunnen bijdragen aan meer kennis over de gezondheidseffecten van verkeers-gerelateerde 
luchtvervuiling in een verouderende populatie. 
Tot slot bespreek ik in hoofdstuk 4 de methodologische beperkingen van onze 
bevindingen, en bespreek ik de belangrijkste bevindingen van mijn studies in relatie tot het 
seizoensgebonden patroon van overlijden en morbiditeit, klimaatveranderingen, en blootstelling 
aan luchtvervuiling binnen de populatie van ouderen.  
In dit proefschrift heb ik een aantal belangrijke gezondheidszaken onderzocht die de 
kwetsbaarheid van een oudere populatie kunnen beïnvloeden tijdens de opkomende uitdagingen 
van klimaatveranderingen. Leefstijlfactoren zoals fysieke activiteit en kwaliteit van het eetpatroon 
vertoonden een seizoensgebonden patroon. Een aanpak waarbij rekening wordt gehouden met 
het seizoen zou aanwijzingen kunnen geven voor factoren die deze leefstijlfactoren beïnvloeden 
gedurende de verschillende seizoenen. Ook vond ik dat cardiovasculaire risicofactoren en 
insulineresistentie een seizoensgebonden patroon vertoonden, en dit patroon kon met name 
verklaard worden door de buitentemperatuur, vooral in ouderen. Deze bevindingen zouden 
kunnen verklaren dat er in de winter meer mensen een cardiovasculair event doormaken, en 
meer mensen hieraan overlijden. Het seizoensgebonden patroon van cognitieve prestatie en 
antimicrobiële resistentie kan een bedreiging vormen voor het aanpassingsvermogen van de 
maatschappij wanneer we te maken krijgen met de uitdagingen van klimaatveranderingen. De 
verwachte last van de genoemde seizoensgebonden patronen kan hoger worden als de populatie 
verouderd, aangezien dit het aantal kwetsbare volwassenen verhoogd. Het is belangrijk om ervoor 
te zorgen dat de maatschappij zich goed kan aanpassen aan klimaatveranderingen, en daarom 
moeten we de mechanismen die ten grondslag liggen aan de patronen van deze 
gezondheidsuitkomsten beter begrijpen. Ook zou het helpen om een transitie te maken van 
gemotoriseerd vervoer naar actief vervoer, om zo verkeers-gerelateerde lucht- en geluidsvervuiling 
te verminderen en fysieke activiteit in de populatie te verhogen. Om actief transport veiliger te 
maken, moeten stakeholders zorgen dat de risico’s ten gevolge van een hogere opname van 
luchtvervuilende deeltjes zo laag mogelijk zijn. Tot slot kunnen toekomstige studies gebaseerd op 
geschatte blootstelling aan luchtvervuiling in de Rotterdam Studie helpen om de 
gezondheidseffecten van verkeers-gerelateerde luchtvervuiling op te helderen. 
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